<SEC-DOCUMENT>0001493152-24-031622.txt : 20240813
<SEC-HEADER>0001493152-24-031622.hdr.sgml : 20240813
<ACCEPTANCE-DATETIME>20240813161539
ACCESSION NUMBER:		0001493152-24-031622
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		53
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240813
DATE AS OF CHANGE:		20240813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Processa Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001533743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				451539785
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39531
		FILM NUMBER:		241201682

	BUSINESS ADDRESS:	
		STREET 1:		7380 COCA COLA DRIVE
		STREET 2:		SUITE 106
		CITY:			HANOVER
		STATE:			MD
		ZIP:			21076
		BUSINESS PHONE:		443-776-3133

	MAIL ADDRESS:	
		STREET 1:		7380 COCA COLA DRIVE
		STREET 2:		SUITE 106
		CITY:			HANOVER
		STATE:			MD
		ZIP:			21076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Heatwurx, Inc.
		DATE OF NAME CHANGE:	20111028
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:PCSA="http://processapharmaceuticals.com/20240630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_070_XDX_form10%2Dq.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_021_US%2DGAAP%2D2024%2D(with%2DECD) -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_PCSA_processapharmaceuticals.com_20240630 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20240101_20240630 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0001533743 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_Segments_0_Segments -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_072_SO_form10%2Dq.xdxs -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000004" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000006" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000007" name="dei:EntityCentralIndexKey">0001533743</ix:nonNumeric>
  <ix:nonFraction name="PCSA:DueToLicensor" contextRef="AsOf2024-06-30" id="xdx2ixbrl0087" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-06-30" id="xdx2ixbrl0090" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-06-30" id="xdx2ixbrl0108" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0109" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-04-012024-06-30" id="xdx2ixbrl0182" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0183" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-06-30" id="xdx2ixbrl0184" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-06-30" id="xdx2ixbrl0185" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0236" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0237" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0244" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0250" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0251" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0252" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-04-012023-06-30_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-04-012023-06-30_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="PCSA:SharesIssuedinConnectionwithLicenseAgreementValue" contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="PCSA:SharesIssuedinConnectionwithLicenseAgreementValue" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-06-30" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2024-01-01to2024-06-30" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2023-01-012023-06-30" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="PCSA:PaymentsForSettlementOfStockAwards" contextRef="From2023-01-012023-06-30" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2023-01-012023-06-30" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="PCSA:StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" contextRef="From2023-01-012023-06-30" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="PCSA:RightofuseAsset" contextRef="From2023-01-012023-06-30" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="PCSA:FinancingLeaseLiability" contextRef="From2023-01-012023-06-30" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="PCSA:NonCashLeaseLiabilityNet" contextRef="From2024-01-01to2024-06-30" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="PCSA:NonCashLeaseLiabilityNet" contextRef="From2023-01-012023-06-30" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="pcsa-20240630.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:SpartanCapitalSecuritesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-222024-01-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-22</xbrli:startDate>
        <xbrli:endDate>2024-01-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-292024-01-30_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-29</xbrli:startDate>
        <xbrli:endDate>2024-01-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-292024-01-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-29</xbrli:startDate>
        <xbrli:endDate>2024-01-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-312024-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-31</xbrli:startDate>
        <xbrli:endDate>2024-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-212024-05-21_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember_srt_MaximumMember_custom_ATMOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PCSA:AllianceGlobalPartnersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:ATMOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-21</xbrli:startDate>
        <xbrli:endDate>2024-05-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_PurchaseAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_PurchaseAgreementMember_custom_PlacementAgentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:PlacementAgentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_ElionOncologyIncMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PCSA:ElionOncologyIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_ConsultantMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PCSA:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_EmployeesAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PCSA:EmployeesAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-28_custom_TwoThousandAndNineteenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_TwoThousandAndNineteenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-282024-06-28_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-28</xbrli:startDate>
        <xbrli:endDate>2024-06-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-282024-06-28_custom_ServiceBasedRestrictedStockUnitsMember_custom_JanuaryOneTwoThousandTwentyFiveVestingMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:JanuaryOneTwoThousandTwentyFiveVestingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-28</xbrli:startDate>
        <xbrli:endDate>2024-06-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-282024-06-28_custom_ServiceBasedRestrictedStockUnitsMember_custom_EmployeesMember_custom_ThreeYearVestingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="PCSA:TitleOfInidividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:ThreeYearVestingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-28</xbrli:startDate>
        <xbrli:endDate>2024-06-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-282024-06-28_custom_FirstPerformanceBasedRSUMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:FirstPerformanceBasedRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-28</xbrli:startDate>
        <xbrli:endDate>2024-06-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-282024-06-28_custom_SecondPerformanceBasedRSUMember_custom_NextGenerationCapecitabineCAPMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:SecondPerformanceBasedRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:NextGenerationCapecitabineCAPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-28</xbrli:startDate>
        <xbrli:endDate>2024-06-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_WarrantMember_custom_OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember790435859">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_FacilityLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">PCSA:FacilityLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_CorLystLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_CROsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PCSA:CROsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-162024-07-16_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-16</xbrli:startDate>
        <xbrli:endDate>2024-07-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-16_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-162024-07-16_us-gaap_SubsequentEventMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-16</xbrli:startDate>
        <xbrli:endDate>2024-07-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-162024-07-16_us-gaap_SubsequentEventMember_custom_ServiceBasedRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:ServiceBasedRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-16</xbrli:startDate>
        <xbrli:endDate>2024-07-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-162024-07-16_custom_FirstPerformanceBasedRSUMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:FirstPerformanceBasedRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-16</xbrli:startDate>
        <xbrli:endDate>2024-07-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-16_us-gaap_SubsequentEventMember_custom_FirstPerformanceBasedRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:FirstPerformanceBasedRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-162024-07-16_custom_SecondPerformanceBasedRSUMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:SecondPerformanceBasedRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-16</xbrli:startDate>
        <xbrli:endDate>2024-07-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-16_us-gaap_SubsequentEventMember_custom_SecondPerformanceBasedRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001533743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:SecondPerformanceBasedRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Segments">
      <xbrli:measure>PCSA:Segments</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>United
States</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>Securities
and Exchange Commission</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; text-transform: uppercase"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>FORM
<span id="xdx_90E_edei--DocumentType_c20240101__20240630_zJzhO6OC1wt2"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000015" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Mark
One)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--DocumentQuarterlyReport_c20240101__20240630_zPBhUZZ5Wkhi"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" format="ixt:booleantrue" id="Fact000016" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>QUARTERLY
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">For
the quarterly period ended <span id="xdx_90F_edei--DocumentPeriodEndDate_c20240101__20240630_zmI5iDzQQiA7"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" format="ixt:datemonthdayyearen" id="Fact000017" name="dei:DocumentPeriodEndDate">June 30, <span id="xdx_902_edei--DocumentFiscalYearFocus_c20240101__20240630_zgMiz6Wo8Y98"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000018" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--DocumentTransitionReport_c20240101__20240630_zZGZ9Us3Ak7c"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" format="ixt:booleanfalse" id="Fact000019" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
    the transition period from ____ to ____</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number <span id="xdx_90C_edei--EntityFileNumber_c20240101__20240630_zSTx1fvY3tRa"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000020" name="dei:EntityFileNumber">001-39531</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_900_edei--EntityRegistrantName_c20240101__20240630_zW4Mbh1LBTI1"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000021" name="dei:EntityRegistrantName">Processa
Pharmaceuticals, Inc.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20240101__20240630_zCkmaZpg3qVa"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" format="ixt-sec:stateprovnameen" id="Fact000022" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20240101__20240630_zIIZnOtGLTY6"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000023" name="dei:EntityTaxIdentificationNumber">45-1539785</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
or other jurisdiction of incorporation or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
Employer Identification No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityAddressAddressLine1_c20240101__20240630_zlPgfECkPEU7"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000024" name="dei:EntityAddressAddressLine1">7380
Coca Cola Drive</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressAddressLine2_c20240101__20240630_zqeBA8XTXoXb"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000025" name="dei:EntityAddressAddressLine2">Suite 106</ix:nonNumeric></span>,</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_907_edei--EntityAddressCityOrTown_c20240101__20240630_zbVl3vvZdgx7"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000026" name="dei:EntityAddressCityOrTown">Hanover</ix:nonNumeric></span>,
<span id="xdx_906_edei--EntityAddressStateOrProvince_c20240101__20240630_zoXmcY8nOgA2"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" format="ixt-sec:stateprovnameen" id="Fact000027" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span> <span id="xdx_904_edei--EntityAddressPostalZipCode_c20240101__20240630_z2PBSGf9Zne"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000028" name="dei:EntityAddressPostalZipCode">21076</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">(<span id="xdx_90A_edei--CityAreaCode_c20240101__20240630_zoWiFz0gj3Sd"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000029" name="dei:CityAreaCode">443</ix:nonNumeric></span>)
<span id="xdx_90F_edei--LocalPhoneNumber_c20240101__20240630_zvmX2Q0IF24c"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000030" name="dei:LocalPhoneNumber">776-3133</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Exchange Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 39%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Each Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 39%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--Security12bTitle_c20240101__20240630_zhFEvf7OqCA8"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000031" name="dei:Security12bTitle">Common
    Stock, $0.0001 par value per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--TradingSymbol_c20240101__20240630_z89AFnEvxR98"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000032" name="dei:TradingSymbol">PCSA</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
    <span id="xdx_909_edei--SecurityExchangeName_c20240101__20240630_zzkwpUyuc1Af"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" format="ixt-sec:exchnameen" id="Fact000033" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_907_edei--EntityCurrentReportingStatus_c20240101__20240630_ztH3uyHv3Hgh"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000034" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
<span id="xdx_907_edei--EntityInteractiveDataCurrent_c20240101__20240630_zbutEV8tIZ0l"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" id="Fact000035" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntityFilerCategory_c20240101__20240630_ztNX5Ooeocw4"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" format="ixt-sec:entityfilercategoryen" id="Fact000036" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntitySmallBusiness_c20240101__20240630_z8switpmGaE3"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" format="ixt:booleantrue" id="Fact000037" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20240101__20240630_zqeKaQzwK114"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" format="ixt:booleanfalse" id="Fact000038" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; <span>No</span> <span id="xdx_903_edei--EntityShellCompany_dbF_c20240101__20240630_zb7EY9IReGR3"><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" format="ixt:booleanfalse" id="Fact000039" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of outstanding shares of the registrant&#8217;s common stock at August 1, 2024 was <span id="xdx_90D_edei--EntityCommonStockSharesOutstanding_iI_c20240801_zY3O6moSK3U9"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-08-01" id="Fact000040" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,256,944</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROCESSA
PHARMACEUTICALS, INC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TABLE
OF CONTENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">Part I. Financial Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Item 1: Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Item 2: Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Item 3. Quantitative and Qualitative Disclosures about Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Item 4. Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Part II. Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Item 1. Legal Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Item 1A. Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Item 3. Defaults Upon Senior Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">Item 4. Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Item 5. Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Item 6. Exhibits</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">Signatures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>Part
I: Financial Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>Item
1: Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Consolidated Balance Sheets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_111_zWI3KHRQVOK9" summary="xdx: Statement - Condensed Consolidated Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240630_z8H6OD5d6vFb" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231_zlWz4ioqlYEb" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_zGBUOUNnIt78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsCurrentAbstract_i01B_zf3Wo2PdMnYd" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzWzj_zoNuotX09raf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30" id="Fact000048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,571,120</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000049" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,706,197</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzWzj_zKNRVnRyGal2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid expenses and other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-06-30" id="Fact000051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,906,854</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">926,300</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrent_i02TI_mtACzWzj_maAzMBh_zDvk4J0fXqD8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 20pt">Total Current Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-06-30" id="Fact000054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,477,974</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,632,497</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pp0p0_maAzMBh_z0ZW0vvTj2Rk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Property and Equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-06-30" id="Fact000057" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,276</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000058" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,554</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsNoncurrentAbstract_i01B_zMY8vfLdZkTa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Other Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--OperatingAndFinancingLeaseRightofUseAsset_i02I_pp0p0_maANOTNztfu_zF1L3x4CAMy2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Lease right-of-use assets, net of accumulated amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:OperatingAndFinancingLeaseRightofUseAsset" contextRef="AsOf2024-06-30" id="Fact000063" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">115,191</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:OperatingAndFinancingLeaseRightofUseAsset" contextRef="AsOf2023-12-31" id="Fact000064" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">146,057</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SecurityDeposit_i02I_pp0p0_maANOTNztfu_zc4CKmVkgBwj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Security deposit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2024-06-30" id="Fact000066" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,535</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2023-12-31" id="Fact000067" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,535</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_i02TI_pp0p0_mtANOTNztfu_maAzMBh_znQCL9pw0SQg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 20pt">Total Other Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" contextRef="AsOf2024-06-30" id="Fact000069" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">120,726</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000070" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">151,592</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Assets_i01TI_pp0p0_mtAzMBh_zpvsaYanKGfd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-06-30" id="Fact000072" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,600,976</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000073" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,786,643</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zzCjR2yF2wv5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesCurrentAbstract_i01B_zOfamAlUNyEh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OperatingAndFinanceLeaseLiabilityCurrent_i02I_pp0p0_maLCzBSp_z2Dmmv2WNZx5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Current maturities of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="PCSA:OperatingAndFinanceLeaseLiabilityCurrent" contextRef="AsOf2024-06-30" id="Fact000081" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">93,181</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="PCSA:OperatingAndFinanceLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000082" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">83,649</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableCurrent_i02I_pp0p0_maLCzBSp_zolvJnWbYHk7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-06-30" id="Fact000084" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">953,086</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000085" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">311,617</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DueToLicensor_i02I_pp0p0_maLCzBSp_zvlRGtRyoMKa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Due to licensor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0087">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:DueToLicensor" contextRef="AsOf2023-12-31" id="Fact000088" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">189,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherLiabilitiesCurrent_i02I_pp0p0_maLCzBSp_zT65C5oZTXWj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt">Due to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0090">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000091" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_i02I_pp0p0_maLCzBSp_zukgmPvDxXue" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-06-30" id="Fact000093" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">505,397</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000094" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">146,274</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesCurrent_i01TI_pp0p0_mtLCzBSp_maLzkcd_zEbF3KQv6po2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 20pt">Total Current Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-06-30" id="Fact000096" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,551,664</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000097" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">730,579</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zSk279alIbl1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Non-current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--OperatingAndFinanceLeaseLiabilityNoncurrent_i02I_pp0p0_maLzkcd_zuUaYMaJxngf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Non-current lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="PCSA:OperatingAndFinanceLeaseLiabilityNoncurrent" contextRef="AsOf2024-06-30" id="Fact000102" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,648</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="PCSA:OperatingAndFinanceLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">66,905</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Liabilities_i01TI_pp0p0_mtLzkcd_maLASEzjgB_zY811Zuhige6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-06-30" id="Fact000105" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,577,312</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000106" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">797,484</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CommitmentsAndContingencies_i01I_pp0p0_maLASEzjgB_zuekN8uHtUe8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Commitments and Contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0108">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0109">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_i02I_pp0p0_maSEzsZQ_zavEl1onLfA1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock, par value $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240630_zvdqCa3UIV21" title="Common stock, par value"><span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zudMWlKYKoMj" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" id="Fact000117" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000119" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20240630_zqKjDwEpsVH6" title="Common stock, shares authorized"><span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zFC9dAVnaWKf" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-30" id="Fact000121" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized: <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20240630_zM1qO6JvzUJ5" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-06-30" id="Fact000125" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,873,883</ix:nonFraction></span> issued and <span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20240630_zLtmGTyMiVYa" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-06-30" id="Fact000127" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,868,883</ix:nonFraction></span> outstanding at June 30, 2024; and <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20231231_zXl63EyPOD23" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000129" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,291,000</ix:nonFraction></span> issued and <span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zIwdKurYuIpb" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000131" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,286,000</ix:nonFraction></span> outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-06-30" id="Fact000114" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">287</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">129</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_pp0p0_maSEzsZQ_zc69I6uvJMn1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2024-06-30" id="Fact000133" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">87,429,165</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2023-12-31" id="Fact000134" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,658,111</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--TreasuryStockValue_i02NI_pp0p0_di_msSEzsZQ_z1ckC4XL3pMe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Treasury stock at cost &#8212; <span id="xdx_907_eus-gaap--TreasuryStockCommonShares_iI_c20240630_zos7w0GyF8Mf" title="Treasury stock shares"><span id="xdx_90F_eus-gaap--TreasuryStockCommonShares_iI_c20231231_z5priLskFOPi" title="Treasury stock shares"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2024-06-30" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2023-12-31" id="Fact000141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></ix:nonFraction></span></span> shares at June 30, 2024 and December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2024-06-30" id="Fact000136" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2023-12-31" id="Fact000137" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEzsZQ_zy2BzI8016Hg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-06-30" id="Fact000143" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">81,105,788</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000144" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">75,369,081</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEzsZQ_maLASEzjgB_zwByC68KDBZe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000146" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,023,664</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000147" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,989,159</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_pp0p0_mtLASEzjgB_zpF98JpwvHqg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000149" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,600,976</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000150" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,786,643</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Consolidated Statements of Operations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_113_zqTzyKPXfb62" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20240401__20240630_z1dvCXPsmrod" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230401__20230630_zUaGPQDSWk26" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20240630_zi49jyhe15zk" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20230630_zgcdorU86EI9" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingExpensesAbstract_iB_zPhPtN2rIuW9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_i01_msOILzJvZ_zKP4SHrBGVL6" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left; padding-left: 10pt">Research and development expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-04-012024-06-30" id="Fact000157" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,730,444</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2023-04-012023-06-30" id="Fact000158" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,688,164</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2024-01-01to2024-06-30" id="Fact000159" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,269,555</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2023-01-012023-06-30" id="Fact000160" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,342,509</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--GeneralAndAdministrativeExpense_i01_msOILzJvZ_zEYBfz5AXjt7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-04-012024-06-30" id="Fact000162" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,351,580</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-04-012023-06-30" id="Fact000163" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,026,301</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-06-30" id="Fact000164" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,622,067</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-06-30" id="Fact000165" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,477,490</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_iT_mtOILzJvZ_maILFCOz7Wf_zu8mjQZiHlz6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-04-012024-06-30" id="Fact000167" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,082,024</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-04-012023-06-30" id="Fact000168" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,714,465</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-06-30" id="Fact000169" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,891,622</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-06-30" id="Fact000170" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,819,999</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherNonoperatingIncomeExpense_maILFCOz7Wf_zqESakI9kj1h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other Income (Expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-04-012024-06-30" id="Fact000172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,698</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-04-012023-06-30" id="Fact000173" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,900</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-01to2024-06-30" id="Fact000174" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,915</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-06-30" id="Fact000175" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,361</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOz7Wf_maNILzgpF_zTjnJRQAW0P9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Operating Loss Before Income Tax Benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-04-012024-06-30" id="Fact000177" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,010,326</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-04-012023-06-30" id="Fact000178" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,612,565</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-01to2024-06-30" id="Fact000179" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,736,707</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-06-30" id="Fact000180" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,634,638</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILzgpF_zw43iJznaGJ9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Income Tax Benefit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0182">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0183">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0184">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0185">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_iT_mtNILzgpF_z58EeSdUbpbf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30" id="Fact000187" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,010,326</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30" id="Fact000188" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,612,565</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-06-30" id="Fact000189" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,736,707</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-06-30" id="Fact000190" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,634,638</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net Loss per Common Share - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20240401__20240630_zphYGbSEE236" title="Net Loss per Common Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20240401__20240630_zPBiFZIWwWL9" title="Net Loss per Common Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-04-012024-06-30" id="Fact000192" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-04-012024-06-30" id="Fact000194" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.01</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20230401__20230630_zgKVtb0zM9Xf" title="Net Loss per Common Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20230401__20230630_zrKZjAAJoFfc" title="Net Loss per Common Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-04-012023-06-30" id="Fact000196" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-04-012023-06-30" id="Fact000198" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.94</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_c20240101__20240630_zgJNW6KlpISd" title="Net Loss per Common Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_c20240101__20240630_zjnTHyAB5Qyb" title="Net Loss per Common Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-06-30" id="Fact000200" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-06-30" id="Fact000202" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.11</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20230101__20230630_zZiRIxNi9it8" title="Net Loss per Common Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20230101__20230630_zWPmwngnGt01" title="Net Loss per Common Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-06-30" id="Fact000204" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-06-30" id="Fact000206" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">5.34</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_zBIA21w5S3Ch" title="Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_znhA7QYDJw2f" title="Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-04-012024-06-30" id="Fact000208" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-012024-06-30" id="Fact000210" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,983,283</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zT5RdDES6ioa" title="Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zioBgoo1zYE4" title="Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-04-012023-06-30" id="Fact000212" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-04-012023-06-30" id="Fact000214" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,346,808</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zFRd7yi80ikh" title="Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zXjauSIZga2k" title="Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-06-30" id="Fact000216" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-06-30" id="Fact000218" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,724,903</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630_z6KcRZBKElne" title="Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630_zMT3nV3tFnQa" title="Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-06-30" id="Fact000220" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-06-30" id="Fact000222" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,243,475</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Consolidated Statements of Changes in Stockholders&#8217; Equity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_114_zEZ6SZ3Wk0Jl" summary="xdx: Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zHjseCQweGh1" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zmWXhmZKuJTj" style="border-bottom: Black 1.5pt solid; text-align: center">Capital</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockCommonMember_zV1WfiKsB23i" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zGXx2DngSJL6" style="border-bottom: Black 1.5pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_zwWeeA7U7iQb" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Additional</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Paid-In</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Treasury Stock</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Capital</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_430_c20230101__20230331_eus-gaap--StockholdersEquity_iS_zTecViSjhJl2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%">Balance at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zld4aJrcFHBd" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000230" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">806,774</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000224" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000225" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,018,222</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zz1nP7CsRP1l" title="Balance. shares" style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000232" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000226" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000227" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">64,247,561</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,470,741</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zaUBD6Tk6K57" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhVB0S8b9jpg" title="Stock-based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000240" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,195</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">341,503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0236">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0237">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31" id="Fact000238" format="ixt:numdotdecimal" decimals="0" unitRef="USD">341,504</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zIqQUv7iBFk3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued in connection with capital raises, net of transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwFgJYaycVJj" title="Shares issued in connection with capital raise, net of transaction costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000248" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">421,611</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000242" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000243" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,352,035</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0244">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0245">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31" id="Fact000246" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,352,077</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zezbzBpxFiUl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0250">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0251">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0252">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="Fact000253" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,022,073</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact000254" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,022,073</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_430_c20230401__20230630_eus-gaap--StockholdersEquity_iS_z8FmY8bCcDre" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znbmO6BLbqXb" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000262" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,231,580</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000257" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,711,760</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zdKkhb3hWbW2" title="Balance. shares" style="text-align: right">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember" id="Fact000264" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember" id="Fact000258" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" id="Fact000259" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">68,269,634</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" id="Fact000260" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,142,249</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zQBRw9PKeeZc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">319,123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0269">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-04-012023-06-30" id="Fact000270" format="ixt:numdotdecimal" decimals="0" unitRef="USD">319,123</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zg8X5A2zSJLi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants issued in connection with a consulting agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0272">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,310,875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0274">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0275">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-04-012023-06-30" id="Fact000276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,310,875</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zUun1N9VZgvd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0280">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="Fact000281" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,612,565</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30" id="Fact000282" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,612,565</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_438_c20230401__20230630_eus-gaap--StockholdersEquity_iE_zNj5x2ge3a78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, June 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zG1Xbf9wykW5" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000290" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,231,580</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000284" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,341,758</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zDWt08nlIdVf" title="Balance. shares" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_TreasuryStockCommonMember" id="Fact000292" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_TreasuryStockCommonMember" id="Fact000286" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" id="Fact000287" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">70,882,199</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" id="Fact000288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,159,682</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Additional</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Paid-In</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Treasury Stock</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Capital</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_434_c20240101__20240331_eus-gaap--StockholdersEquity_iS_zW4SOszx3Cg7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%">Balance at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znhIgxqkSeB8" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000300" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,291,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000295" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,658,111</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zMsd85jtNiBk" title="Balance. shares" style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000302" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember" id="Fact000296" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000297" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">75,369,081</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000298" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,989,159</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zwMg7qQjp2Rh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeuYdaCIwY4f" title="Stock-based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000310" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,176</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000305" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,642</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-03-31" id="Fact000308" format="ixt:numdotdecimal" decimals="0" unitRef="USD">167,643</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zLboLiVJLLC4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued in connection with capital raise, net of transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zi6J6BAMjuD2" title="Shares issued in connection with capital raise, net of transaction costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000318" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,555,555</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000312" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,282,274</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31" id="Fact000316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,282,430</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--SharesIssuedinConnectionwithLicenseAgreementValue_zVSA9RgG4yt8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued in connection with license agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--SharesIssuedinConnectionwithLicenseAgreementShares_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVotg6w2D22j" title="Shares issued in connection with license agreement, shares" style="text-align: right"><ix:nonFraction name="PCSA:SharesIssuedinConnectionwithLicenseAgreementShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000326" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:SharesIssuedinConnectionwithLicenseAgreementValue" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000320" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:SharesIssuedinConnectionwithLicenseAgreementValue" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,999</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PCSA:SharesIssuedinConnectionwithLicenseAgreementValue" contextRef="From2024-01-012024-03-31" id="Fact000324" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_iN_di_zD3UrCg8KLmb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Settlement of stock award</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000329" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,561</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" contextRef="From2024-01-012024-03-31" id="Fact000332" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,561</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--SharesWithheldToPayIncomeTaxOnStockbasedCompensation_iN_di_zyyEaoBvuCM2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares withheld to pay income taxes on stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares_iN_pid_di_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6tEDKZ7vZ88" title="Shares withheld to pay income taxes on stock-based compensation, shares" style="text-align: right">(<ix:nonFraction name="PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000340" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,750</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000334" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000335" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,923</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation" contextRef="From2024-01-012024-03-31" id="Fact000338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,924</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zQLb0x3Nx4tf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact000345" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,726,381</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000346" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,726,381</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20240401__20240630_eus-gaap--StockholdersEquity_iS_zJQylbUlRute" style="vertical-align: bottom; background-color: White">
    <td>Balance, March 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLUyWVssJmz1" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000354" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,860,981</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000348" format="ixt:numdotdecimal" decimals="0" unitRef="USD">286</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000349" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,278,542</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zEPkrB0UXkti" title="Balance. shares" style="text-align: right">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember" id="Fact000356" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember" id="Fact000350" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000351" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">78,095,462</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000352" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,883,366</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20240401__20240630_eus-gaap--StockholdersEquity_iS_z69kHvzkSNHc" style="display: none; vertical-align: bottom; background-color: White">
    <td>Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zU08HJmZRyZb" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000364" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,860,981</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000358" format="ixt:numdotdecimal" decimals="0" unitRef="USD">286</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000359" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,278,542</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zEGSAIzSEFm9" title="Balance. shares" style="text-align: right">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember" id="Fact000366" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember" id="Fact000360" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000361" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">78,095,462</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000362" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,883,366</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zddISftdSav1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXjIgavG1e9c" title="Stock-based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000374" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000369" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-04-012024-06-30" id="Fact000372" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,632</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--SharesWithheldToPayIncomeTaxOnStockbasedCompensation_iN_di_zTlCatmqnAEa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares withheld to pay income taxes on stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares_iN_pid_di_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcBbnke191p7" title="Shares withheld to pay income taxes on stock-based compensation, shares" style="text-align: right">(<ix:nonFraction name="PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000382" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,265</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0376">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000377" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,008</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0378">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation" contextRef="From2024-04-012024-06-30" id="Fact000380" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,008</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zRe8PSabF82e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="Fact000387" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,010,326</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30" id="Fact000388" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,010,326</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_439_c20240401__20240630_eus-gaap--StockholdersEquity_iE_z6btmmty5qKf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance, June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLylrKOZVuJe" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000396" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,873,883</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000390" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000391" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,429,165</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_z6JZ8je0zLze" title="Balance. shares" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember" id="Fact000398" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember" id="Fact000392" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000393" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">81,105,788</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,023,664</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43D_c20240401__20240630_eus-gaap--StockholdersEquity_iE_zGdTUAMwS9j8" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAkJkWN9GCQc" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000406" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,873,883</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000400" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000401" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,429,165</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_z1by3xASpHMf" title="Balance. shares" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember" id="Fact000408" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember" id="Fact000402" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">300,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000403" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">81,105,788</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,023,664</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Consolidated Statements of Cash Flows</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_112_zDohvvClSG98" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20240630_zIe4erK4DcLh" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230630_z5NzURqqdqOl" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zmOUUN55rWYg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Operating Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_i01_maNCPBUz4D6_z2h3rs4lXKQf" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-06-30" id="Fact000413" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,736,707</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-06-30" id="Fact000414" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,634,638</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zWBuAqhArO5b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Depreciation_i02_pp0p0_maNCPBUz4D6_zQZZbfvgXCZ2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-06-30" id="Fact000419" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">278</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseExpense_i02_pp0p0_maNCPBUz4D6_zz2Pr4xdF83e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Non-cash lease expense for right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-01to2024-06-30" id="Fact000422" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,670</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-01-012023-06-30" id="Fact000423" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,982</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensation_i02_maNCPBUz4D6_z2XLoDtgWbLh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-06-30" id="Fact000425" format="ixt:numdotdecimal" decimals="0" unitRef="USD">320,275</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-06-30" id="Fact000426" format="ixt:numdotdecimal" decimals="0" unitRef="USD">660,627</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_maNCPBUz4D6_zE8Eh7eY1Vb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Warrant issued to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--SpartanCapitalSecuritesLLCMember_zKZ8PKzwTGX3" title="Warrants to purchase shares" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIENhc2ggRmxvd3MgKFVuYXVkaXRlZCkgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-06-30_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember" id="Fact000431" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">158,007</ix:nonFraction></span> shares of common stock in connection with a consulting agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2023-01-012023-06-30" id="Fact000429" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,310,875</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zACsFTXs5jBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Net changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUz4D6_zgSX6EjwXyRj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Prepaid expenses and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-01to2024-06-30" id="Fact000436" format="ixt:numdotdecimal" decimals="0" unitRef="USD">980,554</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-06-30" id="Fact000437" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">662,984</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUz4D6_zJs4xzePpKg8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-01to2024-06-30" id="Fact000439" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">41,228</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-06-30" id="Fact000440" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38,233</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUz4D6_zLAJvfQthOpb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-01to2024-06-30" id="Fact000442" format="ixt:numdotdecimal" decimals="0" unitRef="USD">641,469</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-06-30" id="Fact000443" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">88,526</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInDueToRelatedParties_i03_maNCPBUz4D6_zvTkl46JpBki" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Due to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedParties" contextRef="From2024-01-01to2024-06-30" id="Fact000445" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">39</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedParties" contextRef="From2023-01-012023-06-30" id="Fact000446" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">51</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_maNCPBUz4D6_zfY1peh1D8wc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2024-01-01to2024-06-30" id="Fact000448" format="ixt:numdotdecimal" decimals="0" unitRef="USD">359,123</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-01-012023-06-30" id="Fact000449" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">91,559</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUz4D6_maCCERCz1ri_zAQTYtb0noj5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 30pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-06-30" id="Fact000451" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,394,713</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-06-30" id="Fact000452" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,178,539</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_z5DaWUAj3qKg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_pp0p0_maNCPBUzBRF_zQJtyfq7lNf4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Net proceeds from issuance of stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-01to2024-06-30" id="Fact000457" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,282,430</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-06-30" id="Fact000458" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,352,077</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_i01N_pp0p0_di_msNCPBUzBRF_zqnqS9AdLv7l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Shares withheld to pay taxes on stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-01to2024-06-30" id="Fact000460" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,932</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0461">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--PaymentsForSettlementOfStockAwards_i01N_pp0p0_di_msNCPBUzBRF_zXq12ZeDLmni" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Settlement of stock award</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PCSA:PaymentsForSettlementOfStockAwards" contextRef="From2024-01-01to2024-06-30" id="Fact000463" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,561</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FinanceLeasePrincipalPayments_i01N_pp0p0_di_msNCPBUzBRF_zB1HXQ8lhAjd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Payment of finance lease obligation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2024-01-01to2024-06-30" id="Fact000466" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,301</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_pp0p0_mtNCPBUzBRF_maCCERCz1ri_z2YlPBjBoCXj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-06-30" id="Fact000469" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,259,636</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-06-30" id="Fact000470" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,352,077</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_mtCCERCz1ri_zCZugG0rYFxf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net Increase in Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-06-30" id="Fact000472" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">864,923</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-06-30" id="Fact000473" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,173,538</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0_zx6BkEqA3i9k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and Cash Equivalents &#8211; Beginning of Period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000475" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,706,197</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000476" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,503,595</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0_zjfQirKQS5Ik" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and Cash Equivalents &#8211; End of Period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-06-30" id="Fact000478" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,571,120</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-06-30" id="Fact000479" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,677,133</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Non-Cash Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor_i01_pp0p0_zBy9beKD0se6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Issuance of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN5CPWejXrP3" title="Shares issued in connection with license agreement"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="Fact000487" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span> shares of common stock in connection with a licensing agreement which had previously been recorded as a due to licensor</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="PCSA:StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" contextRef="From2024-01-01to2024-06-30" id="Fact000484" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">189,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--RightofuseAsset_i01_zpPFuGAuetMk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="PCSA:RightofuseAsset" contextRef="From2024-01-01to2024-06-30" id="Fact000489" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,804</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0490">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--FinancingLeaseLiability_i01_zuGUhq0wR25d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Financing lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="PCSA:FinancingLeaseLiability" contextRef="From2024-01-01to2024-06-30" id="Fact000492" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,804</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--NonCashLeaseLiabilityNet_i01_pp0p0_zaKBa6uuYCcb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0495">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processa
Pharmaceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Condensed Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000498" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock"><p id="xdx_805_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zC9BccssvBck" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_828_zY8J4EdS8KXh">Organization and Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000500" name="PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock"><p id="xdx_84B_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zyfLjrkM3c7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_862_z78cgDHQuO7a">Organization</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our
Next Generation Chemotherapy (&#8220;NGC&#8221;) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of
existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution <span style="background-color: white">in
the body, </span> while maintaining the well-established existing mechanisms of killing the cancer cells. By modifying the
NGC drugs in this manner, we believe our three NGC treatments will provide improved safety-efficacy profiles when compared to their
currently marketed counterparts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
January 22, 2024, we filed a Certificate of Amendment to our Certificate of Incorporation, as amended with the Secretary of State of
Delaware that effected a <span id="xdx_90C_eus-gaap--StockholdersEquityReverseStockSplit_c20240122__20240122_za2FbPhXsRXg" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-01-222024-01-22" id="Fact000502" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-20 reverse stock split</ix:nonNumeric></span> of our common stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240122_zkV5uoCqAZCk" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-01-22" id="Fact000504" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share (the &#8220;Reverse Stock Split&#8221;).
Pursuant to the Certificate of Amendment, our issued common stock decreased from <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20240121_zjmf2a7KyrS7" title="Common stock shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-01-21" id="Fact000506" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,706,474</ix:nonFraction></span> shares to <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20240122_zo6r78uDu8fg" title="Common stock shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-01-22" id="Fact000508" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,291,000</ix:nonFraction></span> shares and our outstanding
common stock decreased from <span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20240121_zTsbrlIIgSn9" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-01-21" id="Fact000510" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,606,474</ix:nonFraction></span> to <span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20240122_z9Bz4KX7Q8h8" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-01-22" id="Fact000512" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,286,000</ix:nonFraction></span>. The Reverse Stock Split did not affect our authorized common stock of <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20240122_znUn2BYxk9rd" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-01-22" id="Fact000514" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></span>
shares or our common stock par value. All shares of common stock, including common stock underlying warrants, stock options, restricted
stock awards and restricted stock units, as well as exercise prices and per share information in these condensed consolidated financial
statements give retroactive effect to the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000516" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zR3GMsZmAJcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_867_zvtxdjVgydQ9">Basis
of Presentation</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#8220;SEC&#8221;) on Form 10-Q and Article 8 of Regulation S-X.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2023, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000518" name="PCSA:LiquidityPolicyTextBlock"><p id="xdx_84C_ecustom--LiquidityPolicyTextBlock_zE8ajnErawKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_86F_zTTjxihF8auj">Liquidity</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations,
realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses
since inception, are currently devoting substantially all of our efforts toward research and development of our NGC drug product candidates,
including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated deficit
of $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20240630_zzGuRW9nIYDi" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-06-30" id="Fact000520" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">81.1</ix:nonFraction></span> <span style="background-color: white">million
at June 30, 2024. During the six months ended June 30, 2024, we generated a net loss of $</span><span id="xdx_900_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20240630_z72a2i4fTzJh" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-06-30" id="Fact000522" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">5.7</ix:nonFraction></span> <span style="background-color: white">million
and used $</span><span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20240630_zboCTV9vcQec" title="Net cash for operating activities from continuing operations"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-06-30" id="Fact000524" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">5.4</ix:nonFraction></span> <span style="background-color: white">million in net cash for operating activities from continuing operations. To
date, none of our drug candidates have been approved for sale, and therefore we have not generated any product revenue and do not expect
positive cash flow from operations in the foreseeable future.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
have financed our operations primarily through public equity issuances, including an offering we closed on January 30, 2024, where we
sold <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240129__20240130__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zSIMiDrKloLl" title="Number of shares sold"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-292024-01-30_custom_PurchaseAgreementMember" id="Fact000526" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">476,000</ix:nonFraction></span> shares of our common stock, pre-funded warrants to purchase up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240130__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zp63FOwfMDka" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember" id="Fact000528" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,079,555</ix:nonFraction></span> shares of our common stock, and warrants for
the purchase of up to <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zI0kQsZWFyeb" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-01-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember" id="Fact000530" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,555,555</ix:nonFraction></span> shares of our common stock for net proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240129__20240130_zFKr4ofUj8vj" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-292024-01-30" id="Fact000532" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.3</ix:nonFraction></span> million, after deducting placement agent fees and
offering-related expenses. Simultaneously with the closing of the sale, the pre-funded warrants were exercised in exchange for <span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesWarrantExercised_iI_c20240130__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zgekzZOaWhT5" title="Warrant exercised"><ix:nonFraction name="PCSA:StockIssuedDuringPeriodSharesWarrantExercised" contextRef="AsOf2024-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember" id="Fact000534" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,079,555</ix:nonFraction></span>
shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the &#8220;Registration
Statement&#8221;), including a base prospectus relating to the offering of up to $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240531__20240531_zFND77df1Ys" title="Shares issued initial offering"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-05-312024-05-31" id="Fact000536" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span>
in the aggregate of the securities identified in the base prospectus from time to time in one or more offerings; and a prospectus
supplement relating to the shares of our common stock that may be issued and sold under a sales agreement dated May 21, 2024 (the
&#8220;Sales Agreement&#8221;) between us and A.G.P./Alliance Global Partners (the &#8220;Sales Agent&#8221;), through which we may issue and
sell in a registered &#8220;at the market offering&#8221; shares of our common stock having an aggregate offering price of up to
$<span id="xdx_901_ecustom--MaximumValueToBeSoldAtMarketOffering_pn5n6_c20240521__20240521__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_z5Vkxhd3mvQ9" title="Maximum value to be sold at the market offering"><ix:nonFraction name="PCSA:MaximumValueToBeSoldAtMarketOffering" contextRef="From2024-05-212024-05-21_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember_srt_MaximumMember_custom_ATMOfferingMember" id="Fact000538" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.4</ix:nonFraction></span>
million (subject to adjustment) from time to time through or to our Sales Agent (the &#8220;ATM Offering&#8221;). We expect to use
net proceeds, if any, from the ATM Offering over time for continued research and development for our portfolio of drug candidates,
especially our oncology products, and working capital and general corporate purposes. The shares under the ATM Offering will be sold
and issued pursuant to the Registration Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At
June 30, 2024, we had cash and cash equivalents totaling $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20240630_zJIiwe4qLibf" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30" id="Fact000540" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.6</ix:nonFraction></span> <span style="background-color: white">million
which, based on our current business plans, we believe these funds will satisfy our <span style="background-color: white">operating </span>
needs into late 2024, including the beginning of our Phase 2 trial of NGC-Cap in breast cancer. Our ability to execute our
longer-term operating plans, including future preclinical studies and clinical trials for our portfolio of drugs depend on our
ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding
transactions. <span style="background-color: white">We will continue to be dependent
upon equity and/or debt financing until we are able to generate positive cash flows from our operations.</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations,
strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable
to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or
planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in
certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and
distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms
that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of
our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no
assurance that future funding will be available when needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Absent
additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year
or more after the date that these condensed consolidated financial statements are available to be issued based on the timing and amount
of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result,
substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated
financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments
to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification
of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties
described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000542" name="us-gaap:UseOfEstimates"><p id="xdx_843_eus-gaap--UseOfEstimates_z7yg1qGZqK86" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_866_zd4N8dnQYBKb">Use
of Estimates</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules
and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial
statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation,
intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based
on management&#8217;s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable,
actual results could differ materially from those estimates and could impact future results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000544" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_z26Z9yKmjEZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes in accordance with ASC Topic 740, <i>Income Taxes.</i> Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. At June 30, 2024 and December 31, 2023, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed
quarterly and will be maintained until sufficient positive evidence exists to support its reversal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ACS 740-270 <i>Income Taxes &#8211; Interim Reporting</i>, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income
tax benefit or expense is expected for 2024 and the foreseeable future since we expect to generate taxable net operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000546" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_znppZHOwLNJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_86F_zG0UOiRw0515">Concentration
of Credit Risk</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to specified limits. Total cash held by our banks at June 30, 2024, exceeded FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000548" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zv3o7GlGuGDh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_868_z94UFS2MqFub">Recent
Accounting Pronouncements</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#8220;ASU&#8221;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated
financial position or results of operations.</span></p>
</ix:nonNumeric><p id="xdx_859_zqsonrUdij86" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000550" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zz3S3hiE05e5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_82F_zsy1TSs2PCXb">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Preferred
Stock</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20240630_zKu9Q36csaC6" title="Preferred stock, shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20240630_z35p5wi2lwAb" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20231231_z8cAHOoGVlCc" title="Preferred stock, shares issued"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zVeeR41zrJ3" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-06-30" id="Fact000552" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-06-30" id="Fact000554" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000556" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000558" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued or outstanding shares of preferred stock at either June 30, 2024 or December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Common
Stock</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2024, we <span style="background-color: white">sold <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zkha9YZSlre8"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-06-30_custom_PurchaseAgreementMember" id="Fact000559" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">476,000</ix:nonFraction>
</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of common
stock, pre-funded warrants to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zUwdeAAXjcG7"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-06-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember" id="Fact000560" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,079,555</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of common stock
in lieu of shares of common stock (the &#8220;Pre-Funded Warrants&#8221;), and warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zT9NjvAGk7E3"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-06-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember" id="Fact000561" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,555,555</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of our common
stock (the &#8220;Common Warrants&#8217;) in a public offering (the &#8220;Offering&#8221;). The Common Warrants have an exercise price
of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zGAfxiBLtA3j"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember" id="Fact000562" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.50</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">,
are immediately exercisable and expire on <span id="xdx_907_ecustom--WarrantsExercisableAndMaturityDate_dd_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1mNc6nDyCMd"><ix:nonNumeric contextRef="From2024-01-012024-06-30_custom_PurchaseAgreementMember_us-gaap_WarrantMember" format="ixt:datemonthdayyearen" id="Fact000563" name="PCSA:WarrantsExercisableAndMaturityDate">January
30, 2029</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">. The shares
of common stock  were offered at a combined public offering price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zrVkegQ0cBkb"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember" id="Fact000564" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.50</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">per share and accompanying
Common Warrant and $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjCYfXWgibZa"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-06-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember" id="Fact000565" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.4999</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">per Pre-Funded Warrant
and accompanying Common Warrant. The Pre-Funded Warrants had an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zNeYa1yQT3ei"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember" id="Fact000566" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">and were exercised in
full simultaneously with the closing of the Offering in exchange for <span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesWarrantExercised_iI_c20240630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zMukDIr1ri5g"><ix:nonFraction name="PCSA:StockIssuedDuringPeriodSharesWarrantExercised" contextRef="AsOf2024-06-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember" id="Fact000567" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,079,555</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of our common
stock. Gross proceeds in connection with the Offering were $<span id="xdx_909_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zQVMoaFdYYja"><ix:nonFraction name="PCSA:GrossProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-06-30_custom_PurchaseAgreementMember" id="Fact000568" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">million. We received
$<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zwPWQbhcssO1"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-06-30_custom_PurchaseAgreementMember" id="Fact000569" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.3</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">million in net proceeds
from the Offering, after deducting the fees of the placement agent and other offering-related expenses. We also issued to the placement
agent warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_zkjvuzYTZUfb"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-06-30_custom_PurchaseAgreementMember_custom_PlacementAgentMember" id="Fact000570" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,222</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of common stock,
exercisable at $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_zKSfv9c1mPm7"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-30_custom_PurchaseAgreementMember_custom_PlacementAgentMember" id="Fact000571" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.625</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">per share that expire
on <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_z2WpMlnEtEQ"><ix:nonNumeric contextRef="AsOf2024-06-30_custom_PurchaseAgreementMember_custom_PlacementAgentMember" format="ixt:datemonthdayyearen" id="Fact000572" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">February
1, 2027</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2024, we also issued: <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElionOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zG2Bi5hn3Ybi" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-06-30_custom_ElionOncologyIncMember_custom_LicenseAgreementMember" id="Fact000574" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span> shares of common stock to Elion Oncology, Inc. (&#8220;Elion&#8221;) in satisfaction
of the third milestone event under the license agreement; <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z3KL7gTXZBf6" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-06-30_custom_ConsultantMember_custom_ConsultingAgreementMember" id="Fact000576" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares of common stock to a consultant in accordance with their consulting
agreement; and <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesAndConsultantsMember_za80P7C6W111" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-06-30_custom_EmployeesAndConsultantsMember" id="Fact000578" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,328</ix:nonFraction></span> shares of common stock to certain employees and consultants, net of <span id="xdx_90D_ecustom--StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes_c20240101__20240630_zuGeAqqSf13f" title="Stock withheld for income taxes"><ix:nonFraction name="PCSA:StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" contextRef="From2024-01-01to2024-06-30" id="Fact000580" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,015</ix:nonFraction></span> shares of common stock withheld for income
taxes owed upon distribution of the shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000582" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zms0jgFIyhM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Note
3 - <span id="xdx_82D_zeCe8xOvK7H4">Stock-based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
June 19, 2019, our stockholders approved, and we adopted, the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the &#8220;2019
Plan&#8221;). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock
options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and
directors. On June 28, 2024, our shareholders approved an increase of shares available under the 2019 Plan, which now provides for the
aggregate issuance of <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20240628__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_z8Rd0nh27KK5" title="Maximum equity available for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-06-28_custom_TwoThousandAndNineteenPlanMember" id="Fact000584" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800,000</ix:nonFraction></span> shares of our common stock. At June 30, 2024, we have </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20240630__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zJrpxcN9xI34" title="Shares available for future grants"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-06-30_custom_TwoThousandAndNineteenPlanMember" id="Fact000586" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">503,129</ix:nonFraction></span>
<span style="background-color: white">shares available for future grants.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Stock
Compensation Expense</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000588" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z6SzgmbGSO5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
recorded stock-based compensation expense for the three and six months ended June 30, 2024 and 2023 as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zodWD40luq2a" style="display: none">Schedule
of Stock-based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240401__20240630_z5FodJsigOll" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230401__20230630_zsR6fnL7T3Y6" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20240630_zCaIDiOiyqIl" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20230630_z2reTkBdvR18" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zBl0WgR2HB58" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000590" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,583</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-04-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000591" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,678</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000592" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,704</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000593" format="ixt:numdotdecimal" decimals="0" unitRef="USD">209,526</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zvjIzpXWeR6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000595" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,049</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-04-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000596" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,445</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,571</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000598" format="ixt:numdotdecimal" decimals="0" unitRef="USD">451,101</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensation_zIAzCfb6GuPk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-012024-06-30" id="Fact000600" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,632</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-04-012023-06-30" id="Fact000601" format="ixt:numdotdecimal" decimals="0" unitRef="USD">319,123</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-06-30" id="Fact000602" format="ixt:numdotdecimal" decimals="0" unitRef="USD">320,275</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-06-30" id="Fact000603" format="ixt:numdotdecimal" decimals="0" unitRef="USD">660,627</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zVU3URQcY35j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Stock
Options</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock
options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwlLKXKdUA1a" title="Options, forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember" id="Fact000605" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,245</ix:nonFraction></span>
shares of common stock with a weighted-average exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zc3eL8S5aKIb" title="Options, forfeited weighted average exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember" id="Fact000607" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">336.00</ix:nonFraction></span> expired during the six months ended June 30, 2024. At June
30, 2024, we had outstanding and exercisable options for the purchase of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUxcBfA1yEG6" title="Options exercisable, shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember" id="Fact000609" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,747</ix:nonFraction></span>
shares with a weighted average exercise price of $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjJ9FQ6wukZg" title="Options exercisable weighted average exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember" id="Fact000611" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">409.09</ix:nonFraction></span> <span style="background-color: white">and
a weighted average remaining contractual life of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAU3zGfUwJm1" title="Exercisable weighted average remaining contractual term"><ix:nonNumeric contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact000613" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.2</ix:nonNumeric></span>
years. </span>At June 30, 2024, we did not have any unrecognized stock-based compensation expense related to our granted stock
options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Restricted
Stock Awards</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the six months ended June 30, 2024, we vested <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zt8aKX836yGf" title="Number of shares, vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockMember" id="Fact000615" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250</ix:nonFraction></span> Restricted Stock Awards (&#8220;RSAs&#8221;) with a weighted average grant-date fair
value of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zE655AtLV3S7" title="Weighted-average grant-date fair value per share, shares vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockMember" id="Fact000617" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.26</ix:nonFraction></span> per share. We had <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iI_do_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z03ctXbxoPph" title="Number of shares, outstanding"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" contextRef="AsOf2024-06-30_us-gaap_RestrictedStockMember" id="Fact000619" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> RSAs outstanding at June 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Restricted
Stock Units</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000621" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zwID5zmhYv8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Activity
with respect to our Restricted Stock Units (&#8220;RSUs&#8221;) during the six months ended June 30, 2024 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zoYyqIbs2L9d" style="display: none">Schedule
of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of <br/> shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- average <br/> grant-date fair <br/> value per share</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Outstanding at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLWDn2xUoC53" title="Number of shares, Beginning balance" style="width: 18%; text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000623" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">222,722</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8V9qKOT7fs" title="Weighted-average grant-date fair value per share, Beginning balance" style="width: 18%; text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000625" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">45.82</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z68O3XAcTBg3" title="Number of shares, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000627" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,202</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEqZAKfUHhLe" title="Weighted-average grant-date fair value per share, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000629" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.24</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znkTJGQ0iJvl" title="Number of shares, forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000631" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,775</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1Fq3XF0HLJ2" title="Weighted-average grant-date fair value per share, forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000633" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">58.37</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Issued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHFURFCsr4Vj" title="Number of shares, issued" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000635" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,328</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPvQk5Fa07xi" title="Weighted-average grant-date fair value per share, shares issued" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000637" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">99.86</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at June 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxd6fRrteoG3" title="Number of shares, ending balance" style="text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000639" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">238,821</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5X8i7ksTIU6" title="Weighted-average grant-date fair value per share, ending balance" style="text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000641" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">35.31</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Vested and unissued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzHjLHBIqhZ2" title="Number of shares, vested and unissued" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000643" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">143,793</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuOc9MwdxRf4" title="Weighted-average grant-date fair value per share, vested and unissued" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000645" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">50.71</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Unvested at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znuJ5Df36qY5" title="Number of shares, unvested" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000647" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,028</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zauZjCGzc6Y8" title="Weighted-average grant-date fair value per share, unvested" style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000649" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zIX1G5IxUuw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
June 28, 2024, we granted RSUs for the future issuance of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240628__20240628__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zm6da1XEUb8l" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-06-282024-06-28_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember" id="Fact000651" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,202</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of common stock
to our employees which vest accordingly: RSUs for the future issuance of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240628__20240628__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockUnitsMember__us-gaap--VestingAxis__custom--JanuaryOneTwoThousandTwentyFiveVestingMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zakKaOLh1Cci" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-06-282024-06-28_custom_ServiceBasedRestrictedStockUnitsMember_custom_JanuaryOneTwoThousandTwentyFiveVestingMember_custom_EmployeesMember" id="Fact000653" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,969</ix:nonFraction></span> shares of common stock vest on January 1, 2025; RSUs
for the future issuance of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240628__20240628__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockUnitsMember__custom--TitleOfInidividualAxis__custom--EmployeesMember__us-gaap--VestingAxis__custom--ThreeYearVestingMember_zvziE1YPMMM5" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-06-282024-06-28_custom_ServiceBasedRestrictedStockUnitsMember_custom_EmployeesMember_custom_ThreeYearVestingMember" id="Fact000655" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,173</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of common stock
vest over a three-year period upon meeting service requirements; RSUs for the future issuance of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240628__20240628__us-gaap--AwardTypeAxis__custom--FirstPerformanceBasedRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zBsoWhg7uTla" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-06-282024-06-28_custom_FirstPerformanceBasedRSUMember_custom_EmployeesMember" id="Fact000657" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,030</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of common stock
vested upon grant due to regaining Nasdaq compliance; and RSUs for the future issuance of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240628__20240628__us-gaap--AwardTypeAxis__custom--SecondPerformanceBasedRSUMember__us-gaap--TypeOfArrangementAxis__custom--NextGenerationCapecitabineCAPMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zmAcGmjXrZ92" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-06-282024-06-28_custom_SecondPerformanceBasedRSUMember_custom_NextGenerationCapecitabineCAPMember_custom_EmployeesMember" id="Fact000659" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,030</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of common stock
vest upon dosing the first patient in our Phase 2 study in NGC-Cap.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2024, unrecognized stock-based compensation expense of approximately</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zq1wg6oHSroi" title="Unrecognized share based compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000661" format="ixt:numdotdecimal" decimals="0" unitRef="USD">538,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
RSUs is expected to be fully recognized over a weighted average period of <span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9vxgPMIXg79" title="Weighted average period for recognition"><ix:nonNumeric contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact000663" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.7</ix:nonNumeric> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.
The unrecognized expense excludes approximately $<span id="xdx_90E_ecustom--UnrecognizedShareBasedCompensationExpense_pp0p0_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zX2oq6C2lLcd"><ix:nonFraction name="PCSA:UnrecognizedShareBasedCompensationExpense" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000664" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">420,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
expense related to certain grants of RSUs with performance milestones that are not probable of occurring at this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Holders
of our vested RSUs will be issued shares of our common stock upon meeting the distribution restrictions contained in their Restricted
Stock Unit Award Agreement. The distribution restrictions are different (longer) than the vesting schedule, imposing an additional restriction
on the holder. Unlike RSAs, while certain employees may hold fully vested RSUs, the individual does not hold any shares or have any rights
of a shareholder until the distribution restrictions are met. Upon distribution to the employee, each RSU converts into one share of
our common stock. The RSUs contain dividend equivalent rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Warrants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the six months ended June 30, 2024, we did not grant any warrants to purchase shares of our common stock other than warrants to purchase
<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__custom--OfferingMember_zBM1K8LH4wZi" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-06-30_us-gaap_WarrantMember_custom_OfferingMember" id="Fact000666" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,617,777</ix:nonFraction></span> shares of common stock as part of <span style="background-color: white">the O</span>ffering (see Note 2). Warrants to purchase <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zi6uDxFzZ0s8" title="Warrants, expired"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2024-01-012024-06-30_custom_ConsultingAgreementMember" id="Fact000668" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span> shares of our common stock expired
unexercised. We also repurchased a warrant issued to a consultant in 2023 for the purchase of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zAV73yMN6jbl" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2024-01-012024-06-30_custom_ConsultingAgreementMember" id="Fact000670" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000</ix:nonFraction></span> shares of our common stock in exchange
for a payment of $<span id="xdx_906_ecustom--PaymentsForSettlementOfStockAwards_pid_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zLS1FCLyAlZ"><ix:nonFraction name="PCSA:PaymentsForSettlementOfStockAwards" contextRef="From2024-01-012024-06-30_custom_ConsultingAgreementMember" id="Fact000671" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">10,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2024, we had outstanding stock purchase warrants for the purchase of an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeqtYNLZv1Xi" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-06-30_us-gaap_WarrantMember" id="Fact000673" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,778,284</ix:nonFraction></span> <span style="background-color: white">shares
with a weighted average exercise price of $</span><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zim5V1rkjTme" title="Weighted average exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-30_us-gaap_WarrantMember" id="Fact000675" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.17</ix:nonFraction></span> <span style="background-color: white">and
a weighted average remaining contractual life of </span><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zH0gAth99mgj" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact000677" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.3</ix:nonNumeric></span> <span style="background-color: white">years.
All the outstanding stock purchase warrants are exercisable a<span style="background-color: white">s of</span> June 30, 2024. W</span>e did not have any unrecognized stock-based
compensation expense related to our granted stock purchase warrants at June 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000679" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zEFPoujgZDxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_824_zrVP9MjRHqU6">Net Loss per Share of Common Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Net
Loss Per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of
common stock outstanding (which excludes unvested RSAs and includes vested RSUs) during the period. Diluted loss per share is computed
by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock (which includes
the potentially dilutive effect of stock options, unvested RSAs, unvested RSUs and warrants) during the period. Since we experienced
a net loss for all periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three
and six months ended June 30, 2024 and 2023 excludes the impact of potentially dilutive common shares since those shares would have an
anti-dilutive effect on net loss per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000681" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zkFILclMsVr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of net loss per share for the three and six months ended June 30, 2024 and 2023 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zqvf5jbfVNZa" style="display: none">Schedule
of Net Loss Per Share Basic and Diluted</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240401__20240630_zP8owTHBVmj8" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230401__20230630_z5cY1XLgubb8" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20240630_zBucptvGIphl" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20230630_zObYOSOsneM4" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Basic and diluted net loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zt8WbifFm9T" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left">Net loss available to common stockholders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-04-012024-06-30" id="Fact000683" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,010,326</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-04-012023-06-30" id="Fact000684" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,612,565</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-06-30" id="Fact000685" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,736,707</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-06-30" id="Fact000686" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,634,638</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Weighted average number of common shares-basic and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_z9v3dlpQWYzl" title="Weighted average number of common shares-basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zXb6BIWGMsDd" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-04-012024-06-30" id="Fact000688" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-012024-06-30" id="Fact000690" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,983,283</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zYy14PKK31jg" title="Weighted average number of common shares-basic"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zOHJT9CrF9b5" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-04-012023-06-30" id="Fact000692" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-04-012023-06-30" id="Fact000694" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,346,808</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_z2sKeE36uWV" title="Weighted average number of common shares-basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zSKt3sgBDLF2" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-06-30" id="Fact000696" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-06-30" id="Fact000698" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,724,903</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630_zlD7e4ngIuQ4" title="Weighted average number of common shares-basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630_zNsGglfYFfxa" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-06-30" id="Fact000700" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-06-30" id="Fact000702" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,243,475</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20240401__20240630_zwm9qXzfco14" title="Basic net loss per share"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20240401__20240630_z2dhQAi6zQ2b" title="Diluted net loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-04-012024-06-30" id="Fact000704" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-04-012024-06-30" id="Fact000706" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.01</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20230401__20230630_zB9SWxSk5Wge" title="Basic net loss per share"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20230401__20230630_zl03lsAGZXyg" title="Diluted net loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-04-012023-06-30" id="Fact000708" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-04-012023-06-30" id="Fact000710" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.94</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20240101__20240630_zXlGLtMa4p6i" title="Basic net loss per share"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20240101__20240630_zUZUzeJGuXi7" title="Diluted net loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-06-30" id="Fact000712" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-06-30" id="Fact000714" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.11</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20230101__20230630_zKHej9fZceq9" title="Basic net loss per share"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_c20230101__20230630_z5VmYUNuhSg4" title="Diluted net loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-06-30" id="Fact000716" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-06-30" id="Fact000718" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">5.34</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Weighted-average number of common shares outstanding &#8211; basic and diluted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPkYVMlhxqnf" title="Weighted average number of common shares outstanding - basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCdXLDT2t6zb" title="Weighted average number of common shares outstanding - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000720" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000722" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,849,192</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH2smbzqAysa" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl0oSEXGhtt1" title="Weighted average number of common shares outstanding - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="Fact000724" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="Fact000726" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,217,095</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zki6Ilpn51U" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuOkib98Cld3" title="Weighted average number of common shares outstanding - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="Fact000728" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember" id="Fact000730" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,590,530</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zclzYqSqBGd" title="Weighted average number of common shares outstanding - basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9NxXBzEUgl1" title="Weighted average number of common shares outstanding - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember" id="Fact000732" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember" id="Fact000734" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,114,324</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Weighted-average number of vested RSUs&#8211; basic and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zT2rbSOClc5l" title="Weighted average number of vested RSUs - basic"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zy0htHyCVelk" title="Weighted average number of vested RSUs - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000736" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000738" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">134,091</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdBL7WZIk4bj" title="Weighted average number of vested RSUs - basic"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zDGzLfax9I5j" title="Weighted average number of vested RSUs - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000740" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000742" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">129,713</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zmMmgFOVaYi5" title="Weighted average number of vested RSUs - basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zNFrnqLMvaoe" title="Weighted average number of vested RSUs - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember790435859" id="Fact000744" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember790435859" id="Fact000746" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">134,373</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zlHMO9EIDOci" title="Weighted average number of vested RSUs - basic"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_znxi54O59K7l" title="Weighted average number of vested RSUs - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000748" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000750" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">129,151</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average number of common shares-basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_z5x6L5xl4S72" title="Weighted average number of common shares-basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zBA7SJjmhjF8" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-04-012024-06-30" id="Fact000752" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-012024-06-30" id="Fact000754" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,983,283</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zmhE5QPBDIk5" title="Weighted average number of common shares-basic"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zN9GRulGpkLk" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-04-012023-06-30" id="Fact000756" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-04-012023-06-30" id="Fact000758" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,346,808</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zlD8oHQuRrA2" title="Weighted average number of common shares-basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zZUBvM95APPk" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-06-30" id="Fact000760" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-06-30" id="Fact000762" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,724,903</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630_zh8fKkkGk4Db" title="Weighted average number of common shares-basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630_zfJ50RENF3ue" title="Weighted average number of common shares-diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-06-30" id="Fact000764" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-06-30" id="Fact000766" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,243,475</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zl1iEEpC5EPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
diluted net loss per share for the three and six months ended June 30, 2024 and 2023 excluded <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240401__20240630_zlmdipiWLrb7" title="Antidilutive securities excluded from computation of earnings per share, amount"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_zLu1b7SxZftk" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-04-012024-06-30" id="Fact000768" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-06-30" id="Fact000770" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,876,059</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230401__20230630_z26FHDZuLa43" title="Antidilutive securities excluded from computation of earnings per share, amount"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630_ziPOp3dRfio4" title="Antidilutive securities excluded from computation of earnings per share, amount"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-04-012023-06-30" id="Fact000772" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30" id="Fact000774" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">254,314</ix:nonFraction></ix:nonFraction></span></span> of potentially dilutive
common shares, respectively, related to outstanding stock options, warrants and unvested restricted stock since those shares would have
had an anti-dilutive effect on net loss per share during the periods then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000776" name="PCSA:LesseeOperatingAndFinancingLeasesTextBlock"><p id="xdx_802_ecustom--LesseeOperatingAndFinancingLeasesTextBlock_zwpuyOG7tGp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_825_zb6aBuOjQPO5">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold
improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space
lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area
or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group
lease and non-lease components for all leases. We also lease office equipment under a financing lease. Our leases do not provide an implicit
rate and, as such, we have used our incremental borrowing rate of <span id="xdx_906_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_dp_uPure_c20240630_zP17aI9bR8c5" title="Operating and financing lease borrowing rate"><ix:nonFraction name="PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate" contextRef="AsOf2024-06-30" id="Fact000778" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% in determining the present value of the lease payments based on
the information available at the lease commencement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
costs included in our condensed consolidated statements of operations totaled approximately $<span id="xdx_90F_eus-gaap--LeaseCost_c20240401__20240630_zIxYHfMOvk6c" title="Lease cost"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-04-012024-06-30" id="Fact000780" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,000</ix:nonFraction></span>
and $<span id="xdx_901_eus-gaap--LeaseCost_c20230401__20230630_zqXTqwnSLatd" title="Lease cost"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-04-012023-06-30" id="Fact000782" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,000</ix:nonFraction></span> for the three months
ending June 30, 2024 and 2023, respectively, and approximately $<span id="xdx_906_eus-gaap--LeaseCost_c20240101__20240630_zEJyarALW003" title="Lease cost"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-01-01to2024-06-30" id="Fact000784" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,000</ix:nonFraction></span>
and $<span id="xdx_90B_eus-gaap--LeaseCost_c20230101__20230630_zEMithrlV3Xk" title="Lease cost"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-012023-06-30" id="Fact000786" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,000</ix:nonFraction></span> for the six months
ended June 30, 2024, and 2023, respectively. The weighted average remaining lease terms and discount rate for our leases were as
follows at June 30, 2024:</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000788" name="PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock"><p id="xdx_89F_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_zlIAHMkiNVyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zJXetrGWQNSb" style="display: none">Schedule
of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Remaining lease term (years) for our facility lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_902_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zsE3gSqrrD7f" title="Remaining lease term (years)"><ix:nonNumeric contextRef="AsOf2024-06-30_custom_FacilityLeaseMember" format="ixt-sec:duryear" id="Fact000790" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">1.3</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Remaining lease term (years) for our equipment lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zlpOrSizfwYf" title="Remaining lease term (years)"><ix:nonNumeric contextRef="AsOf2024-06-30_us-gaap_EquipmentMember" format="ixt-sec:duryear" id="Fact000792" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm">1.6</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted average discount rate for our facility and equipment leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_dp_uPure_c20240630_zp8o4ogNbs78" title="Weighted average discount rate for our facility and equipment leases"><ix:nonFraction name="PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate" contextRef="AsOf2024-06-30" id="Fact000794" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zWHRJPxg1Fxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000796" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zmFnS3zaci7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for the operating lease were as follows at June 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_z0GFpJajvCc1" style="display: none">Schedule
of Annual Lease Liabilities for all Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20240630_zOfJqtZzaSa1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz79B_z7WbgiuYwWPl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2024-06-30" id="Fact000798" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,797</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz79B_z4bu3Xg49RW9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-06-30" id="Fact000800" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">70,040</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zrSGkdOoYUI2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-06-30" id="Fact000802" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">115,837</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z7JfSWxiOHb5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Less: Interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-06-30" id="Fact000804" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,511</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zXUSwYSh8KY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Present value of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-06-30" id="Fact000806" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">109,326</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zuPo9CgM2bod" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Less: current maturities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-06-30" id="Fact000808" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">87,495</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zF42E3liV1S8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Non-current lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-06-30" id="Fact000810" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,831</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zzo6Rc1dMTl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000812" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89B_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zDnbI74HEoeg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for the financing lease were as follows at June 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zaGGHYTjTJdd" style="display: none">Schedule
of Annual Lease Liabilities for all Financing Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20240630_z6IFVCe0dUqj" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maFLLPDzELQ_zPTfoJuZWHr2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2024-06-30" id="Fact000814" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,232</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzELQ_zTnDbSvB7Hja" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-06-30" id="Fact000816" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,820</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzELQ_zezGMYX0VVQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-06-30" id="Fact000818" format="ixt:numdotdecimal" decimals="0" unitRef="USD">488</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzELQ_zr3wUPaJRYUg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="AsOf2024-06-30" id="Fact000820" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,540</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_z7r2g348drsk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Less: Interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-06-30" id="Fact000822" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,037</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseLiability_iI_z2psB3EStoOg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Present value of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2024-06-30" id="Fact000824" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,503</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zyE5MHpwFoy9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Less: current maturities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2024-06-30" id="Fact000826" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,686</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zUd4KeUfBQtd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Non-current lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2024-06-30" id="Fact000828" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,817</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zJFvDio0s9O2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000830" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zbMS3YmX0Kb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_828_z9CCuyn5sdql">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CorLyst,
LLC (&#8220;CorLyst&#8221;) reimburses us for shared costs related to payroll, health insurance and rent based on actual costs
incurred, which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed
consolidated statement of operations. We recorded approximately $<span id="xdx_902_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20240401__20240630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zdy8jDkzlJHa" title="Rent and other costs reimbursements received"><ix:nonFraction name="PCSA:ProceedsFromRentAndOtherCostsReimbursements" contextRef="From2024-04-012024-06-30_custom_CorLystLLCMember" id="Fact000832" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,000</ix:nonFraction></span>
and $<span id="xdx_902_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20230401__20230630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zv25w51iFcbc" title="Rent and other costs reimbursements received"><ix:nonFraction name="PCSA:ProceedsFromRentAndOtherCostsReimbursements" contextRef="From2023-04-012023-06-30_custom_CorLystLLCMember" id="Fact000834" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,000</ix:nonFraction></span>
of reimbursements during the three months ended June 30, 2024 and 2023, respectively, and approximately $<span id="xdx_905_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20240101__20240630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zpHU3VZa5cWf" title="Rent and other costs reimbursements received"><ix:nonFraction name="PCSA:ProceedsFromRentAndOtherCostsReimbursements" contextRef="From2024-01-012024-06-30_custom_CorLystLLCMember" id="Fact000836" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>
and $<span id="xdx_907_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20230101__20230630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zD1i99G2WPdg" title="Rent and other costs reimbursements received"><ix:nonFraction name="PCSA:ProceedsFromRentAndOtherCostsReimbursements" contextRef="From2023-01-012023-06-30_custom_CorLystLLCMember" id="Fact000838" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,000</ix:nonFraction></span>
for the six months ended June 30, 2024 and 2023, respectively. <span id="xdx_90F_eus-gaap--OtherReceivablesNetCurrent_iI_do_c20240630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_z10eeCOtkkHk" title="Due from related parties"><span id="xdx_904_eus-gaap--OtherReceivablesNetCurrent_iI_do_c20230630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zMHDQveFNXC3" title="Due from related parties"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2024-06-30_custom_CorLystLLCMember" id="Fact000840" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2023-06-30_custom_CorLystLLCMember" id="Fact000842" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></ix:nonFraction></span></span>
amounts were due from CorLyst at June 30, 2024 or 2023. Our President of Research and Development is the CEO of CorLyst, and CorLyst
is a shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000844" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zxGRq6dw7n1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_828_zs8Av13J088b">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Purchase
Obligations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into contracts in the normal course of business with contract research organizations (&#8220;CROs&#8221;) and subcontractors to further develop
our products. The contracts are cancelable, with varying provisions regarding termination. If we terminated a cancelable contract with
a specific vendor, we would only be obligated for products or services that we received at the effective date of the termination and
any applicable cancellation fees. At June 30, 2024, we are contractually obligated to pay up to $<span id="xdx_904_eus-gaap--PurchaseObligation_iI_pn5n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CROsMember_zh994XQkjXc6" title="Purchase obligation"><ix:nonFraction name="us-gaap:PurchaseObligation" contextRef="AsOf2024-06-30_custom_CROsMember" id="Fact000846" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">14.3</ix:nonFraction></span> million of future services under
the agreements with the CROs. Our actual contractual obligations will also vary depending on the progress and results of the remaining
clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-06-30" escape="true" id="Fact000848" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zSmKLVqT6g55" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_820_zXqHW1wz9mJ7">Subsequent Event</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 16, 2024, Russell Skibsted was appointed as our Chief Financial Officer (&#8220;CFO&#8221;). Mr. Skibsted has nearly 30 years of experience
in the pharmaceutical industry, including expertise in financial management, global business development, capital markets, investor
relations and operations. In connection with his employment, Mr. Skibsted will be paid an annual base salary of $<span id="xdx_90C_eus-gaap--OfficersCompensation_c20240716__20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zs6fu2MQWvm3" title="Annual base salary"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-07-162024-07-16_us-gaap_SubsequentEventMember" id="Fact000850" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction></span>
and will be eligible for a $<span id="xdx_909_eus-gaap--SalariesWagesAndOfficersCompensation_c20240716__20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2V4DKVdZrNc" title="Potential base salary increase"><ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2024-07-162024-07-16_us-gaap_SubsequentEventMember" id="Fact000852" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>
base salary increase upon a cumulative (one or multiple) financing of at least $<span id="xdx_90B_ecustom--PotentialBaseSalaryIncreaseFinancingMinimum_iI_pn6n6_c20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zORuhclSycN9" title="Potential base salary increase financing minimum"><ix:nonFraction name="PCSA:PotentialBaseSalaryIncreaseFinancingMinimum" contextRef="AsOf2024-07-16_us-gaap_SubsequentEventMember" id="Fact000854" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">15</ix:nonFraction></span>
million that he leads and substantially participates in. He is also eligible to participate in an executive bonus pool with a target
bonus of <span id="xdx_905_ecustom--CompensationArrangementWithIndividualBonusAwardsGrantedPercentage_dp_uPure_c20240716__20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zB0WtdzoX743" title="Executive bonus percentage"><ix:nonFraction name="PCSA:CompensationArrangementWithIndividualBonusAwardsGrantedPercentage" contextRef="From2024-07-162024-07-16_us-gaap_SubsequentEventMember" id="Fact000856" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35</ix:nonFraction></span>%
of his base compensation. In addition, the Compensation Committee awarded <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240716__20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4WCxhBVH4B3" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-07-162024-07-16_us-gaap_SubsequentEventMember_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000858" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,000</ix:nonFraction></span>
RSUs to Mr. Skibsted, which vest accordingly: <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240716__20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ServiceBasedRSUMember_zY7aLAUt8C62" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-07-162024-07-16_us-gaap_SubsequentEventMember_custom_ServiceBasedRSUMember" id="Fact000860" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,000</ix:nonFraction></span>
RSUs vest on July 16, 2025; <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240716__20240716__us-gaap--AwardTypeAxis__custom--FirstPerformanceBasedRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zO8uMpxch4xc" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-07-162024-07-16_custom_FirstPerformanceBasedRSUMember_us-gaap_SubsequentEventMember" id="Fact000862" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,000</ix:nonFraction></span>
RSUs vest upon Processa reaching a market capitalization (i.e. total value of Processa&#8217;s outstanding shares of stock at the
then current market price) of at least $<span id="xdx_909_ecustom--MarketCapitalization_iI_pn6n6_c20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--FirstPerformanceBasedRSUMember_zA8muWS8EXog" title="Market capitalization"><ix:nonFraction name="PCSA:MarketCapitalization" contextRef="AsOf2024-07-16_us-gaap_SubsequentEventMember_custom_FirstPerformanceBasedRSUMember" id="Fact000864" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">30</ix:nonFraction></span>
million; and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240716__20240716__us-gaap--AwardTypeAxis__custom--SecondPerformanceBasedRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhIJ5j0lYLE4" title="Number of shares, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-07-162024-07-16_custom_SecondPerformanceBasedRSUMember_us-gaap_SubsequentEventMember" id="Fact000866" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,000</ix:nonFraction></span>
RSUs vest upon a cumulative (one or multiple) financing of at least $<span id="xdx_901_ecustom--PerformanceVestingCriteriaValue_iI_pn6n6_c20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--SecondPerformanceBasedRSUMember_zRBsZFSNLBsb" title="Performance vesting criteria"><ix:nonFraction name="PCSA:PerformanceVestingCriteriaValue" contextRef="AsOf2024-07-16_us-gaap_SubsequentEventMember_custom_SecondPerformanceBasedRSUMember" id="Fact000868" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">15</ix:nonFraction></span>
million that he leads and substantially participates in. He will also be eligible for other benefits as described in his employment
agreement.</span></p>

</ix:nonNumeric><p id="xdx_819_zeNjhs5N9bP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>Item
2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forward
Looking Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; that reflect, when made, the Company&#8217;s expectations
or beliefs concerning future events that involve risks and uncertainties. Forward-looking statements frequently are identified by the
words &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;project,&#8221;
&#8220;will be,&#8221; &#8220;will continue,&#8221; &#8220;will likely result,&#8221; or other similar words and phrases. Similarly,
statements herein that describe the Company&#8217;s objectives, plans or goals also are forward-looking statements. Actual results could
differ materially from those projected, implied or anticipated by the Company&#8217;s forward-looking statements. Some of the factors
that could cause actual results to differ include: our limited operating history, limited cash and history of losses; our ability to
achieve profitability; our ability to obtain adequate financing to fund our business operations in the future; our ability to secure
required FDA or other governmental approvals for our product candidates and the breadth of the indication sought; the impact of competitive
or alternative products, technologies and pricing; whether we are successful in developing and commercializing our technology, including
through licensing; the adequacy of protections afforded to us and/or our licensors by the anticipated patents that we own or license
and the cost to us of maintaining, enforcing and defending those patents; our and our licensors&#8217; ability to protect non-patented
intellectual property rights; our exposure to and ability to defend third-party claims and challenges to our and our licensors&#8217;
anticipated patents and other intellectual property rights; and our ability to continue as a going concern. For a discussion of these
and all other known risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements,
see &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, which is available
on the SEC&#8217;s website at www.sec.gov. All forward-looking statements are qualified in their entirety by this cautionary statement,
and the Company undertakes no obligation to revise or update this Quarterly Report on Form 10-Q to reflect events or circumstances after
the date hereof.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>For
purposes of this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, references to the &#8220;Company,&#8221;
&#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to the operations of Processa Pharmaceuticals, Inc. and its direct and
indirect subsidiaries for the periods described herein.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are a clinical-stage biopharmaceutical company focused on utilizing our Regulatory Science Approach, which includes the principles
associated with FDA&#8217;s Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation
Chemotherapy (&#8220;NGC&#8221;) oncology drug products. Our mission is to provide better treatment options than those that presently
exist by extending a patient&#8217;s survival and/or improving a patient&#8217;s quality of life. This is achieved by improving upon
FDA-approved, widely used oncology drugs or the cancer-killing metabolites of these drugs by altering how they are metabolized and/or
distributed in the body, including how they are distributed to the actual cancer cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Regulatory Science Approach was conceived in the early 1990s when the founders of Processa and other faculty at the University of Maryland
worked with the FDA to develop multiple FDA Guidance Documents</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Regulatory science is the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance
of all FDA-regulated products. Over the last 30 years, two of our founders, Dr. David Young and Dr. Sian Bigora, have expanded the original
regulatory science concept by adding focused pre-clinical and clinical studies to justify the benefit-risk assessment required for FDA
approval when designing the development programs of new drug products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
Regulatory Science Approach <span style="background-color: white">identifies </span> the scientific information that the FDA requires to determine whether the benefit outweighs the risk of
a drug in a specific population of patients and at a specific dosage regimen for a specific drug product. The studies are designed to
obtain the necessary scientific information to support the regulatory decision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently,
the FDA has taken steps to define some of the regulatory science required for the FDA approval of oncology products. Through the FDA&#8217;s
Project Optimus Oncology Initiative and the related Draft Guidance on determining the &#8220;optimal&#8221; dosage regimen for an oncology
drug, the FDA has chosen to make the development of oncology drugs more science-based than in the past. Since the principles of the FDA&#8217;s
Project Optimus and the related Draft Guidance have been used by our Regulatory Science Approach in a number of non-oncology drugs in
the past, our experience with the principles of Project Optimus differentiates us from other biotechnology companies by focusing us not
only on the clinical science, but also on the equally important regulatory process. We believe utilizing our Regulatory Science Approach
provides us with three distinct advantages:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
    efficiencies (e.g., the right trial design and trial readouts);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
    possibility of drug approval by the FDA or other regulatory authorities; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
    ability to evaluate the benefit-risk of a drug compared to existing therapy, which allows prescribers to provide better treatment
    options for each patient.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-size: 10pt">Our
strategic prioritization</span><span style="font-size: 8pt"> </span><span style="font-size: 10pt">is to advance our pipeline
of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities that change the metabolism, distribution
and/or elimination of already FDA-approved cancer drugs, or their active metabolites, while maintaining the drug&#8217;s proven mechanism
of action in killing cancer cells. We believe our NGC treatments will provide improved safety-efficacy profiles when compared to their
currently marketed counterparts &#8211; capecitabine, gemcitabine, and irinotecan.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Drug Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><img src="form10-q_001.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
pipeline currently consists of NGC-Cap, NGC-Gem and NGC-Iri (also identified as PCS6422, PCS3117 and PCS11T, respectively) and two non-oncology
drugs (PCS12852 and PCS499). The non-oncology drugs are not included in the pipeline chart above, as we are exploring our options for
those drugs, which may include out-licensing or partnership opportunities. A summary of each drug is provided below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Next
Generation Chemotherapy </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; text-indent: 0.25in; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
much of oncology drug development has searched for novel or different ways to treat cancer. Our approach is to take three current FDA-approved
cancer drugs, e.g. capecitabine, gemcitabine and irinotecan, and modify and improve how the human body metabolizes and/or distributes
these NGC treatments compared to their presently approved counterpart chemotherapy drugs while maintaining the cancer-killing mechanism
of action; thus, our reason for calling our drugs Next Generation Chemotherapy treatments. Part of the development includes
determining the optimal dosage regimen based on the dose-response relationship as described in the FDA&#8217;s Project Optimus Initiative
and Draft Optimal Dosage Regimen Oncology Guidance. To date, we have data that we believe suggests our NGC treatments are likely to have
a better safety-efficacy profile than the current widely used marketed counterpart drugs, not only potentially making the development
and approval process more efficient, but also clearly differentiating our NGC treatments from the existing treatment. We believe our
NGC treatments have the potential to extend the survival and/or quality of life for more patients diagnosed with cancer while decreasing
the number of patients who are required to dose-adjust or discontinue treatment because of side effects or lack of response.&#160;&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Next
Generation Chemotherapy Pipeline</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Next
    Generation Capecitabine (&#8220;NGC-Cap&#8221;) is a combination of PCS6422 and a lower dose of the FDA-approved cancer drug capecitabine. PCS6422
    is an orally administered irreversible inhibitor of the enzyme dihydropyrimidine dehydrogenase (&#8220;DPD&#8221;). DPD metabolizes 5-Fluorouracil
    (&#8220;5-FU&#8221;), the major metabolite of capecitabine and widely used itself as an intravenous chemotherapeutic agent in many types of cancer,
    to multiple metabolites classified as catabolites. These catabolites do not have any cancer-killing properties but frequently cause
    dose-limiting side effects that may require dose adjustments or discontinuation of therapy.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Capecitabine, as presently prescribed and FDA-approved, forms the cancer drug 5-FU which is then further metabolized to anabolites
    (which kill both cancer cells and normal duplicating cells) and catabolites (which cause side effects and have no cancer killing
    properties). When capecitabine is given in combination with PCS6422 in NGC-Cap, PCS6422 significantly changes the metabolism of
    5-FU, which results in a change in the distribution of 5-FU within the body. Due to this change in metabolism and the overall
    metabolite profile of anabolites and catabolites, the side effect and efficacy profile of NGC-Cap has been found to be different
    from capecitabine given without PCS6422. Since the potency of NGC-Cap is also greater than FDA-approved capecitabine based on the
    5-FU systemic exposure per mg of capecitabine administered, the amount of capecitabine anabolites formed from 1 mg of capecitabine
    administered in NGC-Cap will, therefore, be much greater than formed from the administration of 1 mg of existing
    capecitabine.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Phase 1B trial in patients with advanced refractory gastrointestinal tract tumors demonstrated that the irreversible inhibition
    of DPD by PCS6422 could alter the metabolism, distribution and elimination of 5-FU, making NGC-Cap significantly (up to 50 times)
    more potent than capecitabine alone and potentially leading to higher levels of anabolites which can kill replicating cancer and
    normal cells. By administering NGC-Cap to cancer patients, the balance between anabolites and catabolites changes depending on the
    dosage regimens of PCS6422 and capecitabine used, making the efficacy-safety profile of NGC-Cap different than that of FDA-approved
    capecitabine and requiring further evaluation of the PCS6422 and capecitabine regimens to determine the optimal NGC-Cap regimens for
    patients.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    order for NGC-Cap to provide a safer and more efficacious profile for cancer patients compared to existing chemotherapy, understanding
    how the different regimens of PCS6422 and capecitabine may affect the systemic and tumor exposure to the anabolites, as well as the
    systemic exposure to the catabolites, is required. This can be achieved by following the timeline of DPD irreversible inhibition
    and the formation of new DPD using the plasma concentrations of 5-FU and its catabolites.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    an effort to better estimate the timeline of DPD inhibition and formation of new DPD, we modified the protocol for the Phase 1B
    trial and began enrolling patients in the amended Phase 1B trial in April 2022. On November 1, 2022, we announced that data from the
    Phase 1B trial identified multiple dosage regimens with potentially better safety and efficacy profiles than currently existing
    chemotherapy regimens. Since 5-FU exposure is dependent on both the PCS6422 regimen and the capecitabine regimen, safe regimens were
    identified as well as regimens that cause dose-limiting toxicities (&#8220;DLTs&#8221;). One of the early regimens in the Phase 1B
    trial did cause DLTs in two patients, one of whom died. No other DLTs were noted in the study. The Phase 1B trial has now completed
    enrollment and we are currently conducting trial close-out activities. We submitted a new IND for the treatment of advanced and
    metastatic breast cancer and received IND clearance from the FDA on July 24, 2024. The Phase 2 trial is currently being initiated
    and will be a global multicenter, open-label, adaptive design trial comparing two different doses of NGC-Cap to FDA-approved
    monotherapy capecitabine in approximately 60 to 90 patients with advanced or metastatic breast cancer. The trial is designed to
    evaluate the safety-efficacy profile of NGC-Cap versus monotherapy capecitabine, to determine the potential optimal dosage regimens
    of NGC-Cap as required by the FDA Project Optimus Initiative. Our license agreement with Elion for NGC-Cap requires us to use
    commercially reasonable efforts, at our sole cost and expense, to research, develop and commercialize products in one or more
    countries, including meeting specific diligence milestones that include dosing a first patient with a product in a Phase 2 or 3
    clinical trial on or before October 2, 2024. We expect the first patient to be dosed before the conclusion of the third quarter of
    2024, ahead of the required diligence milestone.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Gem
    is a cytidine analog similar to gemcitabine (Gemzar&#174;), but different enough in chemical structure that some patients are more
    likely to respond to PCS3117 than gemcitabine. In addition, we believe those patients inherently resistant or who acquire resistance
    to gemcitabine are likely not to be resistant to NGC-Gem. The difference in response occurs because NGC-Gem is metabolized to its
    active metabolite through a different enzyme system than gemcitabine. We continue to evaluate the potential use of NGC-Gem in patients
    with pancreatic and other potential cancers and to evaluate ways to identify patients who are more likely to respond to NGC-Gem than
    gemcitabine. We plan to meet with the FDA to discuss potential trial designs including implementation of the Project
    Optimus initiative as part of the design. Similar to NGC-Cap, we will need to obtain additional funding before we can begin the Phase
    2 trial for NGC-Gem.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    license agreement with Ocuphire Pharma, Inc. (&#8220;Ocuphire&#8221;) for NGC-Gem requires us to use commercially reasonable efforts,
    at our sole cost and expense to oversee such commercialization efforts, to research, develop and commercialize products in one or
    more countries, including meeting specific diligence milestones that consist of: (i) dosing a patient in a clinical trial prior to
    June 16, 2024; and (ii) dosing a patient in a pivotal clinical trial or in a clinical trial for a second indication of the drug prior
    to June 16, 2026. We are currently in discussions with Ocuphire to extend these deadlines. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NGC-Iri
    is an analog of SN38 (SN38 is the active metabolite of irinotecan) and should have an improved safety/efficacy profile in every type
    of cancer that irinotecan is presently used. The manufacturing process and sites for drug substance and drug product are presently
    being evaluated and IND-enabling toxicology studies will then be initiated. In addition, we are defining the potential paths to approval,
    which include defining the targeted patient population and the type of cancer. In 2025, we plan to expand the preclinical analysis, including additional preclinical efficacy and toxicity studies;
evaluate manufacturing options for PCS11T; and conduct chemistry, manufacturing and control (CMC) activities and pre-IND enabling studies.&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are focused on drug products that improve the survival and/or quality of life for patients by improving the safety and/or efficacy of
the drug in a targeted patient population, while providing a more efficient and probable path to FDA approval and differentiating our
drugs from those on the market or are currently being developed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Other
Drugs in Our Pipeline</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, we completed our Phase 2A trial for PCS12852 in gastroparesis patients with positive results. Additionally, in February 2023, due
primarily to the inability to identify and enroll patients in our rare disease Phase 2 trial for PCS499 in ulcerative Necrobiosis Lipoidica, we decided to cease further enrollment in the PCS499 trial and terminated the trial. We did not experience any safety concerns
during the conduct of either the PCS12852 or PCS499 trial. We continue to evaluate options to monetize these non-core drug assets, which
may include out-licensing or partnering these assets with one or more third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Reverse
Stock Split</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2024, we effected a 1-for-20 reverse stock split, reducing the number of our common shares issued on that date from 24,706,474
shares to 1,291,000 shares. There is no corresponding reduction in the number of authorized shares of common stock and no change in the
par value per share. All share and per share amounts and conversion and exercise prices presented herein have been adjusted retroactively
to reflect this change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Public
Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 30, 2024, we raised gross proceeds of $7.0 million (net proceeds of $6.3 million) from the sale of 476,000 shares of our common
stock, pre-funded warrants to purchase up to 1,079,555 shares of our common stock and warrants to purchase 1,555,555 shares of our common
stock in a public offering, as described in Note 2. Simultaneously with the closing of the sale, the pre-funded warrants were exercised
in exchange for 1,079,555 shares of our common stock. We are using the net proceeds from this financing for continued research and
development for NCG-Cap, and working capital and general corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">ATM
Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the &#8220;Registration Statement&#8221;),
including a base prospectus relating to the offering of up to $50,000,000 in the aggregate of the securities identified in the base prospectus
from time to time in one or more offerings; and a prospectus supplement relating to the shares of our common stock that may be issued
and sold under a sales agreement dated May 21, 2024 (the &#8220;Sales Agreement&#8221;) between us and A.G.P./Alliance Global Partners
(the &#8220;Sales Agent&#8221;), through which we may issue and sell in a registered &#8220;at the market offering&#8221; shares of our
common stock having an aggregate offering price of up to $2.4 million (subject to adjustment) from time to time through or to our Sales
Agent (the &#8220;ATM Offering&#8221;). We expect to use net proceeds, if any, from the ATM Offering over time for continued research
and development for our portfolio of drug candidates, especially our oncology products, and working capital and general corporate purposes.
The shares under the ATM Offering will be sold and issued pursuant to the Registration Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i><span style="text-decoration: underline">New Chief Financial
Officer</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On July 16, 2024, Russell Skibsted
was appointed as our Chief Financial Officer (&#8220;CFO&#8221;). Mr. Skibsted has nearly 30 years of experience in the pharmaceutical industry, including
expertise in financial management, global business development, capital markets, investor relations and operations. In connection with
his employment, Mr. Skibsted will be paid an annual base salary of $400,000 and will be eligible for a $50,000 base salary increase upon
a cumulative (one or multiple) financing of at least $15 million that he leads and substantially participates in. He is also eligible
to participate in an executive bonus pool with a target bonus of 35% of his base compensation. In addition, the Compensation Committee
awarded 28,000 RSUs to Mr. Skibsted, which vest accordingly: 14,000 RSUs vest on July 16, 2025; 7,000 RSUs vest upon Processa reaching
a market capitalization (i.e. total value of Processa&#8217;s outstanding shares of stock at the then current market price) of at least
$30 million; and 7,000 RSUs vest upon a cumulative (one or multiple) financing of at least $15 million that he leads and substantially
participates in. He will also be eligible for other benefits as described in his employment agreement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the three and six months ended June 30, 2024 and 2023</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our net loss during the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Change</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Change</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left; padding-left: 10pt">Research and development expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">1,730,444</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">1,688,164</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">42,280</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">3,269,555</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">3,342,509</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(72,954</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,351,580</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,026,301</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">325,279</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,622,067</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,477,490</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">(855,423</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,082,024</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,714,465</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,891,622</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,819,999</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Other Income (Expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,698</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">101,900</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">(30,141</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">154,915</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">185,361</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">(30,309</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net Operating Loss Before Income Tax Benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,010,326</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,612,565</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,736,707</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,634,638</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income Tax Benefit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,010,326</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,612,565</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,736,707</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,634,638</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have any revenue under contract or any immediate sales prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development costs are expensed as incurred. Research and development expenses include (i) program and testing related expenses
including external consulting and professional fees related to the product testing and our development activities and (ii) internal research
and development staff salaries and other payroll costs including stock-based compensation, payroll taxes and employee benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
for the three- and six-month periods for the periods ended June 30, 2024 and 2023 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Research and development salaries and benefits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">468,724</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">502,626</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">976,554</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">1,048,294</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Preclinical, clinical trial and other costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,261,720</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,185,538</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,293,001</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,294,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,730,444</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,688,164</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,269,555</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,342,509</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended June 30, 2024, our preclinical, clinical trial and other costs increased when compared to the same period in
2023. This was attributable to an increase of approximately $146,000 for ongoing testing and related expenses related to our Phase
1B trial for NGC-Cap and the IND/initiation of our Phase 2 trial for NGC-Cap and offset by a decrease in professional fees of
approximately $70,000, mostly attributable to a decrease in patent-related legal fees. During the same period in 2023, in addition
to clinical trial costs for NGC-Cap, we were incurring closing costs in our clinical trial for PCS12852 and PCS499. We also had an
approximately $23,000 increase in salaries and related costs during the three months ended June 30, 2024 when compared to the same
period in 2023 due to one-time bonuses and increased salary rates for the research and development team in 2024. This was offset by
a decrease in stock-based compensation of approximately $57,000 as we waited for shareholder approval to increase the number of
shares available under the 2019 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2024, we had increases in testing and related expenses of approximately $132,000, and in salaries and
related costs of approximately $61,000, when compared to the same period in 2023. These increases were offset by decreases in
professional fees of approximately $133,000 and in stock-based compensation of approximately $133,000. The reasons for the changes
between the six-month periods in 2024 and 2023 are the same as the reasons between the three-month periods in 2024 and
2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 24, 2024 we received approval of our IND for our Phase 2 trial for NGC-Cap in breast cancer. As we begin this Phase 2 trial and complete
our Phase 1B clinical trial for NGC-Cap, we anticipate our research and development costs will increase. We will also continue incurring
nominal costs for NGC-Gem as we prepare to meet with the FDA to discuss potential study designs and for NGC-Iri should we decide to conduct
IND-enabling and toxicology studies.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
funding necessary to bring a drug candidate to market is subject to numerous uncertainties. Once a drug candidate is identified, the
further development of that drug candidate may be halted or abandoned at any time due to a number of factors. These factors include,
but are not limited to, funding constraints, safety or a change in market demand. For each of our drug candidate programs, we periodically
assess the scientific progress and merits of the programs to determine if continued research and development is economically viable.
Some programs may be terminated due to the lack of scientific progress and lack of prospects for ultimate commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical trial cost accruals are based on estimates of patient enrollment and related costs at clinical investigator sites, as well as
estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct
and manage clinical trials on our behalf.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate preclinical and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and
clinical research organizations that conduct and manage preclinical studies and clinical trials on our behalf. In accruing service fees,
we estimate the time period over which services will be performed and the level of patient enrollment and activity expended in each period.
If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly.
Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses
and expensed when the services are rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our general and administrative expenses for the three months ended June
30, 2024 increased by approximately $325,000 to $1.4 million from $1.0 million for the three months ended June 30, 2023. This increase
was due primarily as a result of an approximately $308,000 increase in professional fees, mostly attributable to an increase of legal
fees; an approximately $115,000 increase in salaries and other payroll-related costs from increased salary rates, primarily paid to our
executive officers; and a net increase of approximately $17,000 in travel, office and other miscellaneous expenses. These increases were
offset by a decrease in employee stock-based compensation of approximately $123,000. We also received approximately $8,000 less in reimbursements
from CorLyst during the three months ended June 30, 2024 when compared to the same period in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">During
the six months ended June 30, 2024, our general and administrative expenses decreased by approximately $855,000 to $2.6 million from
$3.5 million for the six months ended June 30, 2023. This was due primarily to a decrease in professional fees of approximately
$955,000 as a result of the non-recurring expense that was incurred during 2023 in connection with the stock purchase warrant
granted to the placement agent for our registered direct offering in February 2023; and a decrease in employee stock-based
compensation of approximately $247,000 as we waited for shareholder approval to increase the number of shares available under the
2019 Plan. These decreases were primarily offset by increases in salaries and other payroll-related expenses of approximately
$296,000 and in office and other related expenses of approximately $37,000. We also received approximately $14,000 less in
reimbursements from CorLyst during the six months ended June 30, 2024 when compared to the same period in 2023.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income, net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income represents interest income of approximately $72,000 and $102,000 for the three months ended June 30, 2024 and 2023,
respectively, and approximately $155,000 and $185,000 for the six months ended June 30, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
Tax Benefit</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not recognize any income tax benefit for the three or six months ended June 30, 2024 or 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our sources and uses of cash and cash equivalents for the six months ended June 30, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash (used in) provided by:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(5,394,713</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(4,178,539</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,259,636</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,352,077</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net increase in cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">864,923</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,173,538</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
cash used in operating activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
used net cash in our operating activities of $5,394,713 and $4,178,539 during the six months ended June 30, 2024 and 2023,
respectively. The increase in cash used in operating activities was primarily attributable to the prepayment of expenses paid to our CRO for our Phase 2 trial for NGC-Cap during the six months ended June 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we continue our development of NGC-Cap and evaluate the other NGC drugs in our portfolio, we anticipate our research and development
efforts and ongoing general and administrative costs will continue to generate negative cash flows from operating activities for the
foreseeable future. <span style="background-color: white">As we begin our Phase 2 clinical trial for NGC-Cap in <span style="background-color: white">the
second half of </span> 2024, we anticipate our clinical trial costs will increase when compared to prior periods since our current
activities are related primarily to the completion of our Phase 1b trial for NGC-Cap.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
cash provided by financing activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the six months ended June 30, 2024, we sold 476,000 shares of common stock, pre-funded warrants to purchase up to 1,079,555 shares of
common stock in lieu of shares of common stock, all of which were exercised into shares of our common stock, and warrants to purchase
up to 1,555,555 shares of our common stock pursuant to a public offering for net proceeds of $6.3 million.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also used cash classified as financing activities of $12,000 to pay income taxes owed on stock-based compensation, $8,600 for the settlement
of a stock award and $2,300 for payments owed under a financing lease obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2023, we raised net proceeds of $6.4 million from the sale of 421,611 shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="background-color: white">During
the six months ended June 30, 2024,  <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we <span style="background-color: white">began initiation activities for </span> our Phase
2 trial for NGC-Cap in breast cancer. At June 30, 2024, we had cash and cash equivalents totaling $5.6 million which, based on our current
business and drug development plans, we believe will satisfy our <span style="background-color: white">operating </span> needs into late 2024. Absent additional funding, our current
cash and cash equivalents will not be sufficient to fund our planned operations for a period of one year or more after the date that
these condensed consolidated financial statements were available to be issued based on the timing and amount of our projected net loss
from continuing operations and the related amount of cash to be used in operating activities during that period of time. Our ability
to execute our longer-term operating plans, including future preclinical studies and clinical trials for our portfolio of drugs depend
on our ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding
transactions.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
have incurred losses since inception, currently devoting substantially all of our efforts toward research and development of our next
generation chemotherapy drug product candidates, including conducting clinical trials and providing general and administrative support
for these operations, and have an accumulated deficit of $81.1 million at June 30, 2024. During the six months ended June 30, 2024, we
generated a net loss of $5.7 million and used $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4 <span style="background-color: white">million
in net cash for operating activities from continuing operations. To date, none of our drug candidates have been approved for sale, and
therefore we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable future.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
have financed our operations primarily through public equity issuances, including an offering we closed on January 30, 2024 in which
we sold 476,000 shares of our common stock, pre-funded warrants to purchase up to 1,079,555 shares of our common stock, and warrants
for the purchase of up to 1,555,555 shares of our common stock for net proceeds of $6.3 million, after deducting placement agent fees
and offering-related expenses. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously with the
<span style="background-color: white">closing of the sale, the pre-funded warrants were exercised in exchange for 1,079,555 shares of
our common stock. We will continue to be dependent upon equity and/or debt financing until we are able to generate positive cash flows
from <span style="background-color: white">our </span> operations.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Further, in May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the &#8220;Registration
Statement&#8221;), including a base prospectus relating to the offering of up to $50,000,000 in the aggregate of the securities identified
in the base prospectus from time to time in one or more offerings; and a prospectus supplement relating to the shares of our common stock
that may be issued and sold under a sales agreement dated May 21, 2024 (the &#8220;Sales Agreement&#8221;) between us and A.G.P./Alliance
Global Partners (the &#8220;Sales Agent&#8221;), through which we may issue and sell in a registered &#8220;at the market offering&#8221;
shares of our common stock having an aggregate offering price of up to $2.4 million (subject to adjustment) from time to time through
or to our Sales Agent (the &#8220;ATM Offering&#8221;). We expect to use net proceeds, if any, from the ATM Offering over time for continued
research and development for our portfolio of drug candidates, especially our oncology products, and working capital and general corporate
purposes. The shares under the ATM Offering will be sold and issued pursuant to the Registration Statement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations,
strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable
to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or
planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in
certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and
distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms
that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of
our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no
assurance that future funding will be available when needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
Obligations and Commitments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no significant changes to the contractual obligations reported in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off
Balance Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2024, we did not have any off-balance sheet arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Use of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial
statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make
estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent
assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the estimates, assumptions and judgments involved in the accounting policies described in the &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations&#8221; section of our most recent Annual Report on Form 10-K
have the greatest potential impact on our financial statements, so we consider these to be our critical accounting policies. Actual results
could differ from the estimates we use in applying our critical accounting policies. We are not currently aware of any reasonably likely
events or circumstances that would result in materially different amounts being reported.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no changes in our critical accounting policies from those included in our most recent Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have evaluated recently issued accounting pronouncements and determined that there is no material impact on our financial position or
results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>Item
3. Quantitative and Qualitative Disclosures About Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
3 is not applicable to us as a smaller reporting company and has been omitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>Item
4. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30<span style="background-color: white">, 2024</span>, management, with the participation of the Chief Executive Officer and Chief
Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures,
as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the evaluation of its disclosure controls and procedures,
the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at June
30<span style="background-color: white">, 2024</span> to provide reasonable assurance that information required to be disclosed in our
reports under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s
rules and forms and (ii) accumulated and communicated to our management, as appropriate, to allow timely decisions regarding required
disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures,
no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily
applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting during the quarter ended June 30, 2024 that have materially affected,
or are reasonably likely to materially affect the Company&#8217;s internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>Part
II. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>Item
1. Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, to our knowledge, there are no legal proceedings or regulatory actions material to us to which we are a party,
or have been a party to, or of which any of our property is or was the subject matter of, and no such proceedings or actions are known
by us to be contemplated, except as provided below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously disclosed in our Current report on Form 10-Q for the period ended March 31, 2024, on May 7, 2024, the Company received
notification from Elion purporting to terminate the license agreement by and between the Company and Elion as a result of the
Company&#8217;s alleged breach thereof. The Company believes that Elion&#8217;s claims are without merit and disputes that the
license agreement has been validly terminated. On May 10, 2024, the Company filed a summons with notice for damages, declaratory and
injunctive relief against Elion in New York State Court. On June 14, 2024, Elion filed a demand for complaint. On July 5, 2024, the
Company filed a complaint seeking monetary damages, declaratory judgement and injunctive relief. The Company intends to enforce its rights under the license agreement and will pursue such other remedies as it determines
are appropriate.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no material changes to our risk factors as described in Item 1A of our Annual Report on Form 10-K for the year ended December
31, 2023, other than the addition of the following risk factor:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
licenses are subject to termination by the licensor in certain circumstances.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
rights to practice the inventions claimed in the licensed patents and patent applications are subject to our licensors abiding by the
terms of those licenses and not terminating them. Our licenses may be terminated by the licensor if we are in material breach of certain
terms or conditions of the license agreement or in certain other circumstances. Our license agreements each include provisions that allow
the licensor to terminate the license if (i) we breach any payment obligation or other material provision under the agreement and fail
to cure the breach within a fixed time following written notice of termination; (ii) we or any of our affiliates, licensees or sublicensees
directly or indirectly challenge the validity, enforceability, or extension of any of the licensed patents; or (iii) we declare bankruptcy
or dissolve. The majority of license agreements require us to satisfy due diligence milestones that relate to the development of new
products containing the licensed drug or the agreement may be terminated by such counterparty. Our rights under these licenses are subject
to our continued compliance with the terms of the license, including the payment of royalties due under the licenses. Termination of
any of these licenses could prevent us from marketing some or all of our products. Because of the complexity of our products and the
patents we have licensed, determining the scope of the license and related royalty obligations can be difficult and can lead to disputes
between us and the licensor. An unfavorable resolution of such a dispute could lead to an increase in the royalties payable pursuant
to the license. If a licensor believed we were not paying the royalties due under the license or were otherwise not in compliance with
the terms of the license, the licensor might attempt to revoke the license. If such an attempt were successful, we might be barred from
producing and selling some or all of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously disclosed in our Current Report on Form 10-Q for the period ended March 31, 2024, on May 7, 2024, the Company received
notification from Elion purporting to terminate the license agreement by and between us and Elion as a result of the Company&#8217;s
alleged breach thereof. The Company believes that Elion&#8217;s claims are without merit and disputes that the license agreement has
been validly terminated. On May 10, 2024, the Company filed a summons with notice for damages, declaratory and injunctive relief
against Elion in New York State Court. On June 14, 2024, Elion filed a demand for complaint. On July 5, 2024, the Company filed a
complaint seeking monetary damages, declaratory judgement and injunctive relief. The Company intends to enforce its rights under the license agreement and will pursue such other remedies as it determines
are appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unsuccessful or are unable to enforce our rights under the license agreement, our business and results of operations may be adversely
affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span>Item
2. Unregistered Sales of Equity Securities and Use of Proceeds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)
Recent Sale of Unregistered Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 6, 2024, we issued 10,000 shares of common stock to Paramount Advisors, LLC in connection with a consulting agreement. The sale
of shares was exempt from the registration requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
in reliance on Section 4(a)(2) of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no other sales of unregistered securities during the three months ended
June 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)
Use of Proceeds from Public Offering of Common Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)
Issuer Purchases of Equity&#160;Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not repurchase any shares of our common stock during the six months ended June 30, 2024.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>Item
3. Defaults Upon Senior Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>Item
4. Mine Safety Disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>Item
5. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white">During
the three months ended June 30, 2024, none of our directors or officers <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA" id="xdx_900_eecd--Rule10b51ArrAdoptedFlag_dbF_c20240401__20240630_zycWLEJhScNi"><ix:nonNumeric contextRef="From2024-04-012024-06-30" format="ixt:booleanfalse" id="Fact000869" name="ecd:Rule10b51ArrAdoptedFlag">adopted</ix:nonNumeric>
</span>or <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA" id="xdx_90F_eecd--Rule10b51ArrTrmntdFlag_dbF_c20240401__20240630_zDrTMfnSYgNe"><ix:nonNumeric contextRef="From2024-04-012024-06-30" format="ixt:booleanfalse" id="Fact000870" name="ecd:Rule10b51ArrTrmntdFlag">terminated</ix:nonNumeric>
</span>a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA" id="xdx_906_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20240401__20240630_zw6h1KHY3LOc"><ix:nonNumeric contextRef="From2024-04-012024-06-30" format="ixt:booleanfalse" id="Fact000871" name="ecd:NonRule10b51ArrTrmntdFlag">non-Rule</ix:nonNumeric>
</span>10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_013"></span>Item
6. Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC
Ref. No.</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">1.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315224020879/ex1-2.htm" style="-sec-extract: exhibit">Sales Agreement, dated May 21, 2024, by and among Processa Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners (incorporated by reference to Exhibit 1.2 to the Registration Statement on Form S-3 filed on May 21, 2024)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1533743/000149315224028093/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement dated July 16, 2024 by and between Russell Skibsted and Processa Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to Form 8-K filed on July 17, 2024)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Rule 153-14(a) Certification by Principal Executive Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Rule 153-14(a) Certification by Principal Financial Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*++</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Section 1350 Certification of Principal Executive Officer and Principal Financial Officer</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Files</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"># Indicates management contract or compensatory plan
or arrangement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">++
This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350 and are not being
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into
any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing
herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="margin-bottom: 0pt; break-before: page; margin-top: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_014"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROCESSA
    PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    George Ng</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Ng</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    August 13, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Russell Skibsted&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russell
    Skibsted</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    August 13, 2024</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>































<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2Oky3JPCupCSyCInodskxlnRHZre/R+ot25RoGBiGc75zhBiJnFa6QYbToizggG3XKIdQYo2M5ozeka03Kfhb4kVbx8q4/v2BGXkGPZOEcqK80Fvv2mKVQjQby2QspxDLVCYw34rgq2dkal2hcVo1oEwFe6aONTrFryHhoJ5kqH31VUdkq8mkEIfRIL9BRrGEHd3Vg/hqoSgyEYz6CUTOdOu8a/l0aL4kLBtsfZ0d6P8GHwDXSoI= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5in; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
George Ng, Chief Executive Officer of PROCESSA PHARMACEUTICALS, INC. certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this quarterly report on Form 10-Q of PROCESSA PHARMACEUTICALS, INC. for the six months ended June 30, 2024;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant at, and for, the periods presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules13a-15(f) and 15d-15 (f)) for the registrant
and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, at the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of registrant&rsquo;s board of directors (or persons performing equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    George Ng</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Ng</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    13, 2024</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Russell Skibsted, Chief Financial Officer of PROCESSA PHARMACEUTICALS, INC. certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this quarterly report on Form 10-Q of PROCESSA PHARMACEUTICALS, INC. for the six months ended June 30, 2024;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant at, and for, the periods presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules13a-15(f) and 15d-15 (f)) for the registrant
and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, at the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of registrant&rsquo;s board of directors (or persons performing equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Russell Skibsted</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russell
    Skibsted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    13, 2024</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Written
Statement of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. &sect;1350</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely
for the purposes of complying with 18 U.S.C. &sect;1350, I, the undersigned Chief Executive Officer of Processa Pharmaceuticals, Inc.
(the &ldquo;Company&rdquo;), hereby certify, to the best of my knowledge, that the quarterly report on Form 10-Q of the Company for the
quarter ended June 30, 2024 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or Section 15(d) of the
Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
certification is being furnished solely to accompany this Report pursuant to 18 U.S.C. 1350 and is not being filed for purposes of Section
18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant, whether made
before or after the date hereof, regardless of any general incorporation language in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    George Ng</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Ng</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    13, 2024</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely
for the purposes of complying with 18 U.S.C. &sect;1350, I, the undersigned Chief Financial Officer of Processa Pharmaceuticals, Inc.
(the &ldquo;Company&rdquo;), hereby certify, to the best of my knowledge, that the quarterly report on Form 10-Q of the Company for the
quarter ended June 30, 2024 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or Section 15(d) of the
Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
certification is being furnished solely to accompany this Report pursuant to 18 U.S.C. 1350 and is not being filed for purposes of Section
18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant, whether made
before or after the date hereof, regardless of any general incorporation language in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Russell Skibsted</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Russell
    Skibsted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    13, 2024</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>form10-q_001.jpg
<TEXT>
begin 644 form10-q_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $Z EH# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBOBO\
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M]EF&QF(KXG,:F,XSX7RBM@\WK9)3I5\T=3Z]"6%Q-*A^W5%?C7X,_;\_:/\
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M@6/V?[+P+I'A&]\4ZIH,WC'X]WL:V7P^\4:EJ6J:<VNZSX9TZXMIM1U30_[
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M5H]#\2R:$-%^U2#5=-OM-:ZD22WM4*$U^A-%=F'XKXDPF&GA*&=YG3HRPM/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M\,?'O]M>/X2_M"_#K]ESP+\(?$/QC^,GC[X;Z]\8%T&Q\;_#SX<V%I\/?#OB
M33_"E[+I&K_$37M%M?%WC&YU:^8V'@K0A+?'3[.[U34KS3-/C%PU?PO_ ,%(
M_P!DWQ'\4_VE/A)=_$)/!^O?LJS:8GQ/U?QI!#H7AAX;RSTAM1NO#VKO=3_V
MA%X=UW6['P=JT5W;Z==S^*9%L=#MM9M9K:]G\D_X*1_L7_$K]M/P_:^ /#/@
MG]FMK2#03_P@_P =_B%JWQ%T3X[?L[?$2XU&7S_B%\*)/!/AN]76'L=,BTVZ
MT[0I/&?@2"\UVS5==O=0TK9!'YGXK_8;_;,\.^*OVUM2^!/QT\":#+^U!I?[
M-.MZ%\4-?U7Q1I?Q5TCQA\"_"/@?X?\ B[0=273O!GB'1]&L_B?X9\.ZY=1?
M%#0[[4/%/@K6=8@N--\(ZA<6D.HP 'W1<_MS_L?V?PJL_C=<_M%?"V'X67_B
MB]\$6GB]O$MM]CF\9Z9%/<:GX3%F =53Q)I=I;7%_J>B26":EIVFPRZE>VT%
M@C7 KS?MZ?L9VND?"W7KO]I7X1V6C?&NU.H_"W4;WQ;865KXQTG^W?\ A&$U
MS3Y+IHO(\/S^(L:):^(-0%GHMWJCQV5M?33R(C?@+\:_V(_VK_V?+/X:2+JO
MBR37/&W[9?[3'[0&M_&+X,Z3\=?VE-4^%/AKXC_LT:#\+;'PGXR\1:?X-U'X
MV^)/$7C6\CUCPS)XM'@F\TC4;=H=2US4/#DD-G9P^M^%O^"9?QC^.?@WX5_$
MK5/A;H_PF\*?$?\ 8N^$?[,/Q._9)\?_ +0?QV^'$_PVT#X0>)?%3>%_MVO?
M#'2-:U?XIZ'XB\-:W#J^L?#KQ_/X8UG1/$+6S7/B>+5%U38 ?O[\8?CM\'?V
M?O#-MXQ^-/Q'\*_#?PW?:I;:'INH^*-3BL?[6UJ[CEFMM(T:T'F7VL:I+!;W
M%RNGZ7:W=V+6VN;IHA;V\TJ?&'Q,_P""E?PCT+X\_L>_ GX2ZCX ^+-Y^UM;
M:KXKTKQM%\0YM*\':%\.=+O;'2[36-'U/0_"7C*'Q?XI\7:Q-JVB^$O#$<VB
M63ZIX:UJV\3>(O#02VDGZS]J;]F;XI^-?B3^R!\;_@+>?#>[\:?LE^(/B/)I
M_@#XQ:AXHTWP9XR\.?$[X:O\.M2D;Q=X;T3Q=KWA[Q9X9AAL]1T#5SX:UR.Z
M675;&]6 7OVI?F;]F7_@FQ\4?@-\5?V,?'^J_$#X?:Y8_ G0/VW=0^*NG:'9
M^(-'MKOQU^U[X^T+X@Q:9\+='FL;BUMO G@Z^L[[25_MW4-.U.>U@LK^.Q\Z
M\GM+$ ^E/C?^VUXP^''[2-Q^S-\+OV9/'7Q]\:Z1\ D_:+\0R>%O'7@#PBUM
MX)/C6^\#OIF@Z?XRU'3W\2>*FU.SC>TTB&ZL8[Q;N&%+Q)<@]'X=_P""C'['
M&L?!WX,?'#7?C;X3^&_@WX\Z7=:GX M?B;?VW@_Q+*=)U)]#\3V6LZ'>3RSZ
M/-X-\013>'_%M]<R'0]$U:+R+G5_*FM9I_)OC1^SK^UE:?MMZC^UC^SC-^S[
MJ$6N_LEP?LX/IOQE\2_$+0[GPSKT/Q1OOB#%XTATOP;X%\2P>*]+MHY+*U.@
M2Z]X6N;V87"'5;.,)-)\/:S_ ,$:?B)X3TWX0Z9X%^(^D_%+2M+_ &4?'W[,
M?QMT#Q=\5OB_^SM:^.I?B7\3M<^+'C/Q=:ZO\&-,\67^J>$/$GB'Q;XAT[7_
M (1:U;VNEZAH\.AR1^)[?4[%KH@'[,R_M4?LY0V^N7,OQG\ )#X:^+^@_ '7
M6.OVN[2_C1XH?1U\-_#:ZB#&5?%6NC7]&ETK3E1FOK;4;:ZMVDMG,H^>_C5_
MP4<_9W\!_!/]J;XF?";Q[\/_ (\^-?V6/AEXQ^(WBSX6>$_'>GVVJWL/@YKN
MSO+7^U(;/6%ATU=<M)= O_$&G:?K6G:5JZG3[K_3@+5ODVZ_X)6^,A^V;X'^
M)VC^//!^C?LG6NC_  T^(/CSX1V\WB>X\:W7[3/P8^!7BS]GWX:^.-!U#4+*
M]L[O0])\):_HVNW.H:[KK>(KKQ1X5TR_NX+NX#7A^??!?_!&WXQ>'OV;/BK\
M#-6\1?#C5_&T?['?QF_91^"WQAU+XV_'SQ#8-I?Q.U/0[N%M4^#&M>'&\#?"
M+P[>1Z#IVH^*]-\%WOCR>7Q':0W^A-I]NUQ!< '[#P_ML_LSZ=KWPS\!>./C
M+\./ GQ7^)WAOP+KVD?#37/%NG)K]M<_$+3H+[PSHUVS^1#::AK<TKV?AVWU
M/^SKOQ))%G2+2Y+JE:NC?MG?LH^(/BC!\%-%_:!^%NH_%FY\3^*O!,/@"W\5
M:>?$C>,O!,UW!XI\)M8-(KQ^)=(:POGFT.4IJ<]O9W5U:6MQ;6\LR?F#XW_X
M)A_M ^(!\>OA7IGC;X(O\%?VJ?B'^RE\3/B=XYUN/QC-\:/AOJ'[//A_X3:-
MKWAOX;Z1#X?D\->);379/A+ITW@7Q#KWB?PQ<^!4U[6M^B:O*MHQ\L_9X_8L
M_:5^*/Q0\?-XM\/^$?A3\#_A[_P6/^,?[9-KK/BS1_&VF_'/QU'X1CN-.\&6
M?A;3[K0[?PIK/P]\<3:Q!<0_$5O$$=RNBZ?JFD6&C:FMRE[$ ?J</^"E'[ [
M6NI7J_M;? U[?2=#;Q)>M'XYTJ24:-%J3Z1=75K;I(UQJ#Z=J$;P:M9Z?%=7
MVD!&GU2VM+<&6O2O&G[8W[*WPZD^&\7C?]H+X3^&C\7M+TS7?AK)J?C/1H[?
MQ=X>UJXLK32/$NF727,EL/#&IWFI6%E8>)+J:WT.ZO;N"SAU![F18C^9?P3_
M ."7OQ;^&GA_]B_2];\4_"&_OOV</A'^WGX$\976F)XA==9U_P#:KURYU'P;
MJ7AF2[\+V\TUGH]I<-;^,+C51IUZ"TL>F0:K%(Q/A%G_ ,$:OC38>%_A+X?U
MOQ5\._B3I0_8A^%'['_QN\$R?&SX]?!KPK=GX9Z]XFU0:WH]_P##7PS<:I\2
M/!&L6?BBXBN? /BZT\'/!JVG6NK:?KUE)=SI  ?M#-^VE^R?;_%#_A2L_P"T
M%\+8?BP/%VH> 7\ 2^*K"/Q-#XVTS28-=N/"EQISNLEOKTNDW,5[IVF3F.ZU
M>/S$TJ.]E@FCCPOV1?VW/@1^VSH'Q \0? _5]8O8?AIX_P#$?P^\3V.OZ5_9
M6HQ7>AZ[K.B6&OVL4=S>03^'/%J:%>:QX9NFN(M0FTDQ/JNF:3>F2QC^$=1_
MX)I_%B3Q'\5-:T_Q;\,$B\:?\%.OV</VU- -S-XF.HV7PK^">D^ =,U'PKJE
M]_PCTT[^/;I/#&JIHR13W6BLE\CWNNVTEY>[/K[]AG]G#XI?LO:7^T!X$\;Z
MKX$\1^#?&?[2OQG^.7PQ\1>&=1\0OXHN=(^-OC[Q#X_U71?'F@ZMH5AI6AZG
MX9NM6M=*L9O#VO>([76XDN=0N6TJ79:R@'W51110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%>9?&7XF67P;^%WC7XH:CI5YKECX*T676KG2=/FM[>]OXXIH83!;
MSW1%O'(3,&#2G: I[D5K0H5<37HX:A!U*^(K4J%&FFDZE6M4A2I03DXQ3G4J
M0BG*48IR3;2NUS8S&8;+\'B\?C*L:&#P.&Q&,Q=>2E*-'#86C5Q&(JRC",YN
M-*C1JU&H0G-J#482DU%^FT5^/7_#X+X>?]$5\>_^#_PS_P#':/\ A\%\//\
MHBOCW_P?^&?_ ([7U_\ Q#OC3_H0XG_P?@?_ )N/RW_B.WA+_P!%KE__ (1Y
MS_\ .<_86BOQZ_X?!?#S_HBOCW_P?^&?_CM'_#X+X>?]$5\>_P#@_P##/_QV
MC_B'?&?_ $(<3_X/P/\ \W!_Q';PE_Z+7+__  CSG_YSG["T5^/7_#X+X>?]
M$5\>_P#@_P##/_QVC_A\%\//^B*^/?\ P?\ AG_X[1_Q#OC/_H0XG_P?@?\
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MX4YUI?5,XM"%6M&A3;OE";YJTXP7*I.[NTHWDOUBHK\>O^'P7P\_Z(KX]_\
M!_X9_P#CM'_#X+X>?]$5\>_^#_PS_P#':K_B'?&?_0AQ/_@_ _\ S<9_\1V\
M)?\ HM<O_P#"/.?_ )SG["T5^/7_  ^"^'G_ $17Q[_X/_#/_P =H_X?!?#S
M_HBOCW_P?^&?_CM'_$.^,_\ H0XG_P 'X'_YN#_B.WA+_P!%KE__ (1YS_\
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MX3E+EG*R<LHBE[M.;U:7NO7:_P"L%%?CT/\ @L%\/" ?^%*^/>1G_D/^&?\
MX[1_P^"^'G_1%?'O_@_\,_\ QVJ_XAWQI_T(<3_X/P/_ ,W&?_$=O"7_ *+7
M+_\ PCSG_P"<Y^PM%?CU_P /@OAY_P!$5\>_^#_PS_\ ':/^'P7P\_Z(KX]_
M\'_AG_X[1_Q#OC/_ *$.)_\ !^!_^;@_XCMX2_\ 1:Y?_P"$><__ #G/V%HK
M\>O^'P7P\_Z(KX]_\'_AG_X[1_P^"^'G_1%?'O\ X/\ PS_\=H_XAWQG_P!"
M'$_^#\#_ /-P?\1V\)?^BUR__P (\Y_^<Y^PM%?CU_P^"^'G_1%?'O\ X/\
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M/'_8BW?_ *665?5E?*?[<?\ R:5\>/\ L1;O_P!++*O7X?\ ^1]D?_8XRO\
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M&&D>#8[.%6\0ZS\1Y9K:QECUJZU"WM].^SW<<4"17$$D,PE9YKRU1-QMZO\
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M).J3:/ID\=BOB'095M[&\2$W,5J+Z\F@DD:VMY9HXX)OF>W_ ./>#_KC%_Z
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M%L9KQ-7T'6TUYO#5WJZ- \-A%/KUOI:NDBZC-&RD+YY<?LM?&ZYT_4_$F@>
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M('A?_P -TO\ YO/RW_X=+?L[?]#3\4O_  ?Z5_\ *.C_ (=+?L[?]#3\4O\
MP?Z5_P#*.OU(HH_UVXO_ .BCS;_PI7_S,'_$(?"[_H@>%_\ PW2_^;S\M_\
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M/AW^RO=ZU\-]?\8>'/$VJ_&W]F+P5]L\ :_H'A3QI?:%X]_:,^&'@WQ1X?\
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M7_S,9_\ $(?"[_H@.%__  W2_P#F\_+?_ATM^SM_T-/Q2_\ !_I7_P HZ/\
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M)];M-<TN_BELM1TJVF3!^4OVR?V'?C'^T?\ !WQ%+H/QO\5S?%4>.O@M\<?
M?PD^(VL^$M3_ &?_  7\1_@_XZ\-?$-?!^C:KX4^%?AGXAGPUK4^CZAX6&O^
M(M3\27$-MJ$>L-HR3Q+##A_M&>'_ /@H!^T'X&^'3Z7\!_AK\);OPQ\5;6Y\
M;>%+;XL_"CXA?$77_ =]X#\3:5J6I?#GQ_\ $;X$^,_A]\.-1L_%VH:+!>W4
MOA+6_$>N^!O[?M+4Z+>WJV$WFX3+,FKX;"Q>/PJKUL=B*>.Q%7'/!/+L/3IT
MJF%AAL+BJ4HXY8B7UFC/&2<J*J4Z*C'#PJ*K/MQ&/S.C7Q#6$Q#I4L)1GA*-
M/"+%+&UISJ0Q$J^(H5$\*Z*]A4AAERU'"=1R=:4'3C^AGB#]H+X">$K#2]5\
M5?&[X0^&=+US0[3Q/HNI>(/B5X,T6PU?PU?WMOIMCXATN\U+6K:WU#0[W4;N
MUL+35K22:PN;VYM[6&X>>:.-O6+>XM[RW@N[2>&ZM;J&*XMKFWE2>WN+>=%E
MAG@FB9HYH9HV62*6-F21&5T8J03_ "5:1^QK^T;\*_B%^QW^SK??L]?#?XV_
M$[PG_P $R?VOOAGK6F^)?$<=O\,?#.I_$/X[QPZ+K&F?$+4/!&I:"^H:7I/B
M?3Y)M"&E:-JMWX;GUZ#1(+:2U6SE_I6_9*^#NN_L]?LO_L^_ KQ1XCC\7^(_
MA#\'OA]\.]=\30&Z-MK>K>$O#.G:-?W]H;[%X;*:YM)#9&Z5+@VHA\Z..3=&
MJX@R/+,IPV%JX+-XYA5Q-6HX07U6U3!>TS&%+&4XT)SJTH2>"HQ_VGE]L\4I
M8>/)1FV\GS;'YC7KT\5ELL'3H4X*4W[>\,5RX*4\-.5:$:=2:6*JO]QS>R^K
MN-:7/5BE]"T445\J?0'$_$3P9\.?B#X3U#P?\5O"W@SQKX'UJ?2X-4\,^/\
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M[PG1J3I2S:$Y0DXRE1PV,KTFTVGR5:6'=.HKI^]"4HO>,I)J3_L*HK^/4?\
M!U3K# ,O[$.GLK ,K#]H*4AE89# CX0X(((((X(.12_\15&L_P#1D%A_XD#-
M_P#.AK7_ (A3QY_T)8_^'+*__FLS_P"(A<)?]#27_A#C_P#YG/[":*_CV_XB
MJ-9SC_AB'3\XSC_AH&;./7'_  J'I1_Q%4:S_P!&06'_ (D#-_\ .AH_XA3Q
MY_T)8_\ ARRO_P":P_XB%PE_T-)?^$./_P#F<_L)HK^/;_B*HUG_ *,AL/\
MQ(&;_P"=#1_Q%4:S_P!&06'_ (D#-_\ .AH_XA3QY_T)8_\ ARRO_P":P_XB
M%PE_T-)?^$./_P#F<_L)HK^/4_\ !U5JZE0W[$6G N2J _M!2@LP!8JH/PA^
M8A06(&2 ">@-+_Q%4:S_ -&06'_B0,W_ ,Z&C_B%/'G_ $)(_P#ARRO_ .:P
M_P"(A<(_]#27_A#C_P#YG/[":*_CV_XBJ-9_Z,@L/_$@9O\ YT-'_$51K/\
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M_D&N8X#U^BO(/^%H77_0OI_X,S_\@T?\+0NO^A?3_P &9_\ D&@#U^BO(/\
MA:%U_P!"^G_@S/\ \@T?\+0NO^A?3_P9G_Y!H ]?HKQN3XJ7<8R?#J, ,G&I
M$'\ ;+D_YXKKO"OCG2_%#R6J13:?J4*&5["Y*LTD(8*TMM,F$G1"5$@VI(FX
M%HPIW4 =M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %? 'Q1_X*
M._ WX27O[2R^)-"^(^I:+^RWXK^!_P //'6O>%/#VGZ_!KOQ+^/)TYO#'@'P
M98PZU!?ZKKFB0:_X6F\5/?PZ5I^EGQ+IT,5W=RQ7R6OW_7\U?Q(_9M^+OQEL
M_P#@J]^RYX#TB>X^+'B#]OK]F7]I319KO6=/\+->_!WQ<OP=\10>)_#GB/6H
MQI<MSX5L_AOXUL+2(&[EMM=\/C3S:O<2P07'TW#.799F%?%?VK5=/#X?^S)3
MDL1]65.AB<VHX3&8F=11E[F'PTHW]UJ$L3&HTW"!X>>8W'8.E0^H04ZU;Z\H
MQ='VSG5H9=5Q&&H1A>/O5J\7;5.2H2@G[TC]38/^"F?[,X\#>+_%6KK\4?#?
MB[P3\8]!_9[UKX&:W\-->3X[3?&WQ;IL&M^#OAQHGP_TT:D_B'6?%NA7$>O:
M#J&B:G?>'+G0TN-6FUNVL+.[G@N:[_P4/^&7A[4/ GA+4/@[^T\WQ<^(%AXW
MU[2_@39_!C4+SXO:?X-^'=UH]CXI\>ZKX=@U9M,_X0VVO->TFSTO5]*UW56\
M27UW_9_ARVU74+>ZM8/F/XX_\$XM3^'<OP*^,G[+5CJWQ8^,'P@_:\@_:F^*
M>F_&+XCM_P )K^T=<ZQ\/=3^%/B**]^(^KV1T71/%?ASPC>Z='\/K.?3='\%
M:;:Z3)I*PZ7'=M</B?MM_!3X_P#[6_@SPOXBT_\ 8I\9?#?]I'PEI7CF/X!?
M''P7^UM\/O OQ$^ 'BW4'LK?0-2\:ZSX5O1#K?@'5[JWM-?\4^#_  W=?$N"
M[M-)_LP:4FHWZ7UKZU#+N%,16P4J-6H\%BJF+AB:V)S6CA*V7UJ:HTL+"I@J
MTJ.)JY=.;K8ZIB85)XYX10HTU];HU</B?.JXWB"C2Q2J4X?6:$,-*A2H9?4Q
M%+&TINI4Q$H8JFJE"GC815+"0H2A#"+$.56;^KU*=:A]_:Q^V/\ #FS^,\?P
M'\->"_C)\2?'6FV?@+4/B*_P[^&NJZ[X?^#-C\3-\G@N7XLZU=3Z9!X8N]6L
M(;C67T2V35?$.G:#;3:WJ>DV>F>7<R9^H_MS? G3_P!JK4/V.8YO&FK_ !DT
MGX;ZO\3=5AT'P=J6L^&;'3=$TNRUV\\--K5D97N_'1T+5=&UJ#PIIUC>:A+I
M^N:,XVS:C;0O^17C7_@G;^V:G[0GCCQKH076OB%\6OB%^Q?\3(/VN_#?QIU3
MP#I?PHU'X.^%_!GAC]HO3=?^#%EJ>F2^.$^(=IX3U>U\)Z=;^&]:TC4=(\6I
MINOWGAV'2RI]4\ ?L+_MK? []L/X5_'*'6O@W\<O#OAO2OVT/'7Q \4V>@:I
M\//'?CCQO\=]:\+>(M'\(:L-<^)>M:<NL:A%X<\.>!O!?B?2],L_!?P^\(>$
M5L=7\/78N[":WN61\+1HN4<YPM6J\EKU:-+Z_.E.OFL:5&K&<ZDL-4HT</[5
MUL)0P=183%5GRUJT8Q@ZM6%FN?NHHO+,1"FLTI4ZM3ZI&I&EE\JE6FXQ@J].
MK4K.FJ6(K8F'UC#TDW3I2E*7LX??7@/_ (*"_"/X@:[\9_ NG?#W]H+1_BW\
M#/#G@SQAXK^"?B+X/ZY8?%?5O"GQ"NVL?!WB#PCX8MKB^BUS3=7O$>">1M1L
MY= :&ZD\31:+#97TMMRF@_\ !3?]G[Q)X;\->*;'1/B=IMC=?M6Z3^QK\1],
M\5^%(/"?B7X'?&C7UFM]$L?BEH>L:K#+8:'J&MR:+H$>M^'Y_$%JE_XDT>1B
M;-KVXL_B_P#9\^'/_!0'X7^$_P!K[]H?Q!^RJ?$G_!1'X^Z#:WMAXH\4_&+X
M+M\%],31-5&@?"[X+> X-#\9ZAKVE?#SX3^&=5NO%>H7?B.QTV_\>ZW8:L;W
M4(=0U734M_ OB'^S[XZ^&W[#WP[_ &<O$/PG^)/AC]HG]HW_ (*!?LU^)O%W
MQ!\=>,/AKXY\5_'#XRZM\3_#_P 6_C%\8+F;X6^(?$VG^$O"GAKP]X UU;/3
M-2?2T\/^&-*TRRA%S+YUU>=%/A_AV>*J4%6ISB\9EF$IRPN=T,5:^6XO$9WC
M(P5JE7*L)5IPG@<5)?6J]2C6A7H4<'>;RGG&=0H0JNG.+6&QV(FJ^5U:%[8W
M#T<KPSE9PAF&(ISE'%8>+^KTH5:<J56IB5RG],=%%%?G!]J>3_&SXU^ /V??
MA_>_$OXEWNL6?AFTUSPCX9C3P]X:\0>,=>U/Q'X\\5:/X)\(:%HOAKPMINK:
M[J^IZ[XHU_2=)L[:QL)F\Z\628Q6Z2RI'\(/CI\,OCIX2/C/X=Z_/>Z;;^)]
M?\#:OIVO:+K?@_Q3X:\=>%+Z;3?$_@GQ3X0\6:?HWB7PYXKT&^@EAU'1-6TN
MUO43RKR&.:QN;6ZF\>_;A^!'C7]H_P"!=M\,O .N#PSX@;XR_L[^-Y/$,6K+
MHFIZ+H7PR^.WP]^(GB?4O#VI2Z)XBMK?Q39^'?#.IS^&%O=&O;"?74L(+Y$M
M9)9$_-_]LS_@FG\:_%N@>$/ '[,$_@*[T)/^%@>//$OQ1^+&K:->_'N3]H3Q
MC\0/"?C*\^)5_P#$KQ'\,_'FHZ=I>J:=H#6.SX1VWPT\7:3J6G>&M/TCQ!I/
M@_2X-+M?H\LR_)<;AL-3Q>9K+\=7Q>(C.M5DGA<-A*$:3C.M!TTN:M[27L5"
MJZU6=*JE&%.,74\S%8G'4*M65'"_6</3HTG&$$_;5:U1SO&$E*]H<J]HW#D@
MIP;<I-\O[;1>&/!\?C*[\:PZ+H2>/+_PS8>%KWQ)':68\2W7A+1]6U/5-.T.
MXU!4^WRZ)IVMZSJ][:V3R&TMM1U*^F1%GN)2VY]OL=DDGVVT\N*9[>63[1#L
MCGBE6"2"1M^U)HYG2%XV(=)66-E#L ?Q]U+_ ()X?$*7XF>-OBKX5N_!?@'X
MH>./VEOVKO&5S\8M$U;6&\>:;\&?C/\ LL^-?A3\/M(-U#8VMS?#PU\6;OP'
MXXG\"K?VV@:;>>&X?%6FWK>([99+B'X3?L"ZO<7_ .Q]%\1?V:OV=_AMX6_9
M]\5>+-=^)'A7P?XQO/'NB?$_Q@GP.L?A_P"&/B_>:=?_  _\+6^L^)I_&%HF
MK1GQ@-8\0VT=G8>)M6UJ\\36UJ+4GEF5.FJKSU5>2C%2I^SI>U@Z>%JUE2IQ
MJXF]2G.NH8/#JD[PE.=7$4Z-)TU4(XK%\S@LO<.:;:ES3Y)<U:$'.3A2]V2I
MWKU7.ZDHQA3E.?-R_L8+JV+7""X@+VFW[6@FC+6N^,3)]H4-F'="1*OF!=T9
M#C*G-</K7Q3^'OA[Q7X2\"ZMXLTBU\8^/=$\4>(O!7AH3F?5O%.C>"UT5O$U
M[HEM;K*;Y-+_ .$CT,2)$3+.^I6Z6L<[%PGX9?##_@FK^TY\,O!O[0S02^#/
M&7QM\8_#[QIX'@^('Q)^(6@^+_AG\=T\8?&[2?B'=:[X[^%4/P*T35&\6VW@
MVUU?3?#NJ?%[QU\7].\(>)M4.AP6&N_#^]U>"XZS]GO_ ()T?&KX8>(OV:/&
M?Q \ ?!+Q_J_PL^*/[83NFHZOX;@U?X4?#O]H77O"'B[X;:UX!D\._![POX/
MCU/X:ZOX;UJ&X\"^"O"_P_\ #VFW?C"^U#P?=V\:7BWW3/),DIK$R_UBP^(5
M).-"%*%*C4Q-5X&M7C.*K3FH8=8BG3I<TW&I.-94_9T<5!PEFL?CY.DO[-J4
MW-IU)3<IQI1]O"FT^2,>:I[.4IVC>,7#F4JE*2:_;WPSXITOQ7H/AWQ#8)J5
MA;>*-(M=;TO3O$>D:GX8\1)9W5M!="+4O#6O6NGZ[I&H6L=Q$NHZ9J=A:W^G
M3L;>^MX)E9!R7Q>^,WPX^!/@_P#X3CXG>(?[!T2;6M%\,:3!:Z9JWB#Q!XF\
M5^);Y--\.>$?"'A7P[8ZKXE\6^*M>OY%M]*\/>'=*U+5;O;/.EK]EM;J>'\G
M_@9^RI\4_P!E;5O#?Q1^+WPA^%GQOMOAG^SC\$[>U^)MOXN\0:M\4O@5?? +
MX&:CX8\=?#_X1>%9/ &L:CXIT[XA^)[?4/$.CS>&M6\)W?B'4_&^MP>*=(OI
M=+T>._\ L3XX?#OXS_';X??LH_&OP;X2\/\ @SXW_!;Q_P"#_P!H&7X'_$WQ
M%=1Z!>WFO_"KQEX!\?\ PEUSQOX?T356T3Q1HNA_$S7D\,^.+7POK&GV'C'0
M=/ENM';2+V[FMN.KE>7T<?0BL?3Q&65*LZ<L7"M0IQ]I[/&5J5!2O5K482]C
MA:-7%8C"I47B'7<'3=%2UAB\3/#U&\/*GBHPC)490J2?+S483J-6A"<ESUIP
MHTJMY^S5-24N=KZ=^&GQ;\+_ !2\.W7B71].\<>&+>QUB70;_2OB?\/?&OPJ
M\1V>IQQVDR12>'OB%H?AW59K6[AOK233]3L[:YTO4!-Y=G>3S13QQ'B;5/A+
M\';#XF?%SQ//X2\#6T6@#QK\5/&UU%:6-W-X=\$Z,]I#K?B6^AC.H7UAX>T:
MUEM;$RB=;6(2V]G'YL[I)^,GQA_8<_;2^*'P&UWX>+:_#F]L?&7QU^)/C"R\
M!_%_XN:E^T;XI^$'P\\1?!/0? ?@O3/!?Q;^/GPQ^)&G6EQ9?$FS\5^-O$T-
MEX+O-7T3P_XL.F?#KQ'I6MPW=])8U[_@G-\>/&,?Q5\.:UX<^$.H1_%K]AQ/
M@;\3/'_Q.\0V7Q2U7QC\9M+_ &?O '@#P7J_@&YO?AE9_$/X6>$]+^(/A>;5
M_'>F7OC?Q;X5\4C3K'QUHO@O1O'NKZM?UWQR;)5+GEQ!AZ-&I7G3JX>C452I
M'"TJN72;E5J<BFVJV+]DITJZG7P<94[TG[>.#QN.M99;5G.--2A4G'EBZLHX
MI*T(WLO<H\S4Z;5.LU*TO<?[8Z]X\\.:!X0O?&\D]]K6AVFC2Z]$GA/2=3\7
M:SJVGPVQNR?#_A_PY::EK?B"ZDMP9(+'1["\O)P"(H'(('4QW5O+((5FC^T&
MWCNOLS,%N5MY69(YGMV(F2-G1XPS(!YB.F=RL!^-OB+_ ()^>+?&WA7]H774
M^$?P7^&WQ!\>?L(?"_\ 9O\ @?X>T;Q"^I:1\&O&6D1?'V+XB:3X>UO3O!NB
M67A[PSKW_"PO!_G^)?#?AVTU37;>WOK74--B@TZWBN^OTOX=?$[]E+XA_M%?
M';5OV;? _P =_%7BCX@>(/$/PR^+OA?QGJ!^//C&R^*^L> ?"7@']GN]T.]\
M!ZD?"_A/P/<^3HTVNGQC)X!T+P=X7L?%TV@V>IW?B"6SXGE.7U*=2.%S.%;%
MQ<(T\/*6%INM4J\B5.%6=>.&=.@Y6K5HU5.I)5)4:?L*,JALL9B8R3JX64*+
MYG*HE5ER1@Y7E*$:;J\U1*\(.#C%<JG+GG&)]J?M*_M5_#K]ES2/"]_XVTCQ
MSXIU7QI=>*H?#/A+X=>'H/$/B74[/P)X,UOXA>.-8\O4-3T/1K+2?"G@WP]J
MNN:K<ZCK-I+)# EKIEOJ&H7$%G)[;X$\:>'OB3X'\&_$3PE=RW_A3Q[X4\/>
M-/#-]/:76GSWOA[Q3I%GKFBW<UA?107ME+<:;?6TTEI>00W5L[M#<11RHZ#\
MW?\ @I5^R%\5?VLX?A#8>%M,\/>-/!7@67QAK\G@76/'\OPWN?#_ ,:9(_#Q
M^#WQOM]1D\#>/] \?:7\-XK7QMH'B3X2>,]$F\'^-= \?Z@FL:?KL=HNEO\
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M+3]R"CT/(.)9.3EP;&4I.S;6'246^9PC%8F,5>23<E^\=G>=Y2YOSWU_P/\
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MJUQX;TK1H)KFZN[HB!I&8>)2^([7]MKXC^ M ^%2MJ7[)'P+\;:7\2/%WQ3
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M(82I)X@SG1S7W^3%T=>=PO"*Y'*:<4U[%\\8TTX0NXRA4E[6I*M%>S/++?\
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MGC854Z]>%6DZ<U)*,8-5.:G[-P4*<=.2-3GYIM<TUR+I'U^BN?\ ^$J\/_\
M03A_[XG_ /C5'_"5>'_^@G#_ -\3_P#QJO'.TZ"BN?\ ^$J\/_\ 03A_[XG_
M /C5'_"5>'_^@G#_ -\3_P#QJ@#H**Y__A*O#_\ T$X?^^)__C5'_"5>'_\
MH)P_]\3_ /QJ@#H**Y__ (2KP_\ ]!.'_OB?_P"-4?\ "5>'_P#H)P_]\3__
M !J@#H**Y_\ X2KP_P#]!.'_ +XG_P#C5'_"5>'_ /H)P_\ ?$__ ,:H Z"B
MN?\ ^$J\/_\ 03A_[XG_ /C5'_"5>'_^@G#_ -\3_P#QJ@#H**Y__A*O#_\
MT$X?^^)__C5'_"5>'_\ H)P_]\3_ /QJ@#H**Y__ (2KP_\ ]!.'_OB?_P"-
M4?\ "5>'_P#H)P_]\3__ !J@#H**Y_\ X2KP_P#]!.'_ +XG_P#C5'_"5>'_
M /H)P_\ ?$__ ,:H Z"BN?\ ^$J\/_\ 03A_[XG_ /C5'_"5>'_^@G#_ -\3
M_P#QJ@#H**Y__A*O#_\ T$X?^^)__C5'_"5>'_\ H)P_]\3_ /QJ@#H**Y__
M (2KP_\ ]!.'_OB?_P"-4?\ "5>'_P#H)P_]\3__ !J@#H**Y_\ X2KP_P#]
M!.'_ +XG_P#C5'_"5>'_ /H)P_\ ?$__ ,:H Z"BN?\ ^$J\/_\ 03A_[XG_
M /C5'_"5>'_^@G#_ -\3_P#QJ@#H**Y__A*O#_\ T$X?^^)__C5'_"5>'_\
MH)P_]\3_ /QJ@#H**Y__ (2KP_\ ]!.'_OB?_P"-4?\ "5>'_P#H)P_]\3__
M !J@#H**Y_\ X2KP_P#]!.'_ +XG_P#C5'_"5>'_ /H)P_\ ?$__ ,:H Z"B
MN?\ ^$J\/_\ 03A_[XG_ /C5'_"5>'_^@G#_ -\3_P#QJ@#H**Y__A*O#_\
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MK1[G89]-^S2_:;2XL]3TZ6]TR^L[R?SS]MCX >*?VF/@?!\+/!_B)?">K/\
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M)2UQ/-.-*K14U0=*?+&$ITW'V<:[C[2-O:SI1M"2?,I>'_$'_@I=\#9_ ?Q
MU3X!>*]&^(WCSP3=?#>^M=#US1?&7A_0?%?@GQ=\=_!GP3\0>./!6MW^DZ59
M^.?"^@ZMXDN[#_A(O"%]J^C0Z\FDQ75R;'5;&6]Z;Q+^V=K_ (-_9*^+W[2F
MI^!-(UG4OAG\=OBS\)[7PGI^M7FD66K:3X$_:TUW]G/1M5GU:YL=6GM-1NM$
MTZS\2ZG%'936SZJ;FQM!;VDD4L/ ^ /^"5WP5^''@'Q=\+O#WBG6;3P5K8\'
M6'AM-/\ A_\ !/0O&'A3PWX+^*_AGXN:9X<O?B1H'PTTSQ[\0+;^V?">D:)]
ML^('B#Q!>?V#!ON)+KQ#_P 3^O>/''[&/@SQI^S3\5/V9SXU\::)H/Q2^(GQ
M$^)UUXPT\>';CQ1X>\3?$/X\:M^T'<?V1#J.AW>@3Z?HGC#5#I^FVFJZ1?\
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MK_\ $ES_ /\ GT?9O_#Q?]O;_H\+]H7_ ,.7K_\ \DT?\/%_V]O^CPOVA?\
MPY>O_P#R37QE11_862?]";*/_#7EW_S"'^O'&O\ T6'%?_B2Y_\ _/H^S?\
MAXO^WM_T>%^T+_X<O7__ ))H_P"'B_[>W_1X7[0O_AR]?_\ DFOC*BC^PLD_
MZ$V4?^&O+O\ YA#_ %XXU_Z+#BO_ ,27/_\ Y]'V;_P\7_;V_P"CPOVA?_#E
MZ_\ _)-'_#Q?]O;_ */"_:%_\.7K_P#\DU\944?V%DG_ $)LH_\ #7EW_P P
MA_KQQK_T6'%?_B2Y_P#_ #Z/LW_AXO\ M[?]'A?M"_\ AR]?_P#DFC_AXO\
MM[?]'A?M"_\ AR]?_P#DFOC*BC^PLD_Z$V4?^&O+O_F$/]>.-?\ HL.*_P#Q
M)<__ /GT?U6?\$QO$W[77QY^&NE'XB_M+_&[Q)JG[4/BSQMX1TW4M<\=:SJ
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M_P!.T'7=.MK;4/%/B%[CX>\%_#RP_;,^$?@:U^)&@^,O#OAF_GT+Q]:?LY^
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M!CUGXK^'/#/B#X=>!OB)XG^(OAB'P_X"TM_#^J6OQ7\7:1)\(_B+JD\,VI^
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M;ZC_ (<D_P#!-'_HW>7_ ,.K\8O_ )OJ_5NBC_6WBG_HH\\_\.F-_P#EP?\
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M>+KU\5C)X.4I5<#AE3P.7X7$..+>&Q6*H86>$XO_ (5]X4_Z!TG_ ('ZA_\
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M8Y99$20NOS*%8EEY&13KG4+"RBCGO+ZSM()G2.*:YN88(I9) 6CCCDE=$=Y
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MCAFD'D1,_BD7DD>2@:;FNI\"?'?Q!:^)_#7P\^->@^'_  [KWC:*1_AI\1_
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M'&05/E3FXJM-UY>U515IN52:<ZJ4.;DJ1IP]FE1BZ=:HH_C19_\ !4SXW?\
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MF?!OPGJ6AP>'/#?P&^+_ ,1/AM\7?AQ:_$?P)JVF7GP4_: ^'WP8\5:(FO\
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M#1[8?#OP*+;P],]QH%N/"6@"#0[B259I)]'B_L_R],F>95E>6R6!VE59&8L
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M +2?_!?:_P#QJMRB@##_ .$9\._] +2?_!?:_P#QJC_A&?#O_0"TG_P7VO\
M\:K<HH P_P#A&?#O_0"TG_P7VO\ \:H_X1GP[_T M)_\%]K_ /&JW** ,/\
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M/>WN@?\ "(33>%/['N9Y=._X1N670OLW]ER-:GU#^S-9_P"ADN?_  6:7_\
M(]']F:S_ -#)<_\ @LTO_P"1ZKZ[C5MC<8KJSMC,7JN6G"S_ -JU7)1HPMMR
M4:,+<M*E&DG0H/>A1>M]:-%ZWD[ZTGK><W?>\YN]YR<H]"\'>$?"]WK=_P"&
MO"WASP[?>);G3KSQ'>Z%H>F:3=^(+S2-&T_PYI-UK=SI]K;S:K<Z7X>TG2]"
MTZ>_>>6RT;3=/TNV>*QL[>"/HZP/[,UG_H9+G_P6:7_\CT?V9K/_ $,ES_X+
M-+_^1ZYY2E-\TY2G)V3E*4I2:244G*4I-I12BE>R222222T225DDEKHDDM6V
M]$DM6VWIJVV[MMO?HK _LS6?^ADN?_!9I?\ \CT?V9K/_0R7/_@LTO\ ^1ZD
M9\\_M=_ [Q9\=?AIX9T[X?:QX?T;XC?##XQ_!_X[_#X^,?[4_P"$*UCQ7\'O
M'>D>,K+PQXQDT.*XUFT\/>)[6PO=#N]5TNTO[_0I[ZVUZUTS59M,33;KXH^,
MW[$WQQ_:,'QE^+/Q4\(_LYS_ !2\32?LAZ9\,_@QJ6M:]XY^%UEX._9:^/5U
M\<]9L?&_Q&USX96FHS^)/BU<^(O%WA%]0TCX62Z9X1\,SZ?8RVOB--5\1B7]
M7?[,UG_H9+G_ ,%FE_\ R/1_9FL_]#)<_P#@LTO_ .1Z];!9UCLOITH8?V"=
M"=25*K.DY5J<*];#U\10C4C6I-4<15PM"56-O:>ZXTJ]&,YI\=? T,1*<JOM
M'SJ"G",[0E*G"I3I5'%PG^\IPJU%!WY=4Y4YN,6ORV?_ ()Z>(G^)>L_%[28
M?A9X&^)>O_MA:E\9E^(OA>WNQX]\+_!/6?V.%_9YD^'NB^)8_#>FZA<2:-XQ
M$.LV'A-KC3_!M[I&F:=J<[VNLQ1V=O\ /?P3_P""3GB[PA\(Y/AOX^TWX?ZO
M?7_BO]BBQ^(MQJ7Q/UOQYX*^,O@K]F3XV:=\2?&NNZQX"/P5^']AH/B+QOHZ
MZS#;VOB&]^)/B#5[C5Y/#7B[X@W>@65O>S_N;_9FL_\ 0R7/_@LTO_Y'H_LS
M6?\ H9+G_P %FE__ "/7;#BO.H4G2C7@HMT&G[-\\5ADE1C&I[9S5.FHIPIN
M?)3FO:THTJSE5E@\GP,I<[IR;_>77,N5NK?G;C[/EYI7?-)+FDGRS<X6@ODG
M]H7X!>/]2\;_ ++_ ,8OV?+'X=+XI_9AU3QSING?"WQG>:AX*\!>*?AK\2?
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M6?\ H9+G_P %FE__ "/1_9FL_P#0R7/_ (+-+_\ D>@#?HK _LS6?^ADN?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>pcsa-20240630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaOACbP9z5Z8mekhvWBxbcmqzycrw+JuqyoksMsGIQgI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:PCSA="http://processapharmaceuticals.com/20240630" elementFormDefault="qualified" targetNamespace="http://processapharmaceuticals.com/20240630">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" id="StatementsOfCashFlowsParenthetical">
          <link:definition>00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" id="OrganizationAndSummaryOfSignificantAccountingPolicies">
          <link:definition>995513 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>995514 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>995515 - Disclosure - Stock-based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" id="NetLossPerShareOfCommonStock">
          <link:definition>995516 - Disclosure - Net Loss per Share of Common Stock</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Leases" id="Leases">
          <link:definition>995517 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>995518 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>995519 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/SubsequentEvent" id="SubsequentEvent">
          <link:definition>995520 - Disclosure - Subsequent Event</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>995521 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>995522 - Disclosure - Stock-based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" id="NetLossPerShareOfCommonStockTables">
          <link:definition>995523 - Disclosure - Net Loss per Share of Common Stock (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/LeasesTables" id="LeasesTables">
          <link:definition>995524 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>995525 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>995526 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" id="ScheduleOfStock-basedCompensationExpenseDetails">
          <link:definition>995527 - Disclosure - Schedule of Stock-based Compensation Expense (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" id="ScheduleOfRestrictedStockUnitsRsusActivityDetails">
          <link:definition>995528 - Disclosure - Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>995529 - Disclosure - Stock-based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" id="ScheduleOfNetLossPerShareBasicAndDilutedDetails">
          <link:definition>995530 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" id="NetLossPerShareOfCommonStockDetailsNarrative">
          <link:definition>995531 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" id="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails">
          <link:definition>995532 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" id="ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails">
          <link:definition>995533 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" id="ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails">
          <link:definition>995534 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>995535 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>995536 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>995537 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative" id="SubsequentEventDetailsNarrative">
          <link:definition>995538 - Disclosure - Subsequent Event (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="pcsa-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="PCSA_ConsultingAgreementMember" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SpartanCapitalSecuritesLLCMember" name="SpartanCapitalSecuritesLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PreFundedWarrantMember" name="PreFundedWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SalesAgreementMember" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_AllianceGlobalPartnersMember" name="AllianceGlobalPartnersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ATMOfferingMember" name="ATMOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PlacementAgentMember" name="PlacementAgentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ElionOncologyIncMember" name="ElionOncologyIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ConsultantMember" name="ConsultantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_EmployeesAndConsultantsMember" name="EmployeesAndConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_TwoThousandAndNineteenPlanMember" name="TwoThousandAndNineteenPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ServiceBasedRestrictedStockUnitsMember" name="ServiceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember" name="JanuaryOneTwoThousandTwentyFiveVestingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ThreeYearVestingMember" name="ThreeYearVestingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_FirstPerformanceBasedRSUMember" name="FirstPerformanceBasedRSUMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SecondPerformanceBasedRSUMember" name="SecondPerformanceBasedRSUMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_NextGenerationCapecitabineCAPMember" name="NextGenerationCapecitabineCAPMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OfferingMember" name="OfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_FacilityLeaseMember" name="FacilityLeaseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_CorLystLLCMember" name="CorLystLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_CROsMember" name="CROsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ServiceBasedRSUMember" name="ServiceBasedRSUMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OperatingAndFinancingLeaseRightofUseAsset" name="OperatingAndFinancingLeaseRightofUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OperatingAndFinanceLeaseLiabilityCurrent" name="OperatingAndFinanceLeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DueToLicensor" name="DueToLicensor" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" name="OperatingAndFinanceLeaseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SharesIssuedinConnectionwithLicenseAgreementValue" name="SharesIssuedinConnectionwithLicenseAgreementValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SharesIssuedinConnectionwithLicenseAgreementShares" name="SharesIssuedinConnectionwithLicenseAgreementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" name="AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation" name="SharesWithheldToPayIncomeTaxOnStockbasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares" name="SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PaymentsForSettlementOfStockAwards" name="PaymentsForSettlementOfStockAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" name="StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_RightofuseAsset" name="RightofuseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_FinancingLeaseLiability" name="FinancingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_NonCashLeaseLiabilityNet" name="NonCashLeaseLiabilityNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_LesseeOperatingAndFinancingLeasesTextBlock" name="LesseeOperatingAndFinancingLeasesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" name="BusinessActivitiesAndOrganizationPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" name="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OrganizationAbstract" name="OrganizationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OrganizationTable" name="OrganizationTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="PCSA_OrganizationLineItems" name="OrganizationLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_StockIssuedDuringPeriodSharesWarrantExercised" name="StockIssuedDuringPeriodSharesWarrantExercised" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_MaximumValueToBeSoldAtMarketOffering" name="MaximumValueToBeSoldAtMarketOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_WarrantsExercisableAndMaturityDate" name="WarrantsExercisableAndMaturityDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" name="StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_TitleOfInidividualAxis" name="TitleOfInidividualAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="PCSA_TitleOfInidividualDomain" name="TitleOfInidividualDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_UnrecognizedShareBasedCompensationExpense" name="UnrecognizedShareBasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" name="OperatingAndFinancingLeaseWeightedAverageDiscountRate" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ProceedsFromRentAndOtherCostsReimbursements" name="ProceedsFromRentAndOtherCostsReimbursements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PotentialBaseSalaryIncreaseFinancingMinimum" name="PotentialBaseSalaryIncreaseFinancingMinimum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_CompensationArrangementWithIndividualBonusAwardsGrantedPercentage" name="CompensationArrangementWithIndividualBonusAwardsGrantedPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_MarketCapitalization" name="MarketCapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_PerformanceVestingCriteriaValue" name="PerformanceVestingCriteriaValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ExpectedFinancingAmount" name="ExpectedFinancingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationVestedUponCumulativeFinancingValue" name="ShareBasedCompensationVestedUponCumulativeFinancingValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationVestedUponCumulativeFinancing" name="ShareBasedCompensationVestedUponCumulativeFinancing" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedUponGrantsInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedUponGrantsInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PCSA_JuneTwentyEightTwoThousandAndTwentyFiveMember" name="JuneTwentyEightTwoThousandAndTwentyFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>pcsa-20240630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Cover" xlink:href="pcsa-20240630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheets" xlink:href="pcsa-20240630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="pcsa-20240630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:href="pcsa-20240630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="pcsa-20240630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="pcsa-20240630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:href="pcsa-20240630.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="pcsa-20240630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:href="pcsa-20240630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:href="pcsa-20240630.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:href="pcsa-20240630.xsd#NetLossPerShareOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Leases" xlink:href="pcsa-20240630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:href="pcsa-20240630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="pcsa-20240630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SubsequentEvent" xlink:href="pcsa-20240630.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pcsa-20240630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:href="pcsa-20240630.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:href="pcsa-20240630.xsd#NetLossPerShareOfCommonStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/LeasesTables" xlink:href="pcsa-20240630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="pcsa-20240630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:href="pcsa-20240630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="pcsa-20240630.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:href="pcsa-20240630.xsd#ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="pcsa-20240630.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:href="pcsa-20240630.xsd#ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:href="pcsa-20240630.xsd#NetLossPerShareOfCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:href="pcsa-20240630.xsd#ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:href="pcsa-20240630.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:href="pcsa-20240630.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" xlink:href="pcsa-20240630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="pcsa-20240630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="pcsa-20240630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative" xlink:href="pcsa-20240630.xsd#SubsequentEventDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="loc_us-gaapAssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OperatingAndFinancingLeaseRightofUseAsset" xlink:label="loc_PCSAOperatingAndFinancingLeaseRightofUseAsset" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:to="loc_PCSAOperatingAndFinancingLeaseRightofUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OperatingAndFinanceLeaseLiabilityCurrent" xlink:label="loc_PCSAOperatingAndFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_PCSAOperatingAndFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_DueToLicensor" xlink:label="loc_PCSADueToLicensor" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_PCSADueToLicensor" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="loc_PCSAOperatingAndFinanceLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_PCSAOperatingAndFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PaymentsForSettlementOfStockAwards" xlink:label="loc_PCSAPaymentsForSettlementOfStockAwards" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PCSAPaymentsForSettlementOfStockAwards" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="995513 - Disclosure - Organization and Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:title="995514 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:title="995515 - Disclosure - Stock-based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:title="995516 - Disclosure - Net Loss per Share of Common Stock" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Leases" xlink:title="995517 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:title="995518 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="995519 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SubsequentEvent" xlink:title="995520 - Disclosure - Subsequent Event" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995521 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:title="995522 - Disclosure - Stock-based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:title="995523 - Disclosure - Net Loss per Share of Common Stock (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LeasesTables" xlink:title="995524 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995525 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:title="995526 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="995527 - Disclosure - Schedule of Stock-based Compensation Expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:title="995528 - Disclosure - Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="995529 - Disclosure - Stock-based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:title="995530 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:title="995531 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:title="995532 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:title="995533 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:title="995534 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" xlink:title="995535 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="995536 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995537 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative" xlink:title="995538 - Disclosure - Subsequent Event (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>pcsa-20240630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Cover" xlink:href="pcsa-20240630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheets" xlink:href="pcsa-20240630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="pcsa-20240630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:href="pcsa-20240630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="pcsa-20240630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="pcsa-20240630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:href="pcsa-20240630.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="pcsa-20240630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:href="pcsa-20240630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:href="pcsa-20240630.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:href="pcsa-20240630.xsd#NetLossPerShareOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Leases" xlink:href="pcsa-20240630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:href="pcsa-20240630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="pcsa-20240630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SubsequentEvent" xlink:href="pcsa-20240630.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pcsa-20240630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:href="pcsa-20240630.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:href="pcsa-20240630.xsd#NetLossPerShareOfCommonStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/LeasesTables" xlink:href="pcsa-20240630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="pcsa-20240630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:href="pcsa-20240630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="pcsa-20240630.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:href="pcsa-20240630.xsd#ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="pcsa-20240630.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:href="pcsa-20240630.xsd#ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:href="pcsa-20240630.xsd#NetLossPerShareOfCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:href="pcsa-20240630.xsd#ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:href="pcsa-20240630.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:href="pcsa-20240630.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" xlink:href="pcsa-20240630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="pcsa-20240630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="pcsa-20240630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative" xlink:href="pcsa-20240630.xsd#SubsequentEventDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockCommonMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SharesIssuedinConnectionwithLicenseAgreementValue" xlink:label="loc_PCSASharesIssuedinConnectionwithLicenseAgreementValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesIssuedinConnectionwithLicenseAgreementValue_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SharesIssuedinConnectionwithLicenseAgreementShares" xlink:label="loc_PCSASharesIssuedinConnectionwithLicenseAgreementShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesIssuedinConnectionwithLicenseAgreementShares_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:label="loc_PCSAAdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAAdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation" xlink:label="loc_PCSASharesWithheldToPayIncomeTaxOnStockbasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesWithheldToPayIncomeTaxOnStockbasedCompensation_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares" xlink:label="loc_PCSASharesWithheldToPayIncomeTaxOnStockbasedCompensationShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesWithheldToPayIncomeTaxOnStockbasedCompensationShares_60" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ConsultingAgreementMember" xlink:label="loc_PCSAConsultingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAConsultingAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SpartanCapitalSecuritesLLCMember" xlink:label="loc_PCSASpartanCapitalSecuritesLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSASpartanCapitalSecuritesLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="995513 - Disclosure - Organization and Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:title="995514 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:title="995515 - Disclosure - Stock-based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:title="995516 - Disclosure - Net Loss per Share of Common Stock" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Leases" xlink:title="995517 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:title="995518 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="995519 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SubsequentEvent" xlink:title="995520 - Disclosure - Subsequent Event" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995521 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:title="995522 - Disclosure - Stock-based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:title="995523 - Disclosure - Net Loss per Share of Common Stock (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LeasesTables" xlink:title="995524 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995525 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OrganizationLineItems" xlink:label="loc_PCSAOrganizationLineItems" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OrganizationTable" xlink:label="loc_PCSAOrganizationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_PCSAOrganizationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SalesAgreementMember" xlink:label="loc_PCSASalesAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSASalesAgreementMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PreFundedWarrantMember" xlink:label="loc_PCSAPreFundedWarrantMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PCSAPreFundedWarrantMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_AllianceGlobalPartnersMember" xlink:label="loc_PCSAAllianceGlobalPartnersMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_PCSAAllianceGlobalPartnersMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ATMOfferingMember" xlink:label="loc_PCSAATMOfferingMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSAATMOfferingMember_100" xlink:type="arc" order="104" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapNetIncomeLoss_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_120" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_120" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_StockIssuedDuringPeriodSharesWarrantExercised" xlink:label="loc_PCSAStockIssuedDuringPeriodSharesWarrantExercised_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_PCSAStockIssuedDuringPeriodSharesWarrantExercised_120" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_120" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_MaximumValueToBeSoldAtMarketOffering" xlink:label="loc_PCSAMaximumValueToBeSoldAtMarketOffering_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_PCSAMaximumValueToBeSoldAtMarketOffering_120" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_120" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:title="995526 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_LicenseAgreementMember" xlink:label="loc_PCSALicenseAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSALicenseAgreementMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ConsultingAgreementMember" xlink:label="loc_PCSAConsultingAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAConsultingAgreementMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PreFundedWarrantMember" xlink:label="loc_PCSAPreFundedWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PCSAPreFundedWarrantMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PlacementAgentMember" xlink:label="loc_PCSAPlacementAgentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSAPlacementAgentMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ElionOncologyIncMember" xlink:label="loc_PCSAElionOncologyIncMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_PCSAElionOncologyIncMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ConsultantMember" xlink:label="loc_PCSAConsultantMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_PCSAConsultantMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_EmployeesAndConsultantsMember" xlink:label="loc_PCSAEmployeesAndConsultantsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_PCSAEmployeesAndConsultantsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_WarrantsExercisableAndMaturityDate" xlink:label="loc_PCSAWarrantsExercisableAndMaturityDate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAWarrantsExercisableAndMaturityDate_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_StockIssuedDuringPeriodSharesWarrantExercised" xlink:label="loc_PCSAStockIssuedDuringPeriodSharesWarrantExercised_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAStockIssuedDuringPeriodSharesWarrantExercised_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_PCSAGrossProceedsFromIssuanceOfCommonStock_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAGrossProceedsFromIssuanceOfCommonStock_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_120" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_120" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_120" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" xlink:label="loc_PCSAStockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAStockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes_120" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="995527 - Disclosure - Schedule of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:title="995528 - Disclosure - Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="995529 - Disclosure - Stock-based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_TwoThousandAndNineteenPlanMember" xlink:label="loc_PCSATwoThousandAndNineteenPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_PCSATwoThousandAndNineteenPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ServiceBasedRestrictedStockUnitsMember" xlink:label="loc_PCSAServiceBasedRestrictedStockUnitsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAServiceBasedRestrictedStockUnitsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_FirstPerformanceBasedRSUMember" xlink:label="loc_PCSAFirstPerformanceBasedRSUMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAFirstPerformanceBasedRSUMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SecondPerformanceBasedRSUMember" xlink:label="loc_PCSASecondPerformanceBasedRSUMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSASecondPerformanceBasedRSUMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_EmployeesMember" xlink:label="loc_PCSAEmployeesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAEmployeesMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember" xlink:label="loc_PCSAJanuaryOneTwoThousandTwentyFiveVestingMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_PCSAJanuaryOneTwoThousandTwentyFiveVestingMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ThreeYearVestingMember" xlink:label="loc_PCSAThreeYearVestingMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_PCSAThreeYearVestingMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_TitleOfInidividualAxis" xlink:label="loc_PCSATitleOfInidividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_PCSATitleOfInidividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_TitleOfInidividualDomain" xlink:label="loc_PCSATitleOfInidividualDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_PCSATitleOfInidividualAxis" xlink:to="loc_PCSATitleOfInidividualDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_TitleOfInidividualDomain" xlink:label="loc_PCSATitleOfInidividualDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_PCSATitleOfInidividualAxis" xlink:to="loc_PCSATitleOfInidividualDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_EmployeesMember" xlink:label="loc_PCSAEmployeesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PCSATitleOfInidividualDomain" xlink:to="loc_PCSAEmployeesMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_NextGenerationCapecitabineCAPMember" xlink:label="loc_PCSANextGenerationCapecitabineCAPMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSANextGenerationCapecitabineCAPMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ConsultingAgreementMember" xlink:label="loc_PCSAConsultingAgreementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAConsultingAgreementMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OfferingMember" xlink:label="loc_PCSAOfferingMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSAOfferingMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_180" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_180" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_UnrecognizedShareBasedCompensationExpense" xlink:label="loc_PCSAUnrecognizedShareBasedCompensationExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAUnrecognizedShareBasedCompensationExpense_180" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_180" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_180" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_180" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PaymentsForSettlementOfStockAwards" xlink:label="loc_PCSAPaymentsForSettlementOfStockAwards_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAPaymentsForSettlementOfStockAwards_180" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_180" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_180" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:title="995530 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaapEarningsPerShareBasicLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_130" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:title="995531 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:title="995532 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_FacilityLeaseMember" xlink:label="loc_PCSAFacilityLeaseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_PCSAFacilityLeaseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeFinanceLeaseRemainingLeaseTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeFinanceLeaseRemainingLeaseTerm_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:label="loc_PCSAOperatingAndFinancingLeaseWeightedAverageDiscountRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_PCSAOperatingAndFinancingLeaseWeightedAverageDiscountRate_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:title="995533 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:title="995534 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" xlink:title="995535 - Disclosure - Leases (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="995536 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_CorLystLLCMember" xlink:label="loc_PCSACorLystLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_PCSACorLystLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:label="loc_PCSAProceedsFromRentAndOtherCostsReimbursements_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_PCSAProceedsFromRentAndOtherCostsReimbursements_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995537 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_CROsMember" xlink:label="loc_PCSACROsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_PCSACROsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPurchaseObligation_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative" xlink:title="995538 - Disclosure - Subsequent Event (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ServiceBasedRSUMember" xlink:label="loc_PCSAServiceBasedRSUMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAServiceBasedRSUMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_FirstPerformanceBasedRSUMember" xlink:label="loc_PCSAFirstPerformanceBasedRSUMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAFirstPerformanceBasedRSUMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SecondPerformanceBasedRSUMember" xlink:label="loc_PCSASecondPerformanceBasedRSUMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSASecondPerformanceBasedRSUMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapOfficersCompensation_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PotentialBaseSalaryIncreaseFinancingMinimum" xlink:label="loc_PCSAPotentialBaseSalaryIncreaseFinancingMinimum_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_PCSAPotentialBaseSalaryIncreaseFinancingMinimum_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_CompensationArrangementWithIndividualBonusAwardsGrantedPercentage" xlink:label="loc_PCSACompensationArrangementWithIndividualBonusAwardsGrantedPercentage_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_PCSACompensationArrangementWithIndividualBonusAwardsGrantedPercentage_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_MarketCapitalization" xlink:label="loc_PCSAMarketCapitalization_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_PCSAMarketCapitalization_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PerformanceVestingCriteriaValue" xlink:label="loc_PCSAPerformanceVestingCriteriaValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_PCSAPerformanceVestingCriteriaValue_90" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ServiceBasedRestrictedStockUnitsMember" xlink:label="loc_PCSAServiceBasedRestrictedStockUnitsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAServiceBasedRestrictedStockUnitsMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_FirstPerformanceBasedRSUMember" xlink:label="loc_PCSAFirstPerformanceBasedRSUMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAFirstPerformanceBasedRSUMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SecondPerformanceBasedRSUMember" xlink:label="loc_PCSASecondPerformanceBasedRSUMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSASecondPerformanceBasedRSUMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ServiceBasedRSUMember" xlink:label="loc_PCSAServiceBasedRSUMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAServiceBasedRSUMember" xlink:type="arc" order="40" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>pcsa-20240630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ConsultingAgreementMember" xlink:label="PCSA_ConsultingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ConsultingAgreementMember" xlink:to="PCSA_ConsultingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SpartanCapitalSecuritesLLCMember" xlink:label="PCSA_SpartanCapitalSecuritesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SpartanCapitalSecuritesLLCMember" xlink:to="PCSA_SpartanCapitalSecuritesLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SpartanCapitalSecuritesLLCMember_lbl" xml:lang="en-US">Spartan Capital Securites LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PurchaseAgreementMember" xlink:label="PCSA_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PurchaseAgreementMember" xlink:to="PCSA_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PreFundedWarrantMember" xlink:label="PCSA_PreFundedWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PreFundedWarrantMember" xlink:to="PCSA_PreFundedWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PreFundedWarrantMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SalesAgreementMember" xlink:label="PCSA_SalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SalesAgreementMember" xlink:to="PCSA_SalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_AllianceGlobalPartnersMember" xlink:label="PCSA_AllianceGlobalPartnersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AllianceGlobalPartnersMember" xlink:to="PCSA_AllianceGlobalPartnersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_AllianceGlobalPartnersMember_lbl" xml:lang="en-US">Alliance Global Partners [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ATMOfferingMember" xlink:label="PCSA_ATMOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ATMOfferingMember" xlink:to="PCSA_ATMOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ATMOfferingMember_lbl" xml:lang="en-US">ATM Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PlacementAgentMember" xlink:label="PCSA_PlacementAgentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PlacementAgentMember" xlink:to="PCSA_PlacementAgentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PlacementAgentMember_lbl" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ElionOncologyIncMember" xlink:label="PCSA_ElionOncologyIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ElionOncologyIncMember" xlink:to="PCSA_ElionOncologyIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ElionOncologyIncMember_lbl" xml:lang="en-US">Elion Oncology, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_LicenseAgreementMember" xlink:label="PCSA_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LicenseAgreementMember" xlink:to="PCSA_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ConsultantMember" xlink:label="PCSA_ConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ConsultantMember" xlink:to="PCSA_ConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ConsultantMember_lbl" xml:lang="en-US">Consultant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_EmployeesAndConsultantsMember" xlink:label="PCSA_EmployeesAndConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_EmployeesAndConsultantsMember" xlink:to="PCSA_EmployeesAndConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_EmployeesAndConsultantsMember_lbl" xml:lang="en-US">Employees and Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_TwoThousandAndNineteenPlanMember" xlink:label="PCSA_TwoThousandAndNineteenPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TwoThousandAndNineteenPlanMember" xlink:to="PCSA_TwoThousandAndNineteenPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_TwoThousandAndNineteenPlanMember_lbl" xml:lang="en-US">2019 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_EmployeesMember" xlink:label="PCSA_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_EmployeesMember" xlink:to="PCSA_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ServiceBasedRestrictedStockUnitsMember" xlink:label="PCSA_ServiceBasedRestrictedStockUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ServiceBasedRestrictedStockUnitsMember" xlink:to="PCSA_ServiceBasedRestrictedStockUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ServiceBasedRestrictedStockUnitsMember_lbl" xml:lang="en-US">Service Based RSUs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember" xlink:label="PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember" xlink:to="PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember_lbl" xml:lang="en-US">January 1, 2025 Vesting [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_TitleOfInidividualAxis" xlink:label="PCSA_TitleOfInidividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TitleOfInidividualAxis" xlink:to="PCSA_TitleOfInidividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_TitleOfInidividualAxis_lbl" xml:lang="en-US">Title Of Inidividual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ThreeYearVestingMember" xlink:label="PCSA_ThreeYearVestingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ThreeYearVestingMember" xlink:to="PCSA_ThreeYearVestingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ThreeYearVestingMember_lbl" xml:lang="en-US">3-Year Vesting [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_FirstPerformanceBasedRSUMember" xlink:label="PCSA_FirstPerformanceBasedRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FirstPerformanceBasedRSUMember" xlink:to="PCSA_FirstPerformanceBasedRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_FirstPerformanceBasedRSUMember_lbl" xml:lang="en-US">First Performance Based RSUs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SecondPerformanceBasedRSUMember" xlink:label="PCSA_SecondPerformanceBasedRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SecondPerformanceBasedRSUMember" xlink:to="PCSA_SecondPerformanceBasedRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SecondPerformanceBasedRSUMember_lbl" xml:lang="en-US">Second Performance Based RSUs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_NextGenerationCapecitabineCAPMember" xlink:label="PCSA_NextGenerationCapecitabineCAPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NextGenerationCapecitabineCAPMember" xlink:to="PCSA_NextGenerationCapecitabineCAPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_NextGenerationCapecitabineCAPMember_lbl" xml:lang="en-US">Next Generation Capecitabine - Cap [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OfferingMember" xlink:label="PCSA_OfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OfferingMember" xlink:to="PCSA_OfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OfferingMember_lbl" xml:lang="en-US">Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_FacilityLeaseMember" xlink:label="PCSA_FacilityLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FacilityLeaseMember" xlink:to="PCSA_FacilityLeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_FacilityLeaseMember_lbl" xml:lang="en-US">Facility Lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_CorLystLLCMember" xlink:label="PCSA_CorLystLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CorLystLLCMember" xlink:to="PCSA_CorLystLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_CorLystLLCMember_lbl" xml:lang="en-US">CorLyst, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_CROsMember" xlink:label="PCSA_CROsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CROsMember" xlink:to="PCSA_CROsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_CROsMember_lbl" xml:lang="en-US">CROs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ServiceBasedRSUMember" xlink:label="PCSA_ServiceBasedRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ServiceBasedRSUMember" xlink:to="PCSA_ServiceBasedRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ServiceBasedRSUMember_lbl" xml:lang="en-US">Service Based RSU [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and Equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OperatingAndFinancingLeaseRightofUseAsset" xlink:label="PCSA_OperatingAndFinancingLeaseRightofUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinancingLeaseRightofUseAsset" xlink:to="PCSA_OperatingAndFinancingLeaseRightofUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OperatingAndFinancingLeaseRightofUseAsset_lbl" xml:lang="en-US">Lease right-of-use assets, net of accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:to="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_lbl" xml:lang="en-US">Total Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OperatingAndFinanceLeaseLiabilityCurrent" xlink:label="PCSA_OperatingAndFinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinanceLeaseLiabilityCurrent" xlink:to="PCSA_OperatingAndFinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OperatingAndFinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current maturities of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_DueToLicensor" xlink:label="PCSA_DueToLicensor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DueToLicensor" xlink:to="PCSA_DueToLicensor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DueToLicensor_lbl" xml:lang="en-US">Due to licensor</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:to="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.0001, 100,000,000 shares authorized: 2,873,883 issued and 2,868,883 outstanding at June 30, 2024; and 1,291,000 issued and 1,286,000 outstanding at December 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock at cost &#8212; 5,000 shares at June 30, 2024 and December 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Treasury stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Income (Expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net Operating Loss Before Income Tax Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss per Common Share - Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net Loss per Common Share - Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance. shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued in connection with capital raise, net of transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued in connection with capital raise, net of transaction costs, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Warrants issued in connection with a consulting agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SharesIssuedinConnectionwithLicenseAgreementValue" xlink:label="PCSA_SharesIssuedinConnectionwithLicenseAgreementValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesIssuedinConnectionwithLicenseAgreementValue" xlink:to="PCSA_SharesIssuedinConnectionwithLicenseAgreementValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SharesIssuedinConnectionwithLicenseAgreementValue_lbl" xml:lang="en-US">Shares issued in connection with license agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SharesIssuedinConnectionwithLicenseAgreementShares" xlink:label="PCSA_SharesIssuedinConnectionwithLicenseAgreementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesIssuedinConnectionwithLicenseAgreementShares" xlink:to="PCSA_SharesIssuedinConnectionwithLicenseAgreementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SharesIssuedinConnectionwithLicenseAgreementShares_lbl" xml:lang="en-US">Shares issued in connection with license agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:label="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:to="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_lbl" xml:lang="en-US">Settlement of stock award</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation" xlink:label="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation" xlink:to="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation_lbl" xml:lang="en-US">Shares withheld to pay income taxes on stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares" xlink:label="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares" xlink:to="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares_lbl" xml:lang="en-US">Shares withheld to pay income taxes on stock-based compensation, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance. shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Non-cash lease expense for right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Warrant issued to purchase 158,007 shares of common stock in connection with a consulting agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Net changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from issuance of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Shares withheld to pay taxes on stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PaymentsForSettlementOfStockAwards" xlink:label="PCSA_PaymentsForSettlementOfStockAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PaymentsForSettlementOfStockAwards" xlink:to="PCSA_PaymentsForSettlementOfStockAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PCSA_PaymentsForSettlementOfStockAwards_lbl" xml:lang="en-US">Settlement of stock award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payment of finance lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Increase in Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and Cash Equivalents &#8211; Beginning of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and Cash Equivalents &#8211; End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-Cash Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" xlink:label="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" xlink:to="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor_lbl" xml:lang="en-US">Issuance of 5,000 shares of common stock in connection with a licensing agreement which had previously been recorded as a due to licensor</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_RightofuseAsset" xlink:label="PCSA_RightofuseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_RightofuseAsset" xlink:to="PCSA_RightofuseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_RightofuseAsset_lbl" xml:lang="en-US">Right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_FinancingLeaseLiability" xlink:label="PCSA_FinancingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FinancingLeaseLiability" xlink:to="PCSA_FinancingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_FinancingLeaseLiability_lbl" xml:lang="en-US">Financing lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_NonCashLeaseLiabilityNet" xlink:label="PCSA_NonCashLeaseLiabilityNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NonCashLeaseLiabilityNet" xlink:to="PCSA_NonCashLeaseLiabilityNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_NonCashLeaseLiabilityNet_lbl" xml:lang="en-US">Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Shares issued in connection with license agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss per Share of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="PCSA_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DisclosureLeasesAbstract" xlink:to="PCSA_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_LesseeOperatingAndFinancingLeasesTextBlock" xlink:label="PCSA_LesseeOperatingAndFinancingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LesseeOperatingAndFinancingLeasesTextBlock" xlink:to="PCSA_LesseeOperatingAndFinancingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_LesseeOperatingAndFinancingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Event</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" xlink:label="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" xlink:to="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock_lbl" xml:lang="en-US">Organization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_LiquidityPolicyTextBlock" xlink:label="PCSA_LiquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LiquidityPolicyTextBlock" xlink:to="PCSA_LiquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Net Loss Per Share Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" xlink:label="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" xlink:to="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Annual Lease Liabilities for all Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Annual Lease Liabilities for all Financing Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OrganizationTable" xlink:label="PCSA_OrganizationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OrganizationTable" xlink:to="PCSA_OrganizationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OrganizationTable_lbl" xml:lang="en-US">OrganizationTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OrganizationLineItems" xlink:label="PCSA_OrganizationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OrganizationLineItems" xlink:to="PCSA_OrganizationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OrganizationLineItems_lbl" xml:lang="en-US">OrganizationLineItems [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Common stock shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common stock shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common stock shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash for operating activities from continuing operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_StockIssuedDuringPeriodSharesWarrantExercised" xlink:label="PCSA_StockIssuedDuringPeriodSharesWarrantExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedDuringPeriodSharesWarrantExercised" xlink:to="PCSA_StockIssuedDuringPeriodSharesWarrantExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_StockIssuedDuringPeriodSharesWarrantExercised_lbl" xml:lang="en-US">Warrant exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Shares issued initial offering</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_MaximumValueToBeSoldAtMarketOffering" xlink:label="PCSA_MaximumValueToBeSoldAtMarketOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_MaximumValueToBeSoldAtMarketOffering" xlink:to="PCSA_MaximumValueToBeSoldAtMarketOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_MaximumValueToBeSoldAtMarketOffering_lbl" xml:lang="en-US">Maximum value to be sold at the market offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_WarrantsExercisableAndMaturityDate" xlink:label="PCSA_WarrantsExercisableAndMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_WarrantsExercisableAndMaturityDate" xlink:to="PCSA_WarrantsExercisableAndMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_WarrantsExercisableAndMaturityDate_lbl" xml:lang="en-US">Warrants exercisable and maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedDuringPeriodSharesWarrantExercised" xlink:to="PCSA_StockIssuedDuringPeriodSharesWarrantExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_StockIssuedDuringPeriodSharesWarrantExercised_2_lbl" xml:lang="en-US">[custom:StockIssuedDuringPeriodSharesWarrantExercised-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_GrossProceedsFromIssuanceOfCommonStock" xlink:label="PCSA_GrossProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_GrossProceedsFromIssuanceOfCommonStock" xlink:to="PCSA_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from issuance of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" xlink:label="PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" xlink:to="PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes_lbl" xml:lang="en-US">Stock withheld for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_lbl" xml:lang="en-US">Number of shares, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of shares, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_lbl" xml:lang="en-US">Number of shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2_lbl" xml:lang="en-US">Number of shares, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_lbl" xml:lang="en-US">Number of shares, vested and unissued</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, vested and unissued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares, unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TitleOfInidividualAxis" xlink:to="PCSA_TitleOfInidividualAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_TitleOfInidividualAxis_2_lbl" xml:lang="en-US">TitleOfInidividualAxis [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum equity available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for future grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options, forfeited weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercisable weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Exercisable weighted average remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of shares, vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value per share, shares vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_3_lbl" xml:lang="en-US">Number of shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period for recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_UnrecognizedShareBasedCompensationExpense" xlink:label="PCSA_UnrecognizedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_UnrecognizedShareBasedCompensationExpense" xlink:to="PCSA_UnrecognizedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_UnrecognizedShareBasedCompensationExpense_lbl" xml:lang="en-US">Unrecognized share based compensation expense.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Warrants, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PaymentsForSettlementOfStockAwards" xlink:to="PCSA_PaymentsForSettlementOfStockAwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PaymentsForSettlementOfStockAwards_2_lbl" xml:lang="en-US">Payments for settlement of stock awards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss available to common stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average number of common shares-basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted average number of common shares-diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Basic net loss per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Remaining lease term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Remaining lease term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:label="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:to="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate_lbl" xml:lang="en-US">Weighted average discount rate for our facility and equipment leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DisclosureLeasesAbstract" xlink:to="PCSA_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Annual Lease Liabilities For All Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: current maturities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DisclosureLeasesAbstract" xlink:to="PCSA_DisclosureLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="PCSA_DisclosureLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Annual Lease Liabilities For All Financing Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: current maturities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:to="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate_2_lbl" xml:lang="en-US">Operating and financing lease borrowing rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:label="PCSA_ProceedsFromRentAndOtherCostsReimbursements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:to="PCSA_ProceedsFromRentAndOtherCostsReimbursements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ProceedsFromRentAndOtherCostsReimbursements_lbl" xml:lang="en-US">Rent and other costs reimbursements received</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Due from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US">Purchase obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Annual base salary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xml:lang="en-US">Potential base salary increase</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PotentialBaseSalaryIncreaseFinancingMinimum" xlink:label="PCSA_PotentialBaseSalaryIncreaseFinancingMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PotentialBaseSalaryIncreaseFinancingMinimum" xlink:to="PCSA_PotentialBaseSalaryIncreaseFinancingMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PotentialBaseSalaryIncreaseFinancingMinimum_lbl" xml:lang="en-US">Potential base salary increase financing minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_CompensationArrangementWithIndividualBonusAwardsGrantedPercentage" xlink:label="PCSA_CompensationArrangementWithIndividualBonusAwardsGrantedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CompensationArrangementWithIndividualBonusAwardsGrantedPercentage" xlink:to="PCSA_CompensationArrangementWithIndividualBonusAwardsGrantedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_CompensationArrangementWithIndividualBonusAwardsGrantedPercentage_lbl" xml:lang="en-US">Executive bonus percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_MarketCapitalization" xlink:label="PCSA_MarketCapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_MarketCapitalization" xlink:to="PCSA_MarketCapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_MarketCapitalization_lbl" xml:lang="en-US">Market capitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PerformanceVestingCriteriaValue" xlink:label="PCSA_PerformanceVestingCriteriaValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PerformanceVestingCriteriaValue" xlink:to="PCSA_PerformanceVestingCriteriaValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_PerformanceVestingCriteriaValue_lbl" xml:lang="en-US">Performance vesting criteria</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PurchaseAgreementMember" xlink:to="PCSA_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PreFundedWarrantMember" xlink:to="PCSA_PreFundedWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PreFundedWarrantMember_doc" xml:lang="en-US">Pre Funded Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedDuringPeriodSharesWarrantExercised" xlink:to="PCSA_StockIssuedDuringPeriodSharesWarrantExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_StockIssuedDuringPeriodSharesWarrantExercised_doc" xml:lang="en-US">Stock issued during period shares exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_GrossProceedsFromIssuanceOfCommonStock" xlink:to="PCSA_GrossProceedsFromIssuanceOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_GrossProceedsFromIssuanceOfCommonStock_doc" xml:lang="en-US">Gross proceeds from issuance of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PlacementAgentMember" xlink:to="PCSA_PlacementAgentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PlacementAgentMember_doc" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinancingLeaseRightofUseAsset" xlink:to="PCSA_OperatingAndFinancingLeaseRightofUseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_OperatingAndFinancingLeaseRightofUseAsset_doc" xml:lang="en-US">Amount of lessee's right of use underlying asset under operating and finance leases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinanceLeaseLiabilityCurrent" xlink:to="PCSA_OperatingAndFinanceLeaseLiabilityCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_OperatingAndFinanceLeaseLiabilityCurrent_doc" xml:lang="en-US">Operating and finance lease liability current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_DueToLicensor" xlink:to="PCSA_DueToLicensor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_DueToLicensor_doc" xml:lang="en-US">Due to licensor.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:to="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent_doc" xml:lang="en-US">Operating and finance lease liability noncurrent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_TwoThousandAndNineteenPlanMember" xlink:to="PCSA_TwoThousandAndNineteenPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_TwoThousandAndNineteenPlanMember_doc" xml:lang="en-US">2019 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_doc" xml:lang="en-US">Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation" xlink:to="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation_doc" xml:lang="en-US">Shares withheld to pay income tax on stock based compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares" xlink:to="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares_doc" xml:lang="en-US">Shares withheld to pay income tax on stock based compensation shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_UnrecognizedShareBasedCompensationExpense" xlink:to="PCSA_UnrecognizedShareBasedCompensationExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_UnrecognizedShareBasedCompensationExpense_doc" xml:lang="en-US">Unrecognized share based compensation expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:to="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_doc" xml:lang="en-US">Adjustments to additional paid in capital settlement of stock awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesIssuedinConnectionwithLicenseAgreementValue" xlink:to="PCSA_SharesIssuedinConnectionwithLicenseAgreementValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SharesIssuedinConnectionwithLicenseAgreementValue_doc" xml:lang="en-US">Value of shares issued in connection with license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesIssuedinConnectionwithLicenseAgreementShares" xlink:to="PCSA_SharesIssuedinConnectionwithLicenseAgreementShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SharesIssuedinConnectionwithLicenseAgreementShares_doc" xml:lang="en-US">Number of shares issued in connection with license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ConsultingAgreementMember" xlink:to="PCSA_ConsultingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ConsultingAgreementMember_doc" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_PaymentsForSettlementOfStockAwards" xlink:to="PCSA_PaymentsForSettlementOfStockAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_PaymentsForSettlementOfStockAwards_doc" xml:lang="en-US">Payments for settlement of stock awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SpartanCapitalSecuritesLLCMember" xlink:to="PCSA_SpartanCapitalSecuritesLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SpartanCapitalSecuritesLLCMember_doc" xml:lang="en-US">Spartan Capital Securites LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" xlink:to="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor_doc" xml:lang="en-US">Stock issued in connection with licensing agreement which had previously been recorded as due to licensor.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_RightofuseAsset" xlink:to="PCSA_RightofuseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_RightofuseAsset_doc" xml:lang="en-US">Right-of-use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FinancingLeaseLiability" xlink:to="PCSA_FinancingLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_FinancingLeaseLiability_doc" xml:lang="en-US">Financing lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NonCashLeaseLiabilityNet" xlink:to="PCSA_NonCashLeaseLiabilityNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_NonCashLeaseLiabilityNet_doc" xml:lang="en-US">Non cash lease liability net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:to="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate_doc" xml:lang="en-US">Operating and financing lease weighted average discount rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FacilityLeaseMember" xlink:to="PCSA_FacilityLeaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_FacilityLeaseMember_doc" xml:lang="en-US">Facility Lease [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:to="PCSA_ProceedsFromRentAndOtherCostsReimbursements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ProceedsFromRentAndOtherCostsReimbursements_doc" xml:lang="en-US">Rent and other costs reimbursements received.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CorLystLLCMember" xlink:to="PCSA_CorLystLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_CorLystLLCMember_doc" xml:lang="en-US">CorLyst, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CROsMember" xlink:to="PCSA_CROsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_CROsMember_doc" xml:lang="en-US">CROs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ExpectedFinancingAmount" xlink:label="PCSA_ExpectedFinancingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ExpectedFinancingAmount" xlink:to="PCSA_ExpectedFinancingAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ExpectedFinancingAmount_doc" xml:lang="en-US">Expected financing amount.</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationVestedUponCumulativeFinancingValue" xlink:label="PCSA_ShareBasedCompensationVestedUponCumulativeFinancingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationVestedUponCumulativeFinancingValue" xlink:to="PCSA_ShareBasedCompensationVestedUponCumulativeFinancingValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationVestedUponCumulativeFinancingValue_doc" xml:lang="en-US">Share based compensation vested upon cumulative financing value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ElionOncologyIncMember" xlink:to="PCSA_ElionOncologyIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ElionOncologyIncMember_doc" xml:lang="en-US">Elion Oncology, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ConsultantMember" xlink:to="PCSA_ConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ConsultantMember_doc" xml:lang="en-US">Consultant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" xlink:to="PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes_doc" xml:lang="en-US">Stock issued during period shares stock withheld for income taxes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LesseeOperatingAndFinancingLeasesTextBlock" xlink:to="PCSA_LesseeOperatingAndFinancingLeasesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_LesseeOperatingAndFinancingLeasesTextBlock_doc" xml:lang="en-US">Lessee Operating And Financing Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" xlink:to="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_doc" xml:lang="en-US">Schedule Of Weighted Average Remaining Lease Terms And Discount Rate For Our Operatingand Financing Leases [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" xlink:to="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock_doc" xml:lang="en-US">Business Activities And Organization [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LiquidityPolicyTextBlock" xlink:to="PCSA_LiquidityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_LiquidityPolicyTextBlock_doc" xml:lang="en-US">Liquidity [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SalesAgreementMember" xlink:to="PCSA_SalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SalesAgreementMember_doc" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_MarketCapitalization" xlink:to="PCSA_MarketCapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_MarketCapitalization_doc" xml:lang="en-US">Market capitalization.</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationVestedUponCumulativeFinancing" xlink:label="PCSA_ShareBasedCompensationVestedUponCumulativeFinancing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationVestedUponCumulativeFinancing" xlink:to="PCSA_ShareBasedCompensationVestedUponCumulativeFinancing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationVestedUponCumulativeFinancing_doc" xml:lang="en-US">Share based compensation vested upon cumulative financing.</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedUponGrantsInPeriod" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedUponGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedUponGrantsInPeriod" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedUponGrantsInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedUponGrantsInPeriod_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award equity instruments other than options vested upon grants in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AllianceGlobalPartnersMember" xlink:to="PCSA_AllianceGlobalPartnersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_AllianceGlobalPartnersMember_doc" xml:lang="en-US">Alliance Global Partners [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LicenseAgreementMember" xlink:to="PCSA_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_EmployeesAndConsultantsMember" xlink:to="PCSA_EmployeesAndConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_EmployeesAndConsultantsMember_doc" xml:lang="en-US">Employees and Consultants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ATMOfferingMember" xlink:to="PCSA_ATMOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ATMOfferingMember_doc" xml:lang="en-US">ATM Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_WarrantsExercisableAndMaturityDate" xlink:to="PCSA_WarrantsExercisableAndMaturityDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_WarrantsExercisableAndMaturityDate_doc" xml:lang="en-US">Warrants exercisable and maturity date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_NextGenerationCapecitabineCAPMember" xlink:to="PCSA_NextGenerationCapecitabineCAPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_NextGenerationCapecitabineCAPMember_doc" xml:lang="en-US">Next Generation Capecitabine - Cap [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_JuneTwentyEightTwoThousandAndTwentyFiveMember" xlink:label="PCSA_JuneTwentyEightTwoThousandAndTwentyFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_JuneTwentyEightTwoThousandAndTwentyFiveMember" xlink:to="PCSA_JuneTwentyEightTwoThousandAndTwentyFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_JuneTwentyEightTwoThousandAndTwentyFiveMember_doc" xml:lang="en-US">June 28, 2025 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_CompensationArrangementWithIndividualBonusAwardsGrantedPercentage" xlink:to="PCSA_CompensationArrangementWithIndividualBonusAwardsGrantedPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_CompensationArrangementWithIndividualBonusAwardsGrantedPercentage_doc" xml:lang="en-US">Compensation arrangement with individual bonus awards granted percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_FirstPerformanceBasedRSUMember" xlink:to="PCSA_FirstPerformanceBasedRSUMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_FirstPerformanceBasedRSUMember_doc" xml:lang="en-US">First Performance Based RSUs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SecondPerformanceBasedRSUMember" xlink:to="PCSA_SecondPerformanceBasedRSUMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_SecondPerformanceBasedRSUMember_doc" xml:lang="en-US">Second Performance Based RSUs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ServiceBasedRSUMember" xlink:to="PCSA_ServiceBasedRSUMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ServiceBasedRSUMember_doc" xml:lang="en-US">Service Based RSU [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ThreeYearVestingMember" xlink:to="PCSA_ThreeYearVestingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ThreeYearVestingMember_doc" xml:lang="en-US">3-Year Vesting [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ServiceBasedRestrictedStockUnitsMember" xlink:to="PCSA_ServiceBasedRestrictedStockUnitsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_ServiceBasedRestrictedStockUnitsMember_doc" xml:lang="en-US">Service Based RSUs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember" xlink:to="PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember_doc" xml:lang="en-US">January 1, 2025 Vesting [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_OfferingMember" xlink:to="PCSA_OfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PCSA_OfferingMember_doc" xml:lang="en-US">Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:to="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:to="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards_3_lbl" xml:lang="en-US">AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation" xlink:to="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation_3_lbl" xml:lang="en-US">SharesWithheldToPayIncomeTaxOnStockbasedCompensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares" xlink:to="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares_3_lbl" xml:lang="en-US">SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_2_lbl" xml:lang="en-US">Increase (Decrease) in Due to Related Parties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">Equity [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_LesseeOperatingAndFinancingLeasesTextBlock" xlink:to="PCSA_LesseeOperatingAndFinancingLeasesTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_LesseeOperatingAndFinancingLeasesTextBlock_3_lbl" xml:lang="en-US">Lessee Operating And Financing Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:to="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_2_lbl" xml:lang="en-US">Lessee, Finance Lease, Remaining Lease Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_2_lbl" xml:lang="en-US">Finance Lease, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>pcsa-20240630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Cover" xlink:href="pcsa-20240630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheets" xlink:href="pcsa-20240630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:href="pcsa-20240630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:href="pcsa-20240630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="pcsa-20240630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:href="pcsa-20240630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:href="pcsa-20240630.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="pcsa-20240630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:href="pcsa-20240630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:href="pcsa-20240630.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:href="pcsa-20240630.xsd#NetLossPerShareOfCommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Leases" xlink:href="pcsa-20240630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:href="pcsa-20240630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="pcsa-20240630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SubsequentEvent" xlink:href="pcsa-20240630.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pcsa-20240630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:href="pcsa-20240630.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:href="pcsa-20240630.xsd#NetLossPerShareOfCommonStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/LeasesTables" xlink:href="pcsa-20240630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="pcsa-20240630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:href="pcsa-20240630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="pcsa-20240630.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:href="pcsa-20240630.xsd#ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="pcsa-20240630.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:href="pcsa-20240630.xsd#ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:href="pcsa-20240630.xsd#NetLossPerShareOfCommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:href="pcsa-20240630.xsd#ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:href="pcsa-20240630.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:href="pcsa-20240630.xsd#ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" xlink:href="pcsa-20240630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="pcsa-20240630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="pcsa-20240630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative" xlink:href="pcsa-20240630.xsd#SubsequentEventDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OperatingAndFinancingLeaseRightofUseAsset" xlink:label="loc_PCSAOperatingAndFinancingLeaseRightofUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_PCSAOperatingAndFinancingLeaseRightofUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:label="loc_us-gaapAssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OperatingAndFinanceLeaseLiabilityCurrent" xlink:label="loc_PCSAOperatingAndFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_PCSAOperatingAndFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_DueToLicensor" xlink:label="loc_PCSADueToLicensor" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_PCSADueToLicensor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="loc_PCSAOperatingAndFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_PCSAOperatingAndFinanceLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTreasuryStockCommonShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockCommonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SharesIssuedinConnectionwithLicenseAgreementValue" xlink:label="loc_PCSASharesIssuedinConnectionwithLicenseAgreementValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesIssuedinConnectionwithLicenseAgreementValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SharesIssuedinConnectionwithLicenseAgreementShares" xlink:label="loc_PCSASharesIssuedinConnectionwithLicenseAgreementShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesIssuedinConnectionwithLicenseAgreementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:label="loc_PCSAAdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSAAdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation" xlink:label="loc_PCSASharesWithheldToPayIncomeTaxOnStockbasedCompensation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesWithheldToPayIncomeTaxOnStockbasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares" xlink:label="loc_PCSASharesWithheldToPayIncomeTaxOnStockbasedCompensationShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PCSASharesWithheldToPayIncomeTaxOnStockbasedCompensationShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PaymentsForSettlementOfStockAwards" xlink:label="loc_PCSAPaymentsForSettlementOfStockAwards" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_PCSAPaymentsForSettlementOfStockAwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" xlink:label="loc_PCSAStockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_PCSAStockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_RightofuseAsset" xlink:label="loc_PCSARightofuseAsset" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_PCSARightofuseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_FinancingLeaseLiability" xlink:label="loc_PCSAFinancingLeaseLiability" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_PCSAFinancingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_NonCashLeaseLiabilityNet" xlink:label="loc_PCSANonCashLeaseLiabilityNet" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_PCSANonCashLeaseLiabilityNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ConsultingAgreementMember" xlink:label="loc_PCSAConsultingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SpartanCapitalSecuritesLLCMember" xlink:label="loc_PCSASpartanCapitalSecuritesLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_PCSASpartanCapitalSecuritesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="995513 - Disclosure - Organization and Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquity" xlink:title="995514 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensation" xlink:title="995515 - Disclosure - Stock-based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" xlink:title="995516 - Disclosure - Net Loss per Share of Common Stock">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Leases" xlink:title="995517 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="loc_PCSADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_LesseeOperatingAndFinancingLeasesTextBlock" xlink:label="loc_PCSALesseeOperatingAndFinancingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_PCSALesseeOperatingAndFinancingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactions" xlink:title="995518 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:title="995519 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SubsequentEvent" xlink:title="995520 - Disclosure - Subsequent Event">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995521 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock" xlink:label="loc_PCSABusinessActivitiesAndOrganizationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_PCSABusinessActivitiesAndOrganizationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_LiquidityPolicyTextBlock" xlink:label="loc_PCSALiquidityPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_PCSALiquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationTables" xlink:title="995522 - Disclosure - Stock-based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables" xlink:title="995523 - Disclosure - Net Loss per Share of Common Stock (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LeasesTables" xlink:title="995524 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="loc_PCSADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" xlink:label="loc_PCSAScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_PCSAScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995525 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OrganizationAbstract" xlink:label="loc_PCSAOrganizationAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OrganizationTable" xlink:label="loc_PCSAOrganizationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationAbstract" xlink:to="loc_PCSAOrganizationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OrganizationLineItems" xlink:label="loc_PCSAOrganizationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_PCSAOrganizationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SalesAgreementMember" xlink:label="loc_PCSASalesAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSASalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PreFundedWarrantMember" xlink:label="loc_PCSAPreFundedWarrantMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PCSAPreFundedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_AllianceGlobalPartnersMember" xlink:label="loc_PCSAAllianceGlobalPartnersMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_PCSAAllianceGlobalPartnersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ATMOfferingMember" xlink:label="loc_PCSAATMOfferingMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSAATMOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_StockIssuedDuringPeriodSharesWarrantExercised" xlink:label="loc_PCSAStockIssuedDuringPeriodSharesWarrantExercised" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_PCSAStockIssuedDuringPeriodSharesWarrantExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_MaximumValueToBeSoldAtMarketOffering" xlink:label="loc_PCSAMaximumValueToBeSoldAtMarketOffering" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_PCSAMaximumValueToBeSoldAtMarketOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSAOrganizationLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" xlink:title="995526 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="loc_us-gaapClassOfStockDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PurchaseAgreementMember" xlink:label="loc_PCSAPurchaseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_LicenseAgreementMember" xlink:label="loc_PCSALicenseAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSALicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ConsultingAgreementMember" xlink:label="loc_PCSAConsultingAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PreFundedWarrantMember" xlink:label="loc_PCSAPreFundedWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PCSAPreFundedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PlacementAgentMember" xlink:label="loc_PCSAPlacementAgentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSAPlacementAgentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ElionOncologyIncMember" xlink:label="loc_PCSAElionOncologyIncMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_PCSAElionOncologyIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ConsultantMember" xlink:label="loc_PCSAConsultantMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_PCSAConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_EmployeesAndConsultantsMember" xlink:label="loc_PCSAEmployeesAndConsultantsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_PCSAEmployeesAndConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_WarrantsExercisableAndMaturityDate" xlink:label="loc_PCSAWarrantsExercisableAndMaturityDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAWarrantsExercisableAndMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_StockIssuedDuringPeriodSharesWarrantExercised" xlink:label="loc_PCSAStockIssuedDuringPeriodSharesWarrantExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAStockIssuedDuringPeriodSharesWarrantExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_PCSAGrossProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAGrossProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" xlink:label="loc_PCSAStockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_PCSAStockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="995527 - Disclosure - Schedule of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails" xlink:title="995528 - Disclosure - Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="995529 - Disclosure - Stock-based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_TwoThousandAndNineteenPlanMember" xlink:label="loc_PCSATwoThousandAndNineteenPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_PCSATwoThousandAndNineteenPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ServiceBasedRestrictedStockUnitsMember" xlink:label="loc_PCSAServiceBasedRestrictedStockUnitsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAServiceBasedRestrictedStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_FirstPerformanceBasedRSUMember" xlink:label="loc_PCSAFirstPerformanceBasedRSUMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAFirstPerformanceBasedRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SecondPerformanceBasedRSUMember" xlink:label="loc_PCSASecondPerformanceBasedRSUMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSASecondPerformanceBasedRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_EmployeesMember" xlink:label="loc_PCSAEmployeesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_PCSAEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapVestingAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember" xlink:label="loc_PCSAJanuaryOneTwoThousandTwentyFiveVestingMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_PCSAJanuaryOneTwoThousandTwentyFiveVestingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ThreeYearVestingMember" xlink:label="loc_PCSAThreeYearVestingMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_PCSAThreeYearVestingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_TitleOfInidividualAxis" xlink:label="loc_PCSATitleOfInidividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_PCSATitleOfInidividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_TitleOfInidividualDomain" xlink:label="loc_PCSATitleOfInidividualDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSATitleOfInidividualAxis" xlink:to="loc_PCSATitleOfInidividualDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_EmployeesMember" xlink:label="loc_PCSAEmployeesMember_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSATitleOfInidividualDomain" xlink:to="loc_PCSAEmployeesMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_NextGenerationCapecitabineCAPMember" xlink:label="loc_PCSANextGenerationCapecitabineCAPMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSANextGenerationCapecitabineCAPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ConsultingAgreementMember" xlink:label="loc_PCSAConsultingAgreementMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PCSAConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OfferingMember" xlink:label="loc_PCSAOfferingMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PCSAOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:label="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_UnrecognizedShareBasedCompensationExpense" xlink:label="loc_PCSAUnrecognizedShareBasedCompensationExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAUnrecognizedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PaymentsForSettlementOfStockAwards" xlink:label="loc_PCSAPaymentsForSettlementOfStockAwards" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PCSAPaymentsForSettlementOfStockAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" xlink:title="995530 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaapEarningsPerShareBasicLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapEarningsPerShareBasicLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative" xlink:title="995531 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails" xlink:title="995532 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="loc_PCSADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_FacilityLeaseMember" xlink:label="loc_PCSAFacilityLeaseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_PCSAFacilityLeaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeFinanceLeaseRemainingLeaseTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeFinanceLeaseRemainingLeaseTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:label="loc_PCSAOperatingAndFinancingLeaseWeightedAverageDiscountRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_PCSAOperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" xlink:title="995533 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="loc_PCSADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails" xlink:title="995534 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="loc_PCSADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/LeasesDetailsNarrative" xlink:title="995535 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_DisclosureLeasesAbstract" xlink:label="loc_PCSADisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:label="loc_PCSAOperatingAndFinancingLeaseWeightedAverageDiscountRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_PCSAOperatingAndFinancingLeaseWeightedAverageDiscountRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PCSADisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="995536 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_CorLystLLCMember" xlink:label="loc_PCSACorLystLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_PCSACorLystLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ProceedsFromRentAndOtherCostsReimbursements" xlink:label="loc_PCSAProceedsFromRentAndOtherCostsReimbursements" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_PCSAProceedsFromRentAndOtherCostsReimbursements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995537 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_CROsMember" xlink:label="loc_PCSACROsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_PCSACROsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPurchaseObligation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative" xlink:title="995538 - Disclosure - Subsequent Event (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_ServiceBasedRSUMember" xlink:label="loc_PCSAServiceBasedRSUMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAServiceBasedRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_FirstPerformanceBasedRSUMember" xlink:label="loc_PCSAFirstPerformanceBasedRSUMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSAFirstPerformanceBasedRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_SecondPerformanceBasedRSUMember" xlink:label="loc_PCSASecondPerformanceBasedRSUMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PCSASecondPerformanceBasedRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PotentialBaseSalaryIncreaseFinancingMinimum" xlink:label="loc_PCSAPotentialBaseSalaryIncreaseFinancingMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_PCSAPotentialBaseSalaryIncreaseFinancingMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_CompensationArrangementWithIndividualBonusAwardsGrantedPercentage" xlink:label="loc_PCSACompensationArrangementWithIndividualBonusAwardsGrantedPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_PCSACompensationArrangementWithIndividualBonusAwardsGrantedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_MarketCapitalization" xlink:label="loc_PCSAMarketCapitalization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_PCSAMarketCapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pcsa-20240630.xsd#PCSA_PerformanceVestingCriteriaValue" xlink:label="loc_PCSAPerformanceVestingCriteriaValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_PCSAPerformanceVestingCriteriaValue" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481390435040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Aug. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Processa
Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001533743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-1539785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7380
Coca Cola Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hanover<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">21076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">776-3133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PCSA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,256,944<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481393934864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,571,120<span></span>
</td>
<td class="nump">$ 4,706,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">1,906,854<span></span>
</td>
<td class="nump">926,300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">7,477,974<span></span>
</td>
<td class="nump">5,632,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, net</a></td>
<td class="nump">2,276<span></span>
</td>
<td class="nump">2,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OperatingAndFinancingLeaseRightofUseAsset', window );">Lease right-of-use assets, net of accumulated amortization</a></td>
<td class="nump">115,191<span></span>
</td>
<td class="nump">146,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">5,535<span></span>
</td>
<td class="nump">5,535<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment', window );">Total Other Assets</a></td>
<td class="nump">120,726<span></span>
</td>
<td class="nump">151,592<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">7,600,976<span></span>
</td>
<td class="nump">5,786,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OperatingAndFinanceLeaseLiabilityCurrent', window );">Current maturities of lease liabilities</a></td>
<td class="nump">93,181<span></span>
</td>
<td class="nump">83,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">953,086<span></span>
</td>
<td class="nump">311,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DueToLicensor', window );">Due to licensor</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">189,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">505,397<span></span>
</td>
<td class="nump">146,274<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">1,551,664<span></span>
</td>
<td class="nump">730,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent', window );">Non-current lease liabilities</a></td>
<td class="nump">25,648<span></span>
</td>
<td class="nump">66,905<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">1,577,312<span></span>
</td>
<td class="nump">797,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001, 100,000,000 shares authorized: 2,873,883 issued and 2,868,883 outstanding at June 30, 2024; and 1,291,000 issued and 1,286,000 outstanding at December 31, 2023</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">87,429,165<span></span>
</td>
<td class="nump">80,658,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock at cost &#8212; 5,000 shares at June 30, 2024 and December 31, 2023</a></td>
<td class="num">(300,000)<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(81,105,788)<span></span>
</td>
<td class="num">(75,369,081)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">6,023,664<span></span>
</td>
<td class="nump">4,989,159<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 7,600,976<span></span>
</td>
<td class="nump">$ 5,786,643<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DueToLicensor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Due to licensor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DueToLicensor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OperatingAndFinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease liability current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OperatingAndFinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease liability noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OperatingAndFinancingLeaseRightofUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right of use underlying asset under operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OperatingAndFinancingLeaseRightofUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481384630608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">2,873,883<span></span>
</td>
<td class="nump">1,291,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">2,868,883<span></span>
</td>
<td class="nump">1,286,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock shares</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481390407888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">$ 1,730,444<span></span>
</td>
<td class="nump">$ 1,688,164<span></span>
</td>
<td class="nump">$ 3,269,555<span></span>
</td>
<td class="nump">$ 3,342,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,351,580<span></span>
</td>
<td class="nump">1,026,301<span></span>
</td>
<td class="nump">2,622,067<span></span>
</td>
<td class="nump">3,477,490<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Loss</a></td>
<td class="num">(3,082,024)<span></span>
</td>
<td class="num">(2,714,465)<span></span>
</td>
<td class="num">(5,891,622)<span></span>
</td>
<td class="num">(6,819,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other Income (Expense), net</a></td>
<td class="nump">71,698<span></span>
</td>
<td class="nump">101,900<span></span>
</td>
<td class="nump">154,915<span></span>
</td>
<td class="nump">185,361<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net Operating Loss Before Income Tax Benefit</a></td>
<td class="num">(3,010,326)<span></span>
</td>
<td class="num">(2,612,565)<span></span>
</td>
<td class="num">(5,736,707)<span></span>
</td>
<td class="num">(6,634,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (3,010,326)<span></span>
</td>
<td class="num">$ (2,612,565)<span></span>
</td>
<td class="num">$ (5,736,707)<span></span>
</td>
<td class="num">$ (6,634,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss per Common Share - Basic</a></td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (1.94)<span></span>
</td>
<td class="num">$ (2.11)<span></span>
</td>
<td class="num">$ (5.34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss per Common Share - Diluted</a></td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (1.94)<span></span>
</td>
<td class="num">$ (2.11)<span></span>
</td>
<td class="num">$ (5.34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic</a></td>
<td class="nump">2,983,283<span></span>
</td>
<td class="nump">1,346,808<span></span>
</td>
<td class="nump">2,724,903<span></span>
</td>
<td class="nump">1,243,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted</a></td>
<td class="nump">2,983,283<span></span>
</td>
<td class="nump">1,346,808<span></span>
</td>
<td class="nump">2,724,903<span></span>
</td>
<td class="nump">1,243,475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481385365040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Treasury Stock, Common [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 72,018,222<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">$ (64,247,561)<span></span>
</td>
<td class="nump">$ 7,470,741<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance. shares at Dec. 31, 2022</a></td>
<td class="nump">806,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">341,503<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">341,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">3,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in connection with capital raise, net of transaction costs</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">6,352,035<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,352,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in connection with capital raise, net of transaction costs, shares</a></td>
<td class="nump">421,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,022,073)<span></span>
</td>
<td class="num">(4,022,073)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">78,711,760<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(68,269,634)<span></span>
</td>
<td class="nump">10,142,249<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance. shares at Mar. 31, 2023</a></td>
<td class="nump">1,231,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">72,018,222<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(64,247,561)<span></span>
</td>
<td class="nump">7,470,741<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance. shares at Dec. 31, 2022</a></td>
<td class="nump">806,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,634,638)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">80,341,758<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(70,882,199)<span></span>
</td>
<td class="nump">9,159,682<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance. shares at Jun. 30, 2023</a></td>
<td class="nump">1,231,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">78,711,760<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(68,269,634)<span></span>
</td>
<td class="nump">10,142,249<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance. shares at Mar. 31, 2023</a></td>
<td class="nump">1,231,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">319,123<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">319,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,612,565)<span></span>
</td>
<td class="num">(2,612,565)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued in connection with a consulting agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,310,875<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,310,875<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">80,341,758<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(70,882,199)<span></span>
</td>
<td class="nump">9,159,682<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance. shares at Jun. 30, 2023</a></td>
<td class="nump">1,231,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">80,658,111<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(75,369,081)<span></span>
</td>
<td class="nump">4,989,159<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance. shares at Dec. 31, 2023</a></td>
<td class="nump">1,291,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">167,642<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">167,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">13,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in connection with capital raise, net of transaction costs</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">6,282,274<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,282,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in connection with capital raise, net of transaction costs, shares</a></td>
<td class="nump">1,555,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,726,381)<span></span>
</td>
<td class="num">(2,726,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_SharesIssuedinConnectionwithLicenseAgreementValue', window );">Shares issued in connection with license agreement</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">188,999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">189,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_SharesIssuedinConnectionwithLicenseAgreementShares', window );">Shares issued in connection with license agreement, shares</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards', window );">Settlement of stock award</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(8,561)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation', window );">Shares withheld to pay income taxes on stock-based compensation</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(9,923)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares', window );">Shares withheld to pay income taxes on stock-based compensation, shares</a></td>
<td class="num">(3,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">87,278,542<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(78,095,462)<span></span>
</td>
<td class="nump">8,883,366<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance. shares at Mar. 31, 2024</a></td>
<td class="nump">2,860,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">80,658,111<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(75,369,081)<span></span>
</td>
<td class="nump">4,989,159<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance. shares at Dec. 31, 2023</a></td>
<td class="nump">1,291,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,736,707)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 287<span></span>
</td>
<td class="nump">87,429,165<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(81,105,788)<span></span>
</td>
<td class="nump">6,023,664<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance. shares at Jun. 30, 2024</a></td>
<td class="nump">2,873,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">87,278,542<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">(78,095,462)<span></span>
</td>
<td class="nump">8,883,366<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance. shares at Mar. 31, 2024</a></td>
<td class="nump">2,860,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">152,631<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">152,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">14,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,010,326)<span></span>
</td>
<td class="num">(3,010,326)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation', window );">Shares withheld to pay income taxes on stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,008)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,008)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares', window );">Shares withheld to pay income taxes on stock-based compensation, shares</a></td>
<td class="num">(1,265)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 287<span></span>
</td>
<td class="nump">$ 87,429,165<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="num">$ (81,105,788)<span></span>
</td>
<td class="nump">$ 6,023,664<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance. shares at Jun. 30, 2024</a></td>
<td class="nump">2,873,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital settlement of stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_SharesIssuedinConnectionwithLicenseAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in connection with license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_SharesIssuedinConnectionwithLicenseAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_SharesIssuedinConnectionwithLicenseAgreementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued in connection with license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_SharesIssuedinConnectionwithLicenseAgreementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares withheld to pay income tax on stock based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares withheld to pay income tax on stock based compensation shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481385665344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,736,707)<span></span>
</td>
<td class="num">$ (6,634,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">278<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense for right-of-use assets</a></td>
<td class="nump">42,670<span></span>
</td>
<td class="nump">39,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">320,275<span></span>
</td>
<td class="nump">660,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Warrant issued to purchase 158,007 shares of common stock in connection with a consulting agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,310,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="num">(980,554)<span></span>
</td>
<td class="nump">662,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(41,228)<span></span>
</td>
<td class="num">(38,233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">641,469<span></span>
</td>
<td class="num">(88,526)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Due to related parties</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">359,123<span></span>
</td>
<td class="num">(91,559)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,394,713)<span></span>
</td>
<td class="num">(4,178,539)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="nump">6,282,430<span></span>
</td>
<td class="nump">6,352,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay taxes on stock-based compensation</a></td>
<td class="num">(11,932)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_PaymentsForSettlementOfStockAwards', window );">Settlement of stock award</a></td>
<td class="num">(8,561)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease obligation</a></td>
<td class="num">(2,301)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,259,636<span></span>
</td>
<td class="nump">6,352,077<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Increase in Cash</a></td>
<td class="nump">864,923<span></span>
</td>
<td class="nump">2,173,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents &#8211; Beginning of Period</a></td>
<td class="nump">4,706,197<span></span>
</td>
<td class="nump">6,503,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents &#8211; End of Period</a></td>
<td class="nump">5,571,120<span></span>
</td>
<td class="nump">8,677,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-Cash Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor', window );">Issuance of 5,000 shares of common stock in connection with a licensing agreement which had previously been recorded as a due to licensor</a></td>
<td class="nump">189,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_RightofuseAsset', window );">Right-of-use asset</a></td>
<td class="nump">11,804<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_FinancingLeaseLiability', window );">Financing lease liability</a></td>
<td class="num">(11,804)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_NonCashLeaseLiabilityNet', window );">Net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_FinancingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_FinancingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_NonCashLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash lease liability net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_NonCashLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_PaymentsForSettlementOfStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for settlement of stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_PaymentsForSettlementOfStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_RightofuseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_RightofuseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued in connection with licensing agreement which had previously been recorded as due to licensor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481382634496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued in connection with license agreement</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Spartan Capital Securites LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=PCSA_SpartanCapitalSecuritesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=PCSA_SpartanCapitalSecuritesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481571268352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (3,010,326)<span></span>
</td>
<td class="num">$ (2,726,381)<span></span>
</td>
<td class="num">$ (2,612,565)<span></span>
</td>
<td class="num">$ (4,022,073)<span></span>
</td>
<td class="num">$ (5,736,707)<span></span>
</td>
<td class="num">$ (6,634,638)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481395445056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481395514016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_805_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zC9BccssvBck" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_828_zY8J4EdS8KXh">Organization and Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zyfLjrkM3c7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_862_z78cgDHQuO7a">Organization</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our
Next Generation Chemotherapy (&#8220;NGC&#8221;) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of
existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution <span style="background-color: white">in
the body, </span> while maintaining the well-established existing mechanisms of killing the cancer cells. By modifying the
NGC drugs in this manner, we believe our three NGC treatments will provide improved safety-efficacy profiles when compared to their
currently marketed counterparts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
January 22, 2024, we filed a Certificate of Amendment to our Certificate of Incorporation, as amended with the Secretary of State of
Delaware that effected a <span id="xdx_90C_eus-gaap--StockholdersEquityReverseStockSplit_c20240122__20240122_za2FbPhXsRXg" title="Reverse stock split">1-for-20 reverse stock split</span> of our common stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240122_zkV5uoCqAZCk" title="Common stock, par value">0.0001</span> per share (the &#8220;Reverse Stock Split&#8221;).
Pursuant to the Certificate of Amendment, our issued common stock decreased from <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20240121_zjmf2a7KyrS7" title="Common stock shares issued">24,706,474</span> shares to <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20240122_zo6r78uDu8fg" title="Common stock shares issued">1,291,000</span> shares and our outstanding
common stock decreased from <span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20240121_zTsbrlIIgSn9" title="Common stock shares outstanding">24,606,474</span> to <span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20240122_z9Bz4KX7Q8h8" title="Common stock shares outstanding">1,286,000</span>. The Reverse Stock Split did not affect our authorized common stock of <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20240122_znUn2BYxk9rd" title="Common stock shares authorized">100,000,000</span>
shares or our common stock par value. All shares of common stock, including common stock underlying warrants, stock options, restricted
stock awards and restricted stock units, as well as exercise prices and per share information in these condensed consolidated financial
statements give retroactive effect to the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zR3GMsZmAJcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_867_zvtxdjVgydQ9">Basis
of Presentation</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#8220;SEC&#8221;) on Form 10-Q and Article 8 of Regulation S-X.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2023, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_ecustom--LiquidityPolicyTextBlock_zE8ajnErawKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_86F_zTTjxihF8auj">Liquidity</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations,
realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses
since inception, are currently devoting substantially all of our efforts toward research and development of our NGC drug product candidates,
including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated deficit
of $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20240630_zzGuRW9nIYDi" title="Accumulated deficit">81.1</span> <span style="background-color: white">million
at June 30, 2024. During the six months ended June 30, 2024, we generated a net loss of $</span><span id="xdx_900_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20240630_z72a2i4fTzJh" title="Net loss">5.7</span> <span style="background-color: white">million
and used $</span><span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20240630_zboCTV9vcQec" title="Net cash for operating activities from continuing operations">5.4</span> <span style="background-color: white">million in net cash for operating activities from continuing operations. To
date, none of our drug candidates have been approved for sale, and therefore we have not generated any product revenue and do not expect
positive cash flow from operations in the foreseeable future.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
have financed our operations primarily through public equity issuances, including an offering we closed on January 30, 2024, where we
sold <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240129__20240130__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zSIMiDrKloLl" title="Number of shares sold">476,000</span> shares of our common stock, pre-funded warrants to purchase up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240130__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zp63FOwfMDka" title="Warrants to purchase">1,079,555</span> shares of our common stock, and warrants for
the purchase of up to <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zI0kQsZWFyeb" title="Warrants to purchase shares">1,555,555</span> shares of our common stock for net proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240129__20240130_zFKr4ofUj8vj" title="Net proceeds">6.3</span> million, after deducting placement agent fees and
offering-related expenses. Simultaneously with the closing of the sale, the pre-funded warrants were exercised in exchange for <span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesWarrantExercised_iI_c20240130__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zgekzZOaWhT5" title="Warrant exercised">1,079,555</span>
shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the &#8220;Registration
Statement&#8221;), including a base prospectus relating to the offering of up to $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240531__20240531_zFND77df1Ys" title="Shares issued initial offering">50,000,000</span>
in the aggregate of the securities identified in the base prospectus from time to time in one or more offerings; and a prospectus
supplement relating to the shares of our common stock that may be issued and sold under a sales agreement dated May 21, 2024 (the
&#8220;Sales Agreement&#8221;) between us and A.G.P./Alliance Global Partners (the &#8220;Sales Agent&#8221;), through which we may issue and
sell in a registered &#8220;at the market offering&#8221; shares of our common stock having an aggregate offering price of up to
$<span id="xdx_901_ecustom--MaximumValueToBeSoldAtMarketOffering_pn5n6_c20240521__20240521__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_z5Vkxhd3mvQ9" title="Maximum value to be sold at the market offering">2.4</span>
million (subject to adjustment) from time to time through or to our Sales Agent (the &#8220;ATM Offering&#8221;). We expect to use
net proceeds, if any, from the ATM Offering over time for continued research and development for our portfolio of drug candidates,
especially our oncology products, and working capital and general corporate purposes. The shares under the ATM Offering will be sold
and issued pursuant to the Registration Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At
June 30, 2024, we had cash and cash equivalents totaling $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20240630_zJIiwe4qLibf" title="Cash and cash equivalents">5.6</span> <span style="background-color: white">million
which, based on our current business plans, we believe these funds will satisfy our <span style="background-color: white">operating </span>
needs into late 2024, including the beginning of our Phase 2 trial of NGC-Cap in breast cancer. Our ability to execute our
longer-term operating plans, including future preclinical studies and clinical trials for our portfolio of drugs depend on our
ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding
transactions. <span style="background-color: white">We will continue to be dependent
upon equity and/or debt financing until we are able to generate positive cash flows from our operations.</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations,
strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable
to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or
planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in
certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and
distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms
that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of
our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no
assurance that future funding will be available when needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Absent
additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year
or more after the date that these condensed consolidated financial statements are available to be issued based on the timing and amount
of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result,
substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated
financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments
to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification
of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties
described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--UseOfEstimates_z7yg1qGZqK86" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_866_zd4N8dnQYBKb">Use
of Estimates</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules
and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial
statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation,
intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based
on management&#8217;s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable,
actual results could differ materially from those estimates and could impact future results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_z26Z9yKmjEZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes in accordance with ASC Topic 740, <i>Income Taxes.</i> Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. At June 30, 2024 and December 31, 2023, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed
quarterly and will be maintained until sufficient positive evidence exists to support its reversal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ACS 740-270 <i>Income Taxes &#8211; Interim Reporting</i>, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income
tax benefit or expense is expected for 2024 and the foreseeable future since we expect to generate taxable net operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_znppZHOwLNJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_86F_zG0UOiRw0515">Concentration
of Credit Risk</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to specified limits. Total cash held by our banks at June 30, 2024, exceeded FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zv3o7GlGuGDh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_868_z94UFS2MqFub">Recent
Accounting Pronouncements</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#8220;ASU&#8221;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated
financial position or results of operations.</span></p>
<p id="xdx_859_zqsonrUdij86" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481389495904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zz3S3hiE05e5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_82F_zsy1TSs2PCXb">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Preferred
Stock</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20240630_zKu9Q36csaC6" title="Preferred stock, shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20240630_z35p5wi2lwAb" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20231231_z8cAHOoGVlCc" title="Preferred stock, shares issued"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zVeeR41zrJ3" title="Preferred stock, shares outstanding">no</span></span></span></span> issued or outstanding shares of preferred stock at either June 30, 2024 or December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Common
Stock</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2024, we <span style="background-color: white">sold <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zkha9YZSlre8">476,000
</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of common
stock, pre-funded warrants to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zUwdeAAXjcG7">1,079,555
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of common stock
in lieu of shares of common stock (the &#8220;Pre-Funded Warrants&#8221;), and warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zT9NjvAGk7E3">1,555,555
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of our common
stock (the &#8220;Common Warrants&#8217;) in a public offering (the &#8220;Offering&#8221;). The Common Warrants have an exercise price
of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zGAfxiBLtA3j">4.50</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">,
are immediately exercisable and expire on <span id="xdx_907_ecustom--WarrantsExercisableAndMaturityDate_dd_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1mNc6nDyCMd">January
30, 2029</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">. The shares
of common stock  were offered at a combined public offering price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zrVkegQ0cBkb">4.50
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">per share and accompanying
Common Warrant and $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjCYfXWgibZa">4.4999
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">per Pre-Funded Warrant
and accompanying Common Warrant. The Pre-Funded Warrants had an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zNeYa1yQT3ei">0.0001
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">and were exercised in
full simultaneously with the closing of the Offering in exchange for <span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesWarrantExercised_iI_c20240630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zMukDIr1ri5g">1,079,555
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of our common
stock. Gross proceeds in connection with the Offering were $<span id="xdx_909_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zQVMoaFdYYja">7.0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">million. We received
$<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zwPWQbhcssO1">6.3
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">million in net proceeds
from the Offering, after deducting the fees of the placement agent and other offering-related expenses. We also issued to the placement
agent warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_zkjvuzYTZUfb">62,222
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of common stock,
exercisable at $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_zKSfv9c1mPm7">5.625
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">per share that expire
on <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_z2WpMlnEtEQ">February
1, 2027</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2024, we also issued: <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElionOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zG2Bi5hn3Ybi" title="Shares issued">5,000</span> shares of common stock to Elion Oncology, Inc. (&#8220;Elion&#8221;) in satisfaction
of the third milestone event under the license agreement; <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z3KL7gTXZBf6" title="Shares issued">10,000</span> shares of common stock to a consultant in accordance with their consulting
agreement; and <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesAndConsultantsMember_za80P7C6W111" title="Shares issued">12,328</span> shares of common stock to certain employees and consultants, net of <span id="xdx_90D_ecustom--StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes_c20240101__20240630_zuGeAqqSf13f" title="Stock withheld for income taxes">5,015</span> shares of common stock withheld for income
taxes owed upon distribution of the shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481390174880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zms0jgFIyhM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Note
3 - <span id="xdx_82D_zeCe8xOvK7H4">Stock-based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 11pt; text-align: justify; text-indent: -11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
June 19, 2019, our stockholders approved, and we adopted, the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the &#8220;2019
Plan&#8221;). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock
options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and
directors. On June 28, 2024, our shareholders approved an increase of shares available under the 2019 Plan, which now provides for the
aggregate issuance of <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20240628__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_z8Rd0nh27KK5" title="Maximum equity available for issuance">800,000</span> shares of our common stock. At June 30, 2024, we have </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20240630__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zJrpxcN9xI34" title="Shares available for future grants">503,129</span>
<span style="background-color: white">shares available for future grants.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Stock
Compensation Expense</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z6SzgmbGSO5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
recorded stock-based compensation expense for the three and six months ended June 30, 2024 and 2023 as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zodWD40luq2a" style="display: none">Schedule
of Stock-based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240401__20240630_z5FodJsigOll" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230401__20230630_zsR6fnL7T3Y6" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20240630_zCaIDiOiyqIl" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20230630_z2reTkBdvR18" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zBl0WgR2HB58" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">45,583</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">102,678</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">76,704</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">209,526</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zvjIzpXWeR6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">107,049</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">216,445</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">243,571</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">451,101</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensation_zIAzCfb6GuPk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">152,632</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">319,123</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">320,275</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">660,627</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zVU3URQcY35j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Stock
Options</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Stock
options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwlLKXKdUA1a" title="Options, forfeited">4,245</span>
shares of common stock with a weighted-average exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zc3eL8S5aKIb" title="Options, forfeited weighted average exercise price">336.00</span> expired during the six months ended June 30, 2024. At June
30, 2024, we had outstanding and exercisable options for the purchase of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUxcBfA1yEG6" title="Options exercisable, shares">2,747</span>
shares with a weighted average exercise price of $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjJ9FQ6wukZg" title="Options exercisable weighted average exercise price">409.09</span> <span style="background-color: white">and
a weighted average remaining contractual life of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAU3zGfUwJm1" title="Exercisable weighted average remaining contractual term">4.2</span>
years. </span>At June 30, 2024, we did not have any unrecognized stock-based compensation expense related to our granted stock
options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Restricted
Stock Awards</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the six months ended June 30, 2024, we vested <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zt8aKX836yGf" title="Number of shares, vested">1,250</span> Restricted Stock Awards (&#8220;RSAs&#8221;) with a weighted average grant-date fair
value of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zE655AtLV3S7" title="Weighted-average grant-date fair value per share, shares vested">9.26</span> per share. We had <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iI_do_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z03ctXbxoPph" title="Number of shares, outstanding">no</span> RSAs outstanding at June 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Restricted
Stock Units</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zwID5zmhYv8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Activity
with respect to our Restricted Stock Units (&#8220;RSUs&#8221;) during the six months ended June 30, 2024 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zoYyqIbs2L9d" style="display: none">Schedule
of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of <br/> shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- average <br/> grant-date fair <br/> value per share</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Outstanding at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLWDn2xUoC53" style="width: 18%; text-align: right" title="Number of shares, Beginning balance">222,722</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8V9qKOT7fs" style="width: 18%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance">45.82</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z68O3XAcTBg3" style="text-align: right" title="Number of shares, granted">39,202</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEqZAKfUHhLe" style="text-align: right" title="Weighted-average grant-date fair value per share, granted">2.24</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znkTJGQ0iJvl" style="text-align: right" title="Number of shares, forfeited">(10,775</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1Fq3XF0HLJ2" style="text-align: right" title="Weighted-average grant-date fair value per share, forfeited">58.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Issued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHFURFCsr4Vj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, issued">(12,328</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPvQk5Fa07xi" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average grant-date fair value per share, shares issued">99.86</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at June 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxd6fRrteoG3" style="text-align: right" title="Number of shares, ending balance">238,821</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5X8i7ksTIU6" style="text-align: right" title="Weighted-average grant-date fair value per share, ending balance">35.31</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Vested and unissued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzHjLHBIqhZ2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, vested and unissued">143,793</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuOc9MwdxRf4" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued">50.71</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Unvested at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znuJ5Df36qY5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, unvested">95,028</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zauZjCGzc6Y8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average grant-date fair value per share, unvested">12.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zIX1G5IxUuw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
June 28, 2024, we granted RSUs for the future issuance of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240628__20240628__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zm6da1XEUb8l" title="Number of shares, granted">39,202
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of common stock
to our employees which vest accordingly: RSUs for the future issuance of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240628__20240628__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockUnitsMember__us-gaap--VestingAxis__custom--JanuaryOneTwoThousandTwentyFiveVestingMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zakKaOLh1Cci" title="Number of shares, granted">14,969</span> shares of common stock vest on January 1, 2025; RSUs
for the future issuance of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240628__20240628__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockUnitsMember__custom--TitleOfInidividualAxis__custom--EmployeesMember__us-gaap--VestingAxis__custom--ThreeYearVestingMember_zvziE1YPMMM5" title="Number of shares, granted">18,173
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of common stock
vest over a three-year period upon meeting service requirements; RSUs for the future issuance of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240628__20240628__us-gaap--AwardTypeAxis__custom--FirstPerformanceBasedRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zBsoWhg7uTla" title="Number of shares, granted">3,030
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of common stock
vested upon grant due to regaining Nasdaq compliance; and RSUs for the future issuance of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240628__20240628__us-gaap--AwardTypeAxis__custom--SecondPerformanceBasedRSUMember__us-gaap--TypeOfArrangementAxis__custom--NextGenerationCapecitabineCAPMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zmAcGmjXrZ92" title="Number of shares, granted">3,030
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">shares of common stock
vest upon dosing the first patient in our Phase 2 study in NGC-Cap.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2024, unrecognized stock-based compensation expense of approximately</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zq1wg6oHSroi" title="Unrecognized share based compensation expense">538,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
RSUs is expected to be fully recognized over a weighted average period of <span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9vxgPMIXg79" title="Weighted average period for recognition">1.7 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.
The unrecognized expense excludes approximately $<span id="xdx_90E_ecustom--UnrecognizedShareBasedCompensationExpense_pp0p0_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zX2oq6C2lLcd">420,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
expense related to certain grants of RSUs with performance milestones that are not probable of occurring at this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Holders
of our vested RSUs will be issued shares of our common stock upon meeting the distribution restrictions contained in their Restricted
Stock Unit Award Agreement. The distribution restrictions are different (longer) than the vesting schedule, imposing an additional restriction
on the holder. Unlike RSAs, while certain employees may hold fully vested RSUs, the individual does not hold any shares or have any rights
of a shareholder until the distribution restrictions are met. Upon distribution to the employee, each RSU converts into one share of
our common stock. The RSUs contain dividend equivalent rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Warrants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the six months ended June 30, 2024, we did not grant any warrants to purchase shares of our common stock other than warrants to purchase
<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__custom--OfferingMember_zBM1K8LH4wZi" title="Warrants to purchase shares">1,617,777</span> shares of common stock as part of <span style="background-color: white">the O</span>ffering (see Note 2). Warrants to purchase <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zi6uDxFzZ0s8" title="Warrants, expired">5,000</span> shares of our common stock expired
unexercised. We also repurchased a warrant issued to a consultant in 2023 for the purchase of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zAV73yMN6jbl" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures">15,000</span> shares of our common stock in exchange
for a payment of $<span id="xdx_906_ecustom--PaymentsForSettlementOfStockAwards_pid_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zLS1FCLyAlZ">10,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2024, we had outstanding stock purchase warrants for the purchase of an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeqtYNLZv1Xi" title="Warrants to purchase shares">1,778,284</span> <span style="background-color: white">shares
with a weighted average exercise price of $</span><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zim5V1rkjTme" title="Weighted average exercise price">6.17</span> <span style="background-color: white">and
a weighted average remaining contractual life of </span><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zH0gAth99mgj" title="Weighted average remaining contractual life">4.3</span> <span style="background-color: white">years.
All the outstanding stock purchase warrants are exercisable a<span style="background-color: white">s of</span> June 30, 2024. W</span>e did not have any unrecognized stock-based
compensation expense related to our granted stock purchase warrants at June 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481389495904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share of Common Stock<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share of Common Stock</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zEFPoujgZDxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_824_zrVP9MjRHqU6">Net Loss per Share of Common Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Net
Loss Per Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of
common stock outstanding (which excludes unvested RSAs and includes vested RSUs) during the period. Diluted loss per share is computed
by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock (which includes
the potentially dilutive effect of stock options, unvested RSAs, unvested RSUs and warrants) during the period. Since we experienced
a net loss for all periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three
and six months ended June 30, 2024 and 2023 excludes the impact of potentially dilutive common shares since those shares would have an
anti-dilutive effect on net loss per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zkFILclMsVr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of net loss per share for the three and six months ended June 30, 2024 and 2023 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zqvf5jbfVNZa" style="display: none">Schedule
of Net Loss Per Share Basic and Diluted</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240401__20240630_zP8owTHBVmj8" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230401__20230630_z5cY1XLgubb8" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20240630_zBucptvGIphl" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20230630_zObYOSOsneM4" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Basic and diluted net loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zt8WbifFm9T" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left">Net loss available to common stockholders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(3,010,326</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(2,612,565</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(5,736,707</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(6,634,638</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Weighted average number of common shares-basic and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_z9v3dlpQWYzl" title="Weighted average number of common shares-basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zXb6BIWGMsDd" title="Weighted average number of common shares-diluted">2,983,283</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zYy14PKK31jg" title="Weighted average number of common shares-basic"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zOHJT9CrF9b5" title="Weighted average number of common shares-diluted">1,346,808</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_z2sKeE36uWV" title="Weighted average number of common shares-basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zSKt3sgBDLF2" title="Weighted average number of common shares-diluted">2,724,903</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630_zlD7e4ngIuQ4" title="Weighted average number of common shares-basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630_zNsGglfYFfxa" title="Weighted average number of common shares-diluted">1,243,475</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20240401__20240630_zwm9qXzfco14" title="Basic net loss per share"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20240401__20240630_z2dhQAi6zQ2b" title="Diluted net loss per share">(1.01</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20230401__20230630_zB9SWxSk5Wge" title="Basic net loss per share"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20230401__20230630_zl03lsAGZXyg" title="Diluted net loss per share">(1.94</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20240101__20240630_zXlGLtMa4p6i" title="Basic net loss per share"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20240101__20240630_zUZUzeJGuXi7" title="Diluted net loss per share">(2.11</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20230101__20230630_zKHej9fZceq9" title="Basic net loss per share"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_c20230101__20230630_z5VmYUNuhSg4" title="Diluted net loss per share">(5.34</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Weighted-average number of common shares outstanding &#8211; basic and diluted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPkYVMlhxqnf" title="Weighted average number of common shares outstanding - basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCdXLDT2t6zb" title="Weighted average number of common shares outstanding - diluted">2,849,192</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH2smbzqAysa" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl0oSEXGhtt1" title="Weighted average number of common shares outstanding - diluted">1,217,095</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zki6Ilpn51U" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuOkib98Cld3" title="Weighted average number of common shares outstanding - diluted">2,590,530</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zclzYqSqBGd" title="Weighted average number of common shares outstanding - basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9NxXBzEUgl1" title="Weighted average number of common shares outstanding - diluted">1,114,324</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Weighted-average number of vested RSUs&#8211; basic and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zT2rbSOClc5l" title="Weighted average number of vested RSUs - basic"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zy0htHyCVelk" title="Weighted average number of vested RSUs - diluted">134,091</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdBL7WZIk4bj" title="Weighted average number of vested RSUs - basic"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zDGzLfax9I5j" title="Weighted average number of vested RSUs - diluted">129,713</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zmMmgFOVaYi5" title="Weighted average number of vested RSUs - basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zNFrnqLMvaoe" title="Weighted average number of vested RSUs - diluted">134,373</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zlHMO9EIDOci" title="Weighted average number of vested RSUs - basic"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_znxi54O59K7l" title="Weighted average number of vested RSUs - diluted">129,151</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average number of common shares-basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_z5x6L5xl4S72" title="Weighted average number of common shares-basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zBA7SJjmhjF8" title="Weighted average number of common shares-diluted">2,983,283</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zmhE5QPBDIk5" title="Weighted average number of common shares-basic"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zN9GRulGpkLk" title="Weighted average number of common shares-diluted">1,346,808</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zlD8oHQuRrA2" title="Weighted average number of common shares-basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zZUBvM95APPk" title="Weighted average number of common shares-diluted">2,724,903</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630_zh8fKkkGk4Db" title="Weighted average number of common shares-basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630_zfJ50RENF3ue" title="Weighted average number of common shares-diluted">1,243,475</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zl1iEEpC5EPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
diluted net loss per share for the three and six months ended June 30, 2024 and 2023 excluded <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240401__20240630_zlmdipiWLrb7" title="Antidilutive securities excluded from computation of earnings per share, amount"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_zLu1b7SxZftk" title="Antidilutive securities excluded from computation of earnings per share, amount">1,876,059</span></span> and <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230401__20230630_z26FHDZuLa43" title="Antidilutive securities excluded from computation of earnings per share, amount"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630_ziPOp3dRfio4" title="Antidilutive securities excluded from computation of earnings per share, amount">254,314</span></span> of potentially dilutive
common shares, respectively, related to outstanding stock options, warrants and unvested restricted stock since those shares would have
had an anti-dilutive effect on net loss per share during the periods then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481395522272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_LesseeOperatingAndFinancingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_802_ecustom--LesseeOperatingAndFinancingLeasesTextBlock_zwpuyOG7tGp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_825_zb6aBuOjQPO5">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold
improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space
lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area
or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group
lease and non-lease components for all leases. We also lease office equipment under a financing lease. Our leases do not provide an implicit
rate and, as such, we have used our incremental borrowing rate of <span id="xdx_906_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_dp_uPure_c20240630_zP17aI9bR8c5" title="Operating and financing lease borrowing rate">8</span>% in determining the present value of the lease payments based on
the information available at the lease commencement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
costs included in our condensed consolidated statements of operations totaled approximately $<span id="xdx_90F_eus-gaap--LeaseCost_c20240401__20240630_zIxYHfMOvk6c" title="Lease cost">23,000</span>
and $<span id="xdx_901_eus-gaap--LeaseCost_c20230401__20230630_zqXTqwnSLatd" title="Lease cost">24,000</span> for the three months
ending June 30, 2024 and 2023, respectively, and approximately $<span id="xdx_906_eus-gaap--LeaseCost_c20240101__20240630_zEJyarALW003" title="Lease cost">45,000</span>
and $<span id="xdx_90B_eus-gaap--LeaseCost_c20230101__20230630_zEMithrlV3Xk" title="Lease cost">49,000</span> for the six months
ended June 30, 2024, and 2023, respectively. The weighted average remaining lease terms and discount rate for our leases were as
follows at June 30, 2024:</span></p>

<p id="xdx_89F_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_zlIAHMkiNVyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zJXetrGWQNSb" style="display: none">Schedule
of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Remaining lease term (years) for our facility lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_902_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zsE3gSqrrD7f" title="Remaining lease term (years)">1.3</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Remaining lease term (years) for our equipment lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zlpOrSizfwYf" title="Remaining lease term (years)">1.6</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted average discount rate for our facility and equipment leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_dp_uPure_c20240630_zp8o4ogNbs78" title="Weighted average discount rate for our facility and equipment leases">8.0</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A5_zWHRJPxg1Fxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zmFnS3zaci7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for the operating lease were as follows at June 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_z0GFpJajvCc1" style="display: none">Schedule
of Annual Lease Liabilities for all Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20240630_zOfJqtZzaSa1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz79B_z7WbgiuYwWPl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">45,797</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz79B_z4bu3Xg49RW9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">70,040</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zrSGkdOoYUI2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115,837</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z7JfSWxiOHb5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Less: Interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,511</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zXUSwYSh8KY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Present value of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109,326</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zuPo9CgM2bod" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Less: current maturities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(87,495</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zF42E3liV1S8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Non-current lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">21,831</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zzo6Rc1dMTl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zDnbI74HEoeg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for the financing lease were as follows at June 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zaGGHYTjTJdd" style="display: none">Schedule
of Annual Lease Liabilities for all Financing Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20240630_z6IFVCe0dUqj" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maFLLPDzELQ_zPTfoJuZWHr2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">3,232</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzELQ_zTnDbSvB7Hja" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,820</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzELQ_zezGMYX0VVQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">488</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzELQ_zr3wUPaJRYUg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,540</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_z7r2g348drsk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Less: Interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,037</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseLiability_iI_z2psB3EStoOg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Present value of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,503</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zyE5MHpwFoy9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Less: current maturities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,686</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zUd4KeUfBQtd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Non-current lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,817</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zJFvDio0s9O2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_LesseeOperatingAndFinancingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating And Financing Leases [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_LesseeOperatingAndFinancingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481385000336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zbMS3YmX0Kb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_828_z9CCuyn5sdql">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CorLyst,
LLC (&#8220;CorLyst&#8221;) reimburses us for shared costs related to payroll, health insurance and rent based on actual costs
incurred, which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed
consolidated statement of operations. We recorded approximately $<span id="xdx_902_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20240401__20240630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zdy8jDkzlJHa" title="Rent and other costs reimbursements received">27,000</span>
and $<span id="xdx_902_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20230401__20230630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zv25w51iFcbc" title="Rent and other costs reimbursements received">34,000</span>
of reimbursements during the three months ended June 30, 2024 and 2023, respectively, and approximately $<span id="xdx_905_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20240101__20240630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zpHU3VZa5cWf" title="Rent and other costs reimbursements received">50,000</span>
and $<span id="xdx_907_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20230101__20230630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zD1i99G2WPdg" title="Rent and other costs reimbursements received">64,000</span>
for the six months ended June 30, 2024 and 2023, respectively. <span id="xdx_90F_eus-gaap--OtherReceivablesNetCurrent_iI_do_c20240630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_z10eeCOtkkHk" title="Due from related parties"><span id="xdx_904_eus-gaap--OtherReceivablesNetCurrent_iI_do_c20230630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zMHDQveFNXC3" title="Due from related parties">No</span></span>
amounts were due from CorLyst at June 30, 2024 or 2023. Our President of Research and Development is the CEO of CorLyst, and CorLyst
is a shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481389725664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zxGRq6dw7n1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_828_zs8Av13J088b">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Purchase
Obligations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into contracts in the normal course of business with contract research organizations (&#8220;CROs&#8221;) and subcontractors to further develop
our products. The contracts are cancelable, with varying provisions regarding termination. If we terminated a cancelable contract with
a specific vendor, we would only be obligated for products or services that we received at the effective date of the termination and
any applicable cancellation fees. At June 30, 2024, we are contractually obligated to pay up to $<span id="xdx_904_eus-gaap--PurchaseObligation_iI_pn5n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CROsMember_zh994XQkjXc6" title="Purchase obligation">14.3</span> million of future services under
the agreements with the CROs. Our actual contractual obligations will also vary depending on the progress and results of the remaining
clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481389653168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text"><p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zSmKLVqT6g55" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_820_zXqHW1wz9mJ7">Subsequent Event</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 16, 2024, Russell Skibsted was appointed as our Chief Financial Officer (&#8220;CFO&#8221;). Mr. Skibsted has nearly 30 years of experience
in the pharmaceutical industry, including expertise in financial management, global business development, capital markets, investor
relations and operations. In connection with his employment, Mr. Skibsted will be paid an annual base salary of $<span id="xdx_90C_eus-gaap--OfficersCompensation_c20240716__20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zs6fu2MQWvm3" title="Annual base salary">400,000</span>
and will be eligible for a $<span id="xdx_909_eus-gaap--SalariesWagesAndOfficersCompensation_c20240716__20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2V4DKVdZrNc" title="Potential base salary increase">50,000</span>
base salary increase upon a cumulative (one or multiple) financing of at least $<span id="xdx_90B_ecustom--PotentialBaseSalaryIncreaseFinancingMinimum_iI_pn6n6_c20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zORuhclSycN9" title="Potential base salary increase financing minimum">15</span>
million that he leads and substantially participates in. He is also eligible to participate in an executive bonus pool with a target
bonus of <span id="xdx_905_ecustom--CompensationArrangementWithIndividualBonusAwardsGrantedPercentage_dp_uPure_c20240716__20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zB0WtdzoX743" title="Executive bonus percentage">35</span>%
of his base compensation. In addition, the Compensation Committee awarded <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240716__20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4WCxhBVH4B3" title="Number of shares, granted">28,000</span>
RSUs to Mr. Skibsted, which vest accordingly: <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240716__20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ServiceBasedRSUMember_zY7aLAUt8C62" title="Number of shares, granted">14,000</span>
RSUs vest on July 16, 2025; <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240716__20240716__us-gaap--AwardTypeAxis__custom--FirstPerformanceBasedRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zO8uMpxch4xc" title="Number of shares, granted">7,000</span>
RSUs vest upon Processa reaching a market capitalization (i.e. total value of Processa&#8217;s outstanding shares of stock at the
then current market price) of at least $<span id="xdx_909_ecustom--MarketCapitalization_iI_pn6n6_c20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--FirstPerformanceBasedRSUMember_zA8muWS8EXog" title="Market capitalization">30</span>
million; and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240716__20240716__us-gaap--AwardTypeAxis__custom--SecondPerformanceBasedRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhIJ5j0lYLE4" title="Number of shares, granted">7,000</span>
RSUs vest upon a cumulative (one or multiple) financing of at least $<span id="xdx_901_ecustom--PerformanceVestingCriteriaValue_iI_pn6n6_c20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--SecondPerformanceBasedRSUMember_zRBsZFSNLBsb" title="Performance vesting criteria">15</span>
million that he leads and substantially participates in. He will also be eligible for other benefits as described in his employment
agreement.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481389413440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text"><p id="xdx_84B_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zyfLjrkM3c7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_862_z78cgDHQuO7a">Organization</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our
Next Generation Chemotherapy (&#8220;NGC&#8221;) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of
existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution <span style="background-color: white">in
the body, </span> while maintaining the well-established existing mechanisms of killing the cancer cells. By modifying the
NGC drugs in this manner, we believe our three NGC treatments will provide improved safety-efficacy profiles when compared to their
currently marketed counterparts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
January 22, 2024, we filed a Certificate of Amendment to our Certificate of Incorporation, as amended with the Secretary of State of
Delaware that effected a <span id="xdx_90C_eus-gaap--StockholdersEquityReverseStockSplit_c20240122__20240122_za2FbPhXsRXg" title="Reverse stock split">1-for-20 reverse stock split</span> of our common stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240122_zkV5uoCqAZCk" title="Common stock, par value">0.0001</span> per share (the &#8220;Reverse Stock Split&#8221;).
Pursuant to the Certificate of Amendment, our issued common stock decreased from <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20240121_zjmf2a7KyrS7" title="Common stock shares issued">24,706,474</span> shares to <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20240122_zo6r78uDu8fg" title="Common stock shares issued">1,291,000</span> shares and our outstanding
common stock decreased from <span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20240121_zTsbrlIIgSn9" title="Common stock shares outstanding">24,606,474</span> to <span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20240122_z9Bz4KX7Q8h8" title="Common stock shares outstanding">1,286,000</span>. The Reverse Stock Split did not affect our authorized common stock of <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20240122_znUn2BYxk9rd" title="Common stock shares authorized">100,000,000</span>
shares or our common stock par value. All shares of common stock, including common stock underlying warrants, stock options, restricted
stock awards and restricted stock units, as well as exercise prices and per share information in these condensed consolidated financial
statements give retroactive effect to the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zR3GMsZmAJcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_867_zvtxdjVgydQ9">Basis
of Presentation</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#8220;SEC&#8221;) on Form 10-Q and Article 8 of Regulation S-X.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2023, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_84C_ecustom--LiquidityPolicyTextBlock_zE8ajnErawKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_86F_zTTjxihF8auj">Liquidity</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations,
realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses
since inception, are currently devoting substantially all of our efforts toward research and development of our NGC drug product candidates,
including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated deficit
of $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20240630_zzGuRW9nIYDi" title="Accumulated deficit">81.1</span> <span style="background-color: white">million
at June 30, 2024. During the six months ended June 30, 2024, we generated a net loss of $</span><span id="xdx_900_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20240630_z72a2i4fTzJh" title="Net loss">5.7</span> <span style="background-color: white">million
and used $</span><span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20240630_zboCTV9vcQec" title="Net cash for operating activities from continuing operations">5.4</span> <span style="background-color: white">million in net cash for operating activities from continuing operations. To
date, none of our drug candidates have been approved for sale, and therefore we have not generated any product revenue and do not expect
positive cash flow from operations in the foreseeable future.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
have financed our operations primarily through public equity issuances, including an offering we closed on January 30, 2024, where we
sold <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240129__20240130__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zSIMiDrKloLl" title="Number of shares sold">476,000</span> shares of our common stock, pre-funded warrants to purchase up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240130__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zp63FOwfMDka" title="Warrants to purchase">1,079,555</span> shares of our common stock, and warrants for
the purchase of up to <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zI0kQsZWFyeb" title="Warrants to purchase shares">1,555,555</span> shares of our common stock for net proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240129__20240130_zFKr4ofUj8vj" title="Net proceeds">6.3</span> million, after deducting placement agent fees and
offering-related expenses. Simultaneously with the closing of the sale, the pre-funded warrants were exercised in exchange for <span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesWarrantExercised_iI_c20240130__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zgekzZOaWhT5" title="Warrant exercised">1,079,555</span>
shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the &#8220;Registration
Statement&#8221;), including a base prospectus relating to the offering of up to $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240531__20240531_zFND77df1Ys" title="Shares issued initial offering">50,000,000</span>
in the aggregate of the securities identified in the base prospectus from time to time in one or more offerings; and a prospectus
supplement relating to the shares of our common stock that may be issued and sold under a sales agreement dated May 21, 2024 (the
&#8220;Sales Agreement&#8221;) between us and A.G.P./Alliance Global Partners (the &#8220;Sales Agent&#8221;), through which we may issue and
sell in a registered &#8220;at the market offering&#8221; shares of our common stock having an aggregate offering price of up to
$<span id="xdx_901_ecustom--MaximumValueToBeSoldAtMarketOffering_pn5n6_c20240521__20240521__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_z5Vkxhd3mvQ9" title="Maximum value to be sold at the market offering">2.4</span>
million (subject to adjustment) from time to time through or to our Sales Agent (the &#8220;ATM Offering&#8221;). We expect to use
net proceeds, if any, from the ATM Offering over time for continued research and development for our portfolio of drug candidates,
especially our oncology products, and working capital and general corporate purposes. The shares under the ATM Offering will be sold
and issued pursuant to the Registration Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At
June 30, 2024, we had cash and cash equivalents totaling $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20240630_zJIiwe4qLibf" title="Cash and cash equivalents">5.6</span> <span style="background-color: white">million
which, based on our current business plans, we believe these funds will satisfy our <span style="background-color: white">operating </span>
needs into late 2024, including the beginning of our Phase 2 trial of NGC-Cap in breast cancer. Our ability to execute our
longer-term operating plans, including future preclinical studies and clinical trials for our portfolio of drugs depend on our
ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding
transactions. <span style="background-color: white">We will continue to be dependent
upon equity and/or debt financing until we are able to generate positive cash flows from our operations.</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations,
strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable
to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or
planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in
certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and
distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms
that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of
our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no
assurance that future funding will be available when needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Absent
additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year
or more after the date that these condensed consolidated financial statements are available to be issued based on the timing and amount
of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result,
substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated
financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments
to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification
of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties
described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_843_eus-gaap--UseOfEstimates_z7yg1qGZqK86" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_866_zd4N8dnQYBKb">Use
of Estimates</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules
and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial
statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation,
intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based
on management&#8217;s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable,
actual results could differ materially from those estimates and could impact future results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_z26Z9yKmjEZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Income
Taxes</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for income taxes in accordance with ASC Topic 740, <i>Income Taxes.</i> Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. At June 30, 2024 and December 31, 2023, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed
quarterly and will be maintained until sufficient positive evidence exists to support its reversal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ACS 740-270 <i>Income Taxes &#8211; Interim Reporting</i>, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income
tax benefit or expense is expected for 2024 and the foreseeable future since we expect to generate taxable net operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_znppZHOwLNJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline"><span id="xdx_86F_zG0UOiRw0515">Concentration
of Credit Risk</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to specified limits. Total cash held by our banks at June 30, 2024, exceeded FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zv3o7GlGuGDh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_868_z94UFS2MqFub">Recent
Accounting Pronouncements</span></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#8220;ASU&#8221;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated
financial position or results of operations.</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Activities And Organization [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481389338448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z6SzgmbGSO5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
recorded stock-based compensation expense for the three and six months ended June 30, 2024 and 2023 as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zodWD40luq2a" style="display: none">Schedule
of Stock-based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240401__20240630_z5FodJsigOll" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230401__20230630_zsR6fnL7T3Y6" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240101__20240630_zCaIDiOiyqIl" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20230630_z2reTkBdvR18" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zBl0WgR2HB58" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">45,583</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">102,678</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">76,704</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">209,526</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zvjIzpXWeR6c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">107,049</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">216,445</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">243,571</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">451,101</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensation_zIAzCfb6GuPk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">152,632</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">319,123</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">320,275</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">660,627</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zwID5zmhYv8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Activity
with respect to our Restricted Stock Units (&#8220;RSUs&#8221;) during the six months ended June 30, 2024 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zoYyqIbs2L9d" style="display: none">Schedule
of Restricted Stock Units (&#8220;RSUs&#8221;) Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of <br/> shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- average <br/> grant-date fair <br/> value per share</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Outstanding at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLWDn2xUoC53" style="width: 18%; text-align: right" title="Number of shares, Beginning balance">222,722</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8V9qKOT7fs" style="width: 18%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance">45.82</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z68O3XAcTBg3" style="text-align: right" title="Number of shares, granted">39,202</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEqZAKfUHhLe" style="text-align: right" title="Weighted-average grant-date fair value per share, granted">2.24</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znkTJGQ0iJvl" style="text-align: right" title="Number of shares, forfeited">(10,775</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1Fq3XF0HLJ2" style="text-align: right" title="Weighted-average grant-date fair value per share, forfeited">58.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Issued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHFURFCsr4Vj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, issued">(12,328</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPvQk5Fa07xi" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average grant-date fair value per share, shares issued">99.86</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at June 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxd6fRrteoG3" style="text-align: right" title="Number of shares, ending balance">238,821</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5X8i7ksTIU6" style="text-align: right" title="Weighted-average grant-date fair value per share, ending balance">35.31</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Vested and unissued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzHjLHBIqhZ2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, vested and unissued">143,793</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuOc9MwdxRf4" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued">50.71</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Unvested at June 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znuJ5Df36qY5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, unvested">95,028</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zauZjCGzc6Y8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average grant-date fair value per share, unvested">12.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481395293504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Loss Per Share Basic and Diluted</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zkFILclMsVr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
computation of net loss per share for the three and six months ended June 30, 2024 and 2023 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zqvf5jbfVNZa" style="display: none">Schedule
of Net Loss Per Share Basic and Diluted</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240401__20240630_zP8owTHBVmj8" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230401__20230630_z5cY1XLgubb8" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20240630_zBucptvGIphl" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20230630_zObYOSOsneM4" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Basic and diluted net loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zt8WbifFm9T" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left">Net loss available to common stockholders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(3,010,326</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(2,612,565</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(5,736,707</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(6,634,638</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Weighted average number of common shares-basic and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_z9v3dlpQWYzl" title="Weighted average number of common shares-basic"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zXb6BIWGMsDd" title="Weighted average number of common shares-diluted">2,983,283</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zYy14PKK31jg" title="Weighted average number of common shares-basic"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zOHJT9CrF9b5" title="Weighted average number of common shares-diluted">1,346,808</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_z2sKeE36uWV" title="Weighted average number of common shares-basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zSKt3sgBDLF2" title="Weighted average number of common shares-diluted">2,724,903</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630_zlD7e4ngIuQ4" title="Weighted average number of common shares-basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630_zNsGglfYFfxa" title="Weighted average number of common shares-diluted">1,243,475</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20240401__20240630_zwm9qXzfco14" title="Basic net loss per share"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20240401__20240630_z2dhQAi6zQ2b" title="Diluted net loss per share">(1.01</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20230401__20230630_zB9SWxSk5Wge" title="Basic net loss per share"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20230401__20230630_zl03lsAGZXyg" title="Diluted net loss per share">(1.94</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20240101__20240630_zXlGLtMa4p6i" title="Basic net loss per share"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20240101__20240630_zUZUzeJGuXi7" title="Diluted net loss per share">(2.11</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20230101__20230630_zKHej9fZceq9" title="Basic net loss per share"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_c20230101__20230630_z5VmYUNuhSg4" title="Diluted net loss per share">(5.34</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Weighted-average number of common shares outstanding &#8211; basic and diluted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPkYVMlhxqnf" title="Weighted average number of common shares outstanding - basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCdXLDT2t6zb" title="Weighted average number of common shares outstanding - diluted">2,849,192</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH2smbzqAysa" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl0oSEXGhtt1" title="Weighted average number of common shares outstanding - diluted">1,217,095</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zki6Ilpn51U" title="Weighted average number of common shares outstanding - basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuOkib98Cld3" title="Weighted average number of common shares outstanding - diluted">2,590,530</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zclzYqSqBGd" title="Weighted average number of common shares outstanding - basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9NxXBzEUgl1" title="Weighted average number of common shares outstanding - diluted">1,114,324</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Weighted-average number of vested RSUs&#8211; basic and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zT2rbSOClc5l" title="Weighted average number of vested RSUs - basic"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zy0htHyCVelk" title="Weighted average number of vested RSUs - diluted">134,091</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdBL7WZIk4bj" title="Weighted average number of vested RSUs - basic"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zDGzLfax9I5j" title="Weighted average number of vested RSUs - diluted">129,713</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zmMmgFOVaYi5" title="Weighted average number of vested RSUs - basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zNFrnqLMvaoe" title="Weighted average number of vested RSUs - diluted">134,373</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zlHMO9EIDOci" title="Weighted average number of vested RSUs - basic"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_znxi54O59K7l" title="Weighted average number of vested RSUs - diluted">129,151</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average number of common shares-basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_z5x6L5xl4S72" title="Weighted average number of common shares-basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zBA7SJjmhjF8" title="Weighted average number of common shares-diluted">2,983,283</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zmhE5QPBDIk5" title="Weighted average number of common shares-basic"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zN9GRulGpkLk" title="Weighted average number of common shares-diluted">1,346,808</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zlD8oHQuRrA2" title="Weighted average number of common shares-basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zZUBvM95APPk" title="Weighted average number of common shares-diluted">2,724,903</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630_zh8fKkkGk4Db" title="Weighted average number of common shares-basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630_zfJ50RENF3ue" title="Weighted average number of common shares-diluted">1,243,475</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481389513632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock', window );">Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases</a></td>
<td class="text"><p id="xdx_89F_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_zlIAHMkiNVyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zJXetrGWQNSb" style="display: none">Schedule
of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">Remaining lease term (years) for our facility lease</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_902_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zsE3gSqrrD7f" title="Remaining lease term (years)">1.3</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Remaining lease term (years) for our equipment lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zlpOrSizfwYf" title="Remaining lease term (years)">1.6</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted average discount rate for our facility and equipment leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_dp_uPure_c20240630_zp8o4ogNbs78" title="Weighted average discount rate for our facility and equipment leases">8.0</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Annual Lease Liabilities for all Operating Leases</a></td>
<td class="text"><p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zmFnS3zaci7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for the operating lease were as follows at June 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_z0GFpJajvCc1" style="display: none">Schedule
of Annual Lease Liabilities for all Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20240630_zOfJqtZzaSa1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz79B_z7WbgiuYwWPl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">45,797</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz79B_z4bu3Xg49RW9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">70,040</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zrSGkdOoYUI2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115,837</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z7JfSWxiOHb5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Less: Interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,511</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zXUSwYSh8KY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Present value of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109,326</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zuPo9CgM2bod" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Less: current maturities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(87,495</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zF42E3liV1S8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Non-current lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">21,831</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Annual Lease Liabilities for all Financing Leases</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zDnbI74HEoeg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
lease liabilities for the financing lease were as follows at June 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zaGGHYTjTJdd" style="display: none">Schedule
of Annual Lease Liabilities for all Financing Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20240630_z6IFVCe0dUqj" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maFLLPDzELQ_zPTfoJuZWHr2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">3,232</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzELQ_zTnDbSvB7Hja" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,820</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzELQ_zezGMYX0VVQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">488</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzELQ_zr3wUPaJRYUg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,540</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_z7r2g348drsk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Less: Interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,037</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseLiability_iI_z2psB3EStoOg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Present value of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,503</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zyE5MHpwFoy9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Less: current maturities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,686</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zUd4KeUfBQtd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Non-current lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,817</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Weighted Average Remaining Lease Terms And Discount Rate For Our Operatingand Financing Leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481384926976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>May 21, 2024</div></th>
<th class="th"><div>Jan. 30, 2024</div></th>
<th class="th"><div>Jan. 22, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jan. 21, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-20 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,291,000<span></span>
</td>
<td class="nump">2,873,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,873,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,706,474<span></span>
</td>
<td class="nump">1,291,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,286,000<span></span>
</td>
<td class="nump">2,868,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,868,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,606,474<span></span>
</td>
<td class="nump">1,286,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,105,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,105,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,369,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,010,326<span></span>
</td>
<td class="nump">$ 2,726,381<span></span>
</td>
<td class="nump">$ 2,612,565<span></span>
</td>
<td class="nump">$ 4,022,073<span></span>
</td>
<td class="nump">5,736,707<span></span>
</td>
<td class="nump">$ 6,634,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash for operating activities from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,394,713<span></span>
</td>
<td class="nump">4,178,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,282,430<span></span>
</td>
<td class="nump">$ 6,352,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued initial offering</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,282,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,352,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,571,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,571,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,706,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,555,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,555,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,555,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,079,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,079,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,079,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_StockIssuedDuringPeriodSharesWarrantExercised', window );">Warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,079,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,079,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,079,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_SalesAgreementMember', window );">Sales Agreement [Member] | Alliance Global Partners [Member] | Maximum [Member] | ATM Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OrganizationLineItems', window );"><strong>OrganizationLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_MaximumValueToBeSoldAtMarketOffering', window );">Maximum value to be sold at the market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_MaximumValueToBeSoldAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_MaximumValueToBeSoldAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OrganizationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OrganizationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_StockIssuedDuringPeriodSharesWarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_StockIssuedDuringPeriodSharesWarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PCSA_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PCSA_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PCSA_AllianceGlobalPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PCSA_AllianceGlobalPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=PCSA_ATMOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=PCSA_ATMOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481384461472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="nump">$ 6,282,430<span></span>
</td>
<td class="nump">$ 6,352,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes', window );">Stock withheld for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PCSA_EmployeesAndConsultantsMember', window );">Employees and Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">476,000<span></span>
</td>
<td class="nump">476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Placement Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  01,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">1,555,555<span></span>
</td>
<td class="nump">1,555,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_WarrantsExercisableAndMaturityDate', window );">Warrants exercisable and maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 30,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">1,079,555<span></span>
</td>
<td class="nump">1,079,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_StockIssuedDuringPeriodSharesWarrantExercised', window );">[custom:StockIssuedDuringPeriodSharesWarrantExercised-0]</a></td>
<td class="nump">1,079,555<span></span>
</td>
<td class="nump">1,079,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_LicenseAgreementMember', window );">License Agreement [Member] | Elion Oncology, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock withheld for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_StockIssuedDuringPeriodSharesWarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_StockIssuedDuringPeriodSharesWarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_WarrantsExercisableAndMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercisable and maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_WarrantsExercisableAndMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PCSA_EmployeesAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PCSA_EmployeesAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=PCSA_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=PCSA_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PCSA_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PCSA_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PCSA_ElionOncologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PCSA_ElionOncologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PCSA_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PCSA_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481393933328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock-based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">$ 152,632<span></span>
</td>
<td class="nump">$ 319,123<span></span>
</td>
<td class="nump">$ 320,275<span></span>
</td>
<td class="nump">$ 660,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">45,583<span></span>
</td>
<td class="nump">102,678<span></span>
</td>
<td class="nump">76,704<span></span>
</td>
<td class="nump">209,526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">$ 107,049<span></span>
</td>
<td class="nump">$ 216,445<span></span>
</td>
<td class="nump">$ 243,571<span></span>
</td>
<td class="nump">$ 451,101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481384449472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Restricted Stock Units (&#8220;RSUs&#8221;) Activity (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding', window );">Number of shares, Beginning balance | shares</a></td>
<td class="nump">222,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, Beginning balance | $ / shares</a></td>
<td class="nump">$ 45.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted | shares</a></td>
<td class="nump">39,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, granted | $ / shares</a></td>
<td class="nump">$ 2.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, forfeited | shares</a></td>
<td class="num">(10,775)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, forfeited | $ / shares</a></td>
<td class="nump">$ 58.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod', window );">Number of shares, issued | shares</a></td>
<td class="num">(12,328)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, shares issued | $ / shares</a></td>
<td class="nump">$ 99.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding', window );">Number of shares, ending balance | shares</a></td>
<td class="nump">238,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, ending balance | $ / shares</a></td>
<td class="nump">$ 35.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued', window );">Number of shares, vested and unissued | shares</a></td>
<td class="nump">143,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, vested and unissued | $ / shares</a></td>
<td class="nump">$ 50.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, unvested | shares</a></td>
<td class="nump">95,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, unvested | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481390090208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_PaymentsForSettlementOfStockAwards', window );">Payments for settlement of stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,561<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,617,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember', window );">Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Warrants, expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_PaymentsForSettlementOfStockAwards', window );">Payments for settlement of stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options, forfeited weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 409.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share, shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding', window );">Number of shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding', window );">Number of shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 538,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_UnrecognizedShareBasedCompensationExpense', window );">Unrecognized share based compensation expense.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="nump">39,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=PCSA_ServiceBasedRestrictedStockUnitsMember', window );">Service Based RSUs [Member] | 3-Year Vesting [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="nump">18,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=PCSA_ServiceBasedRestrictedStockUnitsMember', window );">Service Based RSUs [Member] | Employees [Member] | January 1, 2025 Vesting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="nump">14,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=PCSA_FirstPerformanceBasedRSUMember', window );">First Performance Based RSUs [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="nump">3,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=PCSA_SecondPerformanceBasedRSUMember', window );">Second Performance Based RSUs [Member] | Employees [Member] | Next Generation Capecitabine - Cap [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="nump">3,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,778,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=PCSA_TwoThousandAndNineteenPlanMember', window );">2019 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum equity available for issuance</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">503,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_PaymentsForSettlementOfStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for settlement of stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_PaymentsForSettlementOfStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_UnrecognizedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized share based compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_UnrecognizedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=PCSA_OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=PCSA_OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=PCSA_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=PCSA_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=PCSA_ThreeYearVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=PCSA_ThreeYearVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_TitleOfInidividualAxis=PCSA_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_TitleOfInidividualAxis=PCSA_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_FirstPerformanceBasedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_FirstPerformanceBasedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_SecondPerformanceBasedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_SecondPerformanceBasedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PCSA_NextGenerationCapecitabineCAPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PCSA_NextGenerationCapecitabineCAPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=PCSA_TwoThousandAndNineteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=PCSA_TwoThousandAndNineteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481394412576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Net Loss Per Share Basic and Diluted (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (3,010,326)<span></span>
</td>
<td class="num">$ (2,612,565)<span></span>
</td>
<td class="num">$ (5,736,707)<span></span>
</td>
<td class="num">$ (6,634,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares-basic</a></td>
<td class="nump">2,983,283<span></span>
</td>
<td class="nump">1,346,808<span></span>
</td>
<td class="nump">2,724,903<span></span>
</td>
<td class="nump">1,243,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares-diluted</a></td>
<td class="nump">2,983,283<span></span>
</td>
<td class="nump">1,346,808<span></span>
</td>
<td class="nump">2,724,903<span></span>
</td>
<td class="nump">1,243,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (1.94)<span></span>
</td>
<td class="num">$ (2.11)<span></span>
</td>
<td class="num">$ (5.34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (1.94)<span></span>
</td>
<td class="num">$ (2.11)<span></span>
</td>
<td class="num">$ (5.34)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares-basic</a></td>
<td class="nump">134,091<span></span>
</td>
<td class="nump">129,713<span></span>
</td>
<td class="nump">134,373<span></span>
</td>
<td class="nump">129,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares-diluted</a></td>
<td class="nump">134,091<span></span>
</td>
<td class="nump">129,713<span></span>
</td>
<td class="nump">134,373<span></span>
</td>
<td class="nump">129,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares-basic</a></td>
<td class="nump">2,849,192<span></span>
</td>
<td class="nump">1,217,095<span></span>
</td>
<td class="nump">2,590,530<span></span>
</td>
<td class="nump">1,114,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares-diluted</a></td>
<td class="nump">2,849,192<span></span>
</td>
<td class="nump">1,217,095<span></span>
</td>
<td class="nump">2,590,530<span></span>
</td>
<td class="nump">1,114,324<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481488149312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share of Common Stock (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">1,876,059<span></span>
</td>
<td class="nump">254,314<span></span>
</td>
<td class="nump">1,876,059<span></span>
</td>
<td class="nump">254,314<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481394406608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate', window );">Weighted average discount rate for our facility and equipment leases</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=PCSA_FacilityLeaseMember', window );">Facility Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term (years)</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term (years)</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and financing lease weighted average discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=PCSA_FacilityLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=PCSA_FacilityLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481394406352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Annual Lease Liabilities for all Operating Leases (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">$ 45,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">70,040<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">115,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(6,511)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">109,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current maturities</a></td>
<td class="num">(87,495)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current lease liability</a></td>
<td class="nump">$ 21,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481388390496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Annual Lease Liabilities for all Financing Leases (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">$ 3,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">6,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">10,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(1,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">9,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current maturities</a></td>
<td class="num">(5,686)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Non-current lease liability</a></td>
<td class="nump">$ 3,817<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481390137888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate', window );">Operating and financing lease borrowing rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and financing lease weighted average discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481394178048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - CorLyst, LLC [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_ProceedsFromRentAndOtherCostsReimbursements', window );">Rent and other costs reimbursements received</a></td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Due from related parties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_ProceedsFromRentAndOtherCostsReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent and other costs reimbursements received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_ProceedsFromRentAndOtherCostsReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=PCSA_CorLystLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=PCSA_CorLystLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481389776240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PCSA_CROsMember', window );">CROs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="nump">$ 14.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PCSA_CROsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PCSA_CROsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140481384372288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 16, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Annual base salary</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Potential base salary increase</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_PotentialBaseSalaryIncreaseFinancingMinimum', window );">Potential base salary increase financing minimum</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_CompensationArrangementWithIndividualBonusAwardsGrantedPercentage', window );">Executive bonus percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Service Based RSU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | First Performance Based RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_MarketCapitalization', window );">Market capitalization</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Second Performance Based RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PCSA_PerformanceVestingCriteriaValue', window );">Performance vesting criteria</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_CompensationArrangementWithIndividualBonusAwardsGrantedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Compensation arrangement with individual bonus awards granted percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_CompensationArrangementWithIndividualBonusAwardsGrantedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_MarketCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_MarketCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_PerformanceVestingCriteriaValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_PerformanceVestingCriteriaValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PCSA_PotentialBaseSalaryIncreaseFinancingMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PCSA_PotentialBaseSalaryIncreaseFinancingMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PCSA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_ServiceBasedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_ServiceBasedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_FirstPerformanceBasedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_FirstPerformanceBasedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PCSA_SecondPerformanceBasedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PCSA_SecondPerformanceBasedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>47
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M7B]"O:JOE+IC9%&=R@MI\(ROFAG>PJ!L ,XOI31/'7O0M_=Z_ ]02P,$%
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MD#X\;H)=1I,,9%AUJ)QL*=N(_!$L""FKUT1<%Q>LCB\@K=O9V@4S'F/0\.4
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M J]E/XJ+''K+-4W>X  4.YH.B=0S ZX=1;!//)GQ.4C&DEA*>3?,3).@Q&H
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MZYQCGJ;T$[/ADC-8R.,9#JD1S7C,6SL A:=A134DTLZD>DW7%I7R)<HF2;Z
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M*PD:E[/XJG]Q/73Z7N$OCFNS\PTNDH52CV[Q>SZ+$T<(!6;6(3!Z/>$-"N&
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M2% JP:62L] X?:D(^]^7"J)D"US>:HZ)-N'QK3*5NJGT7O)VN8W%9F6*E6B
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M?V@F&\7SR5QDLSB;YL]98[4@>3K0F/P.[L$;8JV=L4C3&AMKS(R479H"<*X
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M<FT.?.Q:-S('K>039"1+JR<!T?3M29,4X*])<-+>E<SY0(,<:;Q12A?TQ:+
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MRI(R>;.B7P%J=X#V2T7/;^NX"_J?R^(W4$L#!!0    ( /*!#5GD*EE\6P\
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M^6>X0W>167N1U[.C"_ZE,6-Q/AF)V61V<62]\\XPY[S>^1/K';KPO^<+'QR
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M5J+&,L\/?I:1[U\@CZM3N<;< Q4QZ&4EQ?.DPAMGGT$U 9GNORI6V!M5EJ=
M-H("Q1)K*G,?,3M\]P?HAR;"F3V^1GKLSL*Z")Y^+<M4NAGJDU!_@R,?TYOT
MBHVB\AU4JX-)WJ0A[TVK?6_[%]7=^\%W;][W+PAC3RD)<NI/$T=RWS)P38#;
MKE7).Y$=TEW"?I]5/>8LG04MWBUR!&_32?]SF\E1Q'U4Y*^=G],X:RRE>G;^
MP5_2_)XELR>7%._ 41FI3DZ$^#_6?QWXAJ>Y V$6TA5>O+;4BN_,/+][W;^'
M;<LWGT:CY@L\?6$+DDBL#2&G-[OOHX>G&F>?ZJ+E7CX.=CA\DMO!CRY2)JFJ
MQO O&(JNPFL[LOP>Q!Q>*6[976I^]ZF]$R,_OMR@U[H5OS?D5Q1';Y$4 8,X
MR=%4%J=:/B6 ;]0\_6GZ/.G8S>6V+6Z>/E/L'5%5SGV?5O/3(3VDP^"U=#J<
M.7*^0R]F8U'\=2H;'PJ1L\&/TRKE5OP3/$ZH)L3?J75/NY_YS>./V_KA\3>"
M/TFW EF(4BTQ=3*^OCR)?8#VCV!K_JG;PH9@*_ZX5A)T0@/P_=*"5=,?M$'W
MX\=7_P-02P,$%     @ \H$-65 *!=78 P  % D  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&ULG5;?;]LV$'[77T&H0Y$ BB51/YW8!NRLZUJ@:Q G
MS<.P!UHZ6T(DT24I._GO=Z1LU>ULK]M#XB-Y]]UWY$>>1ELNGF4!H,A+735R
M;!=*K:]=5V8%U$P.^!H:7%ER43.%0[%RY5H RTU07;G4\V*W9F5C3T9F[DY,
M1KQ55=G G2"RK6LF7F=0\>W8]NW]Q'VY*I2><">C-5O!'-3C^D[@R.U1\K*&
M1I:\(0*68WOJ7\\B[6\<OI2PE0<VT94L.'_6@P_YV/8T(:@@4QJ!X<\&;J&J
M-!#2^+K#M/N4.O#0WJ/_9FK'6A9,PBVOGLI<%6,[M4D.2]96ZIYO?X==/89@
MQBMI_I-MYQL%-LE:J7B]"T8&==ETO^QEMP\' :EW(H#N JCAW24R+']EBDU&
M@F^)T-Z(I@U3JHE&<F6C#V6N!*Z6&*<F<\6SYRM=5TYN>8UG+9G9KHL'MJA
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MEB^37#>_L.MB?0>R6AM9=F!24!:B_6=?NG4X!1!V@+#1W29J5+YAABWG2NY
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MC/"-ZO"-GA4^5>R$#/,XR1=M,;2"=HWAZ& ,(=T1FSLCAN,ZAN,#,601I;%
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M(!=?ES2,*=<-U.^WC,FG ^V@?B=T]A]02P,$%     @ \H$-62RT2&^D P
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M:ID"3H!* _%\0P@_;J2#]O\/P7]02P,$%     @ \H$-637NX?'* P  H0T
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M=>XYY]J^+C9</,D5@$+/-65R[*R4:D:N*ZL5U%A>\ :8GEEP46.ENV+IRD8
MGEM03=W \Q*WQH0Y96'')J(L>*LH83 12+9UC<7+%5"^&3N^LQMX(,N5,@-N
M631X"5-0C\U$Z)[;1YF3&I@DG"$!B[%SZ8^N<K/>+OA!8"/WVL@XF7'^9#IW
M\['C&4% H5(F M:_-5P#I2:0EO%K&]/I*0UPO[V+_LEZUUYF6,(UIS_)7*W&
M3N:@.2QP2]4#W]S"UD]LXE6<2OM%FVYM&CBH:J7B]1:L%=2$=7_\O,W#'B X
M!@BV@,#J[HBLRANL<%D(OD'"K-;13,-:M6@MCC"S*5,E]"S1.%5.]2[/6PJ(
M+] E8RVFZ!ZT2W1/\(Q0H@A(I/<>84K1MP8$5H0MNS42G=V PH3*]X6KM!@3
MTJVVQ%<=<7"$^'/++E#H?4"!%T3H<7J#SMZ^"N-J+[VAH#<4V+CAD;B=LB$]
M'2X:QIG#/Y(-KF#LZ-,M0:S!*=^]\1/OXPE58:\J/!6]-":'-'6HQ*+,_5F7
M49SF:>&N!\BBGBSZ%UD\1-:AXCVRU/,B;Y@L[LGBDV3?N=)GAMHST^ 7?5_5
M8/;C W+?C[/PB-6D9T].LM^#E"-TQQ3H/5-#O,D![WD2^_XP;=K3IB=I)^:$
M,(76F+;VZG3^Z9\[,R0E/4R!EX=!,JPEZ[5D_Y&"JA7"*-)UJA5'%62'R<C2
M*(^'%>2]@ORD@J^<G>_X_T[$RY"(_.#,!WX6OMX1=Z^FF>?A"Q9+PJ0F6&B<
M=Y%J%Z(KN5U'\<:6N1E7NFC:YDJ_4B#, CV_X%SM.J9R]N]>^1M02P,$%
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M!FPC\XS"@B.Q*0K"?TTA9[N)Y5C[C=MLG4J]88=!2=9P!_*^7' 5V8U*DA5
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M0%T7,X$[NU&)TQR83#DC A9#ZZS3GW0UW@!^I+"66VNB,YES?J<WY_'0<G1
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ML:1JS#XQ6.**;R3-S>XKMGXN U]II(N_L&OWI@S*C2.C6K!7H(1NOORES>$
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MW'MPYWT4K]]3\>:_:Z/?4$L#!!0    ( /*!#5F7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ \H$-61O >32- P
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M) <?H01!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M
M(:M (:M (:M (:M (:M (6N*0M84A:PI"EE3%+*F*&1-_Y.L'UHO__IG9+LF
MM53-P9]U?WQG7U!+ 0(4 Q0    ( /*!#5D'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ \H$-61RW
M$)WO    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ \H$-69E<G",0!@  G"<  !,              ( !S0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #R@0U9PVP[E^D%  #"
M'P  &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ \H$-66"5R%< !@  'QD  !@              ("!+0X
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( /*!#5GHJ$G%
MP0(  .,'   8              " @6,4  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " #R@0U9_QN1"Y<$  #=$@  &
M@(%:%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ \H$-
M685AD=(2"@  )D\  !@              ("!)QP  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( /*!#5EP2HIM> 8  "P;   8
M      " @6\F  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" #R@0U9:2=N8,D"  #;!P  &               @($=+0  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ \H$-6;3\\6'! @  D D  !@
M             ("!'#   'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4
M Q0    ( /*!#5DNEDC6-0(  /,%   8              " @1,S  !X;"]W
M;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #R@0U9$B$PL=X.  #7
M)0  &0              @(%^-0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM
M;%!+ 0(4 Q0    ( /*!#5GXW>GC0P0  #@*   9              " @9-$
M  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ \H$-60?_
M$E8:"   @Q,  !D              ("!#4D  'AL+W=O<FMS:&5E=',O<VAE
M970Q,BYX;6Q02P$"% ,4    " #R@0U9TJN97(H$  "8#   &0
M    @(%>40  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M /*!#5D(':O.[ 0  ,4+   9              " @1]6  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ \H$-69?CH.C; @  5 8  !D
M             ("!0EL  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " #R@0U9],_!OS0#   >!P  &0              @(%47@  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( /*!#5F'NAF?" ,
M &@&   9              " @;]A  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ \H$-6>0J67Q;#P  ""D  !D              ("!
M_F0  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #R@0U9
M4 H%U=@#   4"0  &0              @(&0=   >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( /*!#5ET@SU^>0,  )H(   9
M      " @9]X  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ \H$-68R@M31X P  .0H  !D              ("!3WP  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #R@0U9F&62,'L)  "):@
M&0              @('^?P  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( /*!#5G G Z"-0<  !\Z   9              " @;")  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ \H$-62RT2&^D
M P  BQ   !D              ("!')$  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " #R@0U9->[A\<H#  "A#0  &0
M@('WE   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( /*!
M#5E U;E+BPD  -Y9   9              " @?B8  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ \H$-679<1+R@!   6Q<  !D
M         ("!NJ(  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    " #R@0U94)C$W+8"   ,"   &0              @(&1IP  >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( /*!#5G"H7/IO@(  *$(
M   9              " @7ZJ  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ \H$-6=(RV]:> @   P<  !D              ("!<ZT
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #R@0U9JG9N
MBJP"  !K!P  &0              @(%(L   >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    ( /*!#5G:,;#*HP(  .0(   9
M  " @2NS  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
M\H$-6?2\LX#4 @  X @  !D              ("!!;8  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " #R@0U9__2&VSL"  #\!   &0
M            @($0N0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( /*!#5E=X^ZU< 0  &X9   9              " @8*[  !X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ \H$-66^X+$\S P
M:A,   T              ( !*<   'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" #R@0U9EXJ[',     3 @  "P              @ &'PP  7W)E;',O+G)E
M;'-02P$"% ,4    " #R@0U9&\!Y-(T#  #E%P  #P              @ %P
MQ   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ \H$-64N*H MS 0  <!4
M !H              ( !*L@  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ \H$-6=\A)QN2 0  ^14  !,              ( !U<D
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "L *P"D"P  F,L

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>120</ContextCount>
  <ElementCount>196</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995513 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995514 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995516 - Disclosure - Net Loss per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock</Role>
      <ShortName>Net Loss per Share of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995517 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995518 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995519 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995520 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995521 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995522 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/Stock-basedCompensation</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995523 - Disclosure - Net Loss per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables</Role>
      <ShortName>Net Loss per Share of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995524 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/Leases</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995526 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/StockholdersEquity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995527 - Disclosure - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails</Role>
      <ShortName>Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995528 - Disclosure - Schedule of Restricted Stock Units (???RSUs???) Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails</Role>
      <ShortName>Schedule of Restricted Stock Units (???RSUs???) Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995529 - Disclosure - Stock-based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995530 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails</Role>
      <ShortName>Schedule of Net Loss Per Share Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995531 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative</Role>
      <ShortName>Net Loss per Share of Common Stock (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995532 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails</Role>
      <ShortName>Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995533 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails</Role>
      <ShortName>Schedule of Annual Lease Liabilities for all Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995534 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails</Role>
      <ShortName>Schedule of Annual Lease Liabilities for all Financing Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995536 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/RelatedPartyTransactions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995537 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995538 - Disclosure - Subsequent Event (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative</Role>
      <ShortName>Subsequent Event (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://processapharmaceuticals.com/role/SubsequentEvent</ParentRole>
      <Position>35</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="form10-q.htm">form10-q.htm</File>
    <File>pcsa-20240630.xsd</File>
    <File>pcsa-20240630_cal.xml</File>
    <File>pcsa-20240630_def.xml</File>
    <File>pcsa-20240630_lab.xml</File>
    <File>pcsa-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-q_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="415">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="3">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>53
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-q.htm": {
   "nsprefix": "PCSA",
   "nsuri": "http://processapharmaceuticals.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "schema": {
     "local": [
      "pcsa-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "pcsa-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pcsa-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pcsa-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pcsa-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 160,
   "keyCustom": 36,
   "axisStandard": 16,
   "axisCustom": 1,
   "memberStandard": 13,
   "memberCustom": 25,
   "hidden": {
    "total": 60,
    "http://fasb.org/us-gaap/2024": 39,
    "http://processapharmaceuticals.com/20240630": 17,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 120,
   "entityCount": 1,
   "segmentCount": 41,
   "elementCount": 425,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 415,
    "http://xbrl.sec.gov/dei/2024": 30,
    "http://xbrl.sec.gov/ecd/2024": 3
   },
   "report": {
    "R1": {
     "role": "http://processapharmaceuticals.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://processapharmaceuticals.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:TreasuryStockCommonShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://processapharmaceuticals.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-03-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://processapharmaceuticals.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
     "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-06-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies",
     "longName": "995513 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://processapharmaceuticals.com/role/StockholdersEquity",
     "longName": "995514 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://processapharmaceuticals.com/role/Stock-basedCompensation",
     "longName": "995515 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock",
     "longName": "995516 - Disclosure - Net Loss per Share of Common Stock",
     "shortName": "Net Loss per Share of Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://processapharmaceuticals.com/role/Leases",
     "longName": "995517 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://processapharmaceuticals.com/role/RelatedPartyTransactions",
     "longName": "995518 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://processapharmaceuticals.com/role/CommitmentsAndContingencies",
     "longName": "995519 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://processapharmaceuticals.com/role/SubsequentEvent",
     "longName": "995520 - Disclosure - Subsequent Event",
     "shortName": "Subsequent Event",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995521 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://processapharmaceuticals.com/role/Stock-basedCompensationTables",
     "longName": "995522 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables",
     "longName": "995523 - Disclosure - Net Loss per Share of Common Stock (Tables)",
     "shortName": "Net Loss per Share of Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://processapharmaceuticals.com/role/LeasesTables",
     "longName": "995524 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "995525 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-222024-01-22",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-222024-01-22",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock",
       "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative",
     "longName": "995526 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
     "longName": "995527 - Disclosure - Schedule of Stock-based Compensation Expense (Details)",
     "shortName": "Schedule of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
     "longName": "995528 - Disclosure - Schedule of Restricted Stock Units (\u201cRSUs\u201d) Activity (Details)",
     "shortName": "Schedule of Restricted Stock Units (\u201cRSUs\u201d) Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "995529 - Disclosure - Stock-based Compensation (Details Narrative)",
     "shortName": "Stock-based Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-06-30",
      "name": "PCSA:PaymentsForSettlementOfStockAwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_us-gaap_WarrantMember_custom_OfferingMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
     "longName": "995530 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)",
     "shortName": "Schedule of Net Loss Per Share Basic and Diluted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative",
     "longName": "995531 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)",
     "shortName": "Net Loss per Share of Common Stock (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails",
     "longName": "995532 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)",
     "shortName": "Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_FacilityLeaseMember",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails",
     "longName": "995533 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)",
     "shortName": "Schedule of Annual Lease Liabilities for all Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails",
     "longName": "995534 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)",
     "shortName": "Schedule of Annual Lease Liabilities for all Financing Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://processapharmaceuticals.com/role/LeasesDetailsNarrative",
     "longName": "995535 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012024-06-30",
      "name": "us-gaap:LeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "PCSA:LesseeOperatingAndFinancingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "995536 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-04-012024-06-30_custom_CorLystLLCMember",
      "name": "PCSA:ProceedsFromRentAndOtherCostsReimbursements",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012024-06-30_custom_CorLystLLCMember",
      "name": "PCSA:ProceedsFromRentAndOtherCostsReimbursements",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "995537 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_CROsMember",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_CROsMember",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative",
     "longName": "995538 - Disclosure - Subsequent Event (Details Narrative)",
     "shortName": "Subsequent Event (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-162024-07-16_us-gaap_SubsequentEventMember",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "PCSA_ATMOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "ATMOfferingMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ATM Offering [Member]",
        "documentation": "ATM Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r417"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r526",
      "r527",
      "r528",
      "r529",
      "r571",
      "r591"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlement of stock award",
        "documentation": "Adjustments to additional paid in capital settlement of stock awards.",
        "label": "AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued in connection with a consulting agreement",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r17",
      "r64"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r448",
      "r459",
      "r469",
      "r494"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r451",
      "r462",
      "r472",
      "r497"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r483"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r490"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r452",
      "r463",
      "r473",
      "r490",
      "r498",
      "r502",
      "r510"
     ]
    },
    "PCSA_AllianceGlobalPartnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "AllianceGlobalPartnersMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alliance Global Partners [Member]",
        "documentation": "Alliance Global Partners [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive securities excluded from computation of earnings per share, amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r77",
      "r90",
      "r107",
      "r137",
      "r140",
      "r142",
      "r143",
      "r145",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r242",
      "r244",
      "r260",
      "r294",
      "r351",
      "r404",
      "r405",
      "r417",
      "r429",
      "r541",
      "r542",
      "r581"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r94",
      "r107",
      "r145",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r242",
      "r244",
      "r260",
      "r417",
      "r541",
      "r542",
      "r581"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Assets",
        "label": "Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r501"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "BusinessActivitiesAndOrganizationPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization",
        "documentation": "Business Activities And Organization [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56"
     ]
    },
    "PCSA_CROsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "CROsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CROs [Member]",
        "documentation": "CROs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r89",
      "r400"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and Cash Equivalents \u2013 Beginning of Period",
        "periodEndLabel": "Cash and Cash Equivalents \u2013 End of Period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r52",
      "r105"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Increase in Cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r52"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDisclosuresAbstract",
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r139",
      "r168",
      "r169",
      "r170",
      "r172",
      "r175",
      "r180",
      "r182",
      "r319",
      "r320",
      "r321",
      "r322",
      "r407",
      "r518",
      "r524"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Weighted average exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase shares",
        "verboseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r72",
      "r296",
      "r338"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r152",
      "r153",
      "r396",
      "r538",
      "r540"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum equity available for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425",
      "r426",
      "r526",
      "r527",
      "r529",
      "r571",
      "r590",
      "r591"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "verboseLabel": "Common stock shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r339"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Common stock shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "verboseLabel": "Common stock shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r42",
      "r339",
      "r357",
      "r591",
      "r592"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value $0.0001, 100,000,000 shares authorized: 2,873,883 issued and 2,868,883 outstanding at June 30, 2024; and 1,291,000 issued and 1,286,000 outstanding at December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r297",
      "r417"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "PCSA_CompensationArrangementWithIndividualBonusAwardsGrantedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "CompensationArrangementWithIndividualBonusAwardsGrantedPercentage",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive bonus percentage",
        "documentation": "Compensation arrangement with individual bonus awards granted percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r81"
     ]
    },
    "PCSA_ConsultantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "ConsultantMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultant [Member]",
        "documentation": "Consultant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ConsultingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "ConsultingAgreementMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreement [Member]",
        "documentation": "Consulting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_CorLystLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "CorLystLLCMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CorLyst, LLC [Member]",
        "documentation": "CorLyst, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r16"
     ]
    },
    "PCSA_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Annual Lease Liabilities For All Operating Leases",
        "terseLabel": "Schedule Of Annual Lease Liabilities For All Financing Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r191",
      "r218",
      "r219",
      "r221",
      "r409"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r443",
      "r455"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "PCSA_DueToLicensor": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "DueToLicensor",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to licensor",
        "documentation": "Due to licensor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Common Share - Basic",
        "verboseLabel": "Basic net loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r123",
      "r126",
      "r130",
      "r131",
      "r132",
      "r136",
      "r237",
      "r240",
      "r254",
      "r255",
      "r291",
      "r305",
      "r401"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r130"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Common Share - Diluted",
        "verboseLabel": "Diluted net loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r126",
      "r130",
      "r131",
      "r132",
      "r136",
      "r237",
      "r240",
      "r254",
      "r255",
      "r291",
      "r305",
      "r401"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share of Common Stock",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r133",
      "r134",
      "r135"
     ]
    },
    "PCSA_ElionOncologyIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "ElionOncologyIncMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elion Oncology, Inc. [Member]",
        "documentation": "Elion Oncology, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized share based compensation expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_EmployeesAndConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "EmployeesAndConsultantsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees and Consultants [Member]",
        "documentation": "Employees and Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "EmployeesMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r85",
      "r98",
      "r99",
      "r100",
      "r108",
      "r109",
      "r110",
      "r112",
      "r117",
      "r119",
      "r121",
      "r138",
      "r146",
      "r147",
      "r148",
      "r184",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r277",
      "r304",
      "r311",
      "r312",
      "r313",
      "r327",
      "r381"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r448",
      "r459",
      "r469",
      "r494"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r445",
      "r456",
      "r466",
      "r491"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_FacilityLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "FacilityLeaseMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Facility Lease [Member]",
        "documentation": "Facility Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Present value of lease liabilities",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r274"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: current maturities",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Annual Lease Liabilities for all Financing Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current lease liability",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2024",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of finance lease obligation",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r273"
     ]
    },
    "PCSA_FinancingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "FinancingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing lease liability",
        "documentation": "Financing lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_FirstPerformanceBasedRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "FirstPerformanceBasedRSUMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Performance Based RSUs [Member]",
        "documentation": "First Performance Based RSUs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r452",
      "r463",
      "r473",
      "r498"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r452",
      "r463",
      "r473",
      "r498"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r452",
      "r463",
      "r473",
      "r498"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r452",
      "r463",
      "r473",
      "r498"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r452",
      "r463",
      "r473",
      "r498"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r361"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "PCSA_GrossProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from issuance of common stock",
        "documentation": "Gross proceeds from issuance of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Operating Loss Before Income Tax Benefit",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r74",
      "r76",
      "r292",
      "r302",
      "r403",
      "r404",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r257",
      "r258",
      "r259",
      "r308",
      "r310",
      "r366",
      "r399",
      "r411",
      "r589"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r257",
      "r258",
      "r259",
      "r308",
      "r310",
      "r366",
      "r399",
      "r411",
      "r589"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income Tax Benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r84",
      "r120",
      "r121",
      "r137",
      "r141",
      "r143",
      "r225",
      "r226",
      "r233",
      "r306",
      "r410"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r223",
      "r224",
      "r227",
      "r228",
      "r229",
      "r230",
      "r318"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due to related parties",
        "label": "Increase (Decrease) in Due to Related Parties",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r523"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r452",
      "r463",
      "r473",
      "r490",
      "r498",
      "r502",
      "r510"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r444",
      "r513"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r444",
      "r513"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r444",
      "r513"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant issued to purchase 158,007 shares of common stock in connection with a consulting agreement",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "PCSA_JanuaryOneTwoThousandTwentyFiveVestingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "JanuaryOneTwoThousandTwentyFiveVestingMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 1, 2025 Vesting [Member]",
        "documentation": "January 1, 2025 Vesting [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r416"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseRemainingLeaseTerm",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Remaining lease term (years)",
        "label": "Lessee, Finance Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r577"
     ]
    },
    "PCSA_LesseeOperatingAndFinancingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "LesseeOperatingAndFinancingLeasesTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "documentation": "Lessee Operating And Financing Leases [Text Block]",
        "label": "Lessee Operating And Financing Leases [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Annual Lease Liabilities for all Operating Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining lease term (years)",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r577"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r107",
      "r145",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r243",
      "r244",
      "r245",
      "r260",
      "r337",
      "r402",
      "r429",
      "r541",
      "r581",
      "r582"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r73",
      "r299",
      "r417",
      "r525",
      "r537",
      "r575"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r88",
      "r107",
      "r145",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r243",
      "r244",
      "r245",
      "r260",
      "r417",
      "r541",
      "r581",
      "r582"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "documentation": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_LiquidityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "LiquidityPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity",
        "documentation": "Liquidity [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_MarketCapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "MarketCapitalization",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market capitalization",
        "documentation": "Market capitalization."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r187",
      "r222",
      "r256",
      "r289",
      "r307",
      "r309",
      "r316",
      "r329",
      "r330",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r397",
      "r398",
      "r406",
      "r407",
      "r408",
      "r412",
      "r413",
      "r414",
      "r415",
      "r418",
      "r543",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ]
    },
    "PCSA_MaximumValueToBeSoldAtMarketOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "MaximumValueToBeSoldAtMarketOffering",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum value to be sold at the market offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net cash for operating activities from continuing operations",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r54"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r54",
      "r75",
      "r86",
      "r95",
      "r96",
      "r100",
      "r107",
      "r111",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r120",
      "r121",
      "r128",
      "r145",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r237",
      "r240",
      "r255",
      "r260",
      "r303",
      "r359",
      "r379",
      "r380",
      "r427",
      "r541"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss available to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r113",
      "r114",
      "r115",
      "r116",
      "r123",
      "r124",
      "r129",
      "r132",
      "r240"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_NextGenerationCapecitabineCAPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "NextGenerationCapecitabineCAPMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Next Generation Capecitabine - Cap [Member]",
        "documentation": "Next Generation Capecitabine - Cap [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_NonCashLeaseLiabilityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "NonCashLeaseLiabilityNet",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net",
        "documentation": "Non cash lease liability net."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Cash Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "OfferingMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Member]",
        "documentation": "Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual base salary",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "PCSA_OperatingAndFinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "OperatingAndFinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current maturities of lease liabilities",
        "documentation": "Operating and finance lease liability current."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "documentation": "Operating and finance lease liability noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_OperatingAndFinancingLeaseRightofUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "OperatingAndFinancingLeaseRightofUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease right-of-use assets, net of accumulated amortization",
        "documentation": "Amount of lessee's right of use underlying asset under operating and finance leases."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "OperatingAndFinancingLeaseWeightedAverageDiscountRate",
     "presentation": [
      "http://processapharmaceuticals.com/role/LeasesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount rate for our facility and equipment leases",
        "verboseLabel": "Operating and financing lease borrowing rate",
        "documentation": "Operating and financing lease weighted average discount rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r403",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense for right-of-use assets",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present value of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: current maturities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "PCSA_OrganizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "OrganizationAbstract",
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "auth_ref": []
    },
    "PCSA_OrganizationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "OrganizationLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OrganizationLineItems [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_OrganizationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "OrganizationTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OrganizationTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to related parties",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r417"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Expense), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due from related parties",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r450",
      "r461",
      "r471",
      "r496"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r453",
      "r464",
      "r474",
      "r499"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r453",
      "r464",
      "r474",
      "r499"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r478"
     ]
    },
    "PCSA_PaymentsForSettlementOfStockAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "PaymentsForSettlementOfStockAwards",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlement of stock award",
        "label": "Payments for settlement of stock awards",
        "documentation": "Payments for settlement of stock awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Shares withheld to pay taxes on stock-based compensation",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "PCSA_PerformanceVestingCriteriaValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "PerformanceVestingCriteriaValue",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance vesting criteria"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_PlacementAgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "PlacementAgentMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent [Member]",
        "documentation": "Placement Agent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "PCSA_PotentialBaseSalaryIncreaseFinancingMinimum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "PotentialBaseSalaryIncreaseFinancingMinimum",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential base salary increase financing minimum"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "PCSA_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre Funded Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r168"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r339",
      "r357",
      "r591",
      "r592"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from issuance of stock",
        "verboseLabel": "Net proceeds",
        "terseLabel": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "PCSA_ProceedsFromRentAndOtherCostsReimbursements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "ProceedsFromRentAndOtherCostsReimbursements",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent and other costs reimbursements received",
        "documentation": "Rent and other costs reimbursements received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r275"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r275",
      "r293",
      "r301",
      "r417"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r275"
     ]
    },
    "PCSA_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase obligation",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r185",
      "r187",
      "r214",
      "r215",
      "r216",
      "r222",
      "r256",
      "r287",
      "r288",
      "r289",
      "r307",
      "r309",
      "r316",
      "r329",
      "r330",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r397",
      "r398",
      "r406",
      "r407",
      "r408",
      "r412",
      "r413",
      "r414",
      "r415",
      "r418",
      "r421",
      "r539",
      "r543",
      "r573",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r185",
      "r187",
      "r214",
      "r215",
      "r216",
      "r222",
      "r256",
      "r287",
      "r288",
      "r289",
      "r307",
      "r309",
      "r316",
      "r329",
      "r330",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r397",
      "r398",
      "r406",
      "r407",
      "r408",
      "r412",
      "r413",
      "r414",
      "r415",
      "r418",
      "r421",
      "r539",
      "r543",
      "r573",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r445",
      "r456",
      "r466",
      "r491"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r186",
      "r281",
      "r282",
      "r295",
      "r300",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r356",
      "r358",
      "r388"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r580"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r362",
      "r363",
      "r366"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r186",
      "r281",
      "r282",
      "r295",
      "r300",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r356",
      "r358",
      "r388",
      "r580"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r324",
      "r325",
      "r326",
      "r364",
      "r365",
      "r366",
      "r385",
      "r387"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r446",
      "r457",
      "r467",
      "r492"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r447",
      "r458",
      "r468",
      "r493"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r454",
      "r465",
      "r475",
      "r500"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r64",
      "r298",
      "r314",
      "r315",
      "r323",
      "r340",
      "r417"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r108",
      "r109",
      "r110",
      "r112",
      "r117",
      "r119",
      "r121",
      "r146",
      "r147",
      "r148",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r246",
      "r248",
      "r249",
      "r251",
      "r253",
      "r268",
      "r269",
      "r311",
      "r313",
      "r327",
      "r591"
     ]
    },
    "PCSA_RightofuseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "RightofuseAsset",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use asset",
        "documentation": "Right-of-use asset."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalariesWagesAndOfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential base salary increase",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Agreement [Member]",
        "documentation": "Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Net Loss Per Share Basic and Diluted",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r12",
      "r126",
      "r127",
      "r130"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r275"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r362",
      "r363",
      "r366"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-based Compensation Expense",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7",
      "r69"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restricted Stock Units (\u201cRSUs\u201d) Activity",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r60",
      "r62",
      "r63",
      "r64",
      "r91",
      "r92",
      "r93",
      "r139",
      "r168",
      "r169",
      "r170",
      "r172",
      "r175",
      "r180",
      "r182",
      "r319",
      "r320",
      "r321",
      "r322",
      "r407",
      "r518",
      "r524"
     ]
    },
    "PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases",
        "documentation": "Schedule Of Weighted Average Remaining Lease Terms And Discount Rate For Our Operatingand Financing Leases [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_SecondPerformanceBasedRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "SecondPerformanceBasedRSUMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Performance Based RSUs [Member]",
        "documentation": "Second Performance Based RSUs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "PCSA_ServiceBasedRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "ServiceBasedRSUMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service Based RSU [Member]",
        "documentation": "Service Based RSU [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ServiceBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "ServiceBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service Based RSUs [Member]",
        "documentation": "Service Based RSUs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares, Beginning balance",
        "periodEndLabel": "Number of shares, ending balance",
        "label": "Number of shares, outstanding",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted-average grant-date fair value per share, Beginning balance",
        "periodEndLabel": "Weighted-average grant-date fair value per share, ending balance",
        "documentation": "Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant-date fair value per share, forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant-date fair value per share, granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, issued",
        "documentation": "Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant-date fair value per share, shares issued",
        "documentation": "Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of shares, unvested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted-average grant-date fair value per share, unvested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, vested and unissued",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant-date fair value per share, vested and unissued",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average grant-date fair value per share, shares vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, expired",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for future grants",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable, shares",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable weighted average exercise price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, forfeited weighted average exercise price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable weighted average remaining contractual term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_SharesIssuedinConnectionwithLicenseAgreementShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "SharesIssuedinConnectionwithLicenseAgreementShares",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in connection with license agreement, shares",
        "documentation": "Number of shares issued in connection with license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_SharesIssuedinConnectionwithLicenseAgreementValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "SharesIssuedinConnectionwithLicenseAgreementValue",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in connection with license agreement",
        "documentation": "Value of shares issued in connection with license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance. shares",
        "periodEndLabel": "Balance. shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "SharesWithheldToPayIncomeTaxOnStockbasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Shares withheld to pay income taxes on stock-based compensation",
        "documentation": "Shares withheld to pay income tax on stock based compensation.",
        "label": "SharesWithheldToPayIncomeTaxOnStockbasedCompensation"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Shares withheld to pay income taxes on stock-based compensation, shares",
        "documentation": "Shares withheld to pay income tax on stock based compensation shares.",
        "label": "SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "PCSA_SpartanCapitalSecuritesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "SpartanCapitalSecuritesLLCMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Spartan Capital Securites LLC [Member]",
        "documentation": "Spartan Capital Securites LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r42",
      "r45",
      "r46",
      "r85",
      "r98",
      "r99",
      "r100",
      "r108",
      "r109",
      "r110",
      "r112",
      "r117",
      "r119",
      "r121",
      "r138",
      "r146",
      "r147",
      "r148",
      "r184",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r277",
      "r304",
      "r311",
      "r312",
      "r313",
      "r327",
      "r381"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r138",
      "r269",
      "r290",
      "r317",
      "r328",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r339",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r360",
      "r361",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r422"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r138",
      "r144",
      "r269",
      "r290",
      "r317",
      "r328",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r339",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r360",
      "r361",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r422"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r449",
      "r460",
      "r470",
      "r495"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued in connection with license agreement",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r64"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in connection with capital raise, net of transaction costs, shares",
        "verboseLabel": "Number of shares sold",
        "terseLabel": "Shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r41",
      "r42",
      "r64",
      "r319",
      "r381",
      "r394"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation, shares",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r41",
      "r42",
      "r64"
     ]
    },
    "PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock withheld for income taxes",
        "documentation": "Stock issued during period shares stock withheld for income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_StockIssuedDuringPeriodSharesWarrantExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesWarrantExercised",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercised",
        "verboseLabel": "[custom:StockIssuedDuringPeriodSharesWarrantExercised-0]",
        "documentation": "Stock issued during period shares exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued in connection with capital raise, net of transaction costs",
        "verboseLabel": "Shares issued initial offering",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r41",
      "r42",
      "r64",
      "r327",
      "r381",
      "r394",
      "r428"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r41",
      "r42",
      "r64"
     ]
    },
    "PCSA_StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor",
     "crdr": "credit",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of 5,000 shares of common stock in connection with a licensing agreement which had previously been recorded as a due to licensor",
        "documentation": "Stock issued in connection with licensing agreement which had previously been recorded as due to licensor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets",
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r45",
      "r46",
      "r57",
      "r341",
      "r357",
      "r382",
      "r383",
      "r417",
      "r429",
      "r525",
      "r537",
      "r575",
      "r591"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders\u2019 Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r106",
      "r167",
      "r169",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r184",
      "r252",
      "r384",
      "r386",
      "r395"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r285"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r285"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r285"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r285"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEventDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r285"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://processapharmaceuticals.com/role/SubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r286"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "PCSA_ThreeYearVestingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "ThreeYearVestingMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "3-Year Vesting [Member]",
        "documentation": "3-Year Vesting [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r536",
      "r579"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "auth_ref": []
    },
    "PCSA_TitleOfInidividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "TitleOfInidividualAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Inidividual [Axis]",
        "verboseLabel": "TitleOfInidividualAxis [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "PCSA_TitleOfInidividualDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "TitleOfInidividualDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury stock shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://processapharmaceuticals.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://processapharmaceuticals.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock at cost \u2014 5,000 shares at June 30, 2024 and December 31, 2023",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r42",
      "r45"
     ]
    },
    "PCSA_TwoThousandAndNineteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "TwoThousandAndNineteenPlanMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2019 Plan [Member]",
        "documentation": "2019 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "PCSA_UnrecognizedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "UnrecognizedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized share based compensation expense.",
        "documentation": "Unrecognized share based compensation expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r79",
      "r80",
      "r82",
      "r83"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative",
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420",
      "r423",
      "r424",
      "r425",
      "r426"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r573",
      "r574"
     ]
    },
    "PCSA_WarrantsExercisableAndMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://processapharmaceuticals.com/20240630",
     "localname": "WarrantsExercisableAndMaturityDate",
     "presentation": [
      "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable and maturity date",
        "documentation": "Warrants exercisable and maturity date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted",
        "verboseLabel": "Weighted average number of common shares-diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r132"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails",
      "http://processapharmaceuticals.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic",
        "verboseLabel": "Weighted average number of common shares-basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r132"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://processapharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>54
<FILENAME>0001493152-24-031622-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-031622-xbrl.zip
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M0UY?@$5@$FPP,UH-0>W<-R,&NM$F909#MH,D<ZJT!.!5=!L1^$E"[ ,0S8P
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M1FP;;S3FIQW'O%29OF5I7L;\"U!+ P04    " #R@0U94- $89/W  #M80D
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M0#&?W00]1&:M34U^#7%_I7UKJ*"==P(QA)\$?T0)8NG&)=P6!!U%&!&:/I+
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M,)&S+G@508QK$^BZA-=QT\5HK7YRJA"6O99:,):);,'6O)3@/,9&-B!K7E)
M;F,C1Y@.F7F"$M('DM!2;KG1),-V8_)&9VWV,'H":UUK"4J4V.9PN3<51Z[S
ML<.9./"%\DS9?.PD=AQ8@S/O:G-^X9RYV7V*"(LII<C-]EE,0%$LI4<_^BQD
MN;B6TJ,7XW-6/)=B#6L)REAKB)CC,$W\K;8X\(73\?&WX>+ &IQYR[$#]A,P
M5 $O!MP[\]JSS#.Q=3-2RZA8UG9/9<'*UFFGBMH$Z@<,EK0;M29QXF"AP5RT
MUYN/'CS8<$+AQI[V/9 X'4!IAT*.15^14+TR C;BIJ0GP,5XIL*&%N,P> 00
M *[8DGPJRHC>EY#/P2TTQKPX1()IPAL5JL@^KJG(I_Y!PQ&K/TUB=4C@2;3^
MU!?Y_F].N%7!AZ@8FC0Z!D"^![RB"D"H:@N*>P*O)[H.PNNY%WM]7>D:&JAJ
M&HA8CY"/7N6#@3#I##&'*6U7'(VB A,OD7&M0*VO]6=!N?9!31"%4HE'H5#P
M!,!.$%OPPUFAB&!301>H ,JBAK]'1?2'&CX= 9]#X",/AWU<(3_D-2YG5Q,?
M?&G"OO4UJDO_=U\3!T/)^9J9)YNOTA1#M=X$+\(5GH?66LW".W_<6]7B]ET
M%^/9'TX^%@7T15<$*H$7 3P/'=0:%[-U>^Z;)R_[X?4VZUU#'#_,@:#IG*JC
MXL2CZ4KLYTR_<]\%S(+&H^F*I^\6G'?8'SO?;G]FH=(7O=,ZNC($:GM0:IZE
MT8^FL$^>;WV3*'*VB]]FD>/DG.218]<];B-R6+M2.''D^)9C;@V:W#HKGQZ=
MY5M;NIW(92,@EUT#<ND=06YH:[LZY%HZDS'USH)$R4:0/<6@>49G^KGUC0 A
M^1I*(B_J)IR$( Y0&*3(SJ0J1!:ZO?['0(<C8,RKR+B,_DO4]H^<]?4S:_[U
MP_,5#N!^>$(7TP8P*[,!/L1>G'7:?<(O7/]W80+_=-[N,X#OVK\+\7V2][M/
M>>^%[SC9M\=Q6B=REA^IV'UQ2(L+9-%B?<3.7*#TN4!K9X+,!4J/"[1VXF<N
M4!I<H'61?2M=H#4@)\L"I<<%6KF_FV6!TN\"K9D),A<H32[0FHF?N4#I<(%6
M3/;E!Q]VG^)IL?+Y5;MTX4Z1[#[ATVCEU\X$F95/CY5?._$S*Y\&*[\NLF]E
MHF-UR(G02&OW!6.CSE 2M5%.9EEQX5GF3*71F=IF)LJ<L0T[8]O,/)DSMS%G
M;@O99GN<P:U ;N 6=[LOCJER(5-Y=B%2O\'=9YS4NI#;Q$29"YDR%W*;F"=S
M(5/C0J:/;<*T2]M]CDF/EQ/QR/YJ7>*HO>MVGW'2Z>5L&1-E7DZ:O)PM8Y[,
MRTF'E[,=;+.EB;*T(C=P-\;=%\=4N9#IZZ 2M37F[C-.:EW(;6*BS(5,F0NY
M3<R3N9"I<2%3Q#;3<X69;Y.2HGIV]1T&,]\DE;[))ID@\RW24U2_=N)GOD$:
MBNK71?;M20^M$SE9>B<]+M#*FRQGZ9GTNT!K9X+,!4J/"[1VXF<N4!I<H#5T
MUS?)SAN:K@R@D9<U0]*=8V?,A=H7-(><"D&8#/GD#574@79Y6=M^!FF-AN"F
M6T5#H'IXZ29CX+DIOHA9RAA!(!" >'@)>IQ4Q^ARO'<9OG?.-??:P\W\T#1M
M,Z9HN(R361AF^MOV1'3SR&68L,AUWK.2R3W;A=)9\^E$SDJ\)OB"+2HPF4/.
M:H?3P!=4[-^F7L:MH?)]SC&(?OL5^2+?P6>YF]7A3"6\FEGQ@+ 9%E'!J2$+
MP![*.>N%[B #U21.@YBPEGNCXE&*3B;R1$@BWN>6\+!;=:TX&J:=3N=WX<*
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M=MHB=DJEL6,G[)1II^UB)S8".ZU#._GX3F;&7H*8K H#418U'>7O/\#W8JA
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M2_TX8=R')D03N#]^R1"LE0ATFA'HQ.5ES8/%LMSX2D.[ABR@G0FPUQD1?!]
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MI8"*9V[%ZL7K6[5ZKIQV^6^C>);$LI6@\T/6JGB6 1TT  ^D>"I>)X@RQ1-
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MQQ ?2-3LUP !AP$A_3*MKQ@2)#MZ-V=3X<V0'6<!,:8MU'KB$,%G%ORAC1.
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M^]!KO_MTJ:$LD,*]A2.DVL2=WES1Q[,EA6MY6,97T'D]M'E7V,B(>L3L6HB
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M1"<GY-39O&:U8J50*B<SAT7G]YP%YV,)GN@&OI;W_)*TE94#>R99+(6/@GS
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M<G&Y0M'J2BF]9#J@@RHZ=^B0,4B"D]!J!X%!+<,[@3Z6":]T[Q57QDL/N]D
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M*D1)$_GSAE%*W..IU+G2,6WG62/=P-8Q9QYU=9\"Y)T#K8?]'@@(B\"<?;6
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M3+FR6:MM2J5JH5*>.2R46W+,,;EVZOK@%.]8",PUMSML[<L#*@ORH^V8KBZ
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M&KU^#]Z>[J(_?OGYN7MZ_O18[_C7_0F_@IRQWBU_\&F\R,V\WM9BO!U]N5*
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MP;C]#P=<4&X-#VJGGP?/A]9PFG2;A<FMOSOJ,FKG)F#/J0V'6J'>'!\1G(O
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M13>;0)V/MZD4\C8%%/@.;X%']VS=!8(JU/;]C<3>N-UYO=QU?AU>G9WL.NW
M117\G"B&9.CPQ8QV1XVFP>R2<,QR8NR4UU)Z T]5$#6..[=9!G1;,[6NCDD9
M&"UQ@/IM5O83#7-(?NAZ>W0 -A0"+;7N7K6SAWNG=M9J7ZQV>'/]DK8B4_U_
M6UORH:X9ZK_RA=+3/L)CR-D=_'GYHTR'XE^Y+&]M\;)D57_*7_7.5N7_HD[O
MGPB0<#S,8*E8_&_:,K/[_KG6(*WT-Z,6O$-I4I'7P6]#=!,4^RBC</M7WK&5
MMM[Y*)^!U&%4/;.0?J5R^*E_Q&/X55!O+(J-__</$#J%Y*!</VZU-3B&,/:
M=HP3&5:U1A2.##T&-#&++F%J(IF)25?\]*V?N&B'BAV4.VQO+T3(L:OUI?*V
M?.K'T7WC#9.1/<?A>6SRCJD80T<G"RY(!MB#BU(7N6Z8MBX2C\Y%''W-4C[6
M<7,/+1OU,NG$LAY1B[H2E;G.AO@Y$VW20$:>&<C(7'.MKT&SDKYYH*MIF!9S
MJ0TLFUR(L(=]^-G6-])>%=UT9)Y?TV6[NV7PW?7KKD56+E,-;:UK:!T7W>B:
M"210M2!BI)A#_UAC(DW'92DNDH4ZH*%K70=?V]%L:CG,<Q@U2E=CH^OFDV6
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MEN,*6L[6GC(HT#^.M#ZI%_CO8UN7WY-?.E2,I3CRQ=Y5O5HN%_ ?E5*I00_
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M$G[5%[4K!F6P'0HB<3\$RSZ6P;Y&'=9RM% Z8FIP*:+<;HMA:%KX&H1J(%5
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M41[YS9C1G/&K/PN[LA1H)6.IZ='02NZ.S[^&T%@2"(W1."M"GY.D>Y8EE$A
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M794C2'M^D*7(&2HZSHS'QEQ2,.=ZG'V#_19@P7COYQ1#ON#DP)P$'2BMW_%
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M'X&9^=B8^U(RRT"7ZFMA[L.4], XHAX\J!ZYF@'8,QS(FH.$57/4\].UC?3
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M>?HZ3=K?*M[.^=[QV^LW?S>CDS]X1S9;D3? _W;37O#J_P-02P,$%     @
M\H$-6:KL*RJ?2P$ 6&X! !    !F;W)M,3 M<5\P,#$N:G!G[+I95%-9&RT:
M%:40,-(K7<H.I!?I(22_4H* @(#T342D%Q$A&B4F)5WH*4%Z(2)""%WH000"
M22"E" BA$5!(0@G22;8"[H(0#O^Y=YS[<A_NO>?UKCW6P]Y[C37V_+YOS6_.
M,?;>ISTVY+B-I;4EY,"! Y";^Q=D;P9B\=^[_ZWQWTW^=_<XL-<#D?CM@.E!
MST,'3D,.2APX)'%@CP&!02 '#O\?"R#_YSAP\)#0X2/"OXD<%=U?T'(<<O#
MH4,'A0X=/BPDM/_VR?Y[B)#$8<E3NI>.2#GZ"9^.E+[X]%GI;V<N-_3*.(WP
MSNK=NA\K<E16[L1)^7,JJN?5U/4-#(V,34PM_KAB:775VL;YAHNKF[N'I__M
M@,"@X)#0J&CT@X>81X_CXA,2"4G)*5G9SW-R\_(+"E^5O2ZO(%62JQJ;FEM:
MV]K?=-#HC+Y^YM_OWH^RQL8G)C]-37.X\_]\75C\MK0,_/BYL;GU"_QW^[^X
M#D ._2_H_[>X)/9Q'102.B0D_%]<!PX^_.\"":'#IW2/2%YR%/:+E#I]\>EO
MTI>?E3;TBIS1<^+)W+H_<E3VK#[G'/!?:/\3V?\S8+'_GY#]+V#_%ZYIB-BA
M _O).R0!04($@O.4E#T(N[1$?YPOMW.:[XY0Z'S; +BEK6&1/#KM9PCK741E
M>A@W*'D#?]ABEZAY+,_ZH5)K$QKN$(B;E,MB76J9/T;-QHOAU,!LSF0F0E8P
M0)3&NG&+':E^$2G$YK:^/4C2]+LQ])DG7&(\2KQ;R1OSEN-:'A5I\#DJU'6Z
M;S&M(G'&;NQK[A>_>M;+9VFX&R&_/(0/W6KBYTD4?>P?K>"!+WR,GF[)J'-#
M;_(PB,>?ENU<2"*]@>TO2"HW:DB;:1,)OKBK-I)\9";V[GM0-.V>XKG,=PW&
M2?X_/E=U1@W7?:0'M&/GC(>4%%6LDIWHD]4V;SEI;2GMW>Y%';8ZG#L/3HYN
MM82,$S8BK^#4^!J[U#U(&#39TXB!4O#AG^')Q2%@2WN0 U@T$$$7J (1"0@5
MT)8N.#RQ4>2ATWF LP>1 =OZ31.?EF/MZH'TFE!M="8A]_'=XN!)$?/R3<9U
M^/U(9=W=#FK(7/H>I%$G!7<1>P%U 'NZ"0AB(!/P$/YA2*8[%2Q5S>RT1>24
M8R^-KU)N302-=!IKM>PZ&?#0B:37OBA*0@U:R\OQ0?>;T8D.?TZ>I.8^%G(V
MAZ.(\\GE1NH8EB:5QO<'1M8Z0R^WC0=/%M60.;KCZDX5+\C,P[[..:9.I5X2
MBS>V;3#1/Z8"3V@:R<VON/S='I?T8[45KI'>,]]TC4109W_S!]JO%,Q?B"Y-
MR#VC_ZZ2TV#P]<0MU1<WR1])R0PKA;@> 3""*D;H[5+@5CP4!\H8/H9A70%T
MT@1(OCQHSL5+K\R>YRW2D,F%1KWB$:B/S8?'-I::YQ0Q64-/5+:^N.Y8^WA(
M^93$?+DL[FNFGYR]RL,J<2CB(1W":4C_/8@DUH<ET,"& LPU_6YYX#.QN;5@
MQP5#I*5RAH][?<OF6P E<?M!CYL]L0=)UL0?ZU8&<1.S0^L?##^B>GXLO=<L
MGO@<%?!9/+7/L>]6)*8EH>QH?HH'?OR;Q4GX.*?Q@WV4FU2B2^34$^.;9;F<
M"76]:J<2,PGYAD0Y+;)3#H8^PH4I--903N8&_.OJ A^6\TQ$I0SG(A6\U,IH
M*Q>YWM0XWM2#V[PI[2>^=5&(,\P!S6I;T<NMMGECM*'N$$;T!?"%] K^/QMN
M\T$]>/ \D4E,1TEN%#^88_<3*P2#A>44QMSQT)+?W_+R&#XP#QZ*OGYHR3/G
M>_K\$RNN9>L$]1C?QRBIKL:_A4A7%F49B*:?JA/OFBC?2LI_L9Z(XCG"IB6T
M<1(@?3[S3X14\)RH0(5_$&0!RT_,>L6Y_V+Q+S%&G,!L%4H9F.F<[396!T>&
MA<PGJ[*BBV&62:@OEW\^Z=AQ;GG$<DA9P83W2:LFE3GE>FRF&9RX04Y(C(@C
M)Z-)MA(>;+71BBJ30'TRI^I]G<18!;M8=:U<?L/G6CWQZK!80_.]$QTR8-X.
M4K??C?[QPS(O-Y(P4!I?EMSC=Z;$K>^6JL74/8%*=T!BHIQ!NM@?80;)J;VC
M)5 Y,>3:.1DPG>T GE]<,ZK"J'+7^S(5L)*\K3C>)(W:M)]3G$:P_(MN,;"8
M<[73;-Z:E#C,(3UM"8_JG_0,(#%V(F1L'X:;+[QE:^G9C$Z<NL"BE!^5[W+Z
MN56[VW G0J"$W><RY(X^QHL[E]$M'[8':39*VL0?_\R_1.!0:)FQOHJCT<:W
M&P!;E:K"H8;Y8HL^-\_B\B^SV0^//7VY]$ZJ6?YE;-B22AO!^TIBM5/ZXP(M
MD]$7I8Y[D'"_4$OM7.C*I[;'TKI:S .7;^#>#IRTS_%V/9INZEZ8_T$_J *Z
M),(1^"70YR^XXRY2;&4L#7A+O =!!+*3\8NI?][<N!'YB=^A6Q*33DIYI&/N
M[MC'N?]Y3@XED^?WXP4M&ND1JE^HINP^GVN4=<2E0&*\1!9]K%J=K*5P\6('
M =+X5\_Q2Q2ZC_#6R]UF9##E.([VCHV7P*J (558OWKP+8!GX)0(5X&::?U9
M,? 19=GS2&H0=VUZ8-F4F-AI]=I[Z9>\3W=19,5G%":M[PDZ,J3B<FL.F?=V
M*Q_(F4O;_**SA07]>4568-^.FV $J;SIA5( 64[ #'BJ6T(P;!W @8+N);HL
M9A+%P'9.8OFAX>-$8D6PK^0;WE:").VG==!=H3:I#1?>O%&I?6-MVH"R>KI\
M3IAC63I)W5C&0F_P@LQRH'M5<XAS>6*Z8K9A_^768R>6[$^X0&^.>T81CR@L
M2=#RET&3FS\R5#SNZLD1:!Q=3&>1A)CO0_A#\7L3,4_IO"V/Q/Y;&MPH^?PA
M/0[V52O4J#;+N1RECT9TB?A%ZE?BOCBBTG%BNU1D\'XQ;5OU(,5 X9ZYPRI@
M*:#7-]?L2^"F1[F-P7V)1\/Y2CRUVN9^D/SRR_2L84>)S)A!S,2/-=5PFT67
M/)LWHYK?5P.[O%9@+P7*@D_*IH <7VH8M5O7Z<SQ.3;<7^A&GTLN.=<\PC<[
M0MZ#_#9!?L31<F-XZA!:O,S"[1=6;A#^&/]G=!5MF_1=1S5+08T4\.)5-=1,
MJ>>%19XZS"/Q$%&BD',_-#HD4%]]<GO62"ZYAZ-JJDL2L1!-HL0S8M1_9'69
M.I%-I5^]+MLXJ9J!/<20T6T8J X:RD71IHAR7-W\.F6FWSW8E(>V<UZ01XN\
M^QMNV.76H#QVDS=UQ5@^^I_<,U*V4"M8"MG81) T=F]0G!&B+\F$7Q1[7?]W
M8S];4L3Z>&.]D,1?5_\^4TEA[.@DX&1!U,[)95CK< 9"%7L%?+ICN8P_T&D+
M7%[O;T-*=[I':UGY@JGLHEHS.UX+Y>D=@TJLXJP4;[:4VZ5GV\!Z-7*@<4PS
M_"YVY4&&:#"&&KL':2'UK7\:Y@@GXZ3YSN CWA[$:41P$/=^#R+<&<7>/=/S
M:_;T'B0^I],?0#(^8AQHLT> [^651>F(1>_)%K.!3(DPMQ+%4;^64;:<X01^
M^L?S9UT&G$UL@-B=1OC[DK"4GH6Y3Z.T"3H^P%8NY>62XP?U *HWPX6<2N=$
M8CK%SX^3%:7W.<UT/&0D>EP$.P_\.OS<O_$Q-HS> OIK#+4[1B9H#@OGXVOU
M?]2T*8E9ZITJ93BH]7"" SP2 W(""F:U*^3CFU*B(T_(NU\S/",C]D?#<^KC
M\Y2^(MC,KZV&49PX_Q8PF=8MBG%5>F@)0'LIPGRYCG:> V,X<=LA'1L#&#%:
M35V;V&'#(OP_QK7@_@\$\JRZ@$(=Z?_HAYMN^XF]N[W5>/0]0%J;WPG%G(9E
MVN'9.E.DZZBI'2Z*1CT,QOZRZ09SX C-"9RZ->?O6L0)C/9H6+YJ-Q!!.-8Y
M7 >V72<ZC%Z>>M[$&QN^*/.>F/C"VJG61K?Z612+82%6-'P/FU,UY"X?]LE>
M/[3_M7_2AWJ,9WK'?5)*M?K%V.A(F?/1;MM7,>A$NA^ OM<9M5K]=;-)[3S/
M\-XRY\*87\FMLPW-5?X76*6N&&7%P9\V%])T)6IS_<C<I?&L_IO!_OB[2R(0
MR:N0@]:JD /OSI9 #F4YV/!Q^SR"XT?S^%1YQ%GL!1Z^=X4:"X-T&WY#0EJ*
M-?H?"M21L@A-S/83U.51N&, ;UM)_KNXW!6?TRM>(N56U1YA<O(ULD8=A.<-
M,X,A<OE\6W /LF,SLPSC.>LH+W>;\P*&>];CY67?\KSHOK+U#9.YV_1^4V*"
MYP"MS5>ZQ.N?1@)#=IN:MN&%2I9[G#6;;N'4D@$5]PQY\*ROH!>,*KEUQ@8-
MG P\9N ?=SWAFG]UTO:$$>S937+ :*F%J*JM;B17\8C:=;+3C:[G72\:'.NJ
MG.BNX1N)[!="@'Z]^S&5P66_@**A\CL(1T7M0SM&*G^#\\9]D8?A#XST2(I6
MT/XVR&*!/].13C_>H#]Q^F3 M4-T[D_8Y[_+4S"CP><R@F]?'QF0JGGV-ZGL
M3*GZ^QB9LS#/+.I1A)Q@$GD"[T^,]S4''0 CSC!]-Q YQ=R*V27>[10MQ1S=
M8?P(<P*'N2U<T)^N+ 0LD,FBU6%?'B\$_P,H-T5Q!E6&9C6B.YM';XT5K 6:
MYQ#6UG9\/;":0%X2]@K/N7>.ES>']0%AO")VPD0Y>Y\HJ6(;R"1E=;"H\AK<
MD1-#^0WSRYG0/]&(<7!HSO$'KBW:LBAGWZ1LF6M[8:Y=7/*B>^^ZU/%R[M=8
M'O8/YMPSGEIHUX3KR6/J0MNQ]LI2V-'X"QFY&DH#)ZV$[5T"!I/*"61WILA&
M!ELUH=?*@!YIZ5,,SSM9&/1(2UMV2'<<@Y?(-<5X/T!EUEIN+$W6%FG:>V15
MY?@Y&S&<Z<Y;CW"J2H1>8G.SVSRICS@3LT4"[^Q!3C8WCR(#"S9A4\X<P=-Y
M:.;C[R0DPQ9Y#"3N:ZS%L4THA&\".MY&&V\&HW4Y8ZQ7G1-P*ZT/IFU)Q:MK
MS;O:(F5J.8#4UH]=\H8&,J6M1(Y'ZC&SA4VM;]T'SP'.\RK5\]GSM@&H9)0$
M7[];I1M$<Y3TK@*B#O#I#E_/D!)%^>(/%M<Z$A))E:%R\NDYC?-6])+3#"NH
MJ?.[S[J(X:FQ1RWG>]57='(E711Z9D65Q&8T2XZIRZAZ&O/5<^#P9=-[*WV[
MI_CF/<-*ME(6J1R4SM9RUV^\BM/H(+CTSVV/6E.)C <<5X]S=V6XGB:,+Y[2
M%Z+^;E)S9@1*WUONBI@:-M71O[3 7,S_\$II92$_3NABTL_.?L4$G;;@6](O
M_E*WX1N#SW;\,P]@74$FP)UA9Q JL6X\)GUXBK#UA'<1+C =@U^* :#SK>DQ
M0!A#^=!X3?3;G2^()V=Z6GGEXU\)B=C3^^YP\\2IT;Z?3QK/KYF1=MNH=\)U
MMC! 'F,MB.U&Z"?MR_%4TX<)X9WAJG\BU((?'\ZCQ8\&4(',?O$H=C>IRAH(
MUT<=1FG5%> /?ODT:(JJ*-,TO#?E(/T+>2SJE^UAS^P>VHEW7T'WW1B]@?K[
M)4@EAVG[7%GM+K=DNM_X-4W5I/0JFPJ5"QG*]Z/GG>615S.$W%\LBB1[? F=
MLE/<@^A7_K!7Y"IRBQ53S]55.O8%HF5%CS:N#ES 8$=K%;M#W3%^/Y9;E@/U
M0RRDX,C5<)E_NW:N8>\#/@2^E!L3*;O.O\01S53 ++)W,XBO5_8@HMJ;[9U:
ME<MSTM\U.W5*0WV/%C%$P[EFF,5F0*FU-$*)6U%+^M!T&&\Z'DC)P_KO> M&
MD4TDPKXUA')(\3AI,(^SOAK&@4X1.;]2#.9@<^#03C].'_B5MJ$C%M)!BHLV
MB1YT^7VL9:#Z2Z#('J2-TM>5FZU44XN6;4*42TY'?7TA7!3XZ7$VS:V'*>5@
MTO=5F2Z3Y&XCE7O47=' \V._V^LR56>]#_6/T&)F-%JM38NJDWW\^8ET':MD
M;!3'5YIYO;R0W?3F:PMHH<8=KOOZ!MMT#2W_Z(->)U,TGI+-!IS(-M+&880H
MW"FF_T002CR1SEGR(S,5W.3BR2F[]%=49;CS#D8P"CN&-=GQG0%W>N:.9#)T
MGOIOX1MYVL\X"G/2RX5BL[K@KQCY*2P"L"PGAQ9&A74,)T:OI(:T*#E;"'H:
MV_.][91J7"\;>N+4=KN0(<,$P[GFB/A./S8LMG"]CYAHVK;*>8F1I/<\G-7J
MXA4STQ&(L.1@JCC6[B%Y^9[O,N+<2#2F;ATW]QJ1<T?@[&-]2RO6<MN9MY*L
MX36%OSVV0$Y(5U6<$P_= &[\J'K6=SV;WJ_7.Y(8]2?FQ;5R&^DGK]>.SKZW
M^SFY;8%!)U GW&0^;D7KF>;GN,7_/*QY[(P&I>]$:$&@H<0']1NE1=R5>[A'
MBE2M!+C/';?ZLD$WX<W"$-R[$=0S 6*7@@R+$ _=@TAW*R]M/USM"YC/G&)Q
MM)C]F1D"=4"&R9#F"7GB.M#FJ)ZY8UC1 .7J@+HOF!24^-1E Z+TBM'U$+WE
M28DK :^]1-;6*A8-YD U'<87Y>$;;?LU$A\.#YN?FRK;B@;+=LS!HW],U*$I
MTGPG<+Z**/891-XXX]:<YS(:G7[_4B6CXTE%*O[84_\8K;6IW*NWI6SI0V<8
MEY_S!C095>\E8TL+'5_DJ#?7?RHT3B;[D>_[+;-UKW^8=WG7?S+<]-.'/^[]
M%1\RSI+:>,I;/^0F8Z6;)QG0V+OC[I)KEMAP0VU AL!8\+BKHU-F'.A.\KI
M"RH(N*M0'9]@X$21F*1]/2&RD%,U5INXFREU>;135#,0,W(68T'..?-7O16F
M=[;RJ^*9XS(I]4(YQEE4231T&LF%QN%.\>_M>SYH EX4?@5@]>U[LCU(#^43
MQ7*\O OH2BR:_Q)%5Q;Q\>*>=7N'YQ;-P* A"/GQNA:-)S#'T1K-W(F^LDY
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MW4-7WS11.BH92QMZ[F<J'7KY.-DFQQ.O"EIM*>SFP(]@O;&G> 2;CY-,95E
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M,+<ZQUXARH"_YO%TI"@&>7FWG._(CJ$*+U$EX;;[G4))\%>LG;:Y/&V1H:S
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MY1$.9R;H1TQ5;]U_.\X/>875BG,81YO',*B2.A3MH/IL+^!8 SYF ;1\'U.
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M=FN,=H;+,4R:*<+!J&/1;V>4M%GN(YOF4)KO14*?0 UXT&!8^PJTI4L,OO)
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MOH#,1!CLYB).8IA<HU2$+,:!^?A):W4,-*[P^]"/R1TG!7,_/Y:;=W/>?ZC
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M^^.U%8<&KIL\'ZYQ>VYS*US"7B;7#5MDASV'H\U1U''#\MQUOB3/6 #J#1.
M4CHQ$ &H7(\]RP,#H0)0-H,A+*T5VW5'BH7C8$4$H**</AS+"@T3@.SJ$$*.
MB!T4@,X.?H#K<5?XX .<[_Q4<@Z.@V/B^58./&MQYL*>-$)=V"%"E$)YMW.
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M]6"ZM,MGO8^CEL>JG=V),-FL"I<SZ;V>).^8Y[W[TBN7AL(OTKVRG**]Q ;
MKODWUI-?5QIF*^!EV#?\!_?9)<3+VA2_,.6>Q7IEDBUOYKLY2"17)'5[#GQ;
M_34B6$/;ZPV3://2T/>];LV/3UQ5IG"/E8V8X"MSMW(CRU?NP)VSVP[DO7S]
M=*5SH^2"%9)!BF%^<O5JS#(JMXT*?^1_HG$*8A[5,S%*T^-X;?2NA=8!>O19
M!48@QU5(FTR3%@H'D5@V\;EQ=_^,*H?25KFD4]D_AS^P7'@UD1EO$-H5J-+P
MLJ%QI/D0Y!RAXFH8W?TQTO7]YD9L2!Q02SV0VFT[R=)C+HV173^,TYY[Y5;U
MR]NTY<'#(56:;BV:X>E#-<Y&@Z\R#MSO:_PXO:_ :PLXK&[9?%@M-(/&_N0/
MD5=T>?8"?8$F ?=8*,JM4(??_%*FI?LJ[MM?7UE%L0_$W<F!?G8#A!/\RCI<
M !HO85=_5]E85\?]6<%QY;^=:1: :JQZO?H0>^Q] A"""]VYY[O!07Q5GMV[
M'R( [;32Y"B* **+;\)]F<*$R@.Y?AP2,;59PNK7T9@ <9HW1;<XHK"G*K@2
M.32#9,1MI[A+F!9^=;R^SNHHC8\2T[]MKHX\O8O+A(8$)%@?0Y.9"UWB>S!6
M8-D<0G99781K,-"!FJ.F2-QABVO&IVX@#BQ-47/(9%ZPP?@#X\ 3<1AI1/E3
MC]^G.\&6:./ G"[*:4Y.^M7F1UO@PP"11CE>^$Y91IE\?-@TXYP[S+?R(=R"
M\ KFG7SVBO>%3[36O/W@U^T'=J]B+#E$^F :6+89G#B5-)L*">*^XOD.;]:(
M0B1B6+" ?:20)(KZ<BLQ'7*.Y$A82HO5F8 V\10-<VK\9W(:WN(D7B!5>P:T
M2IE<&7J(235;I]>PX*1$N]8XX0](^ ,U.W=?C&UZY\RSO5(=31W=AYD$YV&<
M7]=CM)':/>(]UC4715T29,MZV@1VQG<G5O==0'AZYG-;M7L>L40#%9>7 3I.
M4GFB W(K#K+@XFC<)&KK+H-W^BF:Y@"$UB+0N&[+8KAYRM='NS;IZQ[C(1-D
MB/76J27CY1?A2^<J24&QJ*K8K=,G"^0DXY^;-F<;BI.A(;/9WI:4DG)_M'7O
M&IR8M(Y!H6)%LMH/Q#SMG-NSWE(S6Z"WXM/6VEV-4DPBE98]>HE3,\M3I&*?
M[9E(4MJK0M$)HTIK9>QHZ4&N9/?ZY%64O"@%C(Z?ZZGA-EX<Y]F1EXW]%[>W
MP=*;""ETP:_)=L-SCQ*LE4(I+X=-55=6XE<DOC7WC^?U%#^B&06Q$5.A3#)M
M#VG09-7FJA3&AP(Z$7.2RNA@9BU5<G/], ^,IY4:MC$P&D&<+P)0(!#\#"U)
MGS!/%H"\QMJ=GX7SQ?+WMW=DVU',@S!DW3I4]\7N7K&&6@C1/5E+^E"O>-KC
M8TILW9$R)S0A/5]Y(ELLMP=62%*:J'+/ENY*"F\JIA1)=I6J>+];> )+.]VT
MR.0^P1YL=GJ2C1#+TX+42*;U7$;.#QHF6UL@OWSX(^3B11HK]$&%@_R3Z@_M
MAF"I*MZ3:OX[JAP&RFGK!<M"'-5SF&^MP>@OX/WHQ,["@1?ED^B'F@FJNY&;
M\0AS'[_XOCO-8:I.H]>\USVX:H3W<76)$EN%E;<&>>) *',=_ ES@8%!Q58C
M9_8!/IQ>>NDYKN9$5A0*6?4I_+1^G$]BM+A>41ML4>,U@^<<CT0UDY[%&CQM
MRS9+M[_D,8*YL^L4AI/&2'!1G=;:P[S8&O/,]JBY03!@1&=,#28R_$:;40?0
MVH"6ZR@/>3"720+;MP\'OKU<J(H27VJ]LG7:3BW=U;+G^K/YT6Z^,B=GE6!^
MWT3B9M=V+U49JU79S)5U:2BT[^"LW[4^ZA>+/3)L&G/ZN :02"_8QAY+EBOT
MBO>[,&5G'T!:'"65#AYPSS]S)-E*N3#HQJNX/^!B<IP_5,;J?3.]C\N?JSR)
M6-UX?O5QA8^\2@R2I1>TY.A=T%#<KO+!1;RB:*@[Q"LX\VU#Z='WC?HQ1_N4
MUVJN/AF0E2Z::UB5][<JNWL?O6IOGA(E2YL?I5\DW>L*?G$1?2'AZN.S^'T8
MR0GL+SQ]KE;.AK/#(*,)EX:3H"@AU26R!^114BM0Z?G"J1[?S1J2S<RLR^ZY
MCU'_>.A__H2QZ*4O[<V_?HQ<%H :A(*Y7]*;\S+I.<9TW(7,-I*>!6QI6Y;8
MBJ<1,H.L+,.?8Y\OPA.1*AT;< 5"R._D*O_IE4?(?H6BHZV)ET=T- /6$Z'@
MZ,$D[.'7'-)ZLJE!^"6^!>\HT&JDWRQN=2&_EWF[,D;\T^'>6ZIOM]:"1-,'
M5J].3?X9_R D@+Q&4=IK::**1[18]I-I)/<U4\DI'U9*SYK-0&3<@ 1?#L#/
M)2 Z55*2UKX:K$U<P+@2IY:_!7;6SBTU](O9#SV_O*+4[B,WW!WL+6E$8W'>
M-<<RY4/%;A:KZ4:5N9@>2R]GNL@'N=>6P#VJ/*9:_3?8;RWCYF-1R1_>MVG%
MOKR3]>Z[:-"-Z._F#[QJ[//"6!%C/3Y5-B\#TKPBO,J\LU7$)5,)MD?JN?1J
MB_32B3R,^/H'%IM&D>(8OF A><@H5HX<YC0PRUZ+H)5*"?<!$;\&SB[/8*S6
MH GVF7&%>]32F\B4\'&F9K@S4$T=MN[C<S)V"AG!M[]XYG0BMFX"PR@4,W8=
MHRJ?B&Y5A66=G+[(=4UL6EF,)#?%=V 'M@-&43Q;U'.T=]>ZW8OVL34RQBWR
MF1\L].<+#=>OV.]8P?;J*&IH&,U:BH.XCU4!9ABT&7$ REUAWBXR2N5Y/%UN
M[9B?[8E?,W9+I"N.7%K*5T >>7@'B6:T1C:)9<EM#?F^]KURYO=P:%-.)TJ*
MAQCBGT77S#'2FM>5/X;M>!>P$Q3=&)AC-6BY@$7^?E>1R16^Q% ,7B)0V50U
M?N6<5F!#/3=B9DGAYN0@:BL^IZFV_B;SM/\E)]^4U#=C9)'-UB9-75]4A(X]
M>O)WSC!-_UT>1-ZR:3[9H\9#-C/OK <A!0]9'I0&NY[IPYRBTWZJOS0 /@ '
M3_Z!";%$%\?11I.<8NT@HV!]3,-A9\Q4A]A0;ZMON-+A:OFR5#K[>:MG_0;'
MU&)0$MM+5=RLP:5)5FDE8_3N<+:9_!RNBFK"K>Y A5W)3!.PE#,$?HZ1@K%%
ML0X.@2]TP/R("-ESO-;]'IU;HNO'VPNU![#-N\;HY16?H>C9?6A$=T']1Y[6
M7S<CD5ZVMFSC:"69D R-E&!W(B)C462PG'D*B6=:C?#+<!4K07G6<T]6'?<7
MW4B]).U*!@JVVCGFZ<U&LK[AV'U</.]8H/Y>H4G.Y(KGKF'-7(E5]W!?&8#W
MX,H3TU?+1C!61$#WG2IU3?+X=]L70[77UDI@OK\^/.Z@&7!KJX$CF=6NF<!A
M]%"/\*[._#1A+8,YS#E"-$]N=RZ[!+R4E,%(4R?J5IO[S1)@SFW#A*'FQ9@J
M4EWT]*Y'0MBPYGOC)S]5RW$QB$&QYAM2;KF))4INY<P4 L14-Z;R::/26 ^#
M&&@:,=KE0@'GW[J8?=)S*M/+G]S5;/\2+%GB/"#6A&357'[A5&<E#0.GD9((
MN@U_$AUT.B>Z/&F_KWSQO/''USA/ AQ]Z+*&SF!W$V[2=2N18=3<?Z:765>F
M)EPZV_T4[YFV17K .93D+6O#U_5-8ZLF-E,3+4%J_0,UP;A@LRS-W(_3RVOQ
M$4>*3-^//@O])P70X'HX<6($H)P8W*&/87RE4>'T-V.M^(QMG#-R?[1"*Z0'
MJG,/U7/6MH@BJ9N^)N=NHIM(WNNP$;*!/LJW.^K,M:M@=X"X-=G Q6S[P'-H
MT]/FJ"DKID-/@O7,H/_+5^F#73@QB,$SM"N,4\LP]UZ)NL.R6E$[;I61%5F1
M3?_D>DQA,;7L];H*=EQ=EGOGKK41VOY[9Z >PQ"K@6[K*=7A-.=D-KN*AO/E
M@4O/T2T]VX$ZUL<Y_A-\<$H/W"&U8K1.\;>QII5S"1CSZG!HV/C)N[VW#"HV
M+O9&!9=(ULY;7+")J:]N"J/$NA-T7X6CB2H-O;MG3<6:N=(E%[1'DQ6B*U0V
MJ]WR7(Y>=69FAK&MR^B3>?"Q&T\><_).(UJ):72:Y!_>?14>DH<+ICN=7BJ*
MW*]RR@JUW+RE8E&8=^H/N,7S(:"PPV\NE)>W+E2U']QW!:#?+#MBG>-:W@S^
MT)L1;OKUA&W^'S%Q.T=QN\E6_#=<W$Z.+Z"?P7>(-=_+:IC=<Z&I.Z $('4.
MCJ%$W3A KK0^S!/GS-)S]@$"$ N<@8FO!8Q_Y1BE\X\"YTD\Z-PM=I:/QYCU
MB>7<L)TKW _DU&AE[YD>[C'ST_",E;=/']F_;,D/8]]'/5D3@-@SDCML1?[=
MY@UJ%V+**!"PXA2Q9N]AP.:I36 EC!T#\W--V(P%AU^%(L*8?T*.W8DU)$0>
M;T+=.=':09KVLS6HL/]=L^33C;;Z 85@_1,5>7VYBOJ!1XYN$]5_@[QXF'WF
MNI>.C]M%VEDG]RR5<4^/+<\%MV=W;CQK4+I:390Y[_5N:?Y)LX-C3]/>2^O2
M2^ZQ 4I=R1HB.@-UYVR*CT$"51X0M?<N=^B>?ER*SX8&#V;QI2C XQU<BF*/
MNBP0S')VI<&IF1NPO>.JXGV?S!A.U##]C8Q^-]/7S3H&IAU6*N=()?,KG]JW
M\N^OK1&"WH7C&B5[25J^G,&4KY2CX;D1ZD9""6M:[KL45Y"R21221X[S*,-[
MC >M=:Q8WAY"H^ C&Y7\T;&-66D8X=,'Y)+I_)C;^<-U16:(IG.;.33)%*QD
MI)7G>+O?'&)*=X&]-YO63 KXNHIQ1&_=UE-X4M43T.RXKCFFG]7]M0PRV*K\
M3/JJMQ4V<TP 0JG*<@_V=A>Z)F/NF"=M0F6!4;JU&9!0LXR0V%C30&5CM*K0
M?N[JLF,\C;D$1;_7C-K@\>M?7G#-LTPE+O/C?TUQH3KF[%S#'N7Z!YW7=OBY
M@%VL8&8]Z5&5LC4H[I(%,76TMUBR+^H=G&8MU?EZI+N]Z0^:UV8I3H[TM>OT
MO/8NC2KYO%S;4(CWC%ED4ZH.]U ,*4$VLJ5NRBR-1VX[E3X!NT[-7^8AK,P7
M]0\XQM\&#V+?^NRD)-?%N"I_7-DJ/=8"]'%HS"9U98[IPKUVSZF)-*Y"3P1]
M?$,MTO0+9WRF+NMG6I#<SB8EO^Z1887)M6=&I?[8/H1J7?2>*[U0Y*YIQ*RH
MG7EVZ##*:#/GT'1$7&7NG$&PYPCO']PPMXA^W//P5J.M %H$')L6@1U2(I0.
M^?LV=[RGY'%H6P^!( [*J8DS>(^WC[V2<^0#+Q+PXL;I0& L5XF E3MZ'/Y(
M1(+/;Z\2C)Q&HQ<-8^X\/%*RA0Z<&K'X'F/5]L^.@_C=X$6S0#W E&7..?+Z
M!$YLE8KT@]5X340/FOM U3<#<&ZCI>_L[VH2>1I1*XX'*T./H*9$(DY5>[FX
MTZ,B]>U/1M^(H@\_KG&YW^U!L(NWC"YSSU,*J@K^6/^=[E6Y>,NK^W*))$I+
MR\U&(IJVCWE;X^<"]^XO.?LRB*X2#DK?EH%,ST]Q'PI?8>Q/U@4A3E[L=>L,
MJK%58MH:]3$ST!;V8IG+X^[?##RVPKEU%3%STZB4&67N]:>%LYWKHA@OQB98
M-0!0[-HQ+ EE(>L,+H]=,YW@FF^94I.,R,?]$)(PEM6>'KWP05<T_D+20^]7
M1=2[.,5K/!T66-F1J8VWXY"R:ZI7^D32,)JQM<A"^XSJ_K+EN'E&<NWF2HZ,
MQ$^#/O?]=&)>;1!'^HX56A'OUI(VG+?7$',(.;0.5AD]R%S(U.2XE'%4YV:[
M N(6:-B3P]<P[A0-X"Q+PA4Q"G$N?_M\J27.*JRUMI74W3R34^WW]N;#9^ZB
M3QC(%)>]YU@% #?7DLY7 %R9ZHW,?ELZ5907R6F-=)]9>.,QO2P#%'C'KUGU
M4+09HUWY6,A$S(K?H:8]8_?18(8!SXPUXY=AH'G"+)D1CI[1)HI%E7I7.P>'
M>6#>/69Q/.CC,5S3*.B4"6%-P]Y)NLQ5)$ZZPN:9D&3GQ3!YWW(D5L9)[GCI
MA,#<=U%Y[-6%M K3HI$W014/W@1]6U^%V)FGE.H>J>6B,X<=E"'>9Q[H_#Z?
MF 2?4=NUXYT8Y1_">%" >,**#_^7AF8.(]%T8VS3*L(/UIO;;7WT!4/K)?J:
M #1,O_WH4Y-4*V]=IBKWUOVU-(X#W^EJF@#T.TX=M]S&C;S&'P8KK%(L,&X=
M0!)Q\0Y%K;E5>%CT_I%-\;;XE6<X,>!FKTWA?)V!N\5O=Q[!3>G:<B91EK5_
M)+P)QD@+0(^>E.,^@'OQ.W4\O\ 2HSI<#8<__&5' -KRV%F -G[9&7Q1T/QE
M"]'ZY<L\M7$;6E#U'9VS2MY<)FXI-O*[!:!+P7MYJQTMC3LI$\@]O\F]X+V*
MW )\P31V:U;])>21Y*9033.T!:"- U7AVM Q6P'(OT( &E(@D"._[B&^#.;X
M&=G]^(7<3)'F_UEXIQMU$*,[SF!%,E)X0=QR(3F]+)C+D83>^SS>?E9BN^N/
M^5=C.*8VUZXE]9>VX6N;5KX/\K>' >S.S(2/U,=35BJNZ1%+2"H2H; D #5N
MT];O\<7&(7YS5,#!%)&Z'6@\'AT9[?L!8#AQ!PCR>Z4/]15L]("Y42E_VSM'
M1U/K,E=]3K^PXS;^<74\C(G\O,E.)GLH52"D+3RJ7))5EU^UK(5[E%AF/]-(
MRU8LS-.NSLOU3"")Q>CZ$#:+-?V2.$!MGW2WK^,7)<NSG@OWW[C7!&9=NQJT
M5Y'7N[RAYT:R,=%S-2H-?IM&=_&\46<D5P^\VPC[G6LU*X.[,JL$>##7[V(U
M 6L)AQYU98;UX;!9>4S,S>L\*S7& T)'1^&H5Z+K\#%J#EV%FKQQ;TOGNNF?
M)FW/([V_F5%>I=SX]7L1=;*7[44@IZR+W)L?"^9"4S=R#B'=PN "4%*[W>U2
M'<8JM2DZ\F>?AJ'F?OMUVE1E15#1GP;-B]$3NY:.^DD*YAJ3C"WR$,-EI!;'
M/#@A.@H-CH1M79HQ33BG$!G(7U_38ZWJJ^;:NKAM/+4O/__N-^7SYU+2<=>@
M*2H%R=$X";0>$Y^)59Z\A'$ (MA<D7N;T!2LLI 1_=&2MATCUZ,%H/W+<=#$
MM4U8V_1*VUM3M"E9W9'E]SHD/U[\A7R&7&X/(8,UI5NB/#_&=6:%S\J[FSS*
M5KGY?L'9.^MHPMG6Q[$W@:YH'4WXX[W'3+'AK88=GHL/\[:A;Z;7T:V7@15W
MNYZ'C.FR5$N#G(Z><VJJ;SY]R33<K2+#8V#9BY!)=V1&F5 :G4C7]/DDUR\U
MKI-4MH$ E+J)$K\$N+];<!MJZK?RG4!=YN;<FZ:IA&23JV 52/OO/;9T/"?-
M]L[S%2G79Y-+.20)EP0GT55VHS%]\6R "'/U$>:W%":9KA8NF73G]M3&#)A[
MLH(58.Q!11T)5QCYXT1#D>-P62NE8^RZ(:;MG/6,6GZ+HKF4H\%F1Z[IR%XA
M+I(JZO@<V!FV5EE1L;_'%H".\*P2_;B&62$< O^7"&LK %<5OKW0RS\V;(K:
M/XLQ[*!RY2P[&\8BU]K/[L_'3TY8)B5]]%G33_S\*92EGL9VS8+GT ?5!:"N
M.]6+4_@T!MT'AJQ"!_%B;IH(&^-EAL27JI-I1.!JQ#\GS"XNY_J%W;YXKOK]
MRXMVI[(]/MWKCI+ D7I/O;']V>5L7+Y*I;K)RF5"9G3>QV/ZSO[&V.&Q>9J7
M6_0/;<N\\'@XE\A>.!OZTQRU8>'A@L> WB D#Y)P.,8)\&\M]3H*F_>JINU+
M?G],),4SE@O<,4V-.5V=K9Y2W^5)AK%Q-&-.!&LPFZ*H%L&7T9@C!9G@UZCU
M M!5'!(UNDKF"4"K E!S8(:[]>2\4M*G-^_CZ0_,1/(8K_G#L[(8+:Y0::;Q
MM=$>OW(=4APR%W*\&"8Y<HBPUD1XA"@*==G#'F_?<E="AZ2_]ED4>[7#CU@<
M6PG6ECQ,]C/(UXW%_N2[.*#$2.S:NVVJX2+KVVQ32)\Q(5@Z;;*]89-O.WO<
M;C3!,[$>J3KS38VKRZ7.[GG^I6?K@O9RW9.<QI$P?73KM[X?X9=U1NBP A%]
MB.8:4^7=C>+P[RYGBM]M&CT ?S->F=V"\84@$PYKB=C(N((NR1_*F^N[F@*0
M@@"T&0 DD]7X"\*!3G85@%R"WG]#_% -F=V2H6[T6'SK7K1._.$^8G1^ _PN
MOW5F?9Q_[?M/'1%SKET]P"3WUAL!2(SAIZYJ;3Q6MR$ K=&"]JKVB@U,LF#>
M9[*@:][0\#,2D#<:YC= (3**7?(H3?*5/3Q6YQ)/#NB?,TJ/2\Z*9:E"#R[?
M:7VP8YHTWE$RO_-IL;#RT</.6]%DE*S#R:>Y+_)NO)7]1?=]K46C8OHE[+DY
M6?3\_>YV&:<BE%+])J7Z4?7XR3UJ0\/S<3,^]/8"Z9_Z#9>^.AY=(^1"9@TN
MM>62E&I)[/J^4S?SU2"_NG?N!;6<MWP;,.)"U-E83\9==M;KYBQ9#B9C-2(L
MUY-Y" Z1#<UJ5[C>KA/*E)3U1[?,\4F5BW<"51DF':Z7QC=J$D0NC<5H)Q6D
MUFZVI/M*?^QHJ+E@?1TA[&,;H ZW_Q/::="5*T_)8JYA>JN WC<[5W/N/$,W
M!$<PB]8TZ*TI:0;M9TDT<D!M?N'%$5/8),KP<K[2/__,;)X&-+8JN"Y%K/6T
M0 ,@)T'X:&YM"ISEJC(-'[16MN<Z,C-<5:L-,A^*=T=<&6DB/?OX88DS_3:Z
M^XK[^^;%&:F]6NS1,"[P*Y#!/%E6$UXJ 6AP4IC>&:P_P&]VZCJ>A2,.;ZX%
M^TX8->GA5-"WZ'#UHG)@9M;MY:B15L#9=M@SVM60T769JUGL'WG6AIVN,B66
ML;6:3@7U\\3SEC$!*LU&RDZ4 Q-99\<(2=WQ3G+$U"J'%0OT"**U9L>X@GD5
M!3.*(OLE5]/DT]#=$/LS,.GD;"/)E.8+MB+%M2>X<F&7C8\V7^QF(7]_?GGB
M9[6_?I>)I/&8"1Q%UM>"IP">/D6]_[4I4J-+Y65'641.[7+AD5QL*S6I4)H%
M4].R'S/U2PBFNR_BPNXUG^2L95?)M]^L3;9),57,HAS P(%;S%VAIF-T%A0J
M9$3%$I&CSH85Y8&!83OY+RJS0B\(E=RSI=:2+R2F,\QS)&=Z51_B&$SX%.!W
MG_LK71KA A1LT3DMJ?K6Y@:,NSP/4A_7@4XYR75-ANBQ]GRZ5&;O0D19!E<C
M=9W!/87^1LQ15K]6=ZO8TLB/%V&6FY2TNCZ36^%259>D7Y.G5+?(+X%/3X'[
M@RXCO&!FQJPJ.I$6>(*+O6="/>)Z']H$@1*;7^>ZOA[BR1* [8!\V*SABO-K
M+BJ-K#EB\& BW.AXOFG+4A?[57FEENAA%X_DLI2J0#U%+R?72;=\5=&S]H6^
M[_+DJB:J,A/I [(5[@05SZH13Z+N OZ/SS.J0WW?+3\<.=G+XF[<\%+W2PZ7
MWADP5.*-9%GF$?3KLD1<I9,J\KQ\Q;R0K.?">IR6?R$I[V1A>Q^(XFC1P'+6
MJI@+7-<4RDG_3C8NB2I9QS^!QG=9$N_7Z6/.%)XKV>RN+?0B9U]A2$Z93OZ2
MI'7OX-U\V;=1:DV*[G]<_YSXY>G-?9W*H+E,Z5+Z;>MR2L.HM1E/;U0 "C4#
MCH4P<]+5529BVE[SSG-EZ3.*$Q#E+6A:H$9SUF"RD)NES6J(@[73@"JML5;F
M/'/-,N)V";W% ]*2&5+P>;A8XL.G>VW*/5$#QKF9&X,69 ^#?.N8QK/!"L?E
ML.WL@E'Z**VJ5US,2:9*Y=6=/O=L#2DB/.EL[W30<UW/%<\:[]IQ<"%+)593
MW^B(@V[^3W5&N\J>@WKSF]R&"LB[ER>]D$-5R;T.4Q?I<Z?<"0]Z?"H\EE_Q
M@ND^74,T9OU82#I<N[S#XXMD-35H_8<5XAYBRT(X,Y]_?8T8W\1I0^NW>27D
M-^3=HUH"T-@=?_+R#K4$<T4 >KCE(0!=1NTM7G9==RU/X3WT=Q2 0GSXW%/'
M[.1\/FMM_O)W/PKSP6.\@:AR7B!PAS6;7*KQ:LS !*JTY!ZV4S*09W)[)].[
MH4^N=B(7)L?M-5M\K <YH[U_7B).0IZ@TASF10C,<G0GV1,LQ\([IZ*71XK#
M/:I$0I$V-S)9JVO:Q- (I<OU'S#75:43NX>):5V7%[V[6/6;P?U.%+"T$T%E
M([RW$#*V/%SC7LSN5P]S@3T)7/DVRU<SV+7"#8URA:TKLN,C &DO"D I,.S
M[(8)SUT ZN3G"4#O+/<NE%-R]VZS!* =[>\HGBZ"]QXCPK,!BU,7[S%Q/'.A
M==%@'PZ(;EE=$X!L7;N->. E!*^BXE_/7]D\G@YE7#<2@,ISS(1:0GC^^TX!
M2"JE:WWG%S1" )(8$8"^?/]_XEK.YG2& +18T4_E$'#?3^'HQSAM_%1U10&(
M%DW]T<YK^3L[*'-DMK%E3P(J1^7@"+AOV51W[8K_&J*.,$0P]Q#&4.BG2)(
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M>^"E656]TMYYNC$AQ4$$9Z>7AFA=%Z=LA6;?'E*X5\G)13M/HCWI C3&)A)
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M;85?I%$"U:7>L;^H(JT^/77\R-J]F 5'M\+&5';@-A$L(8&O!=U^R@\&#$N
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M277 ;L>YXU"/=%;)C:&:Q7/$%W,*4KO+E'6>KQ>Y)D14C=":KWR)+G%1Q^X
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M*";-/HL+-!JTEI]G:##"!F2$ TK8IM2>:<<);D\R*ARPY.JN["C'&R*5^!8
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MLW33^Z!3:7B1>D[1YZR\PGU5I(X_NG/!0G? A0I@L,\AVW)^Q @=AN5?QJI
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ML15+K$,%U9@YO?&8C9TT@E%L1!AG"[&3^5MQO\;I&WN?O%+?>A^;=!.=+(%
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MP:0G5];B<&O]-2/[\7.B;WUO%I"<-07\H T'[^;_"9T_24LN-7;N##(6/$O
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M@YG*-3_;VF[0F[&T@WHB#W5_--\V+7R?"U9XC=1MSPYFPFWKB)/T9L/4%H6
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M%TD@BK1^F!A+V;B<];V\+\C53;D&E1'[[)2LP]';4;G-%PKR?6F&?S3[WMU
M:+>EZ>E<,!ZGH?^T/D:-;BIP;C%DG+ M=7K59O1J0&;[QT,S,:>L8A;S7J/
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MM%7N6I!A14$DZQ'[O0Z)N@^[L9Z2O]Z/FQQ^234&M><,NIFX$&.7\A7W888
M7^_4L2:V5 M< INO"L599_88VMYG>?GT[-3IGI^!U/K<->^7>.";>P?+\8DV
M")NN,?^6U"^X_XA##;(A_N0^UB=SJ1 1/A3.JMZP V]?QK(5!<]76U;9.51+
MCS9*%U/J%JT_]#@X>-84F_%K6.DX?DJI=3?.2BNQ&_(<R:[N&#2PJ>HP+\A\
MP3=<V.DV^Z;D:>?Z?^RV47;-4%JMZ#^&5MB7@(;H?[-XQ'^#C\/_QWZ>"":F
M+/UG^_CS?P;R/P/YOS&0.GVMUO9\A8)+5TY%.N5>K_5X?<.4&&A<'J]=8&$D
M&AMUT_G3?S[,PV5MR^ %XE;+X)_'H)BGLI.QB;^%<$D;MWWL%P:;E?G"CXS7
M<(.0ANU)2!E\,9?7 GQQ16(G,X[@LHA+.@ADN'X3^4.AQH;$O$52G+PL!7(
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M/>%,=_2:O$ 8(__LHPB]E?Y2H)3E7<_6X.DWI-$QY)V\5&,E?W\?5J;8P3B
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MV7#I+/G9_^0VZ__S$XW]"U!+ P04    " #R@0U9XBV'DP(.  #CC   $0
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M)BFD(JD:W^-OECKJ*<V?6M@V5;3A93I%Z"):<:KAYTT)=<KKIX+FG$RG@"Z
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MKG)0D^0TR[7BV4W'XON/C$3B9P]X/PBYHL1^K/C0BOB<2ABG!ZSI0='FH)9
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M<9KFAQ+%5>0\51( < V*;B.YKF#& \;2H<BO\SSB*+@CUVB:K]5WZ&68'SB
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M%6!(07F)NF);00?/*(SX-H')+4IW26;CCKZX?3;6K:; *6KC3'&U*'Z'[WG
M']L9H+:2P/VEL[8'.D>PJ)6*AF<OS&D+*;Y.0MG:VC<G?T.K[42#X'[:69-6
M:*&0D2\<G=42AC[U-S3*=BJ"K&[SGCI:E;.C^=,, SL+74MQD-VV3>DT8[<K
MA7M7I7]H+/T-YK"&\?B4Q&F"_#1#T1U.)D<*&^Z7F2VU9QM*A&S;6GI:UP\R
MV'P]<9F#+;7BWC3G7'9!7^([^>! 0Q9WQM^Q:DT?:/;]>%+I?7?@'*:/3V^1
MF?:K,LC\/F[?Y+S\;K6-N;?R:/SVV*P5S8%G#?:KD>;UW>K5,7^<1DA.[TB*
MHO+?3PE-KTCZ+YS>8)^,X_"OVB<29SE277UR^ZRS8U6!YFCM[*LS@?-1>$Z2
MXE>\G23RT"\?.\,UH3_0F@W?O_@6)W-VZ@4[>^$_0B]N:O??(K-H(3><.F0M
M<RA"E Y'1=[N,+GAWM(\QP#[6<)@P?0411$.3J9%.UHTE"3,KDEXB^S$I$)
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M'?\&2ON9E6_"/. $>O/7]V\XB6Y/[Q=T%ICF95)06B\>">9(I&;().R"1G:
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M394NRC@\8"V'USM@/13PS@ =*O& -1<[<I'9_/3N1A.RV7_JKG$%2%VSMH^
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MW[]',4OU'7$+1G_\Z_?\QZP[,(^" OUGF6+T_LT18H3XB<N^/7KWPUM>>J\
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MH;AO>7WYJ9G& X(C-F_!:<Z=_+I.,K$@YT<]9U54,%F32@$TDLR$+DU2<_S
MI%'8$X?*Y:IK[H/,^I( L-FFJA9TUA4#G<\6V&T)??0:C/0U_L2?J&?@5KH
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M*JPLJ?$=J#O?L9.4V:K,,8]&EWUS0<19QU& :]D^>@Z#HG)08U[="2=8#]3
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M3L,ZT23RHGS9P>"A3 )R%>>%,>)/(^O,UIG@MM9-)0B"3B9T@@6KY!%3\!,
M*+' <D^S2M#C:"CQ*\NE8'!#!\UZ:/.T9=Z,R+9L,6HX#]BRXX]!' 21[#!J
M@K=V(-<!6JF7)K9:W%YEN2K_;2?P^WMH)T#E\!39*ZD8^IH)?N,[X%O>?^5B
MWL*])3U5)@.B>VJ 6<=Z>['R?+K*#B=HF2&5<D4,#<2&%Q(1$+10XQ+N0>7+
MAOXID5KER.-NL3J,9?C8_4E D0+]9R#:7@+(_AB@IU9GN]+RLT#M$X>!D++S
M/O7/(%IXB$46V^CA^([^2)>7@UR:XUO0#FV9CVKY.)&5I3_3R6:-[0SG(8GY
MAKKV2):%DL,X,<L*]$+%#!H@Z&(-4Q8P]O-B<=M._GJZSD?ZB">I"9)_>_/N
MN3N;JH\-,^JXFQ-8PN\F"@8%$,RR12E.*1H]1!6_?OZF=]K8]60BS=.3=%7D
M=)IC..6GDG0VV=!#;2<?<C$0A-%C$QU#:<[V+TYPBE=QD:-N*NKO?-\Y(6P.
MS%+K/F.R566>DHLYBPK4@&QC_R0R($BB 2;$\1&2I;C**\SOL<.CPSE-(9ZR
M5K%D_D'!DZ*=T?\J4I=(I5Q110.Q88I$! 11U+B$%,2=))W$%)BLX[0B"%/T
MD_&DC[X/B2$R5%84]\$6%6@9;<:RX/BC #B-2*XGQ8^/16TL%0ZPD8"SZ:X4
M6#NW'3P%P00I)&'6^OA(^-67J!UV )S,:F#3R?0VCW/M&0:EJ.-YB1+L:&XB
MR($@BP&<<HXR(DNM[I@N]\4?MR2\(<N<G.=%O.9@/N#B*8MTU+%3<T6C*95H
M*&6C X)>$X *J7KY]1RW)&:7>!"TO+]#71&H*L/UUEU9T!$SC?AE)8;A2B/K
M;!O/!+?=S%,)@N"0"9VPL=?)(YC#7*\:UUGQ#]S.V+#6;MFI>9@7&2LAF2TI
M=4!P;@+0R3,K6B"B):*N2,?TNZ#?@ )KW F7::38NU()NJ*8'FA#*KD4E+@E
M(T( VUTC?/Q^K?,7QEA\LSI/5QG]'&R5*!_I)FE[HHY-E11\TJF"L%73\0IW
M&54E= [&^@ZSNA1V9UJO'$^1$K)J_A)G"3>J-ZN_9VM\RF"1[57PR9ZI^B)\
MTM6F<CK.ZO3!$M<"M"U[VZ(8?UEAJ"X-T>( D?@LSO\L@R1>Q6%=\V7PTFP3
MV1/97(Q/,MM64D=H4QE@26T)W);8X^(8OVF![=8B#&[3P8/6IJ[OY7K#[L.E
M@*LKU'3+G)GE>&+WM&HJZ&U7"$1^3T)N(O@1ZA7'6#TNT)^_Q[Q8T@E[\/@8
M%DUJ24@+)R-* (LG"48KKZ @[)$D9K_@2!*$*3+"TQ\D]C%&]G=I,YQ?9\4=
M_K.,26M/=0/C%&4?>^AV%9+MJ.LU09!M,ES=;GM$2T!I5B!2E=&.@*X=T2S,
M*#]-J E>9A_23<Q"%U518#IA9TYG(^#6U:R4!$$G(SS!K<P5$-=@%U<NXS5?
M#'RXOKWL19SFGH+#.+SE^K&MBFX?0RWKE$<ZN ,:R03AL$B#3DHB1AVV-S9B
MCB_"&+?KE9+.R:+?E%>(P2**U=;[D"8^=MH;O+<$1P59I]%%$CQJZC62<\T,
M*<PQ+P9"H%@A0Z;E!%/PM7O9MWFG:1X1$S?&@C[&&!&H;(#II$#10PK-/+2<
M9FD>1YAX8\C?LT\==)L11J7@FC%ZX&/FR*5!,4@+4<>D(T15/=.IG5S1&7=T
MD?&@D%^"1&%UM-+.SO^:(;?G@=6B("ADQB=<_3J<U_*54H16&1F&X;!\V5XF
MO=)5G]$\F;3\K\#UADJO H)J]CCG+L[]))^3UDN]D:$7]\HSQ6:&3A;2=H8%
M3@ ;&ASEQS0BR?;Q'H<EB8L8*P(1-+).B:*#.V")3!".\=&@&Q.#BF(JRV;;
MG;@/IIR_D)!'Z:LJU1-PR@D!V( ([5,XK3^&)!R^><$DC.D(PX5\M/7/)*B.
MIUX$,>$3*%5=9)).6U\-=4 #40P.'Y38A#@*^KR:SZ(@9W$37-/'*<ZA =M^
M^*/@7#U]2A]O0]D 8E)PQ1D[X UU]-(@&&0%T3RH;-&'@/R!B_H@5G7!L&-2
M758+_R4)^!D@0J[B%%\6>"W+/Z 3=D4F,^"&2&I)$"0RPAL3J%9 M0:B*HPP
M/,L)^HUI(Z[N>GOR0T&2)2;K_&:U)!%%I5MOZX2=>7",@%L'CE(2!(6,\ 3W
M#1VU2!PDB&OQV%:13*[3MW/DZB7SZ+FS9.TR6&V.]OY#2*M@&3  R]X6UC(N
MI/$O8P'GK3P )C0S?PJBRTLA":GWV3/7T7=E@M^^>?C+6PIO$66; JOV#I62
MSN+J]%#;(#JY& @:Z+$)X7%4&C'QX[=]0X]J3?<)0.W)HA-VF/#3DC)J21"L
M,<*3)?:$19[*_O%WJU-@R83<CB@R@,-1I2\!@AQ*6&)2SFSC*Y-5G[Y+LDX+
MFT&F+^ACC!&!RH:83@H$';30; >899WWS/<8HZ6*1M;3"*,FC%(0!&=,Z*8,
M+]ZHTZRD37D6%7)NQQD%S.%0LP284E&'3%C.^,V>6$$]?]G$Q,R'L9A;.LA!
M#MDPE %$!BDP<9^N$?)'A;.R0J"L22?@MOG'P(8-WSP%U.0C2,),LS<>-*)>
M]T=NLR0.8YS?DBR\LMXH46CYV3'15D&^=2)5 <$B>YRFS91&%P5IA%@!.*I.
M?%UYVU=I*Q?U*Z9WEUCH.*>=";Y .I4"+,H94,XEG!^WBKQ6UUE1P]%MZ4W0
M]<L]377T')0H N:B&NU<3K*LBH?@Y2K('WA5ZPM(:W(F1=[\TK&TN:-T$88L
MMT#/W"\>\H)E,AE](!L%%WRT!]Z_*58M[9UYUA"%Z5RKT#'MMT9GOZ/K'&:=
ME#D=Z_.\=WG5(HW$6JILX0[EN.3A[&KVZ3FY$#"LG8M<R(1,'H,T_F>U%&7V
M\KY<KP.R94$5]_%CRC.(L6T2D?3>F7[^9QD76X/=' NYY*@<8)^ 0PDP[)+"
M$GP87 B2Z>/YX*N+U/,*'1WRL?GVO!GZ+FDTN5I]AEDK0XG_F0M<>CE K?^O
M__+]N[?__A.JRO'.TZX2-ZO^@<,[G+"=@M,L+_+[IX#@AR#'T6VPY<&1!D.W
M:Z$N&;V?#]"G^6XE@C&\>ZF&T!.8PO$)TT"URF"/"I %MZ[_2;_^)KN^<ZD@
M^X;^$\SJ'/(B7U_OT-9#.E <\PXU./[MO3.<!R2E$^[\%A->*]-,5RGN=,YK
M #V8_2IDP1#. %"8$=?BB,HCK@#)MHXK8[*:&GF?A-):.J4P6$H9+R7'!;K*
M\AQM6D[1I3FU4VNZ8.>F:U=B;<(\X&QY\]?W;SAC;D_O%SUC>X6I;51-/PVR
M+IAB!9>Q1"OHG2$VZ,;LJ(0.Q( KG.<8WU#B!<SQLTBCBS@-TI#^7;U794$F
M:SMCR?0JM;RQ5X6RDIX'^S 4VWGTJN=XMP$IMDNZ=LE9TO<L-:V*S6HNQS+;
M2O2'-)..=[LU$:B8])BK(:Z'^HJ0)D^JRMD[%R>5 (&4E@[&">K@J6KO752S
MUCM5V=PP+BK'4$H7Q7S7!J=LRZ:KG\%L3BS#)5UG5:]/V$D%@*'L'-22RPV:
M,OA>WZ"4?CX\0(;7JMXFVSNU$'!\UEK@:25 F9WNA'X2L[US^+Y\R/&?)45W
M_FRQDZ,6=[KK:  ]V&14R(*QG@: @DNX%4>5/"2+.*Z+<5=;+>^33_I=:Y4P
M6$89=QE&E#J0SZ:)"UK0R>ASE1\PC?I!/CQZ1WF'T,PRG/EOYE:O]>),+< [
MWW9!K0OV\F[&3H(\SF]6HY"UK9Z?4Y6=1B1.JM @#-%*TSL59\$=<Y KLRV,
M6PJ+VL&]D%'EP([_+.,H+@RD,LBZ<TX;X':N:(6@=X;8H!/\RXVX=XOTD=^&
MGA?Q.BCP^#R<2LBEA9$#[%N2H81W/FAA"9DEZVOD&S'O?+A,PVR-E\&+W9BD
M%G?)$1/H/EM4LF!X8P H'@1BXNRB:P#L.65ME1;5<=^[./_CE&!JYMA?2D^(
M1L.M2\H(?>A_4HJ#89(9H^A2ZFGPF NN@9B*=W)=XT^]Z1?)4OIG6.50G3*-
MGEZ,2QK.K62?FU/+ $/8F<#%?:H0CX[O#,KRSN3[\ E'94+G!UWD9C\*LU[R
M;K57X.Q:F%,_V$X5'CC)9I4$AN$[P1?<:W5A_-R:(J 7G;^PO_>;;>40G&?W
M0),X+'#$J_(QC8N<I_O?:V>8_!9(O63F)YK2?2:^XM7TJWGUTG6XKL2J[R%>
M)OJ:';MZ]^:GN_N/_ 36N[<_?8.:EP#JA..07.:B"A=I=!8G)4L_,*VS32S-
M3Z>:565YYYE4%,!.,@>_KC.T =O=(0!>)-^7K@L]D+^SJ]2O.'Y\HB]:/&,2
M/.([O [BM GYY%GS>0US/BN\8_?'9.2F)&V8:""&B>IZ@?.W._/)NO^DK9?7
MW:N]]TH_]=7UX@8"JC&@%@3B)=973U1]N@*"&!)^B6@+A#]OH2 @H=2CD'".
MZBH.'N*$W0(4%/Q2'ZM1;U9)+D>\':K:'^UF%..]3^V.7=<_%FE:!DG=%YKB
M6!0AXW^0)+T^ (3U53?$.[!]4@DN63ZC:GUV3U 'P^KIF'=B\[YMN&("UP_0
MX)60C9,2(6?3(27 =M8B2'BGC!:6+D2&RZ'?^']V#ONS:/$K12I6G:"7EA>
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M8KLD09H'(4]_=[(=/+$Z(SNI+#\'9F=45WYZ=D)!8 BZ"WKQ; Z70UP0]<H
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MX;D+N?C$SHXYBQ!>0P=V4']I_[<\L;SS@65N3/BYY-QS;J9%DL0L#^//2?;
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ME5HQ0R^?Q(^D(,K(3;OA>F;MCB0IHS[?=B55'R.:)G=)EHSYUKO>(PYGSG+
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MB(2WO#Y3@0\$\'IK(.+?HQX\%#PB07[_2,)07.2\"*3E3>V!L/^ ";N:3P>
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M5W:!8H]RK02QBR*"Z\B/V2HNF8O/A1<6VYS'@79)-W2$B@/EOFG!.HI0QD'
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M\4+VM]Y2<>50- 6CW_W=78MC;"(<!6_QZ?U)<C*?4Y^PY"HR:#V@&U@.W5M
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M'<AP4FDY%&X8UE&B4DK<#D:\2P#HU*-KCQN+U9'PS("<T!FI@1GH':_6'C=
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M@P'F%TAC7"KKAEHLJC?S"%27,0H_'2VR6Y)>1WZ\),) L(N9G\6EC>TQ#CG
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M4F&TV5]A$%@Y*!2_$?]YX!.,_\O_!U!+ 0(4 Q0    ( /*!#5EE++&*AP<
M *@N   *              "  0    !E>#,Q+3$N:'1M4$L! A0#%     @
M\H$-612QO]>*!P  L"X   H              ( !KP<  &5X,S$M,BYH=&U0
M2P$"% ,4    " #R@0U9*%?G?>X$  "3*0  "@              @ %A#P
M97@S,BTQ+FAT;5!+ 0(4 Q0    ( /*!#5E0T 1AD_<  .UA"0 ,
M      "  7<4  !F;W)M,3 M<2YH=&U02P$"% ,4    " #R@0U9JNPK*I]+
M 0!8;@$ $               @ $T# $ 9F]R;3$P+7%?,# Q+FIP9U!+ 0(4
M Q0    ( /*!#5GB+8>3 @X  ..,   1              "  0%8 @!P8W-A
M+3(P,C0P-C,P+GAS9%!+ 0(4 Q0    ( /*!#5FQ>#L?H P   :5   5
M          "  3)F @!P8W-A+3(P,C0P-C,P7V-A;"YX;6Q02P$"% ,4
M" #R@0U9T@)QG"XA  ">-0( %0              @ $%<P( <&-S82TR,#(T
M,#8S,%]D968N>&UL4$L! A0#%     @ \H$-666[Y)3D5P  D_L$ !4
M         ( !9I0" '!C<V$M,C R-# V,S!?;&%B+GAM;%!+ 0(4 Q0    (
M /*!#5DSY;Q?'3L  #?) P 5              "  7WL @!P8W-A+3(P,C0P
A-C,P7W!R92YX;6Q02P4&      H "@!K @  S2<#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:PCSA="http://processapharmaceuticals.com/20240630"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pcsa-20240630.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2024-08-01</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-04-012024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">PCSA:SpartanCapitalSecuritesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-222024-01-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="AsOf2024-01-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <instant>2024-01-21</instant>
        </period>
    </context>
    <context id="From2024-01-292024-01-30_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-29</startDate>
            <endDate>2024-01-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-30</instant>
        </period>
    </context>
    <context id="AsOf2024-01-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-30</instant>
        </period>
    </context>
    <context id="From2024-01-292024-01-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2024-01-29</startDate>
            <endDate>2024-01-30</endDate>
        </period>
    </context>
    <context id="From2024-05-312024-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
        </entity>
        <period>
            <startDate>2024-05-31</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="From2024-05-212024-05-21_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember_srt_MaximumMember_custom_ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PCSA:AllianceGlobalPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:ATMOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-21</startDate>
            <endDate>2024-05-21</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PCSA:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_PurchaseAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_PurchaseAgreementMember_custom_PlacementAgentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_ElionOncologyIncMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PCSA:ElionOncologyIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_ConsultantMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PCSA:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_EmployeesAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PCSA:EmployeesAndConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-28_custom_TwoThousandAndNineteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_TwoThousandAndNineteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PCSA:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-06-282024-06-28_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="From2024-06-282024-06-28_custom_ServiceBasedRestrictedStockUnitsMember_custom_JanuaryOneTwoThousandTwentyFiveVestingMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:JanuaryOneTwoThousandTwentyFiveVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="From2024-06-282024-06-28_custom_ServiceBasedRestrictedStockUnitsMember_custom_EmployeesMember_custom_ThreeYearVestingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">PCSA:ThreeYearVestingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="PCSA:TitleOfInidividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="From2024-06-282024-06-28_custom_FirstPerformanceBasedRSUMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:FirstPerformanceBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="From2024-06-282024-06-28_custom_SecondPerformanceBasedRSUMember_custom_NextGenerationCapecitabineCAPMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">PCSA:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:SecondPerformanceBasedRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:NextGenerationCapecitabineCAPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_WarrantMember_custom_OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PCSA:OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PCSA:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember790435859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_FacilityLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">PCSA:FacilityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_CorLystLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">PCSA:CorLystLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_CROsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PCSA:CROsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-162024-07-16_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-16</startDate>
            <endDate>2024-07-16</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-16_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-16</instant>
        </period>
    </context>
    <context id="From2024-07-162024-07-16_us-gaap_SubsequentEventMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-16</startDate>
            <endDate>2024-07-16</endDate>
        </period>
    </context>
    <context id="From2024-07-162024-07-16_us-gaap_SubsequentEventMember_custom_ServiceBasedRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:ServiceBasedRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-16</startDate>
            <endDate>2024-07-16</endDate>
        </period>
    </context>
    <context id="From2024-07-162024-07-16_custom_FirstPerformanceBasedRSUMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:FirstPerformanceBasedRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-16</startDate>
            <endDate>2024-07-16</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-16_us-gaap_SubsequentEventMember_custom_FirstPerformanceBasedRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:FirstPerformanceBasedRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-16</instant>
        </period>
    </context>
    <context id="From2024-07-162024-07-16_custom_SecondPerformanceBasedRSUMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:SecondPerformanceBasedRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-16</startDate>
            <endDate>2024-07-16</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-16_us-gaap_SubsequentEventMember_custom_SecondPerformanceBasedRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001533743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PCSA:SecondPerformanceBasedRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-16</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Segments">
        <measure>PCSA:Segments</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-06-30" id="Fact000004">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-06-30" id="Fact000005">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-06-30" id="Fact000006">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-06-30" id="Fact000007">0001533743</dei:EntityCentralIndexKey>
    <PCSA:DueToLicensor
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0087"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0090"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0108"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0109"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-04-012024-06-30"
      id="xdx2ixbrl0182"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0183"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-06-30"
      id="xdx2ixbrl0184"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-06-30"
      id="xdx2ixbrl0185"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0236"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0244"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0250"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0251"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-04-012023-06-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-04-012023-06-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:SharesIssuedinConnectionwithLicenseAgreementValue
      contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:SharesIssuedinConnectionwithLicenseAgreementValue
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-06-30"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2024-01-01to2024-06-30"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2023-01-012023-06-30"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:PaymentsForSettlementOfStockAwards
      contextRef="From2023-01-012023-06-30"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2023-01-012023-06-30"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor
      contextRef="From2023-01-012023-06-30"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:RightofuseAsset
      contextRef="From2023-01-012023-06-30"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:FinancingLeaseLiability
      contextRef="From2023-01-012023-06-30"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:NonCashLeaseLiabilityNet
      contextRef="From2024-01-01to2024-06-30"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <PCSA:NonCashLeaseLiabilityNet
      contextRef="From2023-01-012023-06-30"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-06-30" id="Fact000015">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2024-01-01to2024-06-30" id="Fact000016">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-06-30" id="Fact000017">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-06-30" id="Fact000018">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-06-30" id="Fact000019">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-06-30" id="Fact000020">001-39531</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-06-30" id="Fact000021">Processa Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-06-30" id="Fact000022">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-06-30" id="Fact000023">45-1539785</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-06-30" id="Fact000024">7380 Coca Cola Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-06-30" id="Fact000025">Suite 106</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-06-30" id="Fact000026">Hanover</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-06-30" id="Fact000027">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-06-30" id="Fact000028">21076</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-06-30" id="Fact000029">443</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-06-30" id="Fact000030">776-3133</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-01-01to2024-06-30" id="Fact000031">Common     Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-01-01to2024-06-30" id="Fact000032">PCSA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-01-01to2024-06-30" id="Fact000033">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-06-30" id="Fact000034">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-06-30" id="Fact000035">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-06-30" id="Fact000036">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-06-30" id="Fact000037">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-06-30" id="Fact000038">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-06-30" id="Fact000039">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-08-01"
      decimals="INF"
      id="Fact000040"
      unitRef="Shares">3256944</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000048"
      unitRef="USD">5571120</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000049"
      unitRef="USD">4706197</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000051"
      unitRef="USD">1906854</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000052"
      unitRef="USD">926300</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000054"
      unitRef="USD">7477974</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000055"
      unitRef="USD">5632497</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000057"
      unitRef="USD">2276</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000058"
      unitRef="USD">2554</us-gaap:PropertyPlantAndEquipmentNet>
    <PCSA:OperatingAndFinancingLeaseRightofUseAsset
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000063"
      unitRef="USD">115191</PCSA:OperatingAndFinancingLeaseRightofUseAsset>
    <PCSA:OperatingAndFinancingLeaseRightofUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000064"
      unitRef="USD">146057</PCSA:OperatingAndFinancingLeaseRightofUseAsset>
    <us-gaap:SecurityDeposit
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000066"
      unitRef="USD">5535</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000067"
      unitRef="USD">5535</us-gaap:SecurityDeposit>
    <us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000069"
      unitRef="USD">120726</us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment>
    <us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000070"
      unitRef="USD">151592</us-gaap:AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment>
    <us-gaap:Assets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000072"
      unitRef="USD">7600976</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000073"
      unitRef="USD">5786643</us-gaap:Assets>
    <PCSA:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000081"
      unitRef="USD">93181</PCSA:OperatingAndFinanceLeaseLiabilityCurrent>
    <PCSA:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000082"
      unitRef="USD">83649</PCSA:OperatingAndFinanceLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000084"
      unitRef="USD">953086</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000085"
      unitRef="USD">311617</us-gaap:AccountsPayableCurrent>
    <PCSA:DueToLicensor
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000088"
      unitRef="USD">189000</PCSA:DueToLicensor>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000091"
      unitRef="USD">39</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000093"
      unitRef="USD">505397</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000094"
      unitRef="USD">146274</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000096"
      unitRef="USD">1551664</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">730579</us-gaap:LiabilitiesCurrent>
    <PCSA:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000102"
      unitRef="USD">25648</PCSA:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <PCSA:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000103"
      unitRef="USD">66905</PCSA:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000105"
      unitRef="USD">1577312</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000106"
      unitRef="USD">797484</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000117"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000119"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000121"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000123"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000125"
      unitRef="Shares">2873883</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000127"
      unitRef="Shares">2868883</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000129"
      unitRef="Shares">1291000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000131"
      unitRef="Shares">1286000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000114"
      unitRef="USD">287</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000115"
      unitRef="USD">129</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000133"
      unitRef="USD">87429165</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000134"
      unitRef="USD">80658111</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">5000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000141"
      unitRef="Shares">5000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000136"
      unitRef="USD">300000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000137"
      unitRef="USD">300000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000143"
      unitRef="USD">-81105788</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000144"
      unitRef="USD">-75369081</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000146"
      unitRef="USD">6023664</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000147"
      unitRef="USD">4989159</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000149"
      unitRef="USD">7600976</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000150"
      unitRef="USD">5786643</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000157"
      unitRef="USD">1730444</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000158"
      unitRef="USD">1688164</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000159"
      unitRef="USD">3269555</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000160"
      unitRef="USD">3342509</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000162"
      unitRef="USD">1351580</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000163"
      unitRef="USD">1026301</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000164"
      unitRef="USD">2622067</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000165"
      unitRef="USD">3477490</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000167"
      unitRef="USD">-3082024</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000168"
      unitRef="USD">-2714465</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000169"
      unitRef="USD">-5891622</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000170"
      unitRef="USD">-6819999</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000172"
      unitRef="USD">71698</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000173"
      unitRef="USD">101900</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000174"
      unitRef="USD">154915</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000175"
      unitRef="USD">185361</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000177"
      unitRef="USD">-3010326</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000178"
      unitRef="USD">-2612565</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000179"
      unitRef="USD">-5736707</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000180"
      unitRef="USD">-6634638</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000187"
      unitRef="USD">-3010326</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000188"
      unitRef="USD">-2612565</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000189"
      unitRef="USD">-5736707</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000190"
      unitRef="USD">-6634638</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000192"
      unitRef="USDPShares">-1.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000194"
      unitRef="USDPShares">-1.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000196"
      unitRef="USDPShares">-1.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000198"
      unitRef="USDPShares">-1.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000200"
      unitRef="USDPShares">-2.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000202"
      unitRef="USDPShares">-2.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000204"
      unitRef="USDPShares">-5.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000206"
      unitRef="USDPShares">-5.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000208"
      unitRef="Shares">2983283</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000210"
      unitRef="Shares">2983283</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000212"
      unitRef="Shares">1346808</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000214"
      unitRef="Shares">1346808</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000216"
      unitRef="Shares">2724903</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000218"
      unitRef="Shares">2724903</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000220"
      unitRef="Shares">1243475</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000222"
      unitRef="Shares">1243475</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000230"
      unitRef="Shares">806774</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000224"
      unitRef="USD">80</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000225"
      unitRef="USD">72018222</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000232"
      unitRef="Shares">-5000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000226"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000227"
      unitRef="USD">-64247561</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000228"
      unitRef="USD">7470741</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000240"
      unitRef="Shares">3195</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000234"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000235"
      unitRef="USD">341503</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000238"
      unitRef="USD">341504</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000248"
      unitRef="Shares">421611</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000242"
      unitRef="USD">42</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000243"
      unitRef="USD">6352035</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000246"
      unitRef="USD">6352077</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000253"
      unitRef="USD">-4022073</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000254"
      unitRef="USD">-4022073</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000262"
      unitRef="Shares">1231580</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000256"
      unitRef="USD">123</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000257"
      unitRef="USD">78711760</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000264"
      unitRef="Shares">-5000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000258"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000259"
      unitRef="USD">-68269634</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact000260"
      unitRef="USD">10142249</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000267"
      unitRef="USD">319123</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000270"
      unitRef="USD">319123</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000273"
      unitRef="USD">1310875</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000276"
      unitRef="USD">1310875</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000281"
      unitRef="USD">-2612565</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000282"
      unitRef="USD">-2612565</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000290"
      unitRef="Shares">1231580</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000284"
      unitRef="USD">123</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000285"
      unitRef="USD">80341758</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000292"
      unitRef="Shares">-5000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000286"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000287"
      unitRef="USD">-70882199</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000288"
      unitRef="USD">9159682</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000300"
      unitRef="Shares">1291000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000294"
      unitRef="USD">129</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000295"
      unitRef="USD">80658111</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000302"
      unitRef="Shares">-5000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000296"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000297"
      unitRef="USD">-75369081</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000298"
      unitRef="USD">4989159</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000310"
      unitRef="Shares">13176</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000304"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000305"
      unitRef="USD">167642</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000308"
      unitRef="USD">167643</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000318"
      unitRef="Shares">1555555</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000312"
      unitRef="USD">156</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000313"
      unitRef="USD">6282274</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000316"
      unitRef="USD">6282430</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <PCSA:SharesIssuedinConnectionwithLicenseAgreementShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000326"
      unitRef="Shares">5000</PCSA:SharesIssuedinConnectionwithLicenseAgreementShares>
    <PCSA:SharesIssuedinConnectionwithLicenseAgreementValue
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000320"
      unitRef="USD">1</PCSA:SharesIssuedinConnectionwithLicenseAgreementValue>
    <PCSA:SharesIssuedinConnectionwithLicenseAgreementValue
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000321"
      unitRef="USD">188999</PCSA:SharesIssuedinConnectionwithLicenseAgreementValue>
    <PCSA:SharesIssuedinConnectionwithLicenseAgreementValue
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000324"
      unitRef="USD">189000</PCSA:SharesIssuedinConnectionwithLicenseAgreementValue>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000329"
      unitRef="USD">8561</PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards>
    <PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000332"
      unitRef="USD">8561</PCSA:AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards>
    <PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000340"
      unitRef="Shares">3750</PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares>
    <PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000334"
      unitRef="USD">1</PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation>
    <PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000335"
      unitRef="USD">9923</PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation>
    <PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000338"
      unitRef="USD">9924</PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000345"
      unitRef="USD">-2726381</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000346"
      unitRef="USD">-2726381</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000354"
      unitRef="Shares">2860981</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000348"
      unitRef="USD">286</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000349"
      unitRef="USD">87278542</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000356"
      unitRef="Shares">-5000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000350"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000351"
      unitRef="USD">-78095462</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000352"
      unitRef="USD">8883366</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000364"
      unitRef="Shares">2860981</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000358"
      unitRef="USD">286</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000359"
      unitRef="USD">87278542</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000366"
      unitRef="Shares">-5000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000360"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000361"
      unitRef="USD">-78095462</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact000362"
      unitRef="USD">8883366</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000374"
      unitRef="Shares">14167</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000368"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000369"
      unitRef="USD">152631</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000372"
      unitRef="USD">152632</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000382"
      unitRef="Shares">1265</PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensationShares>
    <PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000377"
      unitRef="USD">2008</PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation>
    <PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000380"
      unitRef="USD">2008</PCSA:SharesWithheldToPayIncomeTaxOnStockbasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000387"
      unitRef="USD">-3010326</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000388"
      unitRef="USD">-3010326</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000396"
      unitRef="Shares">2873883</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000390"
      unitRef="USD">287</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000391"
      unitRef="USD">87429165</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000398"
      unitRef="Shares">-5000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000392"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000393"
      unitRef="USD">-81105788</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000394"
      unitRef="USD">6023664</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000406"
      unitRef="Shares">2873883</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000400"
      unitRef="USD">287</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000401"
      unitRef="USD">87429165</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000408"
      unitRef="Shares">-5000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000402"
      unitRef="USD">-300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000403"
      unitRef="USD">-81105788</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000404"
      unitRef="USD">6023664</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000413"
      unitRef="USD">-5736707</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000414"
      unitRef="USD">-6634638</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000419"
      unitRef="USD">278</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000422"
      unitRef="USD">42670</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000423"
      unitRef="USD">39982</us-gaap:OperatingLeaseExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000425"
      unitRef="USD">320275</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000426"
      unitRef="USD">660627</us-gaap:ShareBasedCompensation>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-06-30_custom_ConsultingAgreementMember_custom_SpartanCapitalSecuritesLLCMember"
      decimals="INF"
      id="Fact000431"
      unitRef="Shares">158007</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000429"
      unitRef="USD">1310875</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000436"
      unitRef="USD">980554</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000437"
      unitRef="USD">-662984</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000439"
      unitRef="USD">-41228</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000440"
      unitRef="USD">-38233</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000442"
      unitRef="USD">641469</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000443"
      unitRef="USD">-88526</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000445"
      unitRef="USD">-39</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000446"
      unitRef="USD">-51</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000448"
      unitRef="USD">359123</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000449"
      unitRef="USD">-91559</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000451"
      unitRef="USD">-5394713</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000452"
      unitRef="USD">-4178539</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000457"
      unitRef="USD">6282430</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000458"
      unitRef="USD">6352077</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000460"
      unitRef="USD">11932</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <PCSA:PaymentsForSettlementOfStockAwards
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000463"
      unitRef="USD">8561</PCSA:PaymentsForSettlementOfStockAwards>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000466"
      unitRef="USD">2301</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000469"
      unitRef="USD">6259636</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000470"
      unitRef="USD">6352077</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000472"
      unitRef="USD">864923</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000473"
      unitRef="USD">2173538</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000475"
      unitRef="USD">4706197</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000476"
      unitRef="USD">6503595</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000478"
      unitRef="USD">5571120</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000479"
      unitRef="USD">8677133</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000487"
      unitRef="Shares">5000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <PCSA:StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000484"
      unitRef="USD">189000</PCSA:StockIssuedInConnectionWithLicensingAgreementWhichHadPreviouslyBeenRecordedAsDueToLicensor>
    <PCSA:RightofuseAsset
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000489"
      unitRef="USD">11804</PCSA:RightofuseAsset>
    <PCSA:FinancingLeaseLiability
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000492"
      unitRef="USD">-11804</PCSA:FinancingLeaseLiability>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000498">&lt;p id="xdx_805_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zC9BccssvBck" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_828_zY8J4EdS8KXh"&gt;Organization and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zyfLjrkM3c7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_z78cgDHQuO7a"&gt;Organization&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our
Next Generation Chemotherapy (&#x201c;NGC&#x201d;) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of
existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution &lt;span style="background-color: white"&gt;in
the body, &lt;/span&gt; while maintaining the well-established existing mechanisms of killing the cancer cells. By modifying the
NGC drugs in this manner, we believe our three NGC treatments will provide improved safety-efficacy profiles when compared to their
currently marketed counterparts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
January 22, 2024, we filed a Certificate of Amendment to our Certificate of Incorporation, as amended with the Secretary of State of
Delaware that effected a &lt;span id="xdx_90C_eus-gaap--StockholdersEquityReverseStockSplit_c20240122__20240122_za2FbPhXsRXg" title="Reverse stock split"&gt;1-for-20 reverse stock split&lt;/span&gt; of our common stock, par value $&lt;span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240122_zkV5uoCqAZCk" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share (the &#x201c;Reverse Stock Split&#x201d;).
Pursuant to the Certificate of Amendment, our issued common stock decreased from &lt;span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20240121_zjmf2a7KyrS7" title="Common stock shares issued"&gt;24,706,474&lt;/span&gt; shares to &lt;span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20240122_zo6r78uDu8fg" title="Common stock shares issued"&gt;1,291,000&lt;/span&gt; shares and our outstanding
common stock decreased from &lt;span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20240121_zTsbrlIIgSn9" title="Common stock shares outstanding"&gt;24,606,474&lt;/span&gt; to &lt;span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20240122_z9Bz4KX7Q8h8" title="Common stock shares outstanding"&gt;1,286,000&lt;/span&gt;. The Reverse Stock Split did not affect our authorized common stock of &lt;span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20240122_znUn2BYxk9rd" title="Common stock shares authorized"&gt;100,000,000&lt;/span&gt;
shares or our common stock par value. All shares of common stock, including common stock underlying warrants, stock options, restricted
stock awards and restricted stock units, as well as exercise prices and per share information in these condensed consolidated financial
statements give retroactive effect to the Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zR3GMsZmAJcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zvtxdjVgydQ9"&gt;Basis
of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#x201c;SEC&#x201d;) on Form 10-Q and Article 8 of Regulation S-X.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2023, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--LiquidityPolicyTextBlock_zE8ajnErawKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zTTjxihF8auj"&gt;Liquidity&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Our
condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations,
realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses
since inception, are currently devoting substantially all of our efforts toward research and development of our NGC drug product candidates,
including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated deficit
of $&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20240630_zzGuRW9nIYDi" title="Accumulated deficit"&gt;81.1&lt;/span&gt; &lt;span style="background-color: white"&gt;million
at June 30, 2024. During the six months ended June 30, 2024, we generated a net loss of $&lt;/span&gt;&lt;span id="xdx_900_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20240630_z72a2i4fTzJh" title="Net loss"&gt;5.7&lt;/span&gt; &lt;span style="background-color: white"&gt;million
and used $&lt;/span&gt;&lt;span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20240630_zboCTV9vcQec" title="Net cash for operating activities from continuing operations"&gt;5.4&lt;/span&gt; &lt;span style="background-color: white"&gt;million in net cash for operating activities from continuing operations. To
date, none of our drug candidates have been approved for sale, and therefore we have not generated any product revenue and do not expect
positive cash flow from operations in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
have financed our operations primarily through public equity issuances, including an offering we closed on January 30, 2024, where we
sold &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240129__20240130__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zSIMiDrKloLl" title="Number of shares sold"&gt;476,000&lt;/span&gt; shares of our common stock, pre-funded warrants to purchase up to &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240130__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zp63FOwfMDka" title="Warrants to purchase"&gt;1,079,555&lt;/span&gt; shares of our common stock, and warrants for
the purchase of up to &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zI0kQsZWFyeb" title="Warrants to purchase shares"&gt;1,555,555&lt;/span&gt; shares of our common stock for net proceeds of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240129__20240130_zFKr4ofUj8vj" title="Net proceeds"&gt;6.3&lt;/span&gt; million, after deducting placement agent fees and
offering-related expenses. Simultaneously with the closing of the sale, the pre-funded warrants were exercised in exchange for &lt;span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesWarrantExercised_iI_c20240130__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zgekzZOaWhT5" title="Warrant exercised"&gt;1,079,555&lt;/span&gt;
shares of our common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the &#x201c;Registration
Statement&#x201d;), including a base prospectus relating to the offering of up to $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240531__20240531_zFND77df1Ys" title="Shares issued initial offering"&gt;50,000,000&lt;/span&gt;
in the aggregate of the securities identified in the base prospectus from time to time in one or more offerings; and a prospectus
supplement relating to the shares of our common stock that may be issued and sold under a sales agreement dated May 21, 2024 (the
&#x201c;Sales Agreement&#x201d;) between us and A.G.P./Alliance Global Partners (the &#x201c;Sales Agent&#x201d;), through which we may issue and
sell in a registered &#x201c;at the market offering&#x201d; shares of our common stock having an aggregate offering price of up to
$&lt;span id="xdx_901_ecustom--MaximumValueToBeSoldAtMarketOffering_pn5n6_c20240521__20240521__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_z5Vkxhd3mvQ9" title="Maximum value to be sold at the market offering"&gt;2.4&lt;/span&gt;
million (subject to adjustment) from time to time through or to our Sales Agent (the &#x201c;ATM Offering&#x201d;). We expect to use
net proceeds, if any, from the ATM Offering over time for continued research and development for our portfolio of drug candidates,
especially our oncology products, and working capital and general corporate purposes. The shares under the ATM Offering will be sold
and issued pursuant to the Registration Statement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;At
June 30, 2024, we had cash and cash equivalents totaling $&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20240630_zJIiwe4qLibf" title="Cash and cash equivalents"&gt;5.6&lt;/span&gt; &lt;span style="background-color: white"&gt;million
which, based on our current business plans, we believe these funds will satisfy our &lt;span style="background-color: white"&gt;operating &lt;/span&gt;
needs into late 2024, including the beginning of our Phase 2 trial of NGC-Cap in breast cancer. Our ability to execute our
longer-term operating plans, including future preclinical studies and clinical trials for our portfolio of drugs depend on our
ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding
transactions. &lt;span style="background-color: white"&gt;We will continue to be dependent
upon equity and/or debt financing until we are able to generate positive cash flows from our operations.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations,
strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable
to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or
planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in
certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and
distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms
that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of
our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#x2019; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no
assurance that future funding will be available when needed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Absent
additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year
or more after the date that these condensed consolidated financial statements are available to be issued based on the timing and amount
of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result,
substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated
financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments
to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification
of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties
described above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--UseOfEstimates_z7yg1qGZqK86" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zd4N8dnQYBKb"&gt;Use
of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules
and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial
statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation,
intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based
on management&#x2019;s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable,
actual results could differ materially from those estimates and could impact future results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_z26Z9yKmjEZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for income taxes in accordance with ASC Topic 740, &lt;i&gt;Income Taxes.&lt;/i&gt; Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. At June 30, 2024 and December 31, 2023, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed
quarterly and will be maintained until sufficient positive evidence exists to support its reversal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ACS 740-270 &lt;i&gt;Income Taxes &#x2013; Interim Reporting&lt;/i&gt;, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income
tax benefit or expense is expected for 2024 and the foreseeable future since we expect to generate taxable net operating losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_znppZHOwLNJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zG0UOiRw0515"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) up to specified limits. Total cash held by our banks at June 30, 2024, exceeded FDIC limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zv3o7GlGuGDh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_z94UFS2MqFub"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#x201c;ASU&#x201d;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated
financial position or results of operations.&lt;/span&gt;&lt;/p&gt;
&lt;p id="xdx_859_zqsonrUdij86" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000500">&lt;p id="xdx_84B_ecustom--BusinessActivitiesAndOrganizationPolicyTextBlock_zyfLjrkM3c7h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_z78cgDHQuO7a"&gt;Organization&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our
Next Generation Chemotherapy (&#x201c;NGC&#x201d;) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of
existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution &lt;span style="background-color: white"&gt;in
the body, &lt;/span&gt; while maintaining the well-established existing mechanisms of killing the cancer cells. By modifying the
NGC drugs in this manner, we believe our three NGC treatments will provide improved safety-efficacy profiles when compared to their
currently marketed counterparts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
January 22, 2024, we filed a Certificate of Amendment to our Certificate of Incorporation, as amended with the Secretary of State of
Delaware that effected a &lt;span id="xdx_90C_eus-gaap--StockholdersEquityReverseStockSplit_c20240122__20240122_za2FbPhXsRXg" title="Reverse stock split"&gt;1-for-20 reverse stock split&lt;/span&gt; of our common stock, par value $&lt;span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240122_zkV5uoCqAZCk" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share (the &#x201c;Reverse Stock Split&#x201d;).
Pursuant to the Certificate of Amendment, our issued common stock decreased from &lt;span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20240121_zjmf2a7KyrS7" title="Common stock shares issued"&gt;24,706,474&lt;/span&gt; shares to &lt;span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_c20240122_zo6r78uDu8fg" title="Common stock shares issued"&gt;1,291,000&lt;/span&gt; shares and our outstanding
common stock decreased from &lt;span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20240121_zTsbrlIIgSn9" title="Common stock shares outstanding"&gt;24,606,474&lt;/span&gt; to &lt;span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20240122_z9Bz4KX7Q8h8" title="Common stock shares outstanding"&gt;1,286,000&lt;/span&gt;. The Reverse Stock Split did not affect our authorized common stock of &lt;span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20240122_znUn2BYxk9rd" title="Common stock shares authorized"&gt;100,000,000&lt;/span&gt;
shares or our common stock par value. All shares of common stock, including common stock underlying warrants, stock options, restricted
stock awards and restricted stock units, as well as exercise prices and per share information in these condensed consolidated financial
statements give retroactive effect to the Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2024-01-222024-01-22" id="Fact000502">1-for-20 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-01-22"
      decimals="INF"
      id="Fact000504"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-01-21"
      decimals="INF"
      id="Fact000506"
      unitRef="Shares">24706474</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-01-22"
      decimals="INF"
      id="Fact000508"
      unitRef="Shares">1291000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-01-21"
      decimals="INF"
      id="Fact000510"
      unitRef="Shares">24606474</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-01-22"
      decimals="INF"
      id="Fact000512"
      unitRef="Shares">1286000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-01-22"
      decimals="INF"
      id="Fact000514"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000516">&lt;p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zR3GMsZmAJcd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zvtxdjVgydQ9"&gt;Basis
of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions of the
Securities and Exchange Commission (&#x201c;SEC&#x201d;) on Form 10-Q and Article 8 of Regulation S-X.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accordingly,
they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany
accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our
financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial
statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form
10-K for the year ended December 31, 2023, as filed with the SEC. The results of operations for the interim periods shown in this report
are not necessarily indicative of the results that may be expected for any other interim period or for the full year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <PCSA:LiquidityPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000518">&lt;p id="xdx_84C_ecustom--LiquidityPolicyTextBlock_zE8ajnErawKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zTTjxihF8auj"&gt;Liquidity&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Our
condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations,
realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses
since inception, are currently devoting substantially all of our efforts toward research and development of our NGC drug product candidates,
including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated deficit
of $&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20240630_zzGuRW9nIYDi" title="Accumulated deficit"&gt;81.1&lt;/span&gt; &lt;span style="background-color: white"&gt;million
at June 30, 2024. During the six months ended June 30, 2024, we generated a net loss of $&lt;/span&gt;&lt;span id="xdx_900_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20240101__20240630_z72a2i4fTzJh" title="Net loss"&gt;5.7&lt;/span&gt; &lt;span style="background-color: white"&gt;million
and used $&lt;/span&gt;&lt;span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20240101__20240630_zboCTV9vcQec" title="Net cash for operating activities from continuing operations"&gt;5.4&lt;/span&gt; &lt;span style="background-color: white"&gt;million in net cash for operating activities from continuing operations. To
date, none of our drug candidates have been approved for sale, and therefore we have not generated any product revenue and do not expect
positive cash flow from operations in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
have financed our operations primarily through public equity issuances, including an offering we closed on January 30, 2024, where we
sold &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240129__20240130__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zSIMiDrKloLl" title="Number of shares sold"&gt;476,000&lt;/span&gt; shares of our common stock, pre-funded warrants to purchase up to &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240130__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zp63FOwfMDka" title="Warrants to purchase"&gt;1,079,555&lt;/span&gt; shares of our common stock, and warrants for
the purchase of up to &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zI0kQsZWFyeb" title="Warrants to purchase shares"&gt;1,555,555&lt;/span&gt; shares of our common stock for net proceeds of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240129__20240130_zFKr4ofUj8vj" title="Net proceeds"&gt;6.3&lt;/span&gt; million, after deducting placement agent fees and
offering-related expenses. Simultaneously with the closing of the sale, the pre-funded warrants were exercised in exchange for &lt;span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesWarrantExercised_iI_c20240130__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zgekzZOaWhT5" title="Warrant exercised"&gt;1,079,555&lt;/span&gt;
shares of our common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the &#x201c;Registration
Statement&#x201d;), including a base prospectus relating to the offering of up to $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240531__20240531_zFND77df1Ys" title="Shares issued initial offering"&gt;50,000,000&lt;/span&gt;
in the aggregate of the securities identified in the base prospectus from time to time in one or more offerings; and a prospectus
supplement relating to the shares of our common stock that may be issued and sold under a sales agreement dated May 21, 2024 (the
&#x201c;Sales Agreement&#x201d;) between us and A.G.P./Alliance Global Partners (the &#x201c;Sales Agent&#x201d;), through which we may issue and
sell in a registered &#x201c;at the market offering&#x201d; shares of our common stock having an aggregate offering price of up to
$&lt;span id="xdx_901_ecustom--MaximumValueToBeSoldAtMarketOffering_pn5n6_c20240521__20240521__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AllianceGlobalPartnersMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--ATMOfferingMember_z5Vkxhd3mvQ9" title="Maximum value to be sold at the market offering"&gt;2.4&lt;/span&gt;
million (subject to adjustment) from time to time through or to our Sales Agent (the &#x201c;ATM Offering&#x201d;). We expect to use
net proceeds, if any, from the ATM Offering over time for continued research and development for our portfolio of drug candidates,
especially our oncology products, and working capital and general corporate purposes. The shares under the ATM Offering will be sold
and issued pursuant to the Registration Statement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;At
June 30, 2024, we had cash and cash equivalents totaling $&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20240630_zJIiwe4qLibf" title="Cash and cash equivalents"&gt;5.6&lt;/span&gt; &lt;span style="background-color: white"&gt;million
which, based on our current business plans, we believe these funds will satisfy our &lt;span style="background-color: white"&gt;operating &lt;/span&gt;
needs into late 2024, including the beginning of our Phase 2 trial of NGC-Cap in breast cancer. Our ability to execute our
longer-term operating plans, including future preclinical studies and clinical trials for our portfolio of drugs depend on our
ability to obtain additional funding from the sale of equity and/or debt securities, a strategic transaction or other funding
transactions. &lt;span style="background-color: white"&gt;We will continue to be dependent
upon equity and/or debt financing until we are able to generate positive cash flows from our operations.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations,
strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable
to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or
planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in
certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and
distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms
that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of
our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#x2019; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no
assurance that future funding will be available when needed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Absent
additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year
or more after the date that these condensed consolidated financial statements are available to be issued based on the timing and amount
of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result,
substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated
financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments
to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification
of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties
described above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</PCSA:LiquidityPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-06-30"
      decimals="-5"
      id="Fact000520"
      unitRef="USD">-81100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-06-30"
      decimals="-5"
      id="Fact000522"
      unitRef="USD">-5700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-06-30"
      decimals="-5"
      id="Fact000524"
      unitRef="USD">-5400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-292024-01-30_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000526"
      unitRef="Shares">476000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000528"
      unitRef="Shares">1079555</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-01-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000530"
      unitRef="Shares">1555555</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-292024-01-30"
      decimals="-5"
      id="Fact000532"
      unitRef="USD">6300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <PCSA:StockIssuedDuringPeriodSharesWarrantExercised
      contextRef="AsOf2024-01-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000534"
      unitRef="Shares">1079555</PCSA:StockIssuedDuringPeriodSharesWarrantExercised>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-05-312024-05-31"
      decimals="0"
      id="Fact000536"
      unitRef="USD">50000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <PCSA:MaximumValueToBeSoldAtMarketOffering
      contextRef="From2024-05-212024-05-21_custom_SalesAgreementMember_custom_AllianceGlobalPartnersMember_srt_MaximumMember_custom_ATMOfferingMember"
      decimals="-5"
      id="Fact000538"
      unitRef="USD">2400000</PCSA:MaximumValueToBeSoldAtMarketOffering>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30"
      decimals="-5"
      id="Fact000540"
      unitRef="USD">5600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-06-30" id="Fact000542">&lt;p id="xdx_843_eus-gaap--UseOfEstimates_z7yg1qGZqK86" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zd4N8dnQYBKb"&gt;Use
of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules
and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial
statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation,
intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based
on management&#x2019;s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable,
actual results could differ materially from those estimates and could impact future results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000544">&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_z26Z9yKmjEZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for income taxes in accordance with ASC Topic 740, &lt;i&gt;Income Taxes.&lt;/i&gt; Deferred income taxes are recorded for the expected tax
consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized
for income tax purposes. At June 30, 2024 and December 31, 2023, we recorded a valuation allowance equal to the full recorded amount
of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed
quarterly and will be maintained until sufficient positive evidence exists to support its reversal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ACS 740-270 &lt;i&gt;Income Taxes &#x2013; Interim Reporting&lt;/i&gt;, we are required to project our annual federal and state effective income tax
rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income
tax benefit or expense is expected for 2024 and the foreseeable future since we expect to generate taxable net operating losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-01-01to2024-06-30" id="Fact000546">&lt;p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_znppZHOwLNJ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zG0UOiRw0515"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents.
We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal
Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) up to specified limits. Total cash held by our banks at June 30, 2024, exceeded FDIC limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000548">&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zv3o7GlGuGDh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_z94UFS2MqFub"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies issue new accounting pronouncements.
Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (&#x201c;ASU&#x201d;).
We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements.
We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated
financial position or results of operations.&lt;/span&gt;&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000550">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zz3S3hiE05e5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; &lt;span id="xdx_82F_zsy1TSs2PCXb"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Preferred
Stock&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20240630_zKu9Q36csaC6" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20240630_z35p5wi2lwAb" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20231231_z8cAHOoGVlCc" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zVeeR41zrJ3" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; issued or outstanding shares of preferred stock at either June 30, 2024 or December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Common
Stock&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the six months ended June 30, 2024, we &lt;span style="background-color: white"&gt;sold &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zkha9YZSlre8"&gt;476,000
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;shares of common
stock, pre-funded warrants to purchase up to &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zUwdeAAXjcG7"&gt;1,079,555
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;shares of common stock
in lieu of shares of common stock (the &#x201c;Pre-Funded Warrants&#x201d;), and warrants to purchase up to &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zT9NjvAGk7E3"&gt;1,555,555
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;shares of our common
stock (the &#x201c;Common Warrants&#x2019;) in a public offering (the &#x201c;Offering&#x201d;). The Common Warrants have an exercise price
of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zGAfxiBLtA3j"&gt;4.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;,
are immediately exercisable and expire on &lt;span id="xdx_907_ecustom--WarrantsExercisableAndMaturityDate_dd_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1mNc6nDyCMd"&gt;January
30, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;. The shares
of common stock  were offered at a combined public offering price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zrVkegQ0cBkb"&gt;4.50
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;per share and accompanying
Common Warrant and $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20240630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zjCYfXWgibZa"&gt;4.4999
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;per Pre-Funded Warrant
and accompanying Common Warrant. The Pre-Funded Warrants had an exercise price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zNeYa1yQT3ei"&gt;0.0001
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;and were exercised in
full simultaneously with the closing of the Offering in exchange for &lt;span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesWarrantExercised_iI_c20240630__us-gaap--ClassOfWarrantOrRightAxis__custom--PreFundedWarrantMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zMukDIr1ri5g"&gt;1,079,555
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;shares of our common
stock. Gross proceeds in connection with the Offering were $&lt;span id="xdx_909_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zQVMoaFdYYja"&gt;7.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;million. We received
$&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zwPWQbhcssO1"&gt;6.3
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;million in net proceeds
from the Offering, after deducting the fees of the placement agent and other offering-related expenses. We also issued to the placement
agent warrants to purchase &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_zkjvuzYTZUfb"&gt;62,222
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;shares of common stock,
exercisable at $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_zKSfv9c1mPm7"&gt;5.625
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;per share that expire
on &lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_z2WpMlnEtEQ"&gt;February
1, 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the six months ended June 30, 2024, we also issued: &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ElionOncologyIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zG2Bi5hn3Ybi" title="Shares issued"&gt;5,000&lt;/span&gt; shares of common stock to Elion Oncology, Inc. (&#x201c;Elion&#x201d;) in satisfaction
of the third milestone event under the license agreement; &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z3KL7gTXZBf6" title="Shares issued"&gt;10,000&lt;/span&gt; shares of common stock to a consultant in accordance with their consulting
agreement; and &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesAndConsultantsMember_za80P7C6W111" title="Shares issued"&gt;12,328&lt;/span&gt; shares of common stock to certain employees and consultants, net of &lt;span id="xdx_90D_ecustom--StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes_c20240101__20240630_zuGeAqqSf13f" title="Stock withheld for income taxes"&gt;5,015&lt;/span&gt; shares of common stock withheld for income
taxes owed upon distribution of the shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000552"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000554"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000556"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000558"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-06-30_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000559"
      unitRef="Shares">476000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-06-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000560"
      unitRef="Shares">1079555</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-06-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000561"
      unitRef="Shares">1555555</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000562"
      unitRef="USDPShares">4.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <PCSA:WarrantsExercisableAndMaturityDate
      contextRef="From2024-01-012024-06-30_custom_PurchaseAgreementMember_us-gaap_WarrantMember"
      id="Fact000563">2029-01-30</PCSA:WarrantsExercisableAndMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-30_us-gaap_WarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000564"
      unitRef="USDPShares">4.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-06-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000565"
      unitRef="USDPShares">4.4999</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000566"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <PCSA:StockIssuedDuringPeriodSharesWarrantExercised
      contextRef="AsOf2024-06-30_custom_PreFundedWarrantMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000567"
      unitRef="Shares">1079555</PCSA:StockIssuedDuringPeriodSharesWarrantExercised>
    <PCSA:GrossProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-06-30_custom_PurchaseAgreementMember"
      decimals="-5"
      id="Fact000568"
      unitRef="USD">7000000.0</PCSA:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-06-30_custom_PurchaseAgreementMember"
      decimals="-5"
      id="Fact000569"
      unitRef="USD">6300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-06-30_custom_PurchaseAgreementMember_custom_PlacementAgentMember"
      decimals="INF"
      id="Fact000570"
      unitRef="Shares">62222</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-30_custom_PurchaseAgreementMember_custom_PlacementAgentMember"
      decimals="INF"
      id="Fact000571"
      unitRef="USDPShares">5.625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-06-30_custom_PurchaseAgreementMember_custom_PlacementAgentMember"
      id="Fact000572">2027-02-01</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-06-30_custom_ElionOncologyIncMember_custom_LicenseAgreementMember"
      decimals="INF"
      id="Fact000574"
      unitRef="Shares">5000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-06-30_custom_ConsultantMember_custom_ConsultingAgreementMember"
      decimals="INF"
      id="Fact000576"
      unitRef="Shares">10000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-06-30_custom_EmployeesAndConsultantsMember"
      decimals="INF"
      id="Fact000578"
      unitRef="Shares">12328</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <PCSA:StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000580"
      unitRef="Shares">5015</PCSA:StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000582">&lt;p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zms0jgFIyhM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 11pt; text-align: justify; text-indent: -11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;Note
3 - &lt;span id="xdx_82D_zeCe8xOvK7H4"&gt;Stock-based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 11pt; text-align: justify; text-indent: -11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
June 19, 2019, our stockholders approved, and we adopted, the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the &#x201c;2019
Plan&#x201d;). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock
options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and
directors. On June 28, 2024, our shareholders approved an increase of shares available under the 2019 Plan, which now provides for the
aggregate issuance of &lt;span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20240628__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_z8Rd0nh27KK5" title="Maximum equity available for issuance"&gt;800,000&lt;/span&gt; shares of our common stock. At June 30, 2024, we have &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20240630__us-gaap--PlanNameAxis__custom--TwoThousandAndNineteenPlanMember_zJrpxcN9xI34" title="Shares available for future grants"&gt;503,129&lt;/span&gt;
&lt;span style="background-color: white"&gt;shares available for future grants.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Stock
Compensation Expense&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z6SzgmbGSO5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
recorded stock-based compensation expense for the three and six months ended June 30, 2024 and 2023 as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zodWD40luq2a" style="display: none"&gt;Schedule
of Stock-based Compensation Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240401__20240630_z5FodJsigOll" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230401__20230630_zsR6fnL7T3Y6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20240630_zCaIDiOiyqIl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20230630_z2reTkBdvR18" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zBl0WgR2HB58" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;45,583&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;102,678&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;76,704&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;209,526&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zvjIzpXWeR6c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;107,049&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;216,445&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;243,571&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;451,101&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ShareBasedCompensation_zIAzCfb6GuPk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;152,632&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;319,123&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;320,275&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;660,627&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zVU3URQcY35j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Stock
Options&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Stock
options to purchase &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwlLKXKdUA1a" title="Options, forfeited"&gt;4,245&lt;/span&gt;
shares of common stock with a weighted-average exercise price of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zc3eL8S5aKIb" title="Options, forfeited weighted average exercise price"&gt;336.00&lt;/span&gt; expired during the six months ended June 30, 2024. At June
30, 2024, we had outstanding and exercisable options for the purchase of &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUxcBfA1yEG6" title="Options exercisable, shares"&gt;2,747&lt;/span&gt;
shares with a weighted average exercise price of $&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjJ9FQ6wukZg" title="Options exercisable weighted average exercise price"&gt;409.09&lt;/span&gt; &lt;span style="background-color: white"&gt;and
a weighted average remaining contractual life of &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAU3zGfUwJm1" title="Exercisable weighted average remaining contractual term"&gt;4.2&lt;/span&gt;
years. &lt;/span&gt;At June 30, 2024, we did not have any unrecognized stock-based compensation expense related to our granted stock
options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Restricted
Stock Awards&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;During
the six months ended June 30, 2024, we vested &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zt8aKX836yGf" title="Number of shares, vested"&gt;1,250&lt;/span&gt; Restricted Stock Awards (&#x201c;RSAs&#x201d;) with a weighted average grant-date fair
value of $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zE655AtLV3S7" title="Weighted-average grant-date fair value per share, shares vested"&gt;9.26&lt;/span&gt; per share. We had &lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iI_do_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z03ctXbxoPph" title="Number of shares, outstanding"&gt;no&lt;/span&gt; RSAs outstanding at June 30, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Restricted
Stock Units&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zwID5zmhYv8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Activity
with respect to our Restricted Stock Units (&#x201c;RSUs&#x201d;) during the six months ended June 30, 2024 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zoYyqIbs2L9d" style="display: none"&gt;Schedule
of Restricted Stock Units (&#x201c;RSUs&#x201d;) Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number of &lt;br/&gt; shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted- average &lt;br/&gt; grant-date fair &lt;br/&gt; value per share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%"&gt;Outstanding at January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLWDn2xUoC53" style="width: 18%; text-align: right" title="Number of shares, Beginning balance"&gt;222,722&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8V9qKOT7fs" style="width: 18%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"&gt;45.82&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z68O3XAcTBg3" style="text-align: right" title="Number of shares, granted"&gt;39,202&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEqZAKfUHhLe" style="text-align: right" title="Weighted-average grant-date fair value per share, granted"&gt;2.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znkTJGQ0iJvl" style="text-align: right" title="Number of shares, forfeited"&gt;(10,775&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1Fq3XF0HLJ2" style="text-align: right" title="Weighted-average grant-date fair value per share, forfeited"&gt;58.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Issued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHFURFCsr4Vj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, issued"&gt;(12,328&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPvQk5Fa07xi" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average grant-date fair value per share, shares issued"&gt;99.86&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at June 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxd6fRrteoG3" style="text-align: right" title="Number of shares, ending balance"&gt;238,821&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5X8i7ksTIU6" style="text-align: right" title="Weighted-average grant-date fair value per share, ending balance"&gt;35.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Vested and unissued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzHjLHBIqhZ2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, vested and unissued"&gt;143,793&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuOc9MwdxRf4" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued"&gt;50.71&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Unvested at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znuJ5Df36qY5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, unvested"&gt;95,028&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zauZjCGzc6Y8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average grant-date fair value per share, unvested"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zIX1G5IxUuw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
June 28, 2024, we granted RSUs for the future issuance of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240628__20240628__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zm6da1XEUb8l" title="Number of shares, granted"&gt;39,202
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;shares of common stock
to our employees which vest accordingly: RSUs for the future issuance of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240628__20240628__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockUnitsMember__us-gaap--VestingAxis__custom--JanuaryOneTwoThousandTwentyFiveVestingMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zakKaOLh1Cci" title="Number of shares, granted"&gt;14,969&lt;/span&gt; shares of common stock vest on January 1, 2025; RSUs
for the future issuance of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240628__20240628__us-gaap--AwardTypeAxis__custom--ServiceBasedRestrictedStockUnitsMember__custom--TitleOfInidividualAxis__custom--EmployeesMember__us-gaap--VestingAxis__custom--ThreeYearVestingMember_zvziE1YPMMM5" title="Number of shares, granted"&gt;18,173
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;shares of common stock
vest over a three-year period upon meeting service requirements; RSUs for the future issuance of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240628__20240628__us-gaap--AwardTypeAxis__custom--FirstPerformanceBasedRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zBsoWhg7uTla" title="Number of shares, granted"&gt;3,030
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;shares of common stock
vested upon grant due to regaining Nasdaq compliance; and RSUs for the future issuance of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240628__20240628__us-gaap--AwardTypeAxis__custom--SecondPerformanceBasedRSUMember__us-gaap--TypeOfArrangementAxis__custom--NextGenerationCapecitabineCAPMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zmAcGmjXrZ92" title="Number of shares, granted"&gt;3,030
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;shares of common stock
vest upon dosing the first patient in our Phase 2 study in NGC-Cap.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
June 30, 2024, unrecognized stock-based compensation expense of approximately&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zq1wg6oHSroi" title="Unrecognized share based compensation expense"&gt;538,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for
RSUs is expected to be fully recognized over a weighted average period of &lt;span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9vxgPMIXg79" title="Weighted average period for recognition"&gt;1.7 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years.
The unrecognized expense excludes approximately $&lt;span id="xdx_90E_ecustom--UnrecognizedShareBasedCompensationExpense_pp0p0_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zX2oq6C2lLcd"&gt;420,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of
expense related to certain grants of RSUs with performance milestones that are not probable of occurring at this time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Holders
of our vested RSUs will be issued shares of our common stock upon meeting the distribution restrictions contained in their Restricted
Stock Unit Award Agreement. The distribution restrictions are different (longer) than the vesting schedule, imposing an additional restriction
on the holder. Unlike RSAs, while certain employees may hold fully vested RSUs, the individual does not hold any shares or have any rights
of a shareholder until the distribution restrictions are met. Upon distribution to the employee, each RSU converts into one share of
our common stock. The RSUs contain dividend equivalent rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;During
the six months ended June 30, 2024, we did not grant any warrants to purchase shares of our common stock other than warrants to purchase
&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__custom--OfferingMember_zBM1K8LH4wZi" title="Warrants to purchase shares"&gt;1,617,777&lt;/span&gt; shares of common stock as part of &lt;span style="background-color: white"&gt;the O&lt;/span&gt;ffering (see Note 2). Warrants to purchase &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zi6uDxFzZ0s8" title="Warrants, expired"&gt;5,000&lt;/span&gt; shares of our common stock expired
unexercised. We also repurchased a warrant issued to a consultant in 2023 for the purchase of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zAV73yMN6jbl" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures"&gt;15,000&lt;/span&gt; shares of our common stock in exchange
for a payment of $&lt;span id="xdx_906_ecustom--PaymentsForSettlementOfStockAwards_pid_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zLS1FCLyAlZ"&gt;10,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
June 30, 2024, we had outstanding stock purchase warrants for the purchase of an aggregate of &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeqtYNLZv1Xi" title="Warrants to purchase shares"&gt;1,778,284&lt;/span&gt; &lt;span style="background-color: white"&gt;shares
with a weighted average exercise price of $&lt;/span&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zim5V1rkjTme" title="Weighted average exercise price"&gt;6.17&lt;/span&gt; &lt;span style="background-color: white"&gt;and
a weighted average remaining contractual life of &lt;/span&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zH0gAth99mgj" title="Weighted average remaining contractual life"&gt;4.3&lt;/span&gt; &lt;span style="background-color: white"&gt;years.
All the outstanding stock purchase warrants are exercisable a&lt;span style="background-color: white"&gt;s of&lt;/span&gt; June 30, 2024. W&lt;/span&gt;e did not have any unrecognized stock-based
compensation expense related to our granted stock purchase warrants at June 30, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-06-28_custom_TwoThousandAndNineteenPlanMember"
      decimals="INF"
      id="Fact000584"
      unitRef="Shares">800000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-06-30_custom_TwoThousandAndNineteenPlanMember"
      decimals="INF"
      id="Fact000586"
      unitRef="Shares">503129</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000588">&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z6SzgmbGSO5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;We
recorded stock-based compensation expense for the three and six months ended June 30, 2024 and 2023 as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zodWD40luq2a" style="display: none"&gt;Schedule
of Stock-based Compensation Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240401__20240630_z5FodJsigOll" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230401__20230630_zsR6fnL7T3Y6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20240630_zCaIDiOiyqIl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20230630_z2reTkBdvR18" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zBl0WgR2HB58" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;45,583&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;102,678&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;76,704&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;209,526&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zvjIzpXWeR6c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;107,049&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;216,445&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;243,571&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;451,101&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ShareBasedCompensation_zIAzCfb6GuPk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;152,632&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;319,123&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;320,275&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;660,627&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact000590"
      unitRef="USD">45583</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact000591"
      unitRef="USD">102678</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact000592"
      unitRef="USD">76704</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact000593"
      unitRef="USD">209526</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000595"
      unitRef="USD">107049</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000596"
      unitRef="USD">216445</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000597"
      unitRef="USD">243571</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000598"
      unitRef="USD">451101</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000600"
      unitRef="USD">152632</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000601"
      unitRef="USD">319123</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000602"
      unitRef="USD">320275</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000603"
      unitRef="USD">660627</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000605"
      unitRef="Shares">4245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000607"
      unitRef="USDPShares">336.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000609"
      unitRef="Shares">2747</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000611"
      unitRef="USDPShares">409.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-06-30_us-gaap_EmployeeStockOptionMember"
      id="Fact000613">P4Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact000615"
      unitRef="Shares">1250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact000617"
      unitRef="USDPShares">9.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding
      contextRef="AsOf2024-06-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact000619"
      unitRef="Shares">0</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000621">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zwID5zmhYv8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Activity
with respect to our Restricted Stock Units (&#x201c;RSUs&#x201d;) during the six months ended June 30, 2024 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zoYyqIbs2L9d" style="display: none"&gt;Schedule
of Restricted Stock Units (&#x201c;RSUs&#x201d;) Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number of &lt;br/&gt; shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted- average &lt;br/&gt; grant-date fair &lt;br/&gt; value per share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%"&gt;Outstanding at January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLWDn2xUoC53" style="width: 18%; text-align: right" title="Number of shares, Beginning balance"&gt;222,722&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8V9qKOT7fs" style="width: 18%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance"&gt;45.82&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z68O3XAcTBg3" style="text-align: right" title="Number of shares, granted"&gt;39,202&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEqZAKfUHhLe" style="text-align: right" title="Weighted-average grant-date fair value per share, granted"&gt;2.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znkTJGQ0iJvl" style="text-align: right" title="Number of shares, forfeited"&gt;(10,775&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1Fq3XF0HLJ2" style="text-align: right" title="Weighted-average grant-date fair value per share, forfeited"&gt;58.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Issued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_iN_di_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHFURFCsr4Vj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, issued"&gt;(12,328&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPvQk5Fa07xi" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average grant-date fair value per share, shares issued"&gt;99.86&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at June 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iE_pid_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxd6fRrteoG3" style="text-align: right" title="Number of shares, ending balance"&gt;238,821&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5X8i7ksTIU6" style="text-align: right" title="Weighted-average grant-date fair value per share, ending balance"&gt;35.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Vested and unissued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzHjLHBIqhZ2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, vested and unissued"&gt;143,793&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue_iI_c20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuOc9MwdxRf4" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average grant-date fair value per share, vested and unissued"&gt;50.71&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Unvested at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znuJ5Df36qY5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, unvested"&gt;95,028&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20240101__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zauZjCGzc6Y8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average grant-date fair value per share, unvested"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000623"
      unitRef="Shares">222722</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000625"
      unitRef="USDPShares">45.82</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000627"
      unitRef="Shares">39202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000629"
      unitRef="USDPShares">2.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000631"
      unitRef="Shares">10775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000633"
      unitRef="USDPShares">58.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000635"
      unitRef="Shares">12328</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000637"
      unitRef="USDPShares">99.86</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding
      contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000639"
      unitRef="Shares">238821</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000641"
      unitRef="USDPShares">35.31</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued
      contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000643"
      unitRef="Shares">143793</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued>
    <PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000645"
      unitRef="USDPShares">50.71</PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000647"
      unitRef="Shares">95028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000649"
      unitRef="USDPShares">12.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-06-282024-06-28_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember"
      decimals="INF"
      id="Fact000651"
      unitRef="Shares">39202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-06-282024-06-28_custom_ServiceBasedRestrictedStockUnitsMember_custom_JanuaryOneTwoThousandTwentyFiveVestingMember_custom_EmployeesMember"
      decimals="INF"
      id="Fact000653"
      unitRef="Shares">14969</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-06-282024-06-28_custom_ServiceBasedRestrictedStockUnitsMember_custom_EmployeesMember_custom_ThreeYearVestingMember"
      decimals="INF"
      id="Fact000655"
      unitRef="Shares">18173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-06-282024-06-28_custom_FirstPerformanceBasedRSUMember_custom_EmployeesMember"
      decimals="INF"
      id="Fact000657"
      unitRef="Shares">3030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-06-282024-06-28_custom_SecondPerformanceBasedRSUMember_custom_NextGenerationCapecitabineCAPMember_custom_EmployeesMember"
      decimals="INF"
      id="Fact000659"
      unitRef="Shares">3030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact000661"
      unitRef="USD">538000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact000663">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <PCSA:UnrecognizedShareBasedCompensationExpense
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact000664"
      unitRef="USD">420000</PCSA:UnrecognizedShareBasedCompensationExpense>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-06-30_us-gaap_WarrantMember_custom_OfferingMember"
      decimals="INF"
      id="Fact000666"
      unitRef="Shares">1617777</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2024-01-012024-06-30_custom_ConsultingAgreementMember"
      decimals="INF"
      id="Fact000668"
      unitRef="Shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2024-01-012024-06-30_custom_ConsultingAgreementMember"
      decimals="INF"
      id="Fact000670"
      unitRef="Shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <PCSA:PaymentsForSettlementOfStockAwards
      contextRef="From2024-01-012024-06-30_custom_ConsultingAgreementMember"
      decimals="INF"
      id="Fact000671"
      unitRef="USD">10000</PCSA:PaymentsForSettlementOfStockAwards>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000673"
      unitRef="Shares">1778284</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000675"
      unitRef="USDPShares">6.17</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2024-01-012024-06-30_us-gaap_WarrantMember"
      id="Fact000677">P4Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000679">&lt;p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zEFPoujgZDxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &#x2013; &lt;span id="xdx_824_zrVP9MjRHqU6"&gt;Net Loss per Share of Common Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Net
Loss Per Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of
common stock outstanding (which excludes unvested RSAs and includes vested RSUs) during the period. Diluted loss per share is computed
by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock (which includes
the potentially dilutive effect of stock options, unvested RSAs, unvested RSUs and warrants) during the period. Since we experienced
a net loss for all periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three
and six months ended June 30, 2024 and 2023 excludes the impact of potentially dilutive common shares since those shares would have an
anti-dilutive effect on net loss per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zkFILclMsVr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
computation of net loss per share for the three and six months ended June 30, 2024 and 2023 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zqvf5jbfVNZa" style="display: none"&gt;Schedule
of Net Loss Per Share Basic and Diluted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240401__20240630_zP8owTHBVmj8" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230401__20230630_z5cY1XLgubb8" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20240630_zBucptvGIphl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20230630_zObYOSOsneM4" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Basic and diluted net loss per share:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zt8WbifFm9T" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Net loss available to common stockholders&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(3,010,326&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(2,612,565&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(5,736,707&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(6,634,638&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Weighted average number of common shares-basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_z9v3dlpQWYzl" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zXb6BIWGMsDd" title="Weighted average number of common shares-diluted"&gt;2,983,283&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zYy14PKK31jg" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zOHJT9CrF9b5" title="Weighted average number of common shares-diluted"&gt;1,346,808&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_z2sKeE36uWV" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zSKt3sgBDLF2" title="Weighted average number of common shares-diluted"&gt;2,724,903&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630_zlD7e4ngIuQ4" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630_zNsGglfYFfxa" title="Weighted average number of common shares-diluted"&gt;1,243,475&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted net loss per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20240401__20240630_zwm9qXzfco14" title="Basic net loss per share"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20240401__20240630_z2dhQAi6zQ2b" title="Diluted net loss per share"&gt;(1.01&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20230401__20230630_zB9SWxSk5Wge" title="Basic net loss per share"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20230401__20230630_zl03lsAGZXyg" title="Diluted net loss per share"&gt;(1.94&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20240101__20240630_zXlGLtMa4p6i" title="Basic net loss per share"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20240101__20240630_zUZUzeJGuXi7" title="Diluted net loss per share"&gt;(2.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20230101__20230630_zKHej9fZceq9" title="Basic net loss per share"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareDiluted_c20230101__20230630_z5VmYUNuhSg4" title="Diluted net loss per share"&gt;(5.34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Weighted-average number of common shares outstanding &#x2013; basic and diluted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPkYVMlhxqnf" title="Weighted average number of common shares outstanding - basic"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCdXLDT2t6zb" title="Weighted average number of common shares outstanding - diluted"&gt;2,849,192&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH2smbzqAysa" title="Weighted average number of common shares outstanding - basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl0oSEXGhtt1" title="Weighted average number of common shares outstanding - diluted"&gt;1,217,095&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zki6Ilpn51U" title="Weighted average number of common shares outstanding - basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuOkib98Cld3" title="Weighted average number of common shares outstanding - diluted"&gt;2,590,530&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zclzYqSqBGd" title="Weighted average number of common shares outstanding - basic"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9NxXBzEUgl1" title="Weighted average number of common shares outstanding - diluted"&gt;1,114,324&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Weighted-average number of vested RSUs&#x2013; basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zT2rbSOClc5l" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zy0htHyCVelk" title="Weighted average number of vested RSUs - diluted"&gt;134,091&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdBL7WZIk4bj" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zDGzLfax9I5j" title="Weighted average number of vested RSUs - diluted"&gt;129,713&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zmMmgFOVaYi5" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zNFrnqLMvaoe" title="Weighted average number of vested RSUs - diluted"&gt;134,373&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zlHMO9EIDOci" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_znxi54O59K7l" title="Weighted average number of vested RSUs - diluted"&gt;129,151&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted-average number of common shares-basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_z5x6L5xl4S72" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zBA7SJjmhjF8" title="Weighted average number of common shares-diluted"&gt;2,983,283&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zmhE5QPBDIk5" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zN9GRulGpkLk" title="Weighted average number of common shares-diluted"&gt;1,346,808&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zlD8oHQuRrA2" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zZUBvM95APPk" title="Weighted average number of common shares-diluted"&gt;2,724,903&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630_zh8fKkkGk4Db" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630_zfJ50RENF3ue" title="Weighted average number of common shares-diluted"&gt;1,243,475&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zl1iEEpC5EPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
diluted net loss per share for the three and six months ended June 30, 2024 and 2023 excluded &lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240401__20240630_zlmdipiWLrb7" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240630_zLu1b7SxZftk" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;1,876,059&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230401__20230630_z26FHDZuLa43" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;&lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630_ziPOp3dRfio4" title="Antidilutive securities excluded from computation of earnings per share, amount"&gt;254,314&lt;/span&gt;&lt;/span&gt; of potentially dilutive
common shares, respectively, related to outstanding stock options, warrants and unvested restricted stock since those shares would have
had an anti-dilutive effect on net loss per share during the periods then ended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000681">&lt;p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zkFILclMsVr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
computation of net loss per share for the three and six months ended June 30, 2024 and 2023 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zqvf5jbfVNZa" style="display: none"&gt;Schedule
of Net Loss Per Share Basic and Diluted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240401__20240630_zP8owTHBVmj8" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230401__20230630_z5cY1XLgubb8" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20240630_zBucptvGIphl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20230630_zObYOSOsneM4" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Basic and diluted net loss per share:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zt8WbifFm9T" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Net loss available to common stockholders&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(3,010,326&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(2,612,565&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(5,736,707&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(6,634,638&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Weighted average number of common shares-basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_z9v3dlpQWYzl" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zXb6BIWGMsDd" title="Weighted average number of common shares-diluted"&gt;2,983,283&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zYy14PKK31jg" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zOHJT9CrF9b5" title="Weighted average number of common shares-diluted"&gt;1,346,808&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_z2sKeE36uWV" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zSKt3sgBDLF2" title="Weighted average number of common shares-diluted"&gt;2,724,903&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630_zlD7e4ngIuQ4" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630_zNsGglfYFfxa" title="Weighted average number of common shares-diluted"&gt;1,243,475&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted net loss per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--EarningsPerShareBasic_c20240401__20240630_zwm9qXzfco14" title="Basic net loss per share"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20240401__20240630_z2dhQAi6zQ2b" title="Diluted net loss per share"&gt;(1.01&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20230401__20230630_zB9SWxSk5Wge" title="Basic net loss per share"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20230401__20230630_zl03lsAGZXyg" title="Diluted net loss per share"&gt;(1.94&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20240101__20240630_zXlGLtMa4p6i" title="Basic net loss per share"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_c20240101__20240630_zUZUzeJGuXi7" title="Diluted net loss per share"&gt;(2.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareBasic_c20230101__20230630_zKHej9fZceq9" title="Basic net loss per share"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareDiluted_c20230101__20230630_z5VmYUNuhSg4" title="Diluted net loss per share"&gt;(5.34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Weighted-average number of common shares outstanding &#x2013; basic and diluted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPkYVMlhxqnf" title="Weighted average number of common shares outstanding - basic"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCdXLDT2t6zb" title="Weighted average number of common shares outstanding - diluted"&gt;2,849,192&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH2smbzqAysa" title="Weighted average number of common shares outstanding - basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl0oSEXGhtt1" title="Weighted average number of common shares outstanding - diluted"&gt;1,217,095&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zki6Ilpn51U" title="Weighted average number of common shares outstanding - basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuOkib98Cld3" title="Weighted average number of common shares outstanding - diluted"&gt;2,590,530&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zclzYqSqBGd" title="Weighted average number of common shares outstanding - basic"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9NxXBzEUgl1" title="Weighted average number of common shares outstanding - diluted"&gt;1,114,324&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Weighted-average number of vested RSUs&#x2013; basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zT2rbSOClc5l" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zy0htHyCVelk" title="Weighted average number of vested RSUs - diluted"&gt;134,091&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdBL7WZIk4bj" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zDGzLfax9I5j" title="Weighted average number of vested RSUs - diluted"&gt;129,713&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zmMmgFOVaYi5" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zNFrnqLMvaoe" title="Weighted average number of vested RSUs - diluted"&gt;134,373&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zlHMO9EIDOci" title="Weighted average number of vested RSUs - basic"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_znxi54O59K7l" title="Weighted average number of vested RSUs - diluted"&gt;129,151&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted-average number of common shares-basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240401__20240630_z5x6L5xl4S72" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240401__20240630_zBA7SJjmhjF8" title="Weighted average number of common shares-diluted"&gt;2,983,283&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230401__20230630_zmhE5QPBDIk5" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230401__20230630_zN9GRulGpkLk" title="Weighted average number of common shares-diluted"&gt;1,346,808&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240630_zlD8oHQuRrA2" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240630_zZUBvM95APPk" title="Weighted average number of common shares-diluted"&gt;2,724,903&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230630_zh8fKkkGk4Db" title="Weighted average number of common shares-basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230630_zfJ50RENF3ue" title="Weighted average number of common shares-diluted"&gt;1,243,475&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000683"
      unitRef="USD">-3010326</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000684"
      unitRef="USD">-2612565</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000685"
      unitRef="USD">-5736707</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000686"
      unitRef="USD">-6634638</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000688"
      unitRef="Shares">2983283</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000690"
      unitRef="Shares">2983283</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000692"
      unitRef="Shares">1346808</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000694"
      unitRef="Shares">1346808</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000696"
      unitRef="Shares">2724903</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000698"
      unitRef="Shares">2724903</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000700"
      unitRef="Shares">1243475</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000702"
      unitRef="Shares">1243475</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000704"
      unitRef="USDPShares">-1.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000706"
      unitRef="USDPShares">-1.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000708"
      unitRef="USDPShares">-1.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000710"
      unitRef="USDPShares">-1.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000712"
      unitRef="USDPShares">-2.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000714"
      unitRef="USDPShares">-2.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000716"
      unitRef="USDPShares">-5.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000718"
      unitRef="USDPShares">-5.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000720"
      unitRef="Shares">2849192</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000722"
      unitRef="Shares">2849192</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000724"
      unitRef="Shares">1217095</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000726"
      unitRef="Shares">1217095</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000728"
      unitRef="Shares">2590530</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000730"
      unitRef="Shares">2590530</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000732"
      unitRef="Shares">1114324</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000734"
      unitRef="Shares">1114324</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000736"
      unitRef="Shares">134091</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000738"
      unitRef="Shares">134091</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000740"
      unitRef="Shares">129713</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000742"
      unitRef="Shares">129713</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember790435859"
      decimals="INF"
      id="Fact000744"
      unitRef="Shares">134373</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember790435859"
      decimals="INF"
      id="Fact000746"
      unitRef="Shares">134373</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000748"
      unitRef="Shares">129151</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000750"
      unitRef="Shares">129151</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000752"
      unitRef="Shares">2983283</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000754"
      unitRef="Shares">2983283</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000756"
      unitRef="Shares">1346808</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000758"
      unitRef="Shares">1346808</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000760"
      unitRef="Shares">2724903</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000762"
      unitRef="Shares">2724903</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000764"
      unitRef="Shares">1243475</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000766"
      unitRef="Shares">1243475</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-04-012024-06-30"
      decimals="INF"
      id="Fact000768"
      unitRef="Shares">1876059</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-06-30"
      decimals="INF"
      id="Fact000770"
      unitRef="Shares">1876059</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      id="Fact000772"
      unitRef="Shares">254314</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30"
      decimals="INF"
      id="Fact000774"
      unitRef="Shares">254314</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <PCSA:LesseeOperatingAndFinancingLeasesTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000776">&lt;p id="xdx_802_ecustom--LesseeOperatingAndFinancingLeasesTextBlock_zwpuyOG7tGp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_825_zb6aBuOjQPO5"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold
improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space
lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area
or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group
lease and non-lease components for all leases. We also lease office equipment under a financing lease. Our leases do not provide an implicit
rate and, as such, we have used our incremental borrowing rate of &lt;span id="xdx_906_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_dp_uPure_c20240630_zP17aI9bR8c5" title="Operating and financing lease borrowing rate"&gt;8&lt;/span&gt;% in determining the present value of the lease payments based on
the information available at the lease commencement date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
costs included in our condensed consolidated statements of operations totaled approximately $&lt;span id="xdx_90F_eus-gaap--LeaseCost_c20240401__20240630_zIxYHfMOvk6c" title="Lease cost"&gt;23,000&lt;/span&gt;
and $&lt;span id="xdx_901_eus-gaap--LeaseCost_c20230401__20230630_zqXTqwnSLatd" title="Lease cost"&gt;24,000&lt;/span&gt; for the three months
ending June 30, 2024 and 2023, respectively, and approximately $&lt;span id="xdx_906_eus-gaap--LeaseCost_c20240101__20240630_zEJyarALW003" title="Lease cost"&gt;45,000&lt;/span&gt;
and $&lt;span id="xdx_90B_eus-gaap--LeaseCost_c20230101__20230630_zEMithrlV3Xk" title="Lease cost"&gt;49,000&lt;/span&gt; for the six months
ended June 30, 2024, and 2023, respectively. The weighted average remaining lease terms and discount rate for our leases were as
follows at June 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_zlIAHMkiNVyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zJXetrGWQNSb" style="display: none"&gt;Schedule
of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Remaining lease term (years) for our facility lease&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zsE3gSqrrD7f" title="Remaining lease term (years)"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Remaining lease term (years) for our equipment lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zlpOrSizfwYf" title="Remaining lease term (years)"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted average discount rate for our facility and equipment leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_dp_uPure_c20240630_zp8o4ogNbs78" title="Weighted average discount rate for our facility and equipment leases"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zWHRJPxg1Fxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zmFnS3zaci7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
lease liabilities for the operating lease were as follows at June 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_z0GFpJajvCc1" style="display: none"&gt;Schedule
of Annual Lease Liabilities for all Operating Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20240630_zOfJqtZzaSa1" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz79B_z7WbgiuYwWPl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;45,797&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz79B_z4bu3Xg49RW9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;70,040&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zrSGkdOoYUI2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;115,837&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z7JfSWxiOHb5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"&gt;Less: Interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,511&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zXUSwYSh8KY2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zuPo9CgM2bod" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Less: current maturities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(87,495&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zF42E3liV1S8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Non-current lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;21,831&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zzo6Rc1dMTl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zDnbI74HEoeg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
lease liabilities for the financing lease were as follows at June 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zaGGHYTjTJdd" style="display: none"&gt;Schedule
of Annual Lease Liabilities for all Financing Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20240630_z6IFVCe0dUqj" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maFLLPDzELQ_zPTfoJuZWHr2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;3,232&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzELQ_zTnDbSvB7Hja" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,820&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzELQ_zezGMYX0VVQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;488&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzELQ_zr3wUPaJRYUg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,540&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_z7r2g348drsk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"&gt;Less: Interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,037&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FinanceLeaseLiability_iI_z2psB3EStoOg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zyE5MHpwFoy9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Less: current maturities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,686&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zUd4KeUfBQtd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Non-current lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,817&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zJFvDio0s9O2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</PCSA:LesseeOperatingAndFinancingLeasesTextBlock>
    <PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000778"
      unitRef="Pure">0.08</PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate>
    <us-gaap:LeaseCost
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact000780"
      unitRef="USD">23000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000782"
      unitRef="USD">24000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-01-01to2024-06-30"
      decimals="0"
      id="Fact000784"
      unitRef="USD">45000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact000786"
      unitRef="USD">49000</us-gaap:LeaseCost>
    <PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000788">&lt;p id="xdx_89F_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock_zlIAHMkiNVyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zJXetrGWQNSb" style="display: none"&gt;Schedule
of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;Remaining lease term (years) for our facility lease&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FacilityLeaseMember_zsE3gSqrrD7f" title="Remaining lease term (years)"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Remaining lease term (years) for our equipment lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zlpOrSizfwYf" title="Remaining lease term (years)"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted average discount rate for our facility and equipment leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--OperatingAndFinancingLeaseWeightedAverageDiscountRate_iI_dp_uPure_c20240630_zp8o4ogNbs78" title="Weighted average discount rate for our facility and equipment leases"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2024-06-30_custom_FacilityLeaseMember"
      id="Fact000790">P1Y3M18D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="AsOf2024-06-30_us-gaap_EquipmentMember"
      id="Fact000792">P1Y7M6D</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000794"
      unitRef="Pure">0.080</PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000796">&lt;p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zmFnS3zaci7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
lease liabilities for the operating lease were as follows at June 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_z0GFpJajvCc1" style="display: none"&gt;Schedule
of Annual Lease Liabilities for all Operating Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20240630_zOfJqtZzaSa1" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz79B_z7WbgiuYwWPl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;45,797&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz79B_z4bu3Xg49RW9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;70,040&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz79B_zrSGkdOoYUI2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;115,837&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_z7JfSWxiOHb5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"&gt;Less: Interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,511&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zXUSwYSh8KY2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zuPo9CgM2bod" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Less: current maturities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(87,495&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zF42E3liV1S8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Non-current lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;21,831&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000798"
      unitRef="USD">45797</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000800"
      unitRef="USD">70040</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000802"
      unitRef="USD">115837</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000804"
      unitRef="USD">6511</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000806"
      unitRef="USD">109326</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000808"
      unitRef="USD">87495</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000810"
      unitRef="USD">21831</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000812">&lt;p id="xdx_89B_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zDnbI74HEoeg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual
lease liabilities for the financing lease were as follows at June 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zaGGHYTjTJdd" style="display: none"&gt;Schedule
of Annual Lease Liabilities for all Financing Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20240630_z6IFVCe0dUqj" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maFLLPDzELQ_zPTfoJuZWHr2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;3,232&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maFLLPDzELQ_zTnDbSvB7Hja" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,820&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maFLLPDzELQ_zezGMYX0VVQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;488&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtFLLPDzELQ_zr3wUPaJRYUg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,540&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_z7r2g348drsk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"&gt;Less: Interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,037&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FinanceLeaseLiability_iI_z2psB3EStoOg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zyE5MHpwFoy9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Less: current maturities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,686&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zUd4KeUfBQtd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"&gt;Non-current lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,817&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000814"
      unitRef="USD">3232</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000816"
      unitRef="USD">6820</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000818"
      unitRef="USD">488</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000820"
      unitRef="USD">10540</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000822"
      unitRef="USD">1037</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000824"
      unitRef="USD">9503</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000826"
      unitRef="USD">5686</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000828"
      unitRef="USD">3817</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000830">&lt;p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zbMS3YmX0Kb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &#x2013; &lt;span id="xdx_828_z9CCuyn5sdql"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;CorLyst,
LLC (&#x201c;CorLyst&#x201d;) reimburses us for shared costs related to payroll, health insurance and rent based on actual costs
incurred, which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed
consolidated statement of operations. We recorded approximately $&lt;span id="xdx_902_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20240401__20240630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zdy8jDkzlJHa" title="Rent and other costs reimbursements received"&gt;27,000&lt;/span&gt;
and $&lt;span id="xdx_902_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20230401__20230630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zv25w51iFcbc" title="Rent and other costs reimbursements received"&gt;34,000&lt;/span&gt;
of reimbursements during the three months ended June 30, 2024 and 2023, respectively, and approximately $&lt;span id="xdx_905_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20240101__20240630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zpHU3VZa5cWf" title="Rent and other costs reimbursements received"&gt;50,000&lt;/span&gt;
and $&lt;span id="xdx_907_ecustom--ProceedsFromRentAndOtherCostsReimbursements_c20230101__20230630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zD1i99G2WPdg" title="Rent and other costs reimbursements received"&gt;64,000&lt;/span&gt;
for the six months ended June 30, 2024 and 2023, respectively. &lt;span id="xdx_90F_eus-gaap--OtherReceivablesNetCurrent_iI_do_c20240630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_z10eeCOtkkHk" title="Due from related parties"&gt;&lt;span id="xdx_904_eus-gaap--OtherReceivablesNetCurrent_iI_do_c20230630__us-gaap--RelatedPartyTransactionAxis__custom--CorLystLLCMember_zMHDQveFNXC3" title="Due from related parties"&gt;No&lt;/span&gt;&lt;/span&gt;
amounts were due from CorLyst at June 30, 2024 or 2023. Our President of Research and Development is the CEO of CorLyst, and CorLyst
is a shareholder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <PCSA:ProceedsFromRentAndOtherCostsReimbursements
      contextRef="From2024-04-012024-06-30_custom_CorLystLLCMember"
      decimals="0"
      id="Fact000832"
      unitRef="USD">27000</PCSA:ProceedsFromRentAndOtherCostsReimbursements>
    <PCSA:ProceedsFromRentAndOtherCostsReimbursements
      contextRef="From2023-04-012023-06-30_custom_CorLystLLCMember"
      decimals="0"
      id="Fact000834"
      unitRef="USD">34000</PCSA:ProceedsFromRentAndOtherCostsReimbursements>
    <PCSA:ProceedsFromRentAndOtherCostsReimbursements
      contextRef="From2024-01-012024-06-30_custom_CorLystLLCMember"
      decimals="0"
      id="Fact000836"
      unitRef="USD">50000</PCSA:ProceedsFromRentAndOtherCostsReimbursements>
    <PCSA:ProceedsFromRentAndOtherCostsReimbursements
      contextRef="From2023-01-012023-06-30_custom_CorLystLLCMember"
      decimals="0"
      id="Fact000838"
      unitRef="USD">64000</PCSA:ProceedsFromRentAndOtherCostsReimbursements>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2024-06-30_custom_CorLystLLCMember"
      decimals="0"
      id="Fact000840"
      unitRef="USD">0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2023-06-30_custom_CorLystLLCMember"
      decimals="0"
      id="Fact000842"
      unitRef="USD">0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000844">&lt;p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zxGRq6dw7n1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &#x2013; &lt;span id="xdx_828_zs8Av13J088b"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Purchase
Obligations&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
enter into contracts in the normal course of business with contract research organizations (&#x201c;CROs&#x201d;) and subcontractors to further develop
our products. The contracts are cancelable, with varying provisions regarding termination. If we terminated a cancelable contract with
a specific vendor, we would only be obligated for products or services that we received at the effective date of the termination and
any applicable cancellation fees. At June 30, 2024, we are contractually obligated to pay up to $&lt;span id="xdx_904_eus-gaap--PurchaseObligation_iI_pn5n6_c20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CROsMember_zh994XQkjXc6" title="Purchase obligation"&gt;14.3&lt;/span&gt; million of future services under
the agreements with the CROs. Our actual contractual obligations will also vary depending on the progress and results of the remaining
clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseObligation
      contextRef="AsOf2024-06-30_custom_CROsMember"
      decimals="-5"
      id="Fact000846"
      unitRef="USD">14300000</us-gaap:PurchaseObligation>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-06-30" id="Fact000848">&lt;p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zSmKLVqT6g55" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &#x2013; &lt;span id="xdx_820_zXqHW1wz9mJ7"&gt;Subsequent Event&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 16, 2024, Russell Skibsted was appointed as our Chief Financial Officer (&#x201c;CFO&#x201d;). Mr. Skibsted has nearly 30 years of experience
in the pharmaceutical industry, including expertise in financial management, global business development, capital markets, investor
relations and operations. In connection with his employment, Mr. Skibsted will be paid an annual base salary of $&lt;span id="xdx_90C_eus-gaap--OfficersCompensation_c20240716__20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zs6fu2MQWvm3" title="Annual base salary"&gt;400,000&lt;/span&gt;
and will be eligible for a $&lt;span id="xdx_909_eus-gaap--SalariesWagesAndOfficersCompensation_c20240716__20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2V4DKVdZrNc" title="Potential base salary increase"&gt;50,000&lt;/span&gt;
base salary increase upon a cumulative (one or multiple) financing of at least $&lt;span id="xdx_90B_ecustom--PotentialBaseSalaryIncreaseFinancingMinimum_iI_pn6n6_c20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zORuhclSycN9" title="Potential base salary increase financing minimum"&gt;15&lt;/span&gt;
million that he leads and substantially participates in. He is also eligible to participate in an executive bonus pool with a target
bonus of &lt;span id="xdx_905_ecustom--CompensationArrangementWithIndividualBonusAwardsGrantedPercentage_dp_uPure_c20240716__20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zB0WtdzoX743" title="Executive bonus percentage"&gt;35&lt;/span&gt;%
of his base compensation. In addition, the Compensation Committee awarded &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240716__20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4WCxhBVH4B3" title="Number of shares, granted"&gt;28,000&lt;/span&gt;
RSUs to Mr. Skibsted, which vest accordingly: &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240716__20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ServiceBasedRSUMember_zY7aLAUt8C62" title="Number of shares, granted"&gt;14,000&lt;/span&gt;
RSUs vest on July 16, 2025; &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240716__20240716__us-gaap--AwardTypeAxis__custom--FirstPerformanceBasedRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zO8uMpxch4xc" title="Number of shares, granted"&gt;7,000&lt;/span&gt;
RSUs vest upon Processa reaching a market capitalization (i.e. total value of Processa&#x2019;s outstanding shares of stock at the
then current market price) of at least $&lt;span id="xdx_909_ecustom--MarketCapitalization_iI_pn6n6_c20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--FirstPerformanceBasedRSUMember_zA8muWS8EXog" title="Market capitalization"&gt;30&lt;/span&gt;
million; and &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240716__20240716__us-gaap--AwardTypeAxis__custom--SecondPerformanceBasedRSUMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhIJ5j0lYLE4" title="Number of shares, granted"&gt;7,000&lt;/span&gt;
RSUs vest upon a cumulative (one or multiple) financing of at least $&lt;span id="xdx_901_ecustom--PerformanceVestingCriteriaValue_iI_pn6n6_c20240716__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--SecondPerformanceBasedRSUMember_zRBsZFSNLBsb" title="Performance vesting criteria"&gt;15&lt;/span&gt;
million that he leads and substantially participates in. He will also be eligible for other benefits as described in his employment
agreement.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:OfficersCompensation
      contextRef="From2024-07-162024-07-16_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact000850"
      unitRef="USD">400000</us-gaap:OfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2024-07-162024-07-16_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact000852"
      unitRef="USD">50000</us-gaap:SalariesWagesAndOfficersCompensation>
    <PCSA:PotentialBaseSalaryIncreaseFinancingMinimum
      contextRef="AsOf2024-07-16_us-gaap_SubsequentEventMember"
      decimals="-6"
      id="Fact000854"
      unitRef="USD">15000000</PCSA:PotentialBaseSalaryIncreaseFinancingMinimum>
    <PCSA:CompensationArrangementWithIndividualBonusAwardsGrantedPercentage
      contextRef="From2024-07-162024-07-16_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000856"
      unitRef="Pure">0.35</PCSA:CompensationArrangementWithIndividualBonusAwardsGrantedPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-07-162024-07-16_us-gaap_SubsequentEventMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000858"
      unitRef="Shares">28000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-07-162024-07-16_us-gaap_SubsequentEventMember_custom_ServiceBasedRSUMember"
      decimals="INF"
      id="Fact000860"
      unitRef="Shares">14000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-07-162024-07-16_custom_FirstPerformanceBasedRSUMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000862"
      unitRef="Shares">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <PCSA:MarketCapitalization
      contextRef="AsOf2024-07-16_us-gaap_SubsequentEventMember_custom_FirstPerformanceBasedRSUMember"
      decimals="-6"
      id="Fact000864"
      unitRef="USD">30000000</PCSA:MarketCapitalization>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-07-162024-07-16_custom_SecondPerformanceBasedRSUMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000866"
      unitRef="Shares">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <PCSA:PerformanceVestingCriteriaValue
      contextRef="AsOf2024-07-16_us-gaap_SubsequentEventMember_custom_SecondPerformanceBasedRSUMember"
      decimals="-6"
      id="Fact000868"
      unitRef="USD">15000000</PCSA:PerformanceVestingCriteriaValue>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-04-012024-06-30" id="Fact000869">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-04-012024-06-30" id="Fact000870">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-04-012024-06-30" id="Fact000871">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
